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Described in this thesis are four projects related to the development of synthetic 
methodologies for the preparation of enantioenriched building blocks, and the total 
syntheses of complex tetrahydroisoquinoline natural products. In Chapter 1, the 
development of nickel-catalyzed asymmetric allylic alkylation of lactones and lactams 
with allylic alcohols is presented. In Chapter 2, the development of palladium-catalyzed 
enantioselective decarboxylative allylic alkylation of silicon-containing heterocycles is 
detailed. In these chapters, the utilization of prochiral enolates as nucleophiles has 
enabled access to enantioenriched all-carbon quaternary stereocenters. 
Chapter 3 describes the total syntheses of bis-tetrahydroisoquinoline alkaloids,  
(–)-jorumycin and (–)-jorunnamycin A. A general synthetic strategy, which exploits the 
tandem cross-coupling/hydrogenation approach, represents the first non-biomimetic 
synthetic route and allows for an efficient construction of the pentacyclic core in a highly 
modular fashion. Additional bis-tetrahydroisoquinoline analogs were prepared, and 
preliminary studies to probe their cytotoxicity against cancer cell lines were conducted. 
Finally, an extension of the enantioselective and diastereoselective hydrogenation 
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Nickel-Catalyzed Enantioselective Allylic Alkylation of Lactones and 
Lactams with Unactivated Allylic Alcohols† 
 
 
1.1   INTRODUCTION 
Since the seminal report in 1965 by Tsuji,1 transition metal-catalyzed allylic 
alkylation has emerged as one of the most powerful methods for the construction 
of stereocenters.2 In particular, with the use of prochiral nucleophiles that proceed 
through tetrasubstituted enolates, the transition metal-catalyzed enantioselective 
allylic alkylation has proven to be a formidable strategy for accessing chiral 
quaternary stereocenters in catalytic enantioselective fashion.3 Although this 
transformation has been studied for more than 50 years,4 the use of α-substituted 
	
	
†	This research was performed in collaboration with Carina I. Jette, Dr. Shoshana Bachman, and Dr. Scott 
Virgil. Portions of this chapter have been reproduced with permission from Ngamnithiporn, A.; Jette, C. I.; 
Bachman, S.; Virgil, S. C.; Stoltz, B. M. Chemical Science. 2018, 9, 2547–2551. ã 2018 Royal Society of 
Chemistry. 
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lactones or lactams as prochiral nucleophiles remains significantly under-
developed.5,6 
As part of our ongoing research program directed at the development of 
new strategies for constructing quaternary stereocenters,7 we were drawn to the α-
acyl lactones and lactams, as we envisioned that the α-acyl substituent would 
provide an additional functional handle for further synthetic manipulations. In 
addition, lactone products could also provide access to acyclic quaternary 
stereocenters via ring-opening reactions8 and reduction of the lactam products 
would enable direct access to functionalized piperidine rings, the most prevalent 
nitrogenous heterocycle in drug molecules.9 However, to the best of our 
knowledge, there has been only one report of a transition metal-catalyzed 
enantioselective allylic alkylation of monocyclic α-acyl lactone or lactam prochiral 
nucleophiles to furnish products bearing a quaternary stereocenter.5d  
Recently, Cossy disclosed a palladium-catalyzed decarboxylative 
enantioselective allylic alkylation of enol carbonates derived from γ-
butyrolactones (Scheme 1.1a). Various enol carbonates can be used to obtain 
diverse α-acyl quaternary butyrolactones in moderate to high levels of 
enantioselectivity.  Nonetheless, the limited electrophile scope and challenging 
nucleophile synthesis limits the practicality of this transformation. 
To address this limitation, we chose to investigate the enantioselective 
allylic alkylation of α-acyl lactones and lactams by using an inexpensive transition 
metal catalyst and easily accessible prochiral nucleophiles. Mashima’s recent 
report on nickel-catalyzed enantioselective allylic alkylation of β-keto esters with 
allyl alcohol prompted us to probe nickel in our system.10,11 Furthermore, we 
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anticipated that an intermolecular allylic alkylation would simplify the substrate 
synthesis and provide a more convergent approach to these α-quaternary 
products.12 Herein, we report the first example of nickel-catalyzed intermolecular 
enantioselective allylic alkylation using easily accessible α-acyl lactones and 
lactams as prochiral nucleophiles in conjunction with allylic alcohols as 
electrophilic coupling partners (Scheme 1.1b). 




1.2   REACTION OPTIMIZATION 
 Our studies commenced with an investigation of the enantioselective allylic 
alkylation between α-ethoxycarbonyl lactone 1a and allyl alcohol (2a) using 
Ni(COD)2 and (R)-BINAP (L1) in diethyl ether at 0 °C. Although the α-quaternary 
lactone product 3aa was obtained in good yield, only moderate enantioselectivity 
was achieved (Table 1.1, entry 1).13  






























• Inexpensive catalyst and commercially available ligand
functional handle
diverse substitution
• Easily accessible substrates
• Substrates require low yielding, multistep synthesis
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Table 1.1 Optimization of reaction parameters.a 
 
[a] Conditions: 1a (0.1 mmol), 2a (0.1 mmol), Ni(COD)2 (10 mol %), ligand (12 mol %) in Et2O (1.0 mL). [b] Yields 
determined by 1H NMR of crude reaction mixture using 1,3,5-trimethoxybenzene as a standard. [c] Determined by chiral 
SFC analysis of the isolated product. [d] Ni(COD)2 (5 mol %) and L4 (6 mol %) were used. [e] Reaction time = 48 h. 
Seeking to improve the enantioselectivity, we elected to survey a wide 
variety of commercially available ligand scaffolds. Chiral bisphosphine ligands 
were discovered to exhibit superior enantioselectivity to other classes of ligands, 
including those commonly used in asymmetric allylic alkylations such as 
phosphinooxazolines (PHOX) or C2-asymmetric ligands pioneered by the Trost 
group.14 In the presence of Ni(COD)2 (10 mol %) and chiral bisphosphine ligands 






Ni(COD)2 (10 mol %)
Ligand (12 mol %)


















L1: (R)-BINAP L2: (R)-H8-BINAP L3: (R)-Segphos
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enantioselectivity (Table 1.1, entries 1–4). Using toluene or other ethereal solvents 
results in lower ee.15 The highest enantiomeric excess (ee) was achieved with (R)-
P-phos (L4), which delivers α-quaternary lactone 3aa in 82% yield and 82% ee 
(entry 4). Decreasing the catalyst loading to 5 mol % requires exceedingly long 
reaction time (entry 5). An examination of different temperatures revealed that 
decreasing the temperature improves ee (entries 6–7), albeit with slightly 
diminished yields. Prolonged reaction time (48 h) at –10 °C affords product 3aa in 
80% yield and 85% ee (entry 8). Importantly, a control experiment performed in 
the absence of the chiral ligand shows no background reaction (entry 9).  
 
1.3   SUBSTRATE SCOPE EXPLORATION 
With the optimized reaction conditions in hand, we examined the scope of 
this asymmetric transformation (Table 1.2). The reaction of α-methoxycarbonyl 
lactone 1b, possessing a smaller alkyl group at the ester fragment, with allyl 
alcohol (2a) provides α-quaternary lactone 3ba in comparable yield and ee to the 
allylated product 3aa. Bicyclic lactone 1c could also be used to furnish product 
3ca in slightly diminished yield and enantioselectivity. With respect to the 
electrophile scope, reactions between lactone 1a with various substituted allyl 
alcohols proceed with good ee (78–90% ee) at increased temperature (10 °C). 
Although a trend in enantioselectivity was not observed, we found that the 
electronic nature of the aryl substituent does affect the reactivity. Electrophiles 
containing electron rich aryl substituents provide the corresponding products in 
greater yields than their electron-deficient counterparts (3ac–3ag).  
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Table 1.2 Nucleophile and electrophile scope.a 
 
[a] Reactions performed on 0.2 mmol. [b] Yield of isolated product. [c] Reaction performed at –10 °C. 
[d] Determined by chiral SFC analysis. [e] Absolute configuration determined via single crystal x-ray analysis. 
+
Ni(COD)2 (10 mol %)
L4 (12 mol %)
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Furthermore, we found that para- and meta-substituted aryl rings exhibit 
higher reactivity as compared to the ortho-substituted aryl ring (3ac, 3ah–ai vs. 
3aj). Apart from the aryl-substituted electrophiles, we were pleased to find that 
heteroaryl substitution is also well-tolerated (3ak–3al). The reaction with an 
aliphatic electrophile affords product 3am in slightly diminished yield and ee. In 
addition, an alkenyl-substituted electrophile fares well under our reaction 
conditions, delivering product 3an in an excellent 91% yield and 88% ee. 
At this stage, we questioned whether we could leverage this transformation 
to include nitrogen-containing lactam nucleophiles. To our delight, under slightly 
modified reaction conditions using the same chiral bisphosphine ligand L4,16  
α-ester lactams 4a–4b furnish products 5aa–5ba in good yields and with even 
higher enantioselectivity as compared to their lactone counterparts (Table 3). 
Examination of different protecting groups revealed that the benzoyl-protecting 
group is optimal.17 Reaction of α-ethoxycarbonyl benzoyl-protected lactam 4a with 
branched cinnamyl alcohol affords linear product 5ab in 74% yield and 90% ee. 
Table 1.3 a-acyl lactam prochiral nucleophiles.a 
 
[a] Reactions performed on 0.2 mmol. [b] Yield of isolated product. [c] Determined by chiral SFC analysis.  





Ni(COD)2 (10 mol %)
L4 (12 mol %)
PhMe:MTBE (2:3)
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1.4   PRELIMINARY MECHANISTIC INSIGHTS 
In order to gain mechanistic insights into this transformation, we compared 
the results from reactions using linear and branched cinnamyl alcohols (Table 1.4). 
Only the linear product was detected, indicating that a nickel π-allyl is likely an 
intermediate in the catalytic cycle.18 While additional studies are needed to 
establish the full reaction mechanism and stereocontrolling factors in the process, 
the ability of this catalyst combination to access a single product from two 
electrophilic coupling partners highlights its flexibility in potential synthetic 
applications. 
Table 1.4 Linear vs. branched cinnamyl alcohol.a 
 
[a] Reactions performed on 0.1 mmol scale. [b] Yields determined by 1H NMR of crude reaction mixture using benzyl ether 
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1.5   PRODUCT TRANSFORMATIONS 
To demonstrate the synthetic utility of the α-quaternary products, we performed a 
number of product transformations on both α-quaternary lactone 3aa (Scheme 1.2) and 
lactam 5aa (Scheme 1.3). Selective reduction of the lactone functionality in 3aa provides 
diol 6 in 88% yield. Additionally, vinyl Grignard addition into lactone 3aa affords enone 
7 in 67% yield with no erosion of enantioselectivity. These enantioenriched acyclic 
products 6 and 7 bearing a quaternary stereocenter are envisioned to be useful chiral 
building blocks as they contain multiple functional handles for further manipulations. For 
example, enantioenriched spirocycle 8 can be accessed via ring-closing metathesis 
followed by lactonization of enone 7. 
Scheme 1.2 Product transformations of allylic alkylation product 3aa. 
 
[a] NaBH4, CeCl3×7H2O, THF/MeOH, 0°C, 88% yield; [b] Vinyl–magnesium bromide, THF, –78 °C, 67% yield, 86% ee; 
[c] Grubbs’ II (5 mol %), Toluene, 40 °C; DBU, MeCN, 23 °C, 53% yield. 
We also performed experiments to probe the reactivity of our α-quaternary lactam 
products. Reduction of lactam 5aa with lithium aluminium hydride delivers chiral 
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aldehyde selective Wacker procedure19 affords aldehyde 10 in 75% yield. Lastly, 
cleavage of the benzoyl protecting group under basic conditions provides unprotected 
lactam 11 in 84% yield. 
Scheme 1.3 Product transformations of allylic alkylation product 5aa. 
 
[a] LAH, Ether, 65°C, 80% yield; [b] CuCl×H2O (12 mol %), PdCl2(PhCN)2 (12 mol %), AgNO2 (6 mol %), t-BuOH, 
Nitromethane under O2, 75% yield; [c] NaOEt, EtOH, 23 °C, 84% yield. 
 
1.6  CONCLUSIONS 
In summary, we have developed the first nickel-catalyzed enantioselective allylic 
alkylation of α-substituted lactones and lactams with free allylic alcohols. Utilizing a 
commercially available chiral bisphosphine ligand, α-quaternary lactones and lactams can 
be constructed in good yield (up to 91% yield) and with high enantiomeric excess (up to 
90% ee). A broad range of functional groups are compatible with the reaction conditions.  
A number of product derivatizations showed the synthetic utility of this methodology for 
constructing small chiral building blocks with multiple functional handles. Future work to 
further elucidate the mechanism of this transformation is underway and will be reported 
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1.7  EXPERIMENTAL SECTION 
1.7.1  MATERIALS AND METHODS 
Unless otherwise stated, reactions were performed in flame-dried glassware under 
an argon or nitrogen atmosphere using dry, deoxygenated solvents.  Solvents were dried 
by passage through an activated alumina column under argon. Reaction progress was 
monitored by thin-layer chromatography (TLC) or Agilent 1290 UHPLC-MS.  TLC was 
performed using E. Merck silica gel 60 F254 precoated glass plates (0.25 mm) and 
visualized by UV fluorescence quenching, p-anisaldehyde, or KMnO4 staining.  Silicycle 
SiliaFlash® P60 Academic Silica gel (particle size 40–63 µm) was used for flash 
chromatography.  1H NMR spectra were recorded on Varian Inova 500 MHz, Bruker 400 
MHz, or Varian Mercury 300 MHz spectrometers and are reported relative to residual 
CHCl3 (δ 7.26 ppm).  13C NMR spectra were recorded on Varian Inova 500 MHz 
spectrometer (125 MHz) and Bruker 400 MHz spectrometer (100 MHz) and are reported 
relative to CHCl3 (δ 77.16 ppm). 19F NMR spectra were recorded on Varian Mercury 300 
MHz spectrometer (282 MHz). Data for 1H NMR are reported as follows: chemical shift 
(δ ppm) (multiplicity, coupling constant (Hz), integration).  Multiplicities are reported as 
follows: s = singlet, d = doublet, t = triplet, q = quartet, p = pentet, sept = septuplet, m = 
multiplet, br s = broad singlet, br d = broad doublet, app = apparent.  Data for 13C NMR 
are reported in terms of chemical shifts (δ ppm).  IR spectra were obtained using Perkin 
Elmer Spectrum BXII spectrometer or Nicolet 6700 FTIR spectrometer using thin films 
deposited on NaCl plates and reported in frequency of absorption (cm–1).  Optical 
rotations were measured with a Jasco P-2000 polarimeter operating on the sodium D-line 
(589 nm), using a 100 mm path-length cell and are reported as: [a]DT (concentration in 10 
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mg/1 mL, solvent) .  Analytical SFC was performed with a Mettler SFC supercritical CO2 
analytical chromatography system utilizing Chiralpak (AD-H, AS-H or IC) or Chiralcel 
(OD-H, OJ-H, or OB-H) columns (4.6 mm x 25 cm) obtained from Daicel Chemical 
Industries, Ltd. High resolution mass spectra (HRMS) were obtained from Agilent 6200 
Series TOF with an Agilent G1978A Multimode source in electrospray ionization (ESI+), 
atmospheric pressure chemical ionization (APCI+), or mixed ionization mode (MM: ESI-
APCI+), or obtained from Caltech mass spectrometry laboratory. Low-temperature 
diffraction data (f-and w-scans) were collected on a Bruker AXS D8 VENTURE KAPPA 
diffractometer coupled to a PHOTON 100 CMOS detector with Cu Ka radiation (l = 
1.54178 Å) from an IμS micro-source for the structure of compound P17471. The 
structure was solved by direct methods using SHELXS20 and refined against F2 on all 
data by full-matrix least squares with SHELXL-201621 using established refinement 
techniques.22 All non-hydrogen atoms were refined anisotropically. All hydrogen atoms 
were included into the model at geometrically calculated positions and refined using a 
riding model. The isotropic displacement parameters of all hydrogen atoms were fixed to 
1.2 times the U value of the atoms they are linked to (1.5 times for methyl groups). 
Reagents were purchased from Sigma-Aldrich, Acros Organics, Strem, or Alfa 





Chapter 1 – Nickel-Catalyzed Enantioselective Allylic Alkylation of Lactones and Lactams with 
Unactivated Allylic Alcohols 
  
13 
1.7.2  EXPERIMENTAL PROCEDURES AND SPECTROSCOPIC DATA 
1.7.2.1 Synthesis of Nucleophiles 
General procedure 1: α-acylation of lactones 
 
Ethyl 2-oxotetrahydro-2H-pyran-3-carboxylate (1a):23 To a solution of LHMDS (3.43 
g, 20.5 mmol, 2.05 equiv) in THF (20 mL) was added a mixture of delta-valerolactone 
(1.00 g, 10.0 mmol, 1.00 equiv) and diethyl carbonate (1.3 mL, 11.0 mmol, 1.10 equiv) at 
–78 °C. After stirring at room temperature for 6 hours, the reaction was quenched with 
glacial acetic acid (5 mL), diluted with Et2O (20 mL), and stirred for 5 minutes. The 
insoluble white solid was filtered off and rinsed with more Et2O. The filtrate was 
concentrated and purified by column chromatography (50% to 65% Et2O in PET) to 
afford 1a as a colorless oil (1.20 g, 70% yield); 1H NMR (300 MHz, CDCl3) δ 4.46–4.31 
(m, 2H), 4.25 (qd, J = 7.1, 1.7 Hz, 2H), 3.56 (dd, J = 8.3, 7.5 Hz, 1H), 2.38–2.08 (m, 2H), 
2.08–1.80 (m, 2H), 1.30 (t, J = 7.1 Hz, 3H). All characterization data match those 
reported.24 
 
Methyl 2-oxotetrahydro-2H-pyran-3-carboxylate (1b): Compound 1b was prepared 
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MHz, CDCl3) δ 4.46–4.32 (m, 2H), 3.80 (s, 3H), 3.58 (dd, J = 8.4, 7.5 Hz, 1H), 2.38–
2.06 (m, 2H), 2.02–1.81 (m, 2H). All characterization data match those reported.23 
 
Ethyl 2-oxochromane-3-carboxylate (1c): Compound 1c was prepared from 
dihydrocoumarin and diethyl carbonate using general procedure 1 (0.28 g, 25% yield); 1H 
NMR (300 MHz, CDCl3) δ 7.33–7.18 (m, 2H), 7.17–6.99 (m, 2H), 4.34–4.08 (m, 2H), 
3.76 (dd, J = 8.5, 6.1 Hz, 1H), 3.42 (dd, J = 16.0, 8.5 Hz, 1H), 3.18 (dd, J = 16.0, 6.0 Hz, 
1H), 1.21 (t, J = 7.1 Hz, 3H). All characterization data match those reported.25 
General procedure 2: α-acylation of lactams 
 
Ethyl 1-benzoyl-2-oxopiperidine-3-carboxylate (4a):26 To a solution of 
diisopropylamine (1.7 mL, 12 mmol, 1.2 equiv) in THF (65 mL) at 0 °C, n-BuLi (4.6 mL, 
11 mmol, 2.4 M in hexanes, 1.1 equiv) was added dropwise over 10 minutes. After 
stirring for 30 min at 0 °C, the solution was cooled to –78 °C and a solution of benzoyl-
protected lactam27 (2.0 g, 12 mmol, 1.2 equiv) in THF (17 mL) was then added over 5 
minutes. The reaction mixture was stirred at –78 °C for 2 hours and warmed to –30 °C 
for 1 hour. Ethyl cyanoformate (1.1 mL, 11 mmol, 1.1 equiv) was then added at –78 °C. 
The reaction was allowed to slowly warm to room temperature overnight. Upon complete 









1. LDA, THF, –78 to –30 °C
2. Ethyl cyaoformate
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NH4Cl. The aqueous layer was extracted with EtOAc (50 mL × 4). The combined organic 
phases were washed with brine (50 mL), dried over Na2SO4, filtered, and concentrated 
under vacuum. The crude residue was purified by column chromatography (30% EtOAc 
in hexanes) to provide product 4a as a white amorphous solid (1.47 g, 53% yield); 1H 
NMR (500 MHz, CDCl3) δ 7.73–7.66 (m, 2H), 7.52–7.44 (m, 1H), 7.43–7.34 (m, 2H), 
4.25 (q, J = 7.1 Hz, 2H), 3.89–3.75 (m, 2H), 3.58–3.50 (m, 1H), 2.40–2.27 (m, 1H), 
2.22–2.00 (m, 2H), 2.00–1.89 (m, 1H), 1.32 (t, J = 7.1 Hz, 3H); 13C NMR (125 MHz, 
CDCl3) δ 174.7, 170.0, 169.6, 135.6, 132.0, 128.3, 128.2, 62.0, 51.2, 46.4, 25.6, 20.7, 
14.2; IR (Neat Film, NaCl) 3062, 2980, 1734, 1701, 1683, 1476, 1449, 1392, 1285, 1258, 
1185, 1152, 1113, 1026, 999, 730, 670, 638 cm–1; HRMS (MM) m/z calc’d for 
C15H18NO4 [M+H]+: 276.1230, found 276.1237. 
 
Methyl 1-benzoyl-2-oxopiperidine-3-carboxylate (4b): Compound 4b was prepared 
from Bz-protected lactam and methyl cyanoformate using general procedure 2 and 
purified by column chromatography (40% EtOAc in hexanes) to provide a colorless 
amorphous solid (0.33 g, 51% yield); 1H NMR (400 MHz, CDCl3) δ 7.73–7.65 (m, 2H), 
7.48 (m, 1H), 7.43–7.36 (m, 2H), 3.86–3.80 (m, 2H), 3.79 (s, 3H), 3.59 (t, J = 6.4 Hz, 
1H), 2.39–2.27 (m, 1H), 2.23–2.03 (m, 2H), 2.02–1.89 (m, 1H); 13C NMR (100 MHz, 
CDCl3) δ 174.7, 170.5, 169.6, 135.6, 132.0, 128.3, 128.3, 52.9, 51.1, 46.4, 25.6, 20.9; IR 
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1065, 973, 954, 857, 796, 731, 701, 639; HRMS (MM) m/z calc’d for C14H16NO4 
[M+H]+: 262.1074, found 262.1066. 
 
1-(tert-butyl) 3-ethyl 2-oxopiperidine-1,3-dicarboxylate: This compound was prepared 
from Boc-protected lactam28 using general procedure 2 and purified by column 
chromatography (20% EtOAc in hexanes) to provide a colorless oil (0.47 g, 70% yield); 
1H NMR (400 MHz, CDCl3) δ 4.30 – 4.13 (m, 2H), 3.75 – 3.62 (m, 2H), 3.49 (dd, J = 
8.7, 6.8 Hz, 1H), 2.24 – 2.02 (m, 2H), 1.96 (dtt, J = 14.1, 6.6, 5.2 Hz, 1H), 1.81 (dddt, J = 
14.1, 8.8, 7.5, 5.3 Hz, 1H), 1.52 (s, 9H), 1.29 (t, J = 7.1 Hz, 3H); 13C NMR (100 MHz, 
CDCl3) δ 170.05, 167.60, 152.75, 83.51, 61.72, 51.61, 45.93, 28.13, 24.35, 21.16, 14.23; 
IR (Neat Film, NaCl) 2980, 2939, 1772, 1717, 1478, 1458, 1393, 1369, 1297, 1252, 
1146, 1115, 1096, 1056, 1029, 937, 852, 778, 748, 642; HRMS (MM) m/z calc’d for  
C13H21NO5Na [M+Na]+: 294.1312, found 294.1315. 
 
Ethyl 2-oxo-1-tosylpiperidine-3-carboxylate: This compound was prepared from tosyl-
protected lactam29 using general procedure 1 and purified by column chromatography 
(35% to 40% EtOAc in hexanes) to provide a colorless oil (0.32 g, 41% yield); 1H NMR 
(400 MHz, CDCl3) δ 7.90 (d, J = 8.4 Hz, 2H), 7.31 (d, J = 7.9, 2H), 4.12 (qd, J = 7.1, 1.2 
Hz, 2H), 4.03–3.84 (m, 2H), 3.41 (dd, J = 7.5, 6.3 Hz, 1H), 2.43 (s, 3H), 2.19–1.97 (m, 
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166.6, 145.06, 135.7, 129.5, 128.9, 61.9, 50.9, 46.6, 24.3, 21.8, 21.5, 14.1; IR (Neat Film, 
NaCl) 2980, 1737, 1694,1456, 1353, 1289, 1169, 1089, 1036, 1008, 827, 815, 706, 670, 
653; HRMS (MM) m/z calc’d for C15H20NO5S [M+H]+: 326.1057, found 326.1066. 
 
Ethyl 1-methyl-2-oxopiperidine-3-carboxylate: This compound was prepared from 
methyl-protected lactam using previously reported procedure;30 1H NMR (300 MHz, 
CDCl3) δ 4.31–4.08 (m, 2H), 3.44–3.20 (m, 3H), 2.96 (s, 3H), 2.24–1.89 (m, 3H), 1.89–
1.69 (m, 1H), 1.28 (t, J = 7.1 Hz, 3H). All characterization data match those reported.31 
 
Ethyl 2-oxo-1-phenylpiperidine-3-carboxylate: This compound was prepared from 
phenyl-protected lactam32 using general procedure 2 and purified by column 
chromatography (40% EtOAc in hexanes) to provide a pale yellow solid (0.53 g, 42% 
yield); 1H NMR (400 MHz, CDCl3) δ 7.42–7.35 (m, 2H), 7.29–7.22 (m, 3H), 4.31–4.15 
(m, 2H), 3.76–3.61 (m, 2H), 3.57 (dd, J = 7.8, 6.4 Hz, 1H), 2.35–2.04 (m, 3H), 2.00–1.88 
(m, 1H), 1.30 (t, J = 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 171.1, 166.2, 142.9, 
129.3, 127.0, 126.1, 61.5, 51.4, 49.7, 25.3, 21.5, 14.3; IR (Neat Film, NaCl) 2943, 
1734,1654, 1595, 1494, 1462, 1427, 1371, 1353, 1308, 1259, 1197, 1171, 1036, 763, 697, 
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Ethyl 1-benzyl-2-oxopiperidine-3-carboxylate: This compound was prepared from 
benzyl-protected lactam33 using general procedure 2 (0.32 g, 56% yield); 1H NMR (300 
MHz, CDCl3) δ 7.37–7.23 (m, 5H), 4.73 (d, J = 14.7 Hz, 1H), 4.51 (d, J = 14.7 Hz, 1H), 
4.24 (qd, J = 7.1, 4.0 Hz, 2H), 3.59–3.43 (m, 1H), 3.36–3.12 (m, 2H), 2.29–1.97 (m, 2H), 
1.97–1.83 (m, 1H), 1.82–1.64 (m, 1H), 1.31 (t, J = 7.2 Hz, 3H). All characterization data 
match those reported.34 
1.7.2.2 General Procedure for the Nickel-Catalyzed Allylic Alkylation 
Please note that the absolute configuration was determined only for compound 3af via x-
ray crystallographic analysis. The absolute configuration for all other products has been 
inferred by analogy. For respective HPLC and SFC conditions, please refer to Table S3. 
General procedure 3: Ni-catalyzed asymmetric AA of lactones 
 
In a nitrogen-filled glovebox, to an oven-dried 4-mL vial equipped with a stir bar was 
added (R)-P-Phos ligand L4 (15.5 mg, 0.024 mmol, 12 mol%) and Ni(COD)2 (5.5 mg, 
0.02 mmol, 10 mol%) in Et2O (1.2 mL). The vial was then capped with a PTFE-lined 
septum cap and stirred at room temperature. After 30 minutes, the catalyst mixture was 
cooled to 10 °C. Precooled nucleophile (0.2 mmol, 1 equiv) in Et2O (0.4 mL) and 







Ni(COD)2 (10 mol %)
L4 (12 mol %)
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to the catalyst mixture at 10 °C. The vial was sealed with a PTFE-lined septum cap and 
stirred at 10 °C. After 48 h, the vial was removed from the glovebox. The crude reaction 
mixture was filtered through a silica plug with Et2O, concentrated under vacuum, and 
purified by silica gel flash chromatography to furnish the product.   
General procedure 4: Ni-catalyzed asymmetric AA of lactams 
 
In a nitrogen-filled glovebox, to an oven-dried 4-mL vial equipped with a stir bar was 
added (R)-P-Phos ligand L4 (15.5 mg, 0.024 mmol, 12 mol%) and Ni(COD)2 (5.5 mg, 
0.02 mmol, 10 mol %) in MTBE (1.2 mL). The vial was then capped with a PTFE-lined 
septum cap and stirred at room temperature. After 30 minutes, the catalyst mixture was 
cooled to 10 °C. Precooled nucleophile (0.2 mmol, 1 equiv) in toluene (0.4 mL) and 
electrophile (0.2 mmol, 1 equiv) in toluene (0.4 mL) at 10 °C were prepared and then 
added to the catalyst mixture at 10 °C. The vial was sealed with a PTFE-lined septum cap 
and stirred at 10 °C. After 48 h, the vial was removed from the glovebox. The crude 
reaction mixture was filtered through a silica plug with Et2O, concentrated under vacuum, 






Ni(COD)2 (10 mol %)
L4 (12 mol %)
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1.7.2.3 Additional Optimization Results 
Table 1.5 Results from additional ligands a	
 
 
[a] Reactions performed on 0.02 mmol scale using 3CS high-throughput setup. [b] Determined by chiral SFC analysis. 








Ni(COD)2 (10 mol %)
Ligand (12 mol %)
















































































L5: Ar = 3,5-t-Bu2C6H3
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L21: R = Me
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Table 1.6 Solvent effects in nickel-catalyzed AA of 1aa 
 
















Ni(COD)2 (10 mol %)
Ligand (12 mol %)
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Table 1.7 Optimization of reaction parameters for lactam 4a a	
 
[a] Reactions performed on 0.1 mmol scale.  [b] Yields determined by 1H NMR of crude reaction mixture using 1,3,5-


































Ni(COD)2 (10 mol %)
ligand (12 mol %)














5 70 88L4Bz PhMe:Et2O (2:3)
9 38 52L4Boc PhMe:MTBE (2:3)
10 0 –L4Ts PhMe:MTBE (2:3)
11 ND[f] 31L4Me PhMe:MTBE (2:3)
12 21 53L4Ph PhMe:MTBE (2:3)
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1.7.2.4 Spectroscopic Data for the Alkylation Products 
 
Ethyl (R)-3-allyl-2-oxotetrahydro-2H-pyran-3-carboxylate (3aa): Product 3aa was 
prepared using general procedure 3 at –10 °C and purified by column chromatography 
(15% EtOAc in hexanes) to provide a colorless oil (31.8 mg, 75% yield); 86% ee, [a]D25 
+3.84 (c 0.99, CHCl3); 1H NMR (400 MHz, CDCl3) δ 5.84–5.69 (m, 1H), 5.19–5.08 (m, 
2H), 4.34–4.23 (m, 2H), 4.21 (q, J = 7.1 Hz, 2H), 2.73 (ddt, J = 13.8, 6.8, 1.2 Hz, 1H), 
2.59 (ddt, J = 13.9, 7.9, 1.0 Hz, 1H), 2.38–2.25 (m, 1H), 2.05–1.88 (m, 1H), 1.92–1.79 
(m, 2H), 1.27 (t, J = 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 171.2, 170.0, 132.6, 
119.9, 69.0, 62.2, 54.0, 40.8, 28.0, 20.6, 14.2; IR (Neat Film, NaCl) 2981, 1732, 1457, 
1399, 1367, 1348, 1244, 1200, 1162, 1108, 1026, 974, 925, 857, 640 cm–1; HRMS (MM) 
m/z calc’d for C11H17O4 [M+H]+: 213.1121, found 213.1120; SFC Conditions: 25% IPA, 
2.5 mL/min, Chiralpak IC column, λ = 210 nm, tR (min): major = 2.77, minor = 3.39. 
 
Methyl (R)-3-allyl-2-oxotetrahydro-2H-pyran-3-carboxylate (3ba): Product 3ba was 
prepared using general procedure 3 at –10 °C and purified by column chromatography 
(30% EtOAc in hexanes) to provide a colorless oil (25.5 mg, 64% yield); 86% ee, [a]D25 
+ 5.071 (c 0.896, CHCl3); 1H NMR (400 MHz, CDCl3) δ 5.85–5.66 (m, 1H), 5.20–5.10 
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J = 13.8, 7.8, 1.0 Hz, 1H), 2.39–2.26 (m, 1H), 2.03–1.77 (m, 3H); 13C NMR (100 MHz, 
CDCl3) δ 171.8, 169.9, 132.5, 120.1, 69.2, 54.1, 53.2, 40.9, 28.1, 20.6; IR (Neat Film, 
NaCl) 3079, 2955, 2920, 1733, 1640, 1480, 1436, 1401, 1349, 1321, 1277, 1247, 1204, 
1164, 1122, 1108, 1076, 1000, 978, 126, 844, 716, 659, 640; HRMS (MM) m/z calc’d for 
C10H15O4 [M+H]+: 199.0965, found 199.0970; SFC Conditions 20% IPA, 2.5 mL/min, 
Chiralpak IC column λ = 210 nm, tR (min): major = 3.35, minor = 3.99. 
 
Ethyl (S)-3-allyl-2-oxochromane-3-carboxylate (3ca): Product 3ca was prepared using 
general procedure 3 at –10 °C and purified by column chromatography (5% EtOAc in 
hexanes) to provide a colorless oil (31.9 mg, 61% yield); 64% ee, [a]D25 –30.75 (c 0.92, 
CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.33–7.13 (m, 2H), 7.13–7.00 (m, 2H), 5.91 (ddt, 
J = 16.6, 10.6, 7.3 Hz, 1H), 5.23–5.12 (m, 2H), 4.05 (qq, J = 10.8, 7.1 Hz, 2H), 3.26 (d, 
15.9 Hz, 1 H), 3.04 (d, J = 15.9 Hz, 1H), 2.84–2.67 (m, 2H), 1.02 (t, J = 7.1 Hz, 3H); 13C 
NMR (100 MHz, CDCl3) δ 169.5, 167.2, 151.2, 132.1, 128.7, 128.5, 124.8, 121.4, 120.4, 
116.5, 62.2, 53.3, 38.6, 32.5, 14.0; IR (Neat Film, NaCl) 3079, 2982, 2936, 1774, 1738, 
1653, 1640, 1590, 1541, 1490, 1460, 1344, 1232, 1190, 1145, 1096, 1020, 921, 858, 759, 
658; HRMS (MM) m/z calc’d for C15H17O4 [M+H]+: 261.1121, found 261.1123; SFC 
Conditions: 15% IPA, 2.5 mL/min, Chiralcel OB-H column, λ = 210 nm, tR (min): minor 
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Ethyl (R)-3-cinnamyl-2-oxotetrahydro-2H-pyran-3-carboxylate (3ab): Product 3ab 
was prepared using general procedure 3 and purified by column chromatography (15% 
EtOAc in hexanes) to provide a colorless oil (34.4 mg, 60% yield); 90% ee, [a]D25 –12.15 
(c 0.64, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.38–7.25 (m, 4H), 7.27–7.17 (m, 1H), 
6.47 (dt, J = 16.0, 1.4 Hz, 1H), 6.19 (ddd, J = 15.8, 8.0, 7.0 Hz, 1H), 4.35–4.17 (m, 4H), 
2.91 (ddd, J = 13.8, 7.0, 1.4 Hz, 1H), 2.74 (ddd, J = 13.8, 8.0, 1.2 Hz, 1H), 2.45–2.31 (m, 
1H), 2.11–1.77 (m, 3H), 1.27 (t, J = 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 171.2, 
170.1, 136.9, 134.8, 128.7, 127.7, 126.4, 124.1, 69.1, 62.3, 54.4, 40.1, 28.1, 20.6, 14.2; 
IR (Neat Film, NaCl) 2980, 2342, 1955, 1733, 1577, 1449, 1399, 1367, 1243, 1198, 
1164, 1026, 971, 910, 858, 746, 695, 642, cm–1; HRMS (MM) m/z calc’d for C17H21O4 
[M+H]+: 289.1430, found 289.1434; SFC Conditions: 10% IPA, 2.5 mL/min, Chiralpak 
AD-H column, λ = 254 nm, tR (min): major = 5.43, minor = 6.24. 
 
Ethyl (R,E)-2-oxo-3-(3-(p-tolyl)allyl)tetrahydro-2H-pyran-3-carboxylate (3ac): 
Product 3ac was prepared using general procedure 3 and purified by column 
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62% yield); 90% ee, [a]D25 –14.42 (c 0.95, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.24 
(d, J = 8.1 Hz, 2H), 7.15–6.98 (m, 2H), 6.51–6.33 (m, 1H), 6.13 (ddd, J = 15.8, 8.1, 7.0 
Hz, 1H), 4.31–4.26 (m, 2H), 4.23 (q, J = 7.1 Hz, 2H), 2.90 (ddd, J = 13.8, 7.0, 1.4 Hz, 
1H), 2.72 (ddd, J = 13.8, 8.1, 1.2 Hz, 1H), 2.41–2.25 (m, 4H), 2.02–1.78 (m, 3H), 1.27 (t, 
J = 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 171.3, 170.1, 137.5, 134.7, 134.2, 129.3, 
126.3, 123.0, 69.1, 62.3, 54.4, 40.2, 28.1, 21.3, 20.6, 14.2; IR (Neat Film, NaCl) 2978, 
1731, 1513, 1456, 1399, 1367, 1269, 1242, 1197, 1163, 1096, 1025, 972, 859, 803, 642  
cm–1; HRMS (MM) m/z calc’d for C18H23O4 [M+H]+: 303.1591, found 303.1591; SFC 
Conditions: 10% IPA, 2.5 mL/min, Chiralpak AD-H column, λ = 254 nm, tR (min): major 
6.47, minor = 7.71. 
 
Ethyl (R,E)-3-(3-(4-methoxyphenyl)allyl)-2-oxotetrahydro-2H-pyran-3-carboxylate 
(3ad): Product 3ad was prepared using general procedure 3 and purified by column 
chromatography (15% EtOAc in hexanes) to provide a colorless oil (50.5 mg, 79% 
yield); 88% ee, [a]D25 –15.9 (c 0.95, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.32–7.24 
(m, 2H), 6.89–6.79 (m, 2H), 6.41 (d, 15.8 Hz, 1H), 6.03 (ddd, J = 15.7, 8.0, 7.0 Hz, 1H), 
4.29 (t, J = 5.9 Hz, 2H), 4.22 (q, J = 7.2 Hz, 2H), 3.79 (s, 3H), 2.89 (ddd, J = 13.8, 7.0, 
1.4 Hz, 1H), 2.71 (ddd, J = 13.7, 8.1, 1.2 Hz, 1H), 2.43–2.29 (m, 1H), 2.05–1.87 (m, 2H), 
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159.2, 134.2, 129.8, 127.5, 121.7, 114.0, 69.1, 62.2, 55.4, 54.5, 40.1, 28.1, 20.6, 14.2; IR 
(Neat Film, NaCl) 2978, 2837, 1732, 1608, 1577, 1512, 1457, 1400, 1349, 1367, 1249, 
1198, 1108, 1032, 972, 840, 757, 667, 640 HRMS (MM) m/z calc’d for C18H25O6 
[M+H3O]+: 319.1840, found 319.1525; SFC Conditions: 15% IPA, 2.5 mL/min, 
Chiralpak AD-H column, λ = 254 nm, tR (min): major = 5.37, minor = 6.37. 
 
Ethyl (R,E)-3-(3-(4-fluorophenyl)allyl)-2-oxotetrahydro-2H-pyran-3-carboxylate 
(3ae): Product 3ae was prepared using general procedure 3 and purified by column 
chromatography (15% EtOAc in hexanes) to provide a colorless oil (38.2 mg, 62% 
yield); 88% ee, [a]D25 –10.19 (c 0.86, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.34 – 7.27 
(m, 2H), 7.05 – 6.90 (m, 2H), 6.53–6.34 (m, 1H), 6.20–6.02 (m, 1H), 4.29 (t, J = 5.6 Hz, 
2H), 4.22 (q, J = 7.1 Hz, 2H), 2.87 (ddd, J = 13.9, 7.1, 1.4 Hz, 1H), 2.72 (ddd, J = 13.8, 
7.9, 1.2 Hz, 1H), 2.47–2.31 (m, 1H), 2.07 – 1.78 (m, 3H), 1.26 (t, J = 7.1 Hz, 3H); 13C 
NMR (100 MHz, CDCl3) δ 171.2, 170.1, 162.4 (d, J = 246.8 Hz), 133.5, 133.1 (d, J = 3.3 
Hz), 127.9 (d, J = 8.0 Hz), 123.9 (d, J = 2.2 Hz), 115.5 (d, J = 21.7 Hz), 69.0, 62.3, 54.4, 
40.1, 28.2, 20.6, 14.2; 19F NMR (282 MHz, CDCl3) δ -114.56 (tt, J = 8.6, 5.3 Hz); IR 
(Neat Film, NaCl) 2981, 2342, 1733, 1602, 1508, 1456, 1400, 1368, 1349, 1298, 1269, 
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calc’d for C17H20FO4 [M+H]+: 307.1340 found 307.1343; SFC Conditions: 10% IPA, 2.5 
mL/min, Chiralpak AD-H column, λ = 254 nm, tR (min): major = 5.12, minor = 5.95. 
 
Ethyl (R,E)-3-(3-(4-chlorophenyl)allyl)-2-oxotetrahydro-2H-pyran-3-carboxylate 
(3af): Product 3af was prepared using general procedure 3 and purified by column 
chromatography (15% EtOAc in hexanes) to provide a colorless oil (39.5 mg, 61% 
yield); 87% ee, [a]D25 –10.81 (c 0.83, CHCl3);	1H NMR (400 MHz, CDCl3) δ 7.26 (s, 
4H), 6.42 (dt, J = 15.7, 1.3 Hz, 1H), 6.18 (ddd, J = 15.9, 7.9, 7.1 Hz, 1H), 4.29 (t, J = 5.7 
Hz, 2H), 4.22 (q, J = 7.1 Hz, 2H), 2.87 (ddd, J = 13.9, 7.1, 1.4 Hz, 1H), 2.74 (ddd, J = 
13.8, 7.9, 1.2 Hz, 1H), 2.46–2.32 (m, 1H), 2.15–1.80 (m, 3H), 1.26 (t, J = 7.1 Hz, 3H); 
13C NMR (100 MHz, CDCl3) δ 171.1, 170.1, 135.4, 133.5, 133.2, 128.8, 127.6, 124.9, 
69.0, 62.3, 54.4, 40.1, 28.2, 20.6, 14.2; IR (Neat Film, NaCl) 2979, 2358, 1729, 1490, 
1455, 1404, 1243, 1197, 1164, 1092, 971, 820, 760, 679 cm–1; HRMS (MM) m/z calc’d 
for C17H20ClO4 [(M+H]+: 323.1045, found 323.1041; SFC Conditions: 30% IPA, 2.5 
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carboxylate (3ag): Product 3ag was prepared using general procedure 3 and purified by 
column chromatography (15% EtOAc in hexanes) to provide a colorless oil (31.2 mg, 
44% yield); 86% ee, [a]D25 –6.52 (c 0.98, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.60–
7.47 (m, 2H), 7.47–7.38 (m, 2H), 6.50 (d, J = 15.8 Hz, 1H), 6.32 (dt, J = 15.8, 7.5 Hz, 
1H), 4.30 (dd, J = 6.3, 5.2 Hz, 2H), 4.23 (q, J = 7.1 Hz, 2H), 2.90 (ddd, J = 13.8, 7.1, 1.3 
Hz, 1H), 2.77 (ddd, J = 13.8, 7.7, 1.2 Hz, 1H), 2.47–2.34 (m, 1H), 2.05–1.81 (m, 3H), 
1.26 (t, J = 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 171.1, 170.0, 140.4 (d, J = 1.6 
Hz), 133.4, 129.4 (q, J = 32.4 Hz), 127.2, 126.5, 125.6 (q, J = 3.7 Hz), 122.9, 69.0, 62.4, 
54.4, 40.1, 28.3, 20.6, 14.2; 19F NMR (282 MHz, CDCl3) δ –62.52 (s); IR (Neat Film, 
NaCl) 2982, 1733, 1684, 1616, 1540, 1414, 1326, 1244, 1198, 1163, 1120, 1068, 1016, 
972, 862, 833, 652; HRMS (MM) m/z calc’d for C18H20F3O4 [M+H]+: 357.1308, found 
357.1307; SFC Conditions: 10% IPA, 2.5 mL/min, Chiralpak AD-H column, λ = 254 nm, 
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late (3ah): Product 3ah was prepared using general procedure 3 an purified by column 
chromatography (15% EtOAc in hexanes) to provide a colorless oil (41.0 mg, 65% 
yield); 88% ee, [a]D25 –13.58 (c 0.84, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.00–6.94 
(m, 2H), 6.87 (dt, J = 1.9, 1.0 Hz, 1H), 6.46–6.36 (m, 1H), 6.15 (ddd, J = 15.7, 8.2, 6.8 
Hz, 1H), 4.32–4.27 (m, 2H), 4.27–4.20 (m, 2H), 2.91 (ddd, J = 13.8, 6.8, 1.4 Hz, 1H), 
2.71 (ddd, J = 13.7, 8.2, 1.2 Hz, 1H), 2.43–2.26 (m, 7H), 2.04–1.87 (m, 2H), 1.92–1.79 
(m, 1H), 1.28 (t, J = 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 171.3, 170.2, 138.1, 
136.8, 135.0, 129.4, 124.3, 123.6, 69.1, 62.3, 54.4, 40.2, 28.1, 21.3, 20.6, 14.2; IR (Neat 
Film, NaCl) 2978, 2917, 1731, 1602, 1456, 1398, 1367, 1350, 1242, 1198, 1163, 1096, 
1026, 972, 853, 759, 693, 638 cm–1; HRMS (MM) m/z calc’d for C19H25O4 [M+H]+: 
317.1747, found 317.1749; SFC Conditions: 5% IPA, 2.5 mL/min, Chiralpak AD-H 
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(3ai): Product 3ai was prepared using general procedure 3 and purified by column 
chromatography (15% EtOAc in hexanes) to provide a colorless oil (42.1 mg, 62% 
yield); 88% ee, [a]D25 +27.34 (c 0.82, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.84–7.73 
(m, 3H), 7.72–7.67 (m, 1H), 7.57 (dd, J = 8.5, 1.8 Hz, 1H), 7.52–7.38 (m, 2H), 6.68–6.59 
(m, 1H), 6.34 (ddd, J = 15.8, 8.0, 7.0 Hz, 1H), 4.30 (t, J = 5.8 Hz, 2H), 4.24 (q, J = 7.1 
Hz, 2H), 2.96 (ddd, J = 13.7, 7.0, 1.4 Hz, 1H), 2.81 (ddd, J = 13.7, 8.0, 1.2 Hz, 1H), 
2.48–2.34 (m, 1H), 2.03–1.81 (m, 3H), 1.28 (t, J = 7.1 Hz, 3H); 13C NMR (100 MHz, 
CDCl3) δ 171.2, 170.1, 134.8, 134.3, 133.6, 133.0, 128.2, 128.0, 127.7, 126.3, 126.1, 
125.9, 124.5, 123.6, 69.0, 62.3, 54.4, 40.2, 28.1, 20.6, 14.13; IR (Neat Film, NaCl) 2980, 
1732, 1597, 1507, 1456, 1399, 1367, 1243, 1198, 1097, 1023, 971, 896, 861, 815, 751, 
667, 639, 624; HRMS (MM) m/z calc’d for C21H23O4 [M+H]+: 339.1591, found 
339.1595; SFC Conditions 30% IPA, 2.5 mL/min, Chiralpak AD-H column λ = 254 nm, 
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(3aj): Product 3aj was prepared using general procedure 3 and purified by column 
chromatography (15% EtOAc in hexanes) to provide a colorless oil (32.4 mg, 51% 
yield); 90% ee, [a]D25 –11.96 (c 0.87, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.40 (dd, J 
= 7.7, 1.7 Hz, 1H), 7.21 (ddd, J = 8.2, 7.4, 1.7 Hz, 1H), 6.90 (td, J = 7.6, 1.1 Hz, 1H), 
6.88–6.75 (m, 2H), 6.16 (ddd, J = 15.9, 8.2, 6.9 Hz, 1H), 4.29 (dd, J = 6.2, 5.5 Hz, 2H), 
4.23 (q, J = 7.1 Hz, 2H), 3.83 (s, 3H), 2.92 (ddd, J = 13.8, 6.8, 1.5 Hz, 1H), 2.77 (ddd, J = 
13.7, 8.2, 1.2 Hz, 1H), 2.44–2.29 (m, 1H), 2.03–1.81 (m, 3H), 1.28 (t, J = 7.1 Hz, 3H); 
13C NMR (100 MHz, CDCl3) δ 171.3, 170.2, 156.5, 129.5, 128.7, 126.8, 126.0, 124.5, 
120.7, 110.9, 69.2, 62.2, 55.5, 54.4, 40.6, 28.1, 20.7, 14.2; IR (Neat Film, NaCl) 2978, 
2838, 1732, 1598, 1489, 1464, 1399, 1244, 1198, 1163, 1104, 1051, 1027, 976, 858, 755, 
641; HRMS (MM) m/z calc’d for C18H23O5 [M+H]+: 319.1540, found 319.1542; SFC 
Conditions 10% IPA, 2.5 mL/min, Chiralcel OD-H column λ = 254 nm, tR (min): major = 
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Ethyl (R,E)-3-(3-(furan-2-yl)allyl)-2-oxotetrahydro-2H-pyran-3-carboxylate (3ak): 
Product 3ak was prepared using general procedure 3 and purified by column 
chromatography (15% EtOAc in hexanes) to provide a colorless oil (45.5 mg, 82% 
yield); 88% ee, [a]D25 –11.85 (c 0.99, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.32–7.27 
(m, 1H), 6.37–6.23 (m, 2H), 6.17 (d, J = 3.2 Hz, 1H), 6.14–6.01 (m, 1H), 4.29 (dd, J = 
6.3, 5.5 Hz, 2H), 4.22 (q, J = 7.1 Hz, 2H), 2.86 (ddd, J = 13.9, 7.2, 1.3 Hz, 1H), 2.70 
(ddd, J = 13.9, 8.0, 1.2 Hz, 1H), 2.40–2.29 (m, 1H), 2.05–1.91 (m, 1H), 1.96–1.78 (m, 
2H), 1.26 (t, J = 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 171.2, 170.0, 152.4, 141.9, 
123.2, 122.7, 111.3, 107.6, 69.1, 62.3, 54.4, 39.8, 28.1, 20.6, 14.1; IR (Neat Film, NaCl) 
2980, 1732, 1456, 1399, 1244, 1200, 1166, 1097, 1017, 969, 926, 858, 749, 640 ; HRMS 
(MM) m/z calc’d for C15H19O5 [M+H]+: 343.1329, found 343.1327; SFC Conditions 10% 










Chapter 1 – Nickel-Catalyzed Enantioselective Allylic Alkylation of Lactones and Lactams with 





(3al): Product 3al was prepared using general procedure 3 and purified by column 
chromatography (15% EtOAc in hexanes) to provide a colorless oil (39.9 mg, 68% 
yield); 88% ee, [a]D25 –15.7 (c 0.98, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.12 (dt, J = 
4.9, 1.0 Hz, 1H), 6.97–6.87 (m, 2H), 6.59 (dtt, J = 15.7, 1.4, 0.6 Hz, 1H), 6.00 (ddd, J = 
15.4, 8.0, 7.2 Hz, 1H), 4.29 (t, J = 5.9 Hz, 2H), 4.22 (q, J = 7.1 Hz, 2H), 2.86 (ddd, J = 
13.9, 7.2, 1.4 Hz, 1H), 2.70 (ddd, J = 13.8, 8.0, 1.2 Hz, 1H), 2.42–2.29 (m, 1H), 2.06–
1.80 (m, 3H), 1.27 (t, J = 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 171.2, 170.0, 
142.0, 127.9, 127.4, 125.5, 124.2, 123.7, 69.1, 62.3, 54.4, 40.0, 28.2, 20.6, 14.2; IR (Neat 
Film, NaCl) 3107, 2980, 1731, 1446, 1367, 1348, 1244, 1199, 1165, 1096, 1024, 965, 
855, 750, 704, 643; HRMS (MM) m/z calc’d for C15H19O4S [M+H]+: 295.0999, found 
295.0994; SFC Conditions 10% IPA, 2.5 mL/min, Chiralpak AD-H column λ = 254 nm, 
tR (min): major = 9.05, minor = 9.85. 
 
Ethyl (R,E)-3-(but-2-en-1-yl)-2-oxotetrahydro-2H-pyran-3-carboxylate (3am): 
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chromatography (15% EtOAc in hexanes) to provide a colorless oil (25.6 mg, 57% 
yield); 78% ee, [a]D25 –0.22 (c 1.13, CHCl3); 1H NMR (400 MHz, CDCl3) δ 5.55 (dqt, J 
= 15.0, 6.2, 1.1 Hz, 1H), 5.47–5.30 (m, 1H), 4.27 (t, J = 5.7 Hz, 2H), 4.20 (q, J = 7.1 Hz, 
2H), 2.72–2.61 (m, 1H), 2.51 (ddt, J = 13.8, 7.7, 1.1 Hz, 1H), 2.35–2.26 (m, 1H), 2.02–
1.90 (m, 1H), 1.90–1.78 (m, 2H), 1.65 (dq, J = 6.5, 1.2 Hz, 3H), 1.26 (t, J = 7.1 Hz, 3H); 
13C NMR (100 MHz, CDCl3) δ 171.4, 170.2, 130.7, 124.9, 69.0, 62.1, 54.3, 39.7, 27.9, 
20.6, 18.1, 14.2; IR (Neat Film, NaCl) 2965, 2938, 1730, 1447, 1400, 1272, 1223, 1198, 
1163, 1107, 1077, 973, 856; HRMS (MM) m/z calc’d for C12H19O4 [M+H]+: 227.1278, 
found 227.1275; SFC Conditions 25% IPA, 2.5 mL/min, Chiralpak IC column λ = 210 
nm, tR (min): major = 2.87, minor = 3.69. 
 
Ethyl (R)-2-oxo-3-((2E,4E)-5-phenylpenta-2,4-dien-1-yl)tetrahydro-2H-pyran-3-
carboxylate (3an): Product 3an was prepared using general procedure 3 and purified by 
column chromatography (15% EtOAc in hexanes) to provide a colorless oil (57.3 mg, 
91% yield); 88% ee, [a]D25 –22.45 (c 0.96, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.39–
7.35 (m, 2H), 7.30 (ddd, J = 7.7, 6.8, 1.2 Hz, 2H), 7.24–7.17 (m, 1H), 6.74 (ddd, J = 15.7, 
10.4, 0.8 Hz, 1H), 6.49 (d, J = 15.7 Hz, 1H), 6.28 (ddq, J = 15.4, 10.5, 1.1 Hz, 1H), 5.83–
5.69 (m, 1H), 4.29 (t, J = 5.8 Hz, 2H), 4.23 (q, J = 7.1 Hz, 2H), 2.84 (ddd, J = 13.9, 7.2, 
1.3 Hz, 1H), 2.68 (ddd, J = 13.8, 8.1, 1.1 Hz, 1H), 2.41–2.26 (m, 1H), 2.03–1.80 (m, 3H), 
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132.1, 128.7, 128.5, 128.3, 127.6, 126.4, 69.0, 62.3, 54.4, 39.9, 28.1, 20.6, 14.2; IR (Neat 
Film, NaCl) 3058, 3024, 2980, 1732, 1490, 1478, 1448, 1400, 1367, 1347, 1241, 1198, 
1097, 1025, 994, 910, 857, 750, 694, 667, 640; HRMS (MM) m/z calc’d for C19H23O4 
[M+H]+: 315.1585, found 315.1585; SFC Conditions 15% IPA, 2.5 mL/min, Chiralpak 
AD-H column λ = 254 nm, tR (min): major = 5.30, minor = 6.23. 
 
Ethyl (S)-3-allyl-1-benzoyl-2-oxopiperidine-3-carboxylate (5aa): Product 5aa was 
prepared using general procedure 4 and purified by column chromatography (15% EtOAc 
in hexanes) to provide a colorless oil (45.9 mg, 73% yield); 90% ee, [a]D25 +42.42 (c 
0.968, CHCl3); 1H NMR (400 MHz, CDCl3) δ 1H NMR (400 MHz, CDCl3) δ 7.84–7.70 
(m, 2H), 7.54–7.44 (m, 1H), 7.44–7.34 (m, 2H), 5.80–5.62 (m, 1H), 5.17–5.03 (m, 2H), 
4.30 (q, J = 7.2 Hz, 2H), 3.84–3.71 (m, 2H), 2.72 (ddt, J = 13.8, 6.8, 1.2 Hz, 1H), 2.56 
(ddt, J = 13.8, 7.9, 1.0 Hz, 1H), 2.43–2.25 (m, 1H), 2.04–1.83 (m, 3H), 1.36 (t, J = 7.1 
Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 175.1, 171.9, 171.8, 135.9, 133.0, 131.8, 128.2, 
128.1, 119.7, 62.1, 56.4, 46.6, 40.0, 30.3, 20.3, 14.3; IR (Neat Film, NaCl) 3074, 2936, 
2341, 1734, 1700, 1684, 1450, 1388, 1278, 1147, 1177, 1050, 1027, 919, 824, 726, 694, 
668 cm–1; HRMS (MM) m/z calc’d for C18H22NO4 [M+H]+: 316.1543, found 316.1543; 
SFC Conditions: 20% IPA, 2.5 mL/min, Chiralpak IC column, λ = 254 nm, tR (min): 
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Methyl (S)-3-allyl-1-benzoyl-2-oxopiperidine-3-carboxylate (5ba): Product 5ba was 
prepared using general procedure 4 and purified by column chromatography (20% EtOAc 
in hexanes) to provide a colorless oil (51.0 mg, 85% yield); 90% ee, [a]D25 –+48.58 (c 
0.890, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.77–7.59 (m, 2H), 7.55–7.44 (m, 1H), 
7.40 (ddt, J = 8.3, 6.6, 1.2 Hz, 2H), 5.84–5.63 (m, 1H), 5.20–5.02 (m, 2H), 3.83 (s, 3H), 
3.77 (dd, J = 6.7, 5.4 Hz, 2H), 2.73 (ddt, J = 13.7, 6.8, 1.2 Hz, 1H), 2.57 (ddt, J = 13.7, 
7.7, 1.1 Hz, 1H), 2.41–2.29 (m, 1H), 2.07–1.85 (m, 3H); 13C NMR (100 MHz, CDCl3) δ 
175.1, 172.4, 171.8, 135.9, 133.0, 131.8, 128.2, 128.1, 119.8, 56.5, 52.9, 46.6, 39.9, 30.3, 
20.2; IR (Neat Film, NaCl) 3075, 2953, 1738, 1702, 1683, 1640, 1583, 1478, 1449, 1436, 
1349, 1277, 1252, 1177, 1147, 1078, 1052, 1027, 1001, 844, 819, 796, 726, 695, 651; 
HRMS (MM) m/z calc’d for C17H20NO4 [M+H]+: 302.1387, found 302.1377; SFC 
Conditions 10% IPA, 2.5 mL/min, Chiralpak AD-H column λ = 254 nm, tR (min): minor 
= 4.00, major = 4.57.  
 
Ethyl (S)-1-benzoyl-3-cinnamyl-2-oxopiperidine-3-carboxylate (5ab): Product 5ab 
was prepared using general procedure 4 at 30 °C and purified by column chromatography 
(20% to 40% Et2O in hexanes) to provide a colorless oil (59.0 mg, 75% yield); 91% ee, 
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7.45 (m, 1H), 7.45–7.18 (m, 7H), 6.46 (dt, J = 15.7, 1.3 Hz, 1H), 6.14 (ddd, J = 15.8, 8.0, 
6.9 Hz, 1H), 4.32 (q, J = 7.1 Hz, 2H), 3.86–3.73 (m, 2H), 2.91 (ddd, J = 13.8, 7.0, 1.4 Hz, 
1H), 2.72 (ddd, J = 13.8, 8.0, 1.2 Hz, 1H), 2.49–2.35 (m, 1H), 2.10–1.98 (m, 1H), 2.03–
1.91 (m, 2H), 1.37 (t, J = 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 175.0, 172.0, 
171.9, 137.0, 135.9, 134.6, 131.9, 128.6, 128.2, 128.2, 127.6, 126.4, 124.5, 62.2, 56.9, 
46.6, 39.3, 30.5, 20.3, 14.3; IR (Neat Film, NaCl) 2979, 1728, 1684, 1600, 1578, 1449, 
1390, 1277, 1194, 1172, 1150, 1026, 970, 923, 934, 857, 822, 795, 745, 725, 694, 661 
cm–1; HRMS (MM) m/z calc’d for C24H26NO4 [M+H]+: 392.1856, found 392.1849; SFC 
Conditions: 30% IPA, 2.5 mL/min, Chiralpak AD-H column, λ = 254 nm, tR (min): minor 
= 2.56, major = 2.94. 
1.7.2.5 Experimental Procedures and Characterization Data for Product 
Transformations 
 
Ethyl (S)-2-(hydroxymethyl)-2-(3-hydroxypropyl)pent-4-enoate (6): To a solution of 
allylated product 3aa (42.5 mg, 0.2 mmol, 1 equiv) in 4:1 methanol:THF (1.4 mL), 
CeCl3•7H2O was added (149.0 mg, 0.4 mmol, 2 equiv). After cooling the reaction 
mixture at 0°C for 10 minutes, NaBH4 (37.5 mg, 1.0 mmol, 5 equiv) was added in three 
portions over the course of 20 minutes. Additional methanol (1.5 mL) was added to rinse 
the side of the flask and the reaction mixture was stirred for another 10 minutes. The 
reaction was quenched with glacial acetic acid. The crude mixture was then concentrated 
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NaHCO3 and brine, dried over anhydrous MgSO4, filtered, and purified by column 
chromatography (70% EtOAc/hexanes) to afford diol 6 as a colorless oil (54.1 mg, 88% 
yield). [a]D25 +1.2 (c 0.92, CHCl3); 1H NMR (400 MHz, CDCl3) δ 5.71 (ddt, J = 17.4, 
10.1, 7.4 Hz, 1H), 5.14–4.99 (m, 2H), 4.15 (q, J = 7.1 Hz, 2H), 3.72–3.62 (m, 2H), 3.59 
(td, J = 6.2, 1.6 Hz, 2H), 2.65 (br s, 2H), 2.38 (ddt, J = 14.0, 7.3, 1.2 Hz, 1H), 2.30 (ddt, J 
= 13.9, 7.5, 1.1 Hz, 1H), 1.75–1.58 (m, 2H), 1.58–1.42 (m, 2H), 1.25 (t, J = 7.1 Hz, 3H); 
13C NMR (100 MHz, CDCl3) δ 176.0, 133.4, 118.6, 64.5, 62.9, 60.8, 50.8, 38.0, 29.3, 
27.1, 14.4; IR (Neat Film, NaCl) 2281, 3078, 2940, 1725, 1641, 1465, 1447, 1372, 1329, 
1300, 1219, 1191, 1138, 1112, 1053, 920, 862, 824, 782, 748, 679, 634; HRMS (MM) 
m/z calc’d for C11H21O4 [M+H]+: 217.1434, found 217.1427. 
 
Ethyl (S)-2-allyl-2-(3-hydroxypropyl)-3-oxopent-4-enoate (7): A 0.5 M solution of 
vinylmagnesium bromide in THF (0.3 mmol, 1.5 equiv) was added dropwise to a solution 
of allylated product 3aa (42.5 mg, 0.2 mmol, 1 equiv) in THF (0.7 mL) at –78 °C over 15 
minutes. After 9 hours at –78 °C, the reaction was quenched with NH4Cl. The mixture 
was diluted with EtOAc, washed with brine, and dried over anhydrous Na2SO4. Flash 
column chromatography (50% EtOAc in hexanes) of the crude residue afforded 
compound 7 as a colorless oil (80.0 mg, 67% yield); 86% ee, [a]D25 –9.9 (c 0.798, 
CHCl3); 1H NMR (400 MHz, CDCl3) δ 6.53 (dd, J = 16.9, 10.2 Hz, 1H), 6.39 (dd, J = 
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5.16–5.04 (m, 2H), 4.19 (qd, J = 7.1, 0.7 Hz, 2H), 3.62 (td, J = 6.4, 1.1 Hz, 2H), 2.79–
2.55 (m, 2H), 2.04–1.82 (m, 2H), 1.51–1.30 (m, 3H), 1.23 (t, J = 7.1 Hz, 3H); 13C NMR 
(100 MHz, CDCl3) δ 195.5, 172.1, 132.2, 131.8, 129.5, 119.3, 62.9, 61.7, 61.6, 35.9, 
27.5, 27.0, 14.2; IR (Neat Film, NaCl)340, 3079, 2924, 1732, 1698, 1642, 1612, 1447, 
1402, 1368, 1299, 1262, 1200, 1137, 1096, 1057, 1029, 983, 923, 856,808, 739, 670, 686, 
654; HRMS (MM) m/z calc’d for C13H21O4 [M+H]+: 241.1440, found 241.1443. 
 
(S)-7-oxaspiro[4.5]dec-2-ene-1,6-dione (8): Compound 7 (68.9 mg, 0.29 mmol, 1 equiv) 
in degassed toluene (3.0 mL) was added to a stirred solution of Grubbs’ II catalyst (12.2 
mg, 5 mol%) in toluene (15 mL) at 23 °C. After stirring at 40 °C for 4 hours under argon 
atmosphere, the dark brown solution was filtered through silica plug, flushed with 
acetone, and concentrated under vacuum. The crude residue was then redissolved in 
acetonitrile, 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU) was added (52 uL, 0.35 mmol, 
1.2 equiv), and the reaction mixture was stirred at room temperature. Upon complete 
consumption of the starting material by TLC, the reaction was quenched with NH4Cl, 
extracted with EtOAc, washed with brine, dried over Na2SO4, filtered, and concentrated 
under vacuum. The crude residue was purified by column chromatography (30% acetone 
in hexanes) to provide spirocycle 8 as a colorless oil (25.6 mg, 53% yield). [a]D25 –62.2 
(c 0.75, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.77 (dt, J = 5.6, 2.7 Hz, 1H), 6.14 (dt, J 
= 5.7, 2.2 Hz, 1H), 4.66–4.50 (m, 1H), 4.47–4.40 (m, 1H), 3.39 (dt, J = 18.9, 2.5 Hz, 1H), 
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2H); 13C NMR (100 MHz, CDCl3) δ 206.2, 170.1, 163.8, 131.2, 71.0, 53.9, 44.5, 30.7, 
20.4; IR (Neat Film, NaCl) 3082, 2932, 2871, 1728, 1699, 1592, 1422, 1403, 1343, 1272, 
1217, 1160, 1108, 1080, 963, 816, 763; HRMS (MM) m/z calc’d for C9H11O3 [M+H]+: 
167.0703, found 167.0696. 
 
(S)-(3-allyl-1-benzylpiperidin-3-yl)methanol (9): To a flame-dried microwave vial 
under argon was added lactam 5aa (63 mg, 0.2 mmol) and dry diethyl ether (2.0 mL).  
Lithium aluminum hydride (91 mg, 2.4 mmol) was added slowly. The reaction was 
allowed to stir at room temperature for 10 minutes, after which it was sealed and heated 
to 65°C for 36 h. The reaction was quenched with water and 15% sodium hydroxide  
solution, and extracted with ethyl acetate (5 mL × 4). The combined extracts were dried 
with Na2SO4, filtered, and concentrated under vacuum. The crude residue was purified by 
column chromatography (50% EtOAc in hexanes) to afford alcohol 9 as a colorless oil 
(39.3 mg, 80% yield). [a]D25 +29.4 (c 0.965, CHCl3); 1H NMR (400 MHz, CDCl3) δ 
7.36–7.22 (m, 5H), 5.74 (ddt, J = 16.7, 10.4, 7.6 Hz, 1H), 5.06–4.95 (m, 2H), 3.63 (qd, J 
= 10.6, 1.6 Hz, 2H), 3.52–3.39 (m, 2H), 2.78–2.66 (m, 2H), 2.10–2.00 (m, 3H), 1.91 (d, J 
= 7.5 Hz, 2H), 1.69–1.54 (m, 2H), 1.36–1.19 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 
138.0, 133.9, 129.1, 128.5, 127.3, 117.8, 72.4, 63.5, 62.8, 54.0, 37.2, 33.2, 29.8, 23.0; IR 
(Neat Film, NaCl) 3392, 3065, 3028, 3003, 2932, 2858, 2797, 2759, 1949, 1822, 1730, 
1638, 1586, 1603, 1586, 1553, 1494, 1466, 1453, 1415, 1392, 1370, 1352, 1311, 1300, 
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810, 739, 699, 635, 619; HRMS (MM) m/z calc’d for C16H24NO [M+H]+: 246.1852, 
found 246.1847. 
	  
Ethyl (S)-1-benzoyl-2-oxo-3-(3-oxopropyl)piperidine-3-carboxylate (10): To a flame 
dried vial was added CuCl2·H2O (4.1 mg, 0.024 mmol), PdCl2(PhCN)2 (9.2 mg, 0.024 
mmol), AgNO2(1.9 mg, 0.012 mmol), t-BuOH (3.75 mL), and nitromethane (0.25 mL). 
The solution was sparged with O2 for 15 minutes, and then neat lactam 5aa (63.1 mg, 0.2 
mmol) was added. The solution was then sparged for another 3 minutes and allowed to 
stir for 14 hours under an oxygen atmosphere. Upon reaction completion by TLC, water 
(4 mL) was added and the aqueous layer was extracted with DCM (4 mL × 3). The 
combined organic layers were dried with Na2SO4, filtered, and concentrated under 
reduced pressure. The product was purified by column chromatography (50% EtOAc in 
hexanes) to yield 75% of product 5aa. [a]D25 +3.2 (c 0.685, CHCl3); 1H NMR (400 MHz, 
CDCl3) δ 9.69 (t, J = 1.1 Hz, 1H), 7.78–7.69 (m, 2H), 7.52–7.44 (m, 1H), 7.44–7.35 (m, 
2H), 4.38–4.24 (m, 2H), 3.89–3.70 (m, 2H), 2.73–2.59 (m, 1H), 2.55–2.38 (m, 2H), 2.23–
2.13 (m, 2H), 2.06–1.91 (m, 2H), 1.82 (ddd, J = 13.6, 9.9, 5.4 Hz, 1H), 1.37 (t, J = 7.1 
Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 200.9, 175.0, 172.1, 171.9, 135.8, 132.0, 128.2, 
128.2, 62.4, 55.8, 46.6, 39.9, 31.5, 27.8, 20.2, 14.3; IR (Neat Film, NaCl) 2924, 2853, 
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959, 916, 856, 824, 796, 726, 695, 659; HRMS (MM) m/z calc’d for C18H22NO5 [M+H]+: 
332.1492, found 332.1483. 
 
Ethyl (S)-3-allyl-2-oxopiperidine-3-carboxylate (11)35: To a flame dried vial under 
argon was added NaOEt (17.4 mg, 0.26 mmol) and EtOH (1.3 mL). Lactam 5aa (63.1 
mg, 0.20 mmol) was added and the resulting mixture was stirred for 48 h at 65 °C. The 
reaction was quenched with citric acid (154 mg, 0.80 mmol) and the EtOH was removed 
in vacuo. The resulting oil was then diluted with water (2 mL) and extracted with 
chloroform. The combined organic layers were dried with sodium sulfate and the solvent 
was removed in vacuo. The product was purified by column chromatography (80% 
EtOAc in hexanes) to afford amide 8 as a colorless oil (35.6 mg, 84% yield). [a]D25 +36.2 
(c 0.89, CHCl3); 1H NMR (400 MHz, CDCl3) δ 6.40 (s, 1H), 5.76 (dddd, J = 16.8, 10.2, 
8.1, 6.5 Hz, 1H), 5.20–5.05 (m, 2H), 4.29–4.10 (m, 2H), 3.40–3.18 (m, 2H), 2.78 (ddt, J 
= 13.8, 6.5, 1.3 Hz, 1H), 2.66–2.50 (m, 1H), 2.14–2.04 (m, 1H), 1.93–1.68 (m, 3H), 1.26 
(t, J = 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 172.7, 170.8, 133.7, 119.2, 61.6, 53.5, 
42.5, 40.0, 29.4, 19.6, 14.3; IR (Neat Film, NaCl) 3213, 3077, 2978, 2941, 2873, 1732, 
1668, 1490, 1469, 1417, 1392, 1356, 1326, 1314, 1297, 1282, 1241, 1193, 1153, 1116, 
1094, 1026, 1005, 921, 856, 812, 763, 719, 663; HRMS (MM) m/z calc’d for C11H18NO3 
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1.7.3 DETERMINATION OF ENANTIOMERIC EXCESS 




























Chiracel OB-H, λ = 210 nm
5% IPA/CO2, 2.5 mL/min
tR (min) minor 2.23, major 2.64
Chiralpak IC, λ = 210 nm
25% IPA/CO2, 2.5 mL/min
tR (min) major 2.77, minor 3.39
Chiralpak IC, λ = 210 nm
20% IPA/CO2, 2.5 mL/min
tR (min) major 3.35, minor 3.99
3ab
Chiralpak AD-H, λ = 254 nm
10% IPA/CO2, 2.5 mL/min




Chiralpak AD-H, λ = 254 nm
10% IPA/CO2, 2.5 mL/min
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Table 1.8 Determination of enantiomeric excess 
 








Chiralpak AD-H, λ = 254 nm
5% IPA/CO2, 3 mL/min












Chiralpak AD-H, λ = 254 nm
10% IPA/CO2, 2.5 mL/min
tR (min) major 5.12, minor 5.95
Chiralpak AD-H, λ = 254 nm
10% IPA/CO2, 2.5 mL/min
tR (min) major 4.02, minor 4.72
Chiralpak AD-H, λ = 254 nm
15% IPA/CO2, 2.5 mL/min

















Chiralpak AD-H, λ = 254 nm
30% IPA/CO2, 2.5 mL/min
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Chiralpak AD-H, λ = 254 nm
10% IPA/CO2, 2.5 mL/min
tR (min) major 6.33, minor 7.51
Chiralpak AD-H, λ = 254 nm
10% IPA/CO2, 2.5 mL/min


















Chiralpak AD-H, λ = 254 nm
30% IPA/CO2, 2.5 mL/min




Chiralcel OD-H, λ = 254 nm
10% IPA/CO2, 2.5 mL/min
















Chiralpak IC, λ = 210 nm
25% IPA/CO2, 2.5 mL/min
tR (min) major 2.87, minor 3.69
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Chiralpak AD-H, λ = 254 nm
15% IPA/CO2, 2.5 mL/min













Chiralpak IC, λ = 254 nm
20% IPA/CO2, 2.5 mL/min
















90Chiralpak AD-H, λ = 254 nm30% IPA/CO2, 2.5 mL/min
tR (min) minor 2.56, major 2.94
Chiralpak AD-H, λ = 254 nm
10% IPA/CO2, 2.5 mL/min
tR (min) minor 4.00 major 4.57




Chiralpak IC, λ = 210 nm
10% IPA/CO2, 2.5 mL/min
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 Figure A1.3 13C NMR (125 MHz, CDCl3) of compound 4a. 
 
Figure A1.2 Infrared spectrum (Thin Film, NaCl) of compound 4a. 
 










































































































 Figure A1.6 13C NMR (100 MHz, CDCl3) of compound 4b. 
 
Figure A1.5 Infrared spectrum (Thin Film, NaCl) of compound 4b. 
 













































































































Figure A1.9 13C NMR (100 MHz, CDCl3) of Boc-protected lactam. 
 
Figure A1.8 Infrared spectrum (Thin Film, NaCl) of Boc-protected lactam. 
 













































































































 Figure A1.12 13C NMR (100 MHz, CDCl3) of Ts-protected lactam. 
 
Figure A1.11 Infrared spectrum (Thin Film, NaCl) of Ts-protected lactam. 
 













































































































 Figure A1.15 13C NMR (100 MHz, CDCl3) of Ph-protected lactam. 
 
Figure A1.14 Infrared spectrum (Thin Film, NaCl) of Ph-protected lactam. 
 













































































































 Figure A1.18 13C NMR (100 MHz, CDCl3) of compound 3aa. 
 
Figure A1.17 Infrared spectrum (Thin Film, NaCl) of compound 3aa. 
 













































































































 Figure A1.21 13C NMR (100 MHz, CDCl3) of compound 3ba. 
 
Figure A1.20 Infrared spectrum (Thin Film, NaCl) of compound 3ba. 
 











































































































 Figure A1.24 13C NMR (100 MHz, CDCl3) of compound 3ca. 
 
Figure A1.23 Infrared spectrum (Thin Film, NaCl) of compound 3ca. 
 
















































































































 Figure A1.27 13C NMR (100 MHz, CDCl3) of compound 3ab. 
 
Figure A1.26 Infrared spectrum (Thin Film, NaCl) of compound 3ab. 
 













































































































 Figure A1.30 13C NMR (100 MHz, CDCl3) of compound 3ac. 
 
Figure A1.29 Infrared spectrum (Thin Film, NaCl) of compound 3ac. 
 
















































































































 Figure A1.33 13C NMR (100 MHz, CDCl3) of compound 3ad. 
 
Figure A1.32 Infrared spectrum (Thin Film, NaCl) of compound 3ad. 
 













































































































Figure A1.36 13C NMR (100 MHz, CDCl3) of compound 3ae. 
 
Figure A1.35 Infrared spectrum (Thin Film, NaCl) of compound 3ae. 
 







Figure A1.37 19F NMR (282 MHz, CDCl3) of compound 3ae 












































































































Figure A1.40 13C NMR (100 MHz, CDCl3) of compound 3af. 
 
Figure A1.39 Infrared spectrum (Thin Film, NaCl) of compound 3af. 
 













































































































 Figure A1.43 13C NMR (100 MHz, CDCl3) of compound 3ag. 
 
Figure A1.42 Infrared spectrum (Thin Film, NaCl) of compound 3ag. 
 





 Figure A1.44 19F NMR (282 MHz, CDCl3) of compound 3ag. 
 

















































































































Figure A1.47  13C NMR (100 MHz, CDCl3) of compound 3ah. 
 
Figure A1.46 Infrared spectrum (Thin Film, NaCl) of compound 3ah. 
 












































































































Figure A1.50 13C NMR (100 MHz, CDCl3) of compound 3ai. 
 
Figure A1.49 Infrared spectrum (Thin Film, NaCl) of compound 3ai. 
 














































































































Figure A1.53 13C NMR (100 MHz, CDCl3) of compound 3aj. 
 
Figure A1.52 Infrared spectrum (Thin Film, NaCl) of compound 3aj. 
 













































































































 Figure A1.56 13C NMR (100 MHz, CDCl3) of compound 3ak. 
 
Figure A1.55 Infrared spectrum (Thin Film, NaCl) of compound 3ak. 
 













































































































 Figure A1.59 13C NMR (100 MHz, CDCl3) of compound 3al. 
 
Figure A1.58 Infrared spectrum (Thin Film, NaCl) of compound 3al. 
 















































































































 Figure A1.62 13C NMR (100 MHz, CDCl3) of compound 3am. 
 
Figure A1.61 Infrared spectrum (Thin Film, NaCl) of compound 3am. 
 













































































































 Figure A1.65 13C NMR (100 MHz, CDCl3) of compound 3an. 
 
Figure A1.64 Infrared spectrum (Thin Film, NaCl) of compound 3an. 
 











































































































 Figure A1.68 13C NMR (100 MHz, CDCl3) of compound 5aa. 
 
Figure A1.67 Infrared spectrum (Thin Film, NaCl) of compound 5aa. 
 

















































































































 Figure A1.71 13C NMR (100 MHz, CDCl3) of compound 5ba. 
 
Figure A1.70 Infrared spectrum (Thin Film, NaCl) of compound 5ba. 
 













































































































 Figure A1.74 13C NMR (100 MHz, CDCl3) of compound 5ab. 
 
Figure A1.73 Infrared spectrum (Thin Film, NaCl) of compound 5ab. 
 










































































































 Figure A1.77 13C NMR (100 MHz, CDCl3) of compound 6. 
 
Figure A1.76 Infrared spectrum (Thin Film, NaCl) of compound 6. 
 










































































































Figure A1.80 13C NMR (100 MHz, CDCl3) of compound 7. 
 
Figure A1.79 Infrared spectrum (Thin Film, NaCl) of compound 7. 
 








































































































 Figure A1.83 13C NMR (100 MHz, CDCl3) of compound 8. 
 
Figure A1.82 Infrared spectrum (Thin Film, NaCl) of compound 8. 
 








































































































Figure A1.86 13C NMR (100 MHz, CDCl3) of compound 9. 
 
Figure A1.85 Infrared spectrum (Thin Film, NaCl) of compound 9. 
 













































































































 Figure A1.88 13C NMR (100 MHz, CDCl3) of compound 10. 
 
Figure A1.87 Infrared spectrum (Thin Film, NaCl) of compound 10. 
 








































































































Figure A1.92 13C NMR (100 MHz, CDCl3) of compound 11. 
 
Figure A1.91 Infrared spectrum (Thin Film, NaCl) of compound 11. 
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A2.1   GENERAL EXPERIMENTAL 
X-ray crystallographic analysis was obtained from the Caltech X-Ray 
Crystallography Facility using a Bruker D8 Venture Kappa Duo Photon 100 CMOS 
diffractometer. 
 




The alkylation product 3af (87% ee) was recrystallized from chloroform at  
–30 °C to provide crystals suitable for X-ray analysis. 
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Table A2.1 Crystal data and structure refinement for allylic alkylation product 3af. 
 
Identification code  P17471 
Empirical formula  C17 H19 Cl O4 
Formula weight  322.77 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Orthorhombic 
Space group  P212121 
Unit cell dimensions a = 6.9832(6) Å a = 90°. 
 b = 8.5007(7) Å b = 90°. 
 c = 26.483(2) Å g = 90°. 
Volume 1572.1(2) Å3 
Z 4 
Density (calculated) 1.364 Mg/m3 
Absorption coefficient 2.289 mm-1 
F(000) 680 
Crystal size 0.300 x 0.150 x 0.050 mm3 
Theta range for data collection 3.337 to 74.260°. 
Index ranges -8<=h<=8, -10<=k<=10, -32<=l<=32 
Reflections collected 25120 
Independent reflections 3188 [R(int) = 0.0489] 
Completeness to theta = 67.679° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7538 and 0.6272 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3188 / 0 / 200 
Goodness-of-fit on F2 1.060 
Final R indices [I>2sigma(I)] R1 = 0.0260, wR2 = 0.0656 
R indices (all data) R1 = 0.0278, wR2 = 0.0664 
Absolute structure parameter 0.061(4) 
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Extinction coefficient n/a 
Largest diff. peak and hole 0.227 and -0.175 e.Å-3 
 
Table A2.2 Atomic coordinates (x 10
4





) for 3af. U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
___________________________________________________________________  
O(1) 928(2) 7806(2) 4419(1) 23(1) 
C(1) 835(2) 6277(2) 4310(1) 17(1) 
O(2) -713(2) 5637(2) 4313(1) 24(1) 
C(2) 2622(2) 5380(2) 4140(1) 16(1) 
C(3) 4511(2) 6200(2) 4290(1) 19(1) 
C(4) 4363(3) 7952(2) 4186(1) 24(1) 
C(5) 2756(3) 8620(2) 4498(1) 26(1) 
C(6) 2541(2) 3772(2) 4398(1) 17(1) 
O(3) 2596(2) 2523(1) 4186(1) 24(1) 
C(7) 2528(3) 2501(2) 5202(1) 20(1) 
O(4) 2462(2) 3939(1) 4901(1) 19(1) 
C(8) 2567(3) 3008(2) 5747(1) 27(1) 
C(9) 2380(3) 5189(2) 3561(1) 20(1) 
C(10) 4143(3) 4629(2) 3291(1) 21(1) 
C(11) 4812(3) 5296(2) 2874(1) 22(1) 
C(12) 6521(2) 4825(2) 2586(1) 21(1) 
C(13) 7937(3) 3834(3) 2784(1) 27(1) 
C(14) 9558(3) 3457(3) 2508(1) 29(1) 
C(15) 9789(3) 4068(2) 2030(1) 24(1) 
Cl(1) 11856(1) 3606(1) 1692(1) 34(1) 
C(16) 8423(3) 5039(2) 1816(1) 24(1) 
C(17) 6799(3) 5404(2) 2097(1) 24(1) 
_____________________________________________________________________  
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Table A2.3 Bond lengths [Å] and angles [°] for 3af. 
_____________________________________________________  
O(1)-C(1)  1.333(2) 
O(1)-C(5)  1.467(2) 
C(1)-O(2)  1.210(2) 
C(1)-C(2)  1.530(2) 
C(2)-C(6)  1.530(2) 
C(2)-C(3)  1.543(2) 
C(2)-C(9)  1.551(2) 
C(3)-C(4)  1.518(3) 
C(3)-H(3A)  0.9900 
C(3)-H(3B)  0.9900 
C(4)-C(5)  1.505(3) 
C(4)-H(4A)  0.9900 
C(4)-H(4B)  0.9900 
C(5)-H(5A)  0.9900 
C(5)-H(5B)  0.9900 
C(6)-O(3)  1.202(2) 
C(6)-O(4)  1.340(2) 
C(7)-O(4)  1.459(2) 
C(7)-C(8)  1.508(3) 
C(7)-H(7A)  0.9900 
C(7)-H(7B)  0.9900 
C(8)-H(8A)  0.9800 
C(8)-H(8B)  0.9800 
C(8)-H(8C)  0.9800 
C(9)-C(10)  1.502(2) 
C(9)-H(9A)  0.9900 
C(9)-H(9B)  0.9900 
C(10)-C(11)  1.326(3) 
C(10)-H(10)  0.9500 
C(11)-C(12)  1.472(3) 
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C(11)-H(11)  0.9500 
C(12)-C(17)  1.397(3) 
C(12)-C(13)  1.401(3) 
C(13)-C(14)  1.384(3) 
C(13)-H(13)  0.9500 
C(14)-C(15)  1.379(3) 
C(14)-H(14)  0.9500 
C(15)-C(16)  1.382(3) 
C(15)-Cl(1)  1.7431(19) 
C(16)-C(17)  1.392(3) 
C(16)-H(16)  0.9500 

























































































) for 3af. The anisotropic displacement 
factor exponent takes the form:  -2p2 [ h2 a*2U11 + ...  + 2 h k a* b* U12 ]. 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 




O(1) 22(1)  19(1) 28(1)  -3(1) 0(1)  4(1) 
C(1) 16(1)  19(1) 17(1)  2(1) 0(1)  2(1) 
O(2) 15(1)  27(1) 32(1)  4(1) 1(1)  0(1) 
C(2) 13(1)  16(1) 19(1)  -1(1) -1(1)  0(1) 
C(3) 15(1)  21(1) 22(1)  -1(1) -1(1)  -2(1) 
C(4) 25(1)  19(1) 29(1)  2(1) -2(1)  -7(1) 
C(5) 31(1)  16(1) 30(1)  -4(1) -2(1)  -4(1) 
C(6) 11(1)  18(1) 23(1)  0(1) -1(1)  -1(1) 
O(3) 31(1)  16(1) 27(1)  -3(1) 2(1)  -1(1) 
C(7) 17(1)  17(1) 26(1)  6(1) 0(1)  2(1) 
O(4) 22(1)  16(1) 20(1)  2(1) 0(1)  0(1) 
C(8) 28(1)  28(1) 24(1)  6(1) 1(1)  6(1) 
C(9) 17(1)  22(1) 21(1)  0(1) -1(1)  0(1) 
C(10) 20(1)  21(1) 22(1)  -3(1) -1(1)  2(1) 
C(11) 20(1)  22(1) 24(1)  1(1) -2(1)  2(1) 
C(12) 20(1)  22(1) 21(1)  -1(1) -1(1)  -3(1) 
C(13) 24(1)  38(1) 18(1)  4(1) 0(1)  3(1) 
C(14) 24(1)  40(1) 24(1)  2(1) -3(1)  7(1) 
C(15) 21(1)  27(1) 23(1)  -4(1) 1(1)  -3(1) 
Cl(1) 27(1)  48(1) 28(1)  -1(1) 8(1)  5(1) 
C(16) 27(1)  27(1) 19(1)  2(1) 1(1)  -4(1) 




Table A2.5 Hydrogen coordinates (x 10
4




) for 3af. 
________________________________________________________________________________  
 x  y  z  U(eq) 
___________________________________________________________________  
H(3A) 4771 6023 4653 23 
H(3B) 5585 5747 4093 23 
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H(4A) 5583 8477 4274 29 
H(4B) 4108 8133 3822 29 
H(5A) 3106 8551 4859 31 
H(5B) 2594 9746 4413 31 
H(7A) 3689 1884 5119 24 
H(7B) 1387 1843 5134 24 
H(8A) 3645 3726 5802 40 
H(8B) 2714 2082 5964 40 
H(8C) 1367 3547 5830 40 
H(9A) 1329 4433 3497 24 
H(9B) 1991 6214 3417 24 
H(10) 4813 3751 3425 25 
H(11) 4115 6171 2748 26 
H(13) 7782 3413 3113 32 
H(14) 10505 2782 2648 35 
H(16) 8589 5447 1485 29 
H(17) 5851 6067 1953 28 
___________________________________________________________________ 
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Palladium-Catalyzed Enantioselective  
Decarboxylative Allylic Alkylation of Cyclic Siloxyketones† 
 
 
2.1   INTRODUCTION 
Silicon-containing heterocycles are an important class of organic molecules 
often used in the context of temporary functional groups in the synthesis of natural 
products and drug molecules.1 In particular, oxasilacycles or cyclic siloxanes are 
frequently employed in various stages of total syntheses.2 These moieties are 
characterized not only by their high tolerance to a range of reaction conditions, but 




†	 This research was performed in collaboration with Dr. Toshihiko Iwayama and Dr. Michael D. 
Bartberger. Portions of this chapter have been reproduced with permission from Ngamnithiporn, A.; 
Iwayama, T.; Bartberger, M. D.; Stoltz, B. M. Chemical Science. 2020, 11, 11068–11071. ã 2020 Royal 
Society of Chemistry. 
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While a number of non-asymmetric methods have been reported for the 
preparation of cyclic siloxanes, 3  methods to access enantioenriched cyclic 
siloxanes are limited, with a majority of examples requiring the use of 
enantioenriched starting materials.4 To the best of our knowledge, there are only 
two existing reports detailing the enantioselective synthesis of cyclic siloxanes.5 In 
2001, Hoveyda, Schrock and coworkers reported an enantioselective 
desymmetrization of trienes via asymmetric ring-closing metathesis utilizing their 
developed Mo-catalyst (Scheme 2.1a).5a An enantioenriched cyclic siloxane could 
be obtained in 98% yield with excellent enantioselectivity. Jacobsen later disclosed 
a method for asymmetric transannular Diels–Alder reactions (Scheme 2.1b).5b In 
the presence of a chiral oxazaborolidine catalyst, the fused cyclic siloxane was 
obtained with good enantioselectivity. Subsequent oxidative cleavage of this 
siloxane provided a precursor to a number of sesquiterpine natural products. 
Although these two reports showcase unique synthetic strategies to access cyclic 
siloxanes in an enantioselective fashion, the substrate scope in each report only 
contains a single example of a cyclic siloxane. Furthermore, an enantioselective 
method to access cyclic siloxanes bearing all-carbon quaternary stereocenters has 
not been reported to date. 
To this end, we sought to target the synthesis of this useful motif as part of 
our on-going research interest in the development of asymmetric allylic alkylation 
methodologies.6,7 Namely, we envisioned performing an enantioselective 
decarboxylative allylic alkylation of a cyclic siloxy-b-ketoester  to access a 
siloxyketone bearing a quaternary stereocenter (Scheme 2.1c).8 Furthermore, we 
believe that utilization of the silicon functionality in the alkylation products would 
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allow for the synthesis of enantioenriched acyclic quaternary stereocenters, a motif 
that still poses a significant challenge in organic synthesis.9 Herein, we report our 
efforts toward the realization of these goals. 
Scheme 2.1 Enantioselective synthesis of cyclic siloxanes. 
 
 
2.2   SUBSTRATE SYNTHESIS 
 As the synthesis of cyclic siloxy-b-ketoester substrates had not been 
previously reported, we initiated our study by first establishing a synthetic route to 
access the cyclic siloxy-b-ketoester substrates (Scheme 2). Our developed process 
began with intermolecular O-silylation of alcohol 12 with silyl chloride 13, 
affording b-ketoester 14. Cyclization via intramolecular nucleophilic substitution 
and subsequent transesterification with allyl alcohol provided allyl b-ketoester 15 












































to acyclic building blocks
First example of enantioselective synthesis of cyclic siloxanes
bearing an all-carbon quaternary stereocenter
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in 57% yield over 2 steps. Lastly, functionalization of 15 with various electrophiles 
delivered a variety of siloxy-b-ketoester substrates 16.10 
Scheme 2.2 Siloxy-b-ketoester substrate synthesis. 
 
 
2.3   REACTION OPTIMIZATION 
With the substrates in hand, our studies continued with an investigation of 
the palladium-catalyzed decarboxylative allylic alkylation (Table 2.1). We were 
pleased to find that treatment of 16a to commonly employed allylic alkylation 
conditions11 using Pd2(dba)3 and (S)-t-BuPHOX ligand (L41) in toluene proceeded 
smoothly with >95% conversion and provided the desired cyclic siloxane 17a in a 
moderate 75% ee (Table 2.1, entry 1). An examination of additional ligands 
revealed that switching to the more electron-deficient PHOX ligand L28 delivered 
the product in an excellent 91% ee (entry 2), while the use of Trost-type 
bisphosphine ligand L4212 provided 17a in a slightly diminished 89% ee (entry 3). 
Continuing with the optimal ligand L28, a survey of different solvents revealed 
















THF, 0 °C, 1 h
2. allyl alcohol
DMAP, toluene
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4–7), toluene remained the optimal solvent. Finally, by performing the reaction at 
0 °C, the highest ee of 94% was obtained with no loss in reactivity. 
Table 2.1 Optimization of reaction parameters.a 
 
[a] Conditions: 16a (0.1 mmol), Pd2(dba)3 (5 mol %), ligand (12.5 mol %) in solvent (3 mL). [b] Conversion determined by 1H 
NMR of crude reaction mixture using 1,3,5-trimethoxybenzene as a standard. [c] % ee determined by chiral SFC analysis of 
the isolated product. [d] Reaction performed at 0 °C. 
 
2.4   SUBSTRATE SCOPE EXPLORATION 
Having identified the optimal reaction conditions, we next explored the 
substrate scope of this transformation (Table 2.2). With the benzyl group at the a-










BnPd2(dba)3 (5 mol %)
ligand (12.5 mol %)
solvent (0.033 M), 23 °C
20 h















































Chapter 2 – Palladium-Catalyzed Enantioselective 
Decarboxylative Allylic Alkylation of Cyclic Siloxyketones 
  
133 
in 91% yield with 94% ee. An investigation of the electronic nature of this benzyl 
group demonstrated that both electron-withdrawing and electron-donating groups 
(17b–17e) were well tolerated (90–93% ee). A sterically hindered ortho-
substituted benzyl substrate fared well under our optimized reaction conditions, 
providing product 17f in 83% yield with 92% ee. A significant loss of reactivity, 
however, was observed when a methyl-substituted substrate was employed (17g, 
ca. 30% conversion). Pleasingly, we were able to improve the reactivity of this 
substrate by increasing the temperature to 23 °C, delivering product 17g in 79% 
yield with 89% ee. Additionally, cyclic siloxane starting materials bearing ester 
(16h) and Boc-protected alkyl amine (16i) functionalities delivered products 17h 
and 17g in 94% ee and 90% ee, respectively. 
Despite several attempts at procuring x-ray quality crystals for 
determination of the absolute stereochemistry of the products, these efforts proved 
fruitless, presumably due to the non-polar nature and flexibility of these molecules. 
Thus, vibrational circular dichroism (VCD) was utilized for the determination of 
absolute configuration of products 17a and 17g.  Sufficient agreement between the 
computed and measured VCD spectra were achieved such that the absolute 
configurations of 17a and 17g could be assigned with confidence as (R) and (S), 
respectively, as depicted in Table 2.2.13 Additionally, the measured optical rotation 
of 17g was found to be consistent with that computed for the Boltzmann-weighted 
conformational ensemble of the (S) enantiomer. With these configurations 
assigned, the absolute configurations for all other products have been inferred by 
analogy. 
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Table 2.2 Substrate scope.a 
 
[a] Reactions performed on 0.2 mmol scale. [b] Yield of isolated product. [c] %ee determined by chiral SFC 
analysis. [d] Reaction performed at 23 °C. [e] Absolute configuration determined by experimental and computed 
VCD and optical rotation, see text. 
 
2.5   PRODUCT TRANSFORMATIONS 
In order to demonstrate the utility of this transformation, the final stage of 
our study involved the utilization of the silyl fragment as a functional handle to 
access acyclic chiral building blocks (Scheme 2.3). Unfortunately, the direct ring-
opening of cyclic siloxane 17a proved to be challenging as both neutral (TBAF) 
and oxidative (Tamao oxidation) conditions failed to deliver the desired acyclic 
products. However, we were pleased to find that with prior hydoboration/oxidation 
and concomitant ketone reduction, facile ring opening could be achieved. The diol 
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opening was then achieved with TBAF either in the absence or presence of NaBO3 
as an oxidant to deliver triol 19 or tetraol 20 in 77% yield and 51% yield, 
respectively. 
Scheme 2.3 Synthesis of highly oxygenated, chiral, acyclic quaternary stereocenters. 
 
 
We also sought to further demonstrate the utility of these highly oxygenated 
acyclic building blocks by preparing a densely functionalized lactone (22, Scheme 2.4). 
First, selective monobenzylation of triol 19 provided 21 via a stannylene acetal 
intermediate.15 Subsequently, d-lactone 22, bearing vicinal quaternary-trisubstituted 
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Scheme 2.4 Synthesis of lactone bearing vicinal quaternary-trisubstituted stereocenters. 
 
 
2.6  CONCLUSIONS 
In summary, we have developed the first enantioselective synthesis of cyclic 
siloxanes bearing an all-carbon quaternary stereocenter. Through Pd-catalyzed 
decarboxylative allylic alkylation, enantioenriched cyclic siloxanes can be constructed in 
good yield (up to 91% yield) and with high enantiomeric excess (up to 94% ee). The 
reaction conditions exhibit a high tolerance toward a range of functional groups, and the 
alkylation products can be further derivatized to obtain stereochemically rich acyclic 
building blocks. Efforts to further extend the substrate scope of this transformation, as 





























reflux, 18 h (65% yield)
b) BnBr, TBABr
toluene, reflux, 20 h
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2.7  EXPERIMENTAL SECTION 
2.7.1  MATERIALS AND METHODS 
Unless otherwise stated, reactions were performed in flame-dried glassware under 
an argon or nitrogen atmosphere using dry, deoxygenated solvents.  Solvents were dried 
by passage through an activated alumina column under argon. Reaction progress was 
monitored by thin-layer chromatography (TLC) or Agilent 1290 UHPLC-MS.  TLC was 
performed using E. Merck silica gel 60 F254 precoated glass plates (0.25 mm) and 
visualized by UV fluorescence quenching, p-anisaldehyde, or KMnO4 staining.  Silicycle 
SiliaFlash® P60 Academic Silica gel (particle size 40–63 µm) was used for flash 
chromatography. 1H NMR spectra were recorded on Bruker 400 MHz or Varian Mercury 
300 MHz spectrometers and are reported relative to residual CHCl3 (δ 7.26 ppm) or 
CH3OH (δ 3.31 ppm).  13C NMR spectra were recorded on Bruker 400 MHz spectrometer 
(100 MHz) and are reported relative to CHCl3 (δ 77.16 ppm) or CH3OH (δ 49.00 ppm). 
19F NMR spectra were recorded on Varian Mercury 300 MHz spectrometer (282 MHz). 
Data for 1H NMR are reported as follows: chemical shift (δ ppm) (multiplicity, coupling 
constant (Hz), integration).  Multiplicities are reported as follows: s = singlet, d = 
doublet, t = triplet, q = quartet, p = pentet, sept = septuplet, m = multiplet, br s = broad 
singlet, br d = broad doublet, app = apparent.  Data for 13C NMR are reported in terms of 
chemical shifts (δ ppm).  IR spectra were obtained using Perkin Elmer Spectrum BXII 
spectrometer or Nicolet 6700 FTIR spectrometer using thin films deposited on NaCl 
plates and reported in frequency of absorption (cm–1).  Optical rotations were measured 
with a Jasco P-2000 polarimeter operating on the sodium D-line (589 nm), using a 100 
mm path-length cell and are reported as: [a]DT (concentration in 10 mg/1 mL, solvent).  
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Analytical SFC was performed with a Mettler SFC supercritical CO2 analytical 
chromatography system utilizing Chiralpak (AD-H, AS-H or IC) or Chiralcel (OD-H, OJ-
H, or OB-H) columns (4.6 mm x 25 cm) obtained from Daicel Chemical Industries, Ltd. 
Analytical chiral GC was performed with an Agilent 6850 GC utilizing a Chiraldex G-
TA (30 m x 0.25cm) column (1.0 mL/min carrier gas flow). High resolution mass spectra 
(HRMS) were obtained from Agilent 6200 Series TOF with an Agilent G1978A 
Multimode source in electrospray ionization (ESI+), atmospheric pressure chemical 
ionization (APCI+), or mixed ionization mode (MM: ESI-APCI+), or obtained from the 
Caltech mass spectrometry laboratory.  
Reagents were purchased from Sigma-Aldrich, Acros Organics, Strem, or Alfa 
Aesar, and used as received unless otherwise stated. 
 
2.7.2  EXPERIMENTAL PROCEDURES AND SPECTROSCOPIC DATA 
2.7.2.1 Synthesis of allyl b-ketoester starting materials 
 
Ethyl 4-(((iodomethyl)diisopropylsilyl)oxy)-3-oxobutanoate (14): To a solution of 
alcohol 1216 (3.14 g, 21.5 mmol, 1.00 equiv) in THF (72 mL) at 0 °C was added 
chlorosilane 1317 (6.25 g, 21.5 mmol, 1.00 equiv), triethylamine (3.0 mL, 21.5 mmol, 
1.00 equiv), and DMAP (0.14 g, 1.1 mmol, 0.05 equiv). The reaction mixture was 
warmed to room temperature and stirred for 1 hour. After complete consumption of the 
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quenched with saturated aqueous NH4Cl. The layers were separated and the aqueous 
layer was extracted with CH2Cl2 twice. The combined organic phases were dried over 
Na2SO4, filtered, and concentrated under vacuum. The crude residue was purified by 
column chromatography (5% to 10% EtOAc in hexanes) to afford 14 as a colorless oil 
(5.89 g, 68% yield); 1H NMR (400 MHz, CDCl3) δ 4.40 (s, 2H), 4.20 (q, J = 7.2 Hz, 2H), 
3.62 (s, 2H), 2.09 (s, 2H), 1.32 – 1.24 (m, 5H), 1.10 (d, J = 4.0 Hz, 6H), 1.08 (d, J = 3.8 
Hz, 6H); 13C NMR (100 MHz, CDCl3) δ 203.6, 167.3, 69.6, 61.6, 45.8, 17.6, 17.5, 14.3, 
12.3; IR (Neat Film, NaCl) 2944, 2867, 1743, 1726, 1464, 1369, 1320, 1227, 1134, 1109, 
1035, 882, 810, 731 cm–1; HRMS (MM) m/z calc’d for C13H26IO4Si [M+H]+: 401.0640, 
found 401.0625. 
 
Ethyl 2,2-diisopropyl-5-oxo-1,2-oxasilinane-4-carboxylate (23): To a solution of 14 
(2.95 g, 7.37 mmol, 1.00 equiv) in THF (74 mL) at 0 °C, NaH (60% in mineral oil, 0.34 
g, 8.11 mmol, 1.10 equiv) was added. The reaction mixture was stirred for 1 hour at 0 °C, 
at which point complete consumption of the starting material was observed by TLC. The 
reaction was quenched with saturated aqueous NH4Cl. The layers were separated and the 
aqueous layer was extracted with EtOAc twice. The combined organics were washed 
with brine, dried over Na2SO4, filtered, and concentrated under vacuum. The crude 
residue was purified by column chromatography (10% EtOAc in hexanes) to afford 23 as 
a colorless oil (1.70 g, 85% yield); 1H NMR (400 MHz, CDCl3) δ 12.50 (s, 1H, OH), 4.44 
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3H), 1.01 (d, J = 6.1 Hz, 14H); 13C NMR (100 MHz, CDCl3) δ 173.7, 170.6, 95.3, 64.6, 
61.0, 17.1, 17.1, 14.4, 12.8, 1.9; IR (Neat Film, NaCl) 2943, 2866, 1655, 1464, 1314, 
1221, 1154, 1104, 1048, 882, 785 cm–1; HRMS (MM) m/z calc’d for C13H25O4Si 
[M+H]+: 273.1517, found 273.1514. 
 
Allyl 2,2-diisopropyl-5-oxo-1,2-oxasilinane-4-carboxylate (15): To a solution of 23 
(0.50 g, 1.84 mmol, 1.00 equiv) in toluene (6 mL) in a sealed tube, allyl alcohol (3.12 
mL, 45.9 mmol, 25.0 equiv) and DMAP (22.4 mg, 0.18 mmol, 0.10 equiv) were added. 
The reaction mixture was heated to 125 °C and stirred for 6 hours. The reaction was 
allowed to cool to room temperature and concentrated under vacuum. The crude residue 
was purified by column chromatography (5% EtOAc in hexanes) to afford 15 as a 
colorless oil (0.38 g, 67% yield); 1H NMR (400 MHz, CDCl3) δ 12.40 (s, 1H, OH), 5.99 
(ddt, J = 17.2, 10.5, 5.6 Hz, 1H), 5.36 (dq, J = 17.2, 1.6 Hz, 1H), 5.28 (dq, J = 10.4, 1.3 
Hz, 1H), 4.71 (dt, J = 5.5, 1.4 Hz, 2H), 4.45 (t, J = 1.4 Hz, 2H), 1.47 (t, J = 1.4 Hz, 2H), 
1.04 – 0.98 (m, 14H); 13C NMR (100 MHz, CDCl3) δ 173.2, 171.1, 132.2, 118.4, 95.2, 
65.5, 64.6, 17.1, 17.1, 12.8, 1.9; IR (Neat Film, NaCl) 2943, 2892, 2866, 1656, 1463, 
1313, 1216, 1153, 1108, 993, 882, 786, 736 cm–1; HRMS (MM) m/z calc’d for 
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General Procedure 1:  
To a solution of b-keto ester 15 (1.00 equiv) in DMF (0.10 M), alkyl halide (1.10 equiv), 
K2CO3 (1.10 equiv), and TBAI (1.10 equiv) were added sequentially. The reaction 
mixture was stirred at room temperature overnight, then quenched with saturated NH4Cl. 
The layers were separated and the aqueous phase was extracted with Et2O twice. The 
combined organic layers were dried over Na2SO4, filtered, and concentrated. The crude 
residue was purified by column chromatography to afford alkylated product 16. 
 
Allyl 4-benzyl-2,2-diisopropyl-5-oxo-1,2-oxasilinane-4-carboxylate (16a): Prepared 
according to General Procedure 1 using benzyl bromide and purified by column 
chromatography (10% Et2O in hexanes) to afford 16a as a colorless oil (378 mg, 83% 
yield). 1H NMR (400 MHz, CDCl3) δ 7.19 – 7.12 (m, 3H), 7.10 – 7.03 (m, 2H), 5.66 (ddt, 
J = 17.2, 10.4, 5.9 Hz, 1H), 5.21 – 5.08 (m, 2H), 4.50 (ddt, J = 13.0, 5.8, 1.3 Hz, 1H), 
4.44 (d, J = 18.4 Hz, 1H), 4.31 (ddt, J = 13.0, 6.0, 1.3 Hz, 1H), 4.20 (dd, J = 18.4, 0.6 Hz, 
1H), 3.26 (d, J = 13.6 Hz, 1H), 2.88 (d, J = 13.6 Hz, 1H), 1.67 (d, J = 15.2 Hz, 1H), 1.10 
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136.5, 131.3, 130.7, 128.1, 126.9, 119.2, 70.3, 66.2, 59.9, 42.5, 17.7, 17.3, 17.1, 17.1, 
15.3, 13.4, 12.7; IR (Neat Film, NaCl) 2944, 2867, 1718, 1462, 1269, 1245, 1192, 1093, 
995, 883, 781, 743, 701 cm–1; HRMS (MM) m/z calc’d for C21H31O4Si [M+H]+: 
375.1986, found 375.1991. 
 
Allyl 4-(4-bromobenzyl)-2,2-diisopropyl-5-oxo-1,2-oxasilinane-4-carboxylate (16b): 
Prepared according to General Procedure 1 using 4-bromobenzyl bromide and purified by 
column chromatography (0 to 5% Et2O in hexanes) to afford 5b as a colorless oil (154 
mg, 38% yield). 1H NMR (400 MHz, CDCl3) δ 7.36 (d, J = 8.4 Hz, 2H), 7.03 (d, J = 8.4 
Hz, 2H), 5.73 (ddt, J = 17.3, 10.4, 5.9 Hz, 1H), 5.27 – 5.17 (m, 2H), 4.56 (ddt, J = 13.0, 
5.8, 1.4 Hz, 1H), 4.50 (d, J = 18.5 Hz, 1H), 4.38 (ddt, J = 13.0, 6.1, 1.3 Hz, 1H), 4.26 (d, 
J = 18.4 Hz, 1H), 3.27 (d, J = 13.6 Hz, 1H), 2.89 (d, J = 13.7 Hz, 1H), 1.71 (d, J = 15.2 
Hz, 1H), 1.07 – 0.97 (m, 14H), 0.71 (d, J = 15.2 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 
208.7, 170.5, 135.5, 132.4, 131.2, 131.1, 121.0, 119.4, 70.2, 66.3, 59.7, 41.9, 17.6, 17.3, 
17.1, 17.0, 15.5, 13.4, 12.7; IR (Neat Film, NaCl) 2944, 2895, 2867, 1719, 1488, 1463, 
1192, 1094, 995, 883, 777 cm–1; HRMS (MM) m/z calc’d for C21H30BrO4Si [M+H]+: 
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carboxylate (16c): Prepared according to General Procedure 1 using 4-
(trifluoromethyl)benzyl bromide and purified by column chromatography (0 to 3% Et2O 
in hexanes) to afford 5c as a colorless oil (215 mg, 42% yield). 1H NMR (400 MHz, 
CDCl3) δ 7.48 (d, J = 8.1 Hz, 2H), 7.26 (d, J = 8.0 Hz, 2H), 5.65 (ddt, J = 17.2, 10.4, 5.9 
Hz, 1H), 5.21 – 5.11 (m, 2H), 4.56 – 4.44 (m, 2H), 4.39 – 4.21 (m, 2H), 3.37 (d, J = 13.5 
Hz, 1H), 2.95 (d, J = 13.5 Hz, 1H), 1.72 (d, J = 15.1 Hz, 1H), 1.06 – 0.95 (m, 14H), 0.72 
(d, J = 15.1 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 208.6, 170.4, 140.8, 131.0, 131.0, 
129.2 (q, J = 32.0 Hz), 125.0 (q, J = 3.8 Hz), 124.4 (q, J = 272.4 Hz), 119.5, 70.2, 66.4, 
59.8, 42.3, 17.6, 17.3, 17.1, 17.0, 15.8, 13.4, 12.7; 19F NMR (282 MHz, CDCl3) δ -62.50; 
IR (Neat Film, NaCl) 2945, 2868, 1719, 1463, 1325, 1192, 1165, 1126, 1113, 1068, 
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carboxylate (16d): Prepared according to General Procedure 1 using tert-butyl 4-
(bromomethyl)benzoate and purified by column chromatography (5% Et2O in hexanes) to 
afford 16d as a white solid (282 mg, 54% yield). 1H NMR (400 MHz, CDCl3) δ 7.87 (d, J 
= 8.3 Hz, 2H), 7.18 (d, J = 8.3 Hz, 2H), 5.76 (ddt, J = 17.2, 10.4, 5.9 Hz, 1H), 5.31 – 5.16 
(m, 2H), 4.59 (ddt, J = 13.0, 5.8, 1.3 Hz, 1H), 4.50 (d, J = 18.5 Hz, 1H), 4.40 (ddt, J = 
13.0, 6.2, 1.3 Hz, 1H), 4.28 (d, J = 18.4 Hz, 1H), 3.35 (d, J = 13.5 Hz, 1H), 2.99 (d, J = 
13.6 Hz, 1H), 1.71 (d, J = 15.2 Hz, 1H), 1.58 (s, 9H), 1.07 – 0.95 (m, 14H), 0.71 (d, J = 
15.2 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 208.5, 170.4, 165.9, 141.3, 131.2, 130.7, 
130.5, 129.3, 119.5, 81.0, 70.2, 66.4, 59.8, 42.4, 28.4, 17.7, 17.3, 17.1, 17.1, 15.3, 13.4, 
12.7; IR (Neat Film, NaCl) 2941, 2867, 1716, 1611.5, 1462, 1368, 1292, 1254, 1170, 
1106, 1020, 778, 758, 706 cm–1; HRMS (MM) m/z calc’d for C26H39O6Si [M+H]+: 
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(16e): Prepared according to General Procedure 1 using 4-(methoxy)benzyl bromide and 
purified by column chromatography (5 to 15% Et2O in hexanes) to afford 16e as a 
colorless oil (153 mg, 31% yield). 1H NMR (400 MHz, CDCl3) δ 7.08 – 7.03 (m, 2H), 
6.81 – 6.76 (m, 2H), 5.75 (ddt, J = 17.2, 10.4, 5.9 Hz, 1H), 5.27 – 5.16 (m, 2H), 4.58 
(ddt, J = 13.0, 5.7, 1.4 Hz, 1H), 4.49 (d, J = 18.4 Hz, 1H), 4.39 (ddt, J = 13.0, 6.0, 1.3 Hz, 
1H), 4.26 (d, J = 18.6 Hz, 1H), 3.77 (s, 3H), 3.26 (d, J = 13.7 Hz, 1H), 2.90 (d, J = 13.8 
Hz, 1H), 1.72 (d, J = 15.2 Hz, 1H), 1.17 – 0.94 (m, 14H), 0.71 (d, J = 15.3 Hz, 1H); 13C 
NMR (100 MHz, CDCl3) δ 208.9, 170.7, 158.6, 131.6, 131.4, 128.4, 119.1, 113.5, 70.3, 
66.2, 59.8, 55.3, 41.7, 17.7, 17.3, 17.1, 17.1, 15.2, 13.4, 12.7; IR (Neat Film, NaCl) 2944, 
2867, 1719, 1613, 1514, 1464, 1442, 1271, 1249, 1193, 1178, 1094, 1036, 884, 776, 727, 
709 cm–1; HRMS (MM) m/z calc’d for C22H33O5Si [M+H]+: 405.2092, found 405.2093. 
 
Allyl 2,2-diisopropyl-4-(2-methylbenzyl)-5-oxo-1,2-oxasilinane-4-carboxylate (16f): 
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by column chromatography (5 to 15% Et2O in hexanes) to afford 16f as a colorless oil 
(157 mg, 35% yield). 1H NMR (400 MHz, CDCl3) δ 7.13 – 7.08 (m, 4H), 5.74 (ddt, J = 
17.2, 10.4, 5.9 Hz, 1H), 5.24 (dq, J = 17.2, 1.5 Hz, 1H), 5.21 – 5.17 (m, 1H), 4.60 (ddt, J 
= 13.0, 5.7, 1.4 Hz, 1H), 4.54 (d, J = 18.4 Hz, 1H), 4.37 (ddt, J = 13.0, 6.2, 1.3 Hz, 1H), 
4.31 (d, J = 18.5 Hz, 1H), 3.40 (d, J = 14.2 Hz, 1H), 3.07 (d, J = 14.3 Hz, 1H), 2.27 (s, 
3H), 1.74 (d, J = 15.1 Hz, 1H), 1.21 – 0.91 (m, 14H), 0.74 (d, J = 15.2 Hz, 1H); 13C NMR 
(100 MHz, CDCl3) δ 208.9, 170.8, 137.3, 134.8, 131.3, 131.3, 130.6, 126.9, 125.6, 119.2, 
70.2, 66.3, 59.5, 37.8, 20.1, 17.7, 17.3, 17.1, 17.1, 15.1, 13.4, 12.7; IR (Neat Film, NaCl) 
3021, 2944, 2894.4, 2867, 1719, 1463, 1270, 1220, 1191, 1093, 884, 779, 747, 710 cm–1; 
HRMS (MM) m/z calc’d for C22H33O4Si [M+H]+: 389.2143, found 389.2136. 
 
Allyl 2,2-diisopropyl-4-methyl-5-oxo-1,2-oxasilinane-4-carboxylate (16g): Prepared 
according to General Procedure 1 using methyl iodide, without TBAI, and purified by 
column chromatography (3 to 15% Et2O in hexanes) to afford 16g as a colorless oil (271 
mg, 60% yield). 1H NMR (400 MHz, CDCl3) δ 5.88 (ddt, J = 17.2, 10.5, 5.7 Hz, 1H), 
5.31 (dq, J = 17.2, 1.5 Hz, 1H), 5.24 (dq, J = 10.5, 1.3 Hz, 1H), 4.68 (ddt, J = 13.2, 5.6, 
1.4 Hz, 1H), 4.56 (ddt, J = 13.2, 5.9, 1.4 Hz, 1H), 4.50 (d, J = 18.6 Hz, 1H), 4.30 (d, J = 
18.6 Hz, 1H), 1.85 (d, J = 15.5 Hz, 1H), 1.43 (s, 3H), 1.18 – 0.99 (m, 14H), 0.77 (d, J = 
15.5 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 209.7, 172.6, 131.5, 118.9, 70.1, 66.3, 54.7, 
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1262, 1195, 1162, 1124, 1095, 1067, 993, 883, 780, 733, 712 cm–1; HRMS (MM) m/z 
calc’d for C15H27O4Si [M+H]+: 299.1673, found 299.1669. 
 
Allyl 4-(3-ethoxy-3-oxopropyl)-2,2-diisopropyl-5-oxo-1,2-oxasilinane-4-carboxylate 
(16h): Prepared according to General Procedure 1 using ethyl acrylate, without TBAI, 
and purified by column chromatography (10 to 15% Et2O in hexanes) to afford 16h as a 
colorless oil (150 mg, 32% yield). 1H NMR (400 MHz, CDCl3) δ 5.89 (ddt, J = 17.2, 
10.5, 5.9 Hz, 1H), 5.33 (dq, J = 17.2, 1.5 Hz, 1H), 5.26 (dq, J = 10.4, 1.2 Hz, 1H), 4.71 
(ddt, J = 13.0, 5.7, 1.4 Hz, 1H), 4.59 – 4.53 (m, 1H), 4.50 (d, J = 18.5 Hz, 1H), 4.29 – 
4.22 (m, 1H), 4.12 (q, J = 7.2 Hz, 2H), 2.44–2.19 (m, 3H), 2.08–2.01 (m, 1H), 1.80 (d, J 
= 15.2 Hz, 1H), 1.25 (t, J = 7.1 Hz, 3H), 1.11 – 0.95 (m, 14H), 0.70 (d, J = 15.2 Hz, 1H); 
13C NMR (100 MHz, CDCl3) δ 208.8, 173.1, 171.1, 131.3, 119.4, 70.1, 66.5, 60.7, 57.2, 
31.8, 29.7, 17.6, 17.3, 17.1, 17.1, 14.9, 14.4, 13.4, 12.7; IR (Neat Film, NaCl) 2944, 
2868, 1737, 1719, 1464, 1377, 1299, 1251, 1192, 1140, 1096, 883, 781, 733, 713 cm–1; 
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4-carboxylate (16i): To a solution of b-keto ester 15 (275 mg, 0.97 mmol, 1.00 equiv) in 
CH2Cl2 ( 3.2 mL), sulfonylmethyl carbamate18 (315 mg, 1.16 mmol, 1.20 equiv) and 
Cs2CO3 (792 mg, 2.43 mmol, 2.5 equiv) were added. The reaction mixture was stirred at 
room temperature overnight. Upon complete consumption of the starting material, as 
observed by TLC, the reaction was quenched with saturated NH4Cl. The layers were 
separated and the aqueous phase was extracted with DCM twice. The combined organic 
layers were dried over Na2SO4, filtered, and concentrated. The crude residue was purified 
by column chromatography (5 to 10% EtOAc in hexanes) to afford alkylated product 16i 
as a colorless viscous oil (344 mg, 86% yield). 1H NMR (400 MHz, CDCl3) δ 5.89 (ddt, J 
= 16.5, 10.4, 5.9 Hz, 1H), 5.32 (dq, J = 17.2, 1.5 Hz, 1H), 5.24 (dq, J = 10.5, 1.2 Hz, 1H), 
5.16 – 5.07 (m, 1H), 4.68 (ddt, J = 12.9, 5.8, 1.4 Hz, 1H), 4.58 – 4.45 (m, 2H), 4.26 (d, J 
= 18.8 Hz, 1H), 3.62 (dd, J = 13.9, 7.8 Hz, 1H), 3.39 (dd, J = 13.8, 5.7 Hz, 1H), 1.73 (d, J 
= 15.5 Hz, 1H), 1.40 (s, 9H), 1.16 – 0.95 (m, 14H), 0.80 (d, J = 15.4 Hz, 1H); 13C NMR 
(100 MHz, CDCl3) δ 210.4, 170.1, 155.9, 131.4, 119.3, 79.5, 70.2, 66.8, 59.3, 46.4, 28.4, 
17.5, 17.2, 17.1, 17.0, 13.3, 12.7, 12.3; IR (Neat Film, NaCl) 3465, 2943, 2868, 1749, 
1720, 1501, 1464, 366, 1248, 1167, 1106, 1068, 883, 779, 739 cm–1; HRMS (MM) m/z 
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2.7.2.2 General Procedure for the Palladium-Catalyzed Allylic Alkylation 
Please note that the absolute configuration was determined only for compounds 17a and 
17g via vibrational circular dichroism (VCD) and optical rotation. The absolute 
configuration for all other products has been inferred by analogy. For respective HPLC, 
SFC, or GC conditions, please refer to Table 2.3. 
 
General procedure 2: 
In a nitrogen-filled glovebox, to an oven-dried 4-mL vial equipped with a stir bar was 
added Pd2(dba)3 (5 mol %), (S)-(CF3)3-t-BuPHOX (12.5 mol %) and toluene (0.003 M 
based on Pd source). After stirring at room temperature for 30 min, the catalyst mixture 
was cooled to 0 °C and a solution of starting material 16 in toluene (0.066 M) was then 
added. The vial was sealed with a PTFE-lined septum cap and stirred at 0 °C. After 20 
hours, the vial was removed from the glovebox. The crude reaction mixture was filtered 
through a silica plug with Et2O, concentrated under vacuum, and purified by silica gel 






toluene (0.033 M) 













R RPd2(dba)3 (5 mol %)
(S)-(CF3)3-t-BuPHOX (12.5 mol %)
*
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2.7.2.3 Spectroscopic Data for the Alkylation Products 
 
(R)-4-allyl-4-benzyl-2,2-diisopropyl-1,2-oxasilinan-5-one (17a): Product 17a was 
prepared using General Procedure 2 and purified by column chromatography (5% Et2O in 
hexanes) to provide a colorless oil (60.0 mg, 91% yield); 94% ee, [a]D25 +3.47 (c 0.92, 
CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.33 – 7.21 (m, 3H), 7.17 – 7.12 (m, 2H), 5.81 
(dddd, J = 16.9, 10.3, 7.8, 6.5 Hz, 1H), 5.29 – 5.07 (m, 2H), 4.46 (d, J = 18.8 Hz, 1H), 
4.42 (d, J = 18.8 Hz, 1H), 3.14 (d, J = 13.7 Hz, 1H), 2.93 (d, J = 13.8 Hz, 1H), 2.52 (ddt, 
J = 14.3, 7.8, 1.2 Hz, 1H), 2.34 (ddt, J = 14.4, 6.5, 1.4 Hz, 1H), 1.11 – 1.02 (m, 14H), 
0.98 (d, J = 1.9 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 213.8, 137.5, 134.0, 130.7, 
128.2, 126.6, 118.9, 71.6, 52.5, 42.5, 41.0, 17.6, 17.5, 17.3, 15.0, 13.6, 13.4; IR (Neat 
Film, NaCl) 3064, 3029, 2943, 2893, 2866, 1710, 1496, 1464, 1438, 1146, 1100, 918, 
883, 789, 736, 702; HRMS (MM) m/z calc’d for C20H34O2NSi [M+NH4]+: 348.2353, 
found 348.2353; SFC Conditions: 5% IPA, 2.5 mL/min, Chiralpak AD-H column, λ = 
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(R)-4-allyl-4-(4-bromobenzyl)-2,2-diisopropyl-1,2-oxasilinan-5-one (17b): Product 
17b was prepared using General Procedure 2 and purified by column chromatography 
(3% Et2O in hexanes) to provide a colorless oil (72.2 mg, 88% yield); 93% ee, [a]D25 
+3.48 (c 1.00, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.44 – 7.33 (m, 2H), 7.05 – 6.97 
(m, 2H), 5.73 (dddd, J = 16.9, 10.2, 7.7, 6.7 Hz, 1H), 5.19 – 5.07 (m, 2H), 4.39 (s, 2H), 
2.98 (d, J = 13.8 Hz, 1H), 2.88 (d, J = 13.8 Hz, 1H), 2.54 (ddt, J = 14.5, 7.7, 1.2 Hz, 1H), 
2.27 (ddt, J = 14.4, 6.6, 1.4 Hz, 1H), 1.08 – 0.97 (m, 14H), 0.90 (s, 2H); 13C NMR (100 
MHz, CDCl3) δ 213.6, 136.6, 133.6, 132.5, 131.3, 120.6, 119.2, 71.5, 52.4, 41.7, 41.0, 
17.5, 17.5, 17.3, 17.3, 14.8, 13.6, 13.4; IR (Neat Film, NaCl) 2943, 2866, 1711, 1488, 
1463, 1101, 1074, 1012, 882, 785, 756; HRMS (FAB+) m/z calc’d for C20H30BrO2Si 
[M+H]+: 409.1198, found 409.1187; SFC Conditions: 10% IPA, 2.5 mL/min, Chiralpak 
AD-H column, λ = 210 nm, tR (min): major = 3.01, minor = 3.33. 
 
(R)-4-allyl-2,2-diisopropyl-4-(4-(trifluoromethyl)benzyl)-1,2-oxasilinan-5-one (17c): 
Product 6c was prepared using General Procedure 2 and purified by column 
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yield); 90% ee, [a]D25 –6.05 (c 0.99, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.52 (d, J = 
8.0 Hz, 2H), 7.31 – 7.13 (m, 2H), 5.75 (dddd, J = 17.0, 10.3, 7.6, 6.7 Hz, 1H), 5.25 – 5.08 
(m, 2H), 4.41 (s, 2H), 3.06 (d, J = 13.7 Hz, 1H), 3.01 (d, J = 13.7 Hz, 1H), 2.58 (ddt, J = 
14.5, 7.6, 1.3 Hz, 1H), 2.28 (ddt, J = 14.5, 6.7, 1.4 Hz, 1H), 1.11 – 0.95 (m, 14H), 0.91 (s, 
2H); 13C NMR (100 MHz, CDCl3) δ 213.5, 142.0, 133.5, 131.1, 128.9 (q, J = 32.4 Hz), 
125.1 (q, J = 3.8 Hz), 124.4 (q, J = 271.8 Hz), 119.3, 71.5, 52.5, 42.1, 41.2, 17.5, 17.5, 
17.3, 17.3, 14.9, 13.6, 13.4; 19F NMR (282 MHz, CDCl3) δ –62.44; IR (Neat Film, NaCl) 
2946, 2896, 2868, 1712, 1619, 1464, 1441, 1417, 1326, 1164, 1125, 1069, 1020, 788, 
757; HRMS (FAB+) m/z calc’d for C21H30F3O2Si [M+H]+: 399.1967, found 399.1943; 
SFC Conditions: 3% IPA, 2.5 mL/min, Chiralpak AD-H column, λ = 210 nm, tR (min): 
major = 2.38, minor = 2.96. 
	 	
tert-butyl (R)-4-((4-allyl-2,2-diisopropyl-5-oxo-1,2-oxasilinan-4-yl)methyl)benzoate 
(17d): Product 17d was prepared using General Procedure 2 and purified by column 
chromatography (5% Et2O in hexanes) to provide a colorless oil (80.4 mg, 93% yield); 
93% ee, [a]D25 +1.44 (c 0.99, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.88 (d, J = 8.3 Hz, 
2H), 7.22 – 7.11 (m, 2H), 5.74 (dddd, J = 17.0, 10.3, 7.6, 6.7 Hz, 1H), 5.19 – 5.10 (m, 
2H), 4.40 (s, 2H), 3.09 (d, J = 13.6 Hz, 1H), 2.95 (d, J = 13.6 Hz, 1H), 2.55 (ddt, J = 
14.4, 7.6, 1.2 Hz, 1H), 2.26 (ddt, J = 14.4, 6.6, 1.3 Hz, 1H), 1.58 (s, 9H), 1.09 – 0.94 (m, 
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130.3, 130.3, 129.3, 119.2, 81.0, 71.5, 52.5, 42.2, 41.0, 28.3, 17.5, 17.5, 17.3, 15.0, 13.6, 
13.4; IR (Neat Film, NaCl) 3402, 3077, 1944, 2895, 2867, 1713, 1611, 1463, 1367, 1293, 
1255, 1169, 1117, 1108, 1020, 883, 790, 773, 744; HRMS (MM) m/z calc’d for 
C25H42O4NSi [M+NH4]+: 448.2878, found 448.2883; SFC Conditions: 10% IPA, 2.5 
mL/min, Chiralpak AD-H column, λ = 210 nm, tR (min): major = 2.72, minor = 3.12. 
 
(R)-4-allyl-2,2-diisopropyl-4-(4-methoxybenzyl)-1,2-oxasilinan-5-one (6e): Product 6e 
was prepared using General Procedure 2 and purified by column chromatography (10% 
Et2O in hexanes) to provide a colorless oil (61.8 mg, 85% yield); 93% ee, [a]D25 +3.12 (c 
0.96, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.13 – 6.96 (m, 2H), 6.85 – 6.75 (m, 2H), 
5.77 (dddd, J = 16.8, 10.3, 7.8, 6.5 Hz, 1H), 5.17 – 5.07 (m, 2H), 4.43 (d, J = 19.1 Hz, 
1H), 4.38 (d, J = 19.1 Hz, 1H), 3.78 (s, 3H), 3.06 (d, J = 13.9 Hz, 1H), 2.83 (d, J = 13.9 
Hz, 1H), 2.46 (ddt, J = 14.3, 7.8, 1.2 Hz, 1H), 2.31 (ddt, J = 14.3, 6.5, 1.4 Hz, 1H), 1.15 – 
0.97 (m, 14H), 0.94 (s, 2H); 13C NMR (100 MHz, CDCl3) δ 214.0, 158.3, 134.1, 131.6, 
129.4, 118.8, 113.6, 71.6, 55.3, 52.6, 41.7, 41.0, 17.6, 17.5, 17.3, 17.3, 14.8, 13.5, 13.5; 
IR (Neat Film, NaCl) 3075, 2944, 2866, 1710, 1612, 1514, 1464, 1441, 1301, 1250, 
1179, 1146, 1111, 1099, 1038, 994, 918, 883, 788, 772, 751; HRMS (MM) m/z calc’d for 
C21H36O3NSi [M+NH4]+: 378.2459, found 378.2457; SFC Conditions: 5% IPA, 2.5 
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(R)-4-allyl-2,2-diisopropyl-4-(2-methylbenzyl)-1,2-oxasilinan-5-one (6f): Product 6f 
was prepared using General Procedure 2 and purified by column chromatography (0 to 
3% Et2O in hexanes) to provide a colorless oil (57.0 mg, 83% yield); 92% ee, [a]D25 –
0.73 (c 0.95, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.20 – 7.00 (m, 4H), 5.74 (dddd, J = 
16.9, 10.3, 7.6, 6.7 Hz, 1H), 5.19 – 5.03 (m, 2H), 4.44 (d, J = 18.6 Hz, 1H), 4.38 (d, J = 
16.9 Hz, 1H), 3.10 (d, J = 14.5 Hz, 1H), 3.06 (d, J = 14.6 Hz, 1H), 2.51 – 2.43 (m, 2H), 
2.31 (s, 3H), 1.13 – 0.93 (m, 16H); 13C NMR (100 MHz, CDCl3) δ 214.0, 137.3, 136.4, 
134.1, 130.7, 130.6, 126.5, 125.8, 118.9, 71.7, 53.1, 42.0, 38.5, 20.7, 17.6, 17.5, 17.4, 
17.3, 14.2, 13.6, 13.5; IR (Neat Film, NaCl) 3076, 3020, 2943, 2894, 2866, 1710, 1463, 
1146, 1098, 994, 918, 883, 791, 742; HRMS (MM) m/z calc’d for C21H36O2NSi 
[M+NH4]+: 362.2510, found 362.2514; SFC Conditions: 1% IPA, 2.5 mL/min, Chiralcel 
OJ-H column, λ = 210 nm, tR (min): major = 3.96, minor = 4.51. 
 
(S)-4-allyl-2,2-diisopropyl-4-methyl-1,2-oxasilinan-5-one (17g): Product 17g was 
prepared using General Procedure 2 at 23 °C instead of 0 °C and purified by column 
chromatography (5% Et2O in hexanes) to provide a pale yellow oil (40.0 mg, 79% yield); 
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16.9, 10.4, 7.8, 6.9 Hz, 1H), 5.14 – 5.02 (m, 2H), 4.40 (d, J = 18.6 Hz, 1H), 4.32 (d, J = 
18.6 Hz, 1H), 2.45 (ddt, J = 13.8, 7.7, 1.2 Hz, 1H), 2.33 (ddt, J = 13.8, 7.0, 1.3 Hz, 1H), 
1.23 (s, 3H), 1.07 – 1.01 (m, 15H), 0.89 (d, J = 15.5 Hz, 1H); 13C NMR (100 MHz, 
CDCl3) δ 215.2, 134.2, 118.5, 70.9, 47.9, 44.2, 25.0, 17.5, 17.5, 17.3, 17.2, 13.5, 13.4; IR 
(Neat Film, NaCl) 3076, 2943, 2894, 2867, 1713, 1463, 1249, 1164, 1114, 994, 916, 883, 
787, 753, 738; HRMS (MM) m/z calc’d for C14H27O2Si [M+H]+: 255.1775, found 
255.1768; GC Conditions: G-TA column, 100 °C, isotherm,  tR (min): minor = 98.83, 
major = 100.76. 
 
Ethyl (S)-3-(4-allyl-2,2-diisopropyl-5-oxo-1,2-oxasilinan-4-yl)propanoate (17h): 
Product 17h was prepared using General Procedure 2 and purified by column 
chromatography (10 to 15% Et2O in hexanes) to provide a pale yellow oil (43.0 mg, 63% 
yield); 94% ee, [a]D25 –3.67 (c 0.93, CHCl3); 1H NMR (400 MHz, CDCl3) δ 5.67 (dddd, J 
= 16.2, 10.8, 7.7, 6.8 Hz, 1H), 5.15 – 5.03 (m, 2H), 4.36 (d, J = 0.7 Hz, 2H), 4.12 (q, J = 
7.1 Hz, 2H), 2.53 (ddt, J = 14.3, 7.8, 1.2 Hz, 1H), 2.38 – 2.26 (m, 2H), 2.20 – 2.07 (m, 
2H), 1.91 (ddd, J = 13.9, 11.4, 5.4 Hz, 1H), 1.25 (t, J = 7.1 Hz, 3H), 1.11 – 1.01 (m, 
14H), 0.97 (d, J = 4.4 Hz, 2H). 13C NMR (100 MHz, CDCl3) δ 214.1, 173.5, 133.2, 
119.0, 71.2, 60.7, 50.7, 40.7, 31.4, 29.4, 17.5, 17.5, 17.3, 14.9, 14.3, 13.5, 13.5; IR (Neat 
Film, NaCl) 2943, 2867, 1738, 1710, 1464, 1376, 1303, 1250, 1177, 1104, 918, 883, 788, 
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Conditions: 3% IPA, 2.5 mL/min, Chiralpak IC column, λ = 210 nm, tR (min): minor = 
9.30, major = 9.86. 
 
tert-butyl (R)-((4-allyl-2,2-diisopropyl-5-oxo-1,2-oxasilinan-4-yl)methyl)carbamate 
(17i): Product 17i was prepared using General Procedure 2 and purified by column 
chromatography (5% EtOAc in hexanes, then 5% acetone in hexanes) to provide a 
colorless oil (57.9 mg, 78% yield); 90% ee, [a]D25 +29.83 (c 0.94, CHCl3); 1H NMR (400 
MHz, CDCl3) δ 5.67 (ddt, J = 19.2, 9.4, 7.4 Hz, 1H), 5.12 (s, 1H), 5.10 – 5.05 (m, 1H), 
4.92 (t, J = 6.7 Hz, 1H), 4.34 (d, J = 1.2 Hz, 2H), 3.29 (d, J = 6.7 Hz, 2H), 2.62 (ddt, J = 
14.3, 7.5, 1.3 Hz, 1H), 2.45 – 2.33 (m, 1H), 1.40 (s, 9H), 1.13 – 0.91 (m, 16H).	 13C NMR 
(100 MHz, CDCl3) δ 215.6, 156.5, 132.4, 119.5, 79.3, 71.0, 53.1, 46.3, 39.9, 28.5, 17.5, 
17.4, 17.2, 13.6, 13.3, 12.1; IR (Neat Film, NaCl) 3465, 3369, 3078, 2943, 2896, 2867, 
1708, 1504, 1464, 1366, 1247, 1169, 1109, 883, 787, 751; HRMS (MM) m/z calc’d for 
C19H36NO4Si [M+H]+: 370.2408, found 370.2409; SFC Conditions: 5% IPA, 2.5 
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2.7.2.4 Experimental Procedures and Characterization Data for Product 
Transformation 
 
4R,5S)-4-benzyl-4-(3-hydroxypropyl)-2,2-diisopropyl-1,2-oxasilinan-5-ol (18): To a 
solution of 17a (257 mg, 0.78 mmol) in THF (3.8 mL) in a 10 mL round-bottom flask 
was added 2.0 M solution of BH3•SMe2 in THF (0.78 mL, 1.56 M) at room temperature 
and stirred for 18 hours. Upon complete consumption of starting material 17a as observed 
by TLC, H2O (1 mL) was added dropwise. After stirring for 10 minutes, NaBO3•4H2O 
(840 mg, 5.45 mmol) was added and the mixture was stirred for an additional 4 hours. 
The reaction mixture was quenched with 2 M HCl, the organic layer was collected, and 
the aqueous phase was extracted with EtOAc twice. The organic phases were combined, 
dried over Na2SO4, and concentrated. The crude material was purified by column 
chromatography  (40 to 50% EtOAc in hexanes) to furnish product 18 as a viscous, 
colorless oil (158 mg, 58% yield) as a 93:7 mixture of diastereomers; [a]D25 –16.53 (c 
0.38, CHCl3). Major diastereomer: 1H NMR (400 MHz, CDCl3) δ 7.33 – 7.17 (m, 5H), 
4.09 (dd, J = 12.3, 1.7 Hz, 1H), 3.89 (dd, J = 12.3, 3.9 Hz, 1H), 3.63 (t, J = 6.6 Hz, 2H), 
3.39 (dd, J = 3.5, 1.8 Hz, 1H), 2.92 (d, J = 13.3 Hz, 1H), 2.75 (d, J = 13.3 Hz, 1H), 1.72 
(ddt, J = 12.8, 8.3, 4.3 Hz, 2H), 1.42 – 1.15 (m, 2H), 1.15 – 0.97 (m, 14H), 0.83 (d, J = 
15.2 Hz, 1H), 0.56 (d, J = 15.1 Hz, 1H);	13C NMR (100 MHz, CDCl3) δ 138.4, 130.7, 






BH3 • SMe2, THF
23 °C, 18 h
then H2O, 10 min
then NaBO3 • 4H2O
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14.2, 13.2, 12.7; IR (Neat Film, NaCl) 3387, 2941, 2865, 1462, 1130, 1054, 882, 828, 
733, 703 cm–1; HRMS (MM) m/z calc’d for C20H35O3Si [M+H]+: 351.2350, found 
351.2353. 
 
(2S,3S)-3-benzyl-3-methylhexane-1,2,6-triol (19): To a solution of 18 (45.5 mg, 0.13 
mmol) in DMF (1.3  mL) in a 1-dram vial was added 1.0 M solution of TBAF in THF 
(0.52 mL, 0.52 mmol) at room temperature and sealed with a Teflon-lined cap. The 
solution was stirred at 80 °C for 18 hours, then 5% aqueous LiCl was added and the 
organic phase was collected. The aqueous was extracted with EtOAc three times. The 
organic phases were combined, washed with water, then brine, dried over Na2SO4, and 
concentrated. The crude residue was purified by column chromatography  (100% EtOAc) 
to furnish product 19 as a white solid (23.9 mg, 77% yield); [a]D25 –5.10 (c 0.18, 
CH3OH); 1H NMR (400 MHz, CD3OD) δ 7.27 – 7.13 (m, 5H), 3.78 (dd, J = 10.0, 1.3 Hz, 
1H), 3.55 – 3.44 (m, 4H), 2.76 (d, J = 13.2 Hz, 1H), 2.62 (d, J = 13.2 Hz, 1H), 1.72 – 
1.59 (m, 1H), 1.59–1.47 (m, 1H), 1.39 (ddd, J = 13.6, 12.5, 4.3 Hz, 1H), 1.11 – 1.00 (m, 
1H), 0.86 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 140.0, 131.9, 128.7, 126.9, 77.6, 64.0, 
63.7, 42.6, 40.9, 32.8, 27.7, 21.1; IR (Neat Film, NaCl) 3363, 2924, 2854, 1660, 1450, 
1056, 1016, 830, 702, 683 cm–1; HRMS (ES+) m/z calc’d for C14H23O3 [M+H]+: 
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(2S,3S)-3-benzyl-3-(hydroxymethyl)hexane-1,2,6-triol (20): To a solution of 18 (13.8 
mg, 0.039 mmol) in THF (0.4 mL) in a 1-dram vial was added a 1.0 M solution of TBAF 
in THF (0.16 mL, 0.16 mmol) and NaBO3•4H2O (24.2 mg, 0.16 mmol) at room 
temperature. The vial was sealed with a Teflon-lined cap and the reaction mixture was 
heated to 60 °C and stirred for 18 hours. Upon complete consumption of the starting 
material as judged by TLC, the reaction mixture was quenched with 2 M HCl. The 
organic layer was collected and the aqueous phase was extracted with EtOAc twice. The 
organic phases were combined, washed with brine, dried over Na2SO4, and concentrated 
under vacuum. The crude residue was purified by preparative-TLC  (10% MeOH in 
CH2Cl2) to furnish product 20 as a colorless solid (5.0 mg, 51% yield); [a]D25 –0.94 (c 
0.26, CH3OH); 1H NMR (400 MHz, CD3OD) δ 7.31 – 7.21 (m, 4H), 7.21 – 7.15 (m, 1H), 
3.75 (dd, J = 11.5, 3.2 Hz, 1H), 3.65 (dd, J = 11.5, 7.0 Hz, 1H), 3.55 – 3.43 (m, 5H), 2.86 
(d, J = 13.4 Hz, 1H), 2.72 (d, J = 13.4 Hz, 1H), 1.77 – 1.65 (m, 1H), 1.65 – 1.53 (m, 1H), 
1.30 (ddd, J = 13.8, 12.3, 4.4 Hz, 1H, overlapped with an OH proton), 1.14 – 1.05 (m, 
1H).; 13C NMR (100 MHz, CD3OD) δ 139.3, 131.9, 128.9, 127.1, 77.2, 65.5, 63.9, 63.7, 
45.0, 37.9, 28.0, 27.4 ; IR (Neat Film, NaCl) 3339, 2926, 2874, 2860, 1455, 1052, 753, 
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(4S,5S)-4-benzyl-6-(benzyloxy)-4-methylhexane-1,5-diol (21): To a solution of 19 (10 
mg, 0.042 mmol) in MeOH (0.4  mL) in a 1-dram vial was added Bu2SnO (11 mg, 0.044 
mmol) at room temperature. The vial was sealed with a Teflon-lined cap and stirred at 70 
°C. After 18 hours, the reaction mixture was concentrated, then redissolved in toluene 
(0.4 mL). Benzyl bromide (6 uL, 0.05 mmol) and TBAB (16 mg, 0.05 mmol) were added 
and the reaction was heated to reflux in a sealed vial. After refluxing overnight, the 
reaction was cooled to room temperature. EtOAc and H2O were added. The organic layer 
was collected and the aqueous phase was extracted with EtOAc three times. The organic 
phases were combined, washed with brine, dried over Na2SO4, and concentrated under 
vacuum. The crude residue was purified by preparative-TLC  (50% EtOAc in hexanes) to 
furnish product 21 as a colorless solid (8.3 mg, 60% yield); [a]D25 3.29 (c 0.23, CHCl3); 
1H NMR (400 MHz, CDCl3) δ 7.40 – 7.29 (m, 5H), 7.28 – 7.22 (m, 2H), 7.22 – 7.15 (m, 
3H), 4.56 (d, J = 3.6 Hz, 2H), 3.72 – 3.63 (m, 2H), 3.58 (t, J = 6.5 Hz, 2H), 3.49 (td, J = 
9.7, 9.1, 1.9 Hz, 1H), 2.83 (d, J = 13.3 Hz, 1H), 2.57 (d, J = 13.2 Hz, 1H), 1.73 – 1.46 (m, 
2H), 1.39 (ddd, J = 13.6, 12.0, 4.6 Hz, 1H), 1.06 (ddd, J = 13.6, 12.1, 4.6 Hz, 1H), 0.89 
(s, 3H); 13C NMR (100 MHz, CDCl3) δ 138.6, 138.0, 131.0, 128.7, 128.0, 128.0, 127.9, 
126.1, 74.0, 73.6, 71.24, 63.7, 41.6, 39.5, 31.5, 26.9, 20.7; IR (Neat Film, NaCl) 3427, 
2926, 2870, 1455, 1372, 1256, 1064, 908, 732, 702, 666, 634 cm–1; HRMS (ES+) m/z 
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To a solution of 21 (8.3 mg, 0.025 mmol) in CH2Cl2 (0.3  mL) in a 1-dram vial was 
added (diacetoxyiodo)benzene (PIDA) (25.7 mg, 0.08 mmol) and TEMPO (1.0 mg, 0.005 
mmol) at room temperature. The vial was sealed with a Teflon-lined cap and the solution 
was stirred for 18 hours. At this point, complete consumption of the starting material was 
observed by TLC, and the reaction was quenched with saturated aqueous Na2S2O3. 
Additional Et2O was added, the organic phase was collected, and the aqueous phase was 
extracted with Et2O three times. The organic phases were combined, washed with brine, 
dried over Na2SO4, and concentrated under vacuum. The crude residue was purified by 
preparative-TLC  (50% EtOAc in hexanes) to furnish product 22 as a colorless solid (5.3 
mg, 65% yield); [a]D25 14.81 (c 0.51, CHCl3); 1H NMR (300 MHz, CDCl3) δ 7.42 – 7.19 
(m, 8H), 7.16 – 7.06 (m, 2H), 4.61 (d, J = 1.6 Hz, 2H), 4.29 (dd, J = 5.0, 3.6 Hz, 1H), 
3.82 (dd, J = 4.3, 3.3 Hz, 2H), 2.78 – 2.47 (m, 4H), 1.88 (ddd, J = 14.1, 7.9, 6.4 Hz, 1H), 
1.42 (dt, J = 14.4, 7.6 Hz, 1H), 1.03 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 171.5, 137.8, 
136.7, 130.6, 128.6, 128.3, 128.0, 127.9, 126.8, 68.9, 73.9, 69.4, 39.7, 35.3, 29.9, 27.2, 
23.7; IR (Neat Film, NaCl) 2927, 1732, 1454, 1354, 1256, 1202, 1166, 1074, 730, 700, 
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2.7.3 DETERMINATION OF ENANTIOMERIC EXCESS 





















entry compound analytic conditions ee (%)
1 94SFC, Chiralpak AD-H, λ = 210 nm5% IPA/CO2, 2.5 mL/min






2 93SFC, Chiralpak AD-H, λ = 210 nm
10% IPA/CO2, 2.5 mL/min
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3 90SFC, Chiralpak AD-H, λ = 210 nm
3% IPA/CO2, 2.5 mL/min







4 93SFC, Chiralpak AD-H, λ = 210 nm
10% IPA/CO2, 2.5 mL/min







entry compound analytic conditions ee (%)
5 93SFC, Chiralpak AD-H, λ = 210 nm
5% IPA/CO2, 2.5 mL/min






6 92SFC, Chiralcel OJ-H, λ = 210 nm
10% IPA/CO2, 2.5 mL/min






7 89GC, G-TA column
100 °C, isotherm
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2.7.4 DETERMINATION OF ABSOLUTE CONFIGURATION 
2.7.4.1 Determination of Absolute Configuration of 17g via VCD and OR 
Method 1 – Vibrational Circular Dichroism (VCD): 
Experimental Protocol.  A solution of 17g (30 mg/mL) was prepared in CDCl3 and 
loaded into a front-loading SL-4 cell (International Crystal Laboratories) possessing BaF2 
windows and 100 μm path length.   Infrared (IR) and VCD spectra were acquired on a 
BioTools ChiralIR-2X VCD spectrometer as a set of 30 one-hour blocks (30 blocks, 3120 
scans per block) in dual PEM mode.  A 15-minute acquisition of neat (+)-α-pinene 
control (separate 75 μm BaF2 cell) yielded a VCD spectrum in agreement with literature 
spectra.  IR and VCD spectra were background-corrected using a 30-minute block IR 
acquisition of the empty instrument chamber under gentle N2 purge, and were solvent 
corrected using a 4-hour (4 blocks, 3120 scans per block) IR/VCD acquisition of CDCl3 
in the same 100 μm BaF2 cell.  The reported spectra represent the result of block 
averaging. 
entry compound analytic conditions ee (%)
8 94SFC, Chiralpak IC, λ = 210 nm
3% IPA/CO2, 2.5 mL/min







9 90SFC, Chiralpak AD-H, λ = 210 nm
5% IPA/CO2, 2.5 mL/min
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Computational Protocol.  The arbitrarily chosen (S) enantiomer of compound 17g was 
subjected to an exhaustive initial molecular mechanics-based conformational search 
(MMFF94 force field, 0.08 Å geometric RMSD cutoff, and 30 kcal/mol energy window) 
as implemented in MOE 2019.0102 (Chemical Computing Group, Montreal, CA).  All 
conformers retained the (S) configuration.  All MMFF94 conformers under a 10 kcal/mol 
energy window were then subjected to geometry optimization, harmonic frequency 
calculation, and VCD rotational strength evaluation using density functional theory.  All 
quantum mechanical calculations first utilized the B3LYP functional, small 6-31G* basis, 
and IEFPCM model (chloroform solvent) as an initial filter, followed by subsequent 
optimization using B3PW91 functional, cc-pVTZ basis, and implicit IEFPCM 
chloroform solvation model on all IEFPCM-B3LYP/6-31G* conformers below 5 
kcal/mol.   All calculations were performed with the Gaussian 16 program system (Rev. 
C.01; Frisch et al., Gaussian, Inc., Wallingford, CT).  Resultant IEFPCM-B3PW91/cc-
pVTZ harmonic frequencies were scaled by 0.98.	 All structurally unique conformers 
possessing all positive Hessian eigenvalues were Boltzmann weighted by relative free 
energy at 298.15 K.  The predicted IR and VCD frequencies and intensities of the 
retained conformers were convolved using Lorentzian line shapes (γ = 4 cm-1) and 
summed using the respective Boltzmann weights to yield the final predicted IR and VCD 
spectra of the (S) enantiomer of 17g.  The predicted VCD of the corresponding (R) 
enantiomer was generated by inversion of sign.  From the reasonable agreement between 
the predicted and measured IR and VCD spectra in the useful range (1000-1400 cm-1; see 
below) supported by a separate, optical rotation-based assignment (see Method 2), the 
absolute configuration of 17g was established as (S). 
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Figure 2.1 Experimental (left) and computed (right) IR and VCD spectra for 17g. 
	
 
Method 2 – Optical Rotation (OR): 
Computational Protocol.  The ensemble of unique IEFPCM-B3PW91/cc-pVTZ 
conformers of the (S)-enantiomer of 17g  generated in Method 1 above were subjected to 
optical rotation calculation at 589.0 nm using the B3LYP hybrid density functional, the 
large and diffuse 6-311++G(2df,2pd) basis set, and the IEFPCM implicit chloroform 
solvent model.  From the computed IEFPCM-B3PW91/cc-pVTZ free energies at 298.15 
K and IEFPCM-B3LYP/6-31++G(2df,2pd) optical rotations, a Boltzmann-weighted OR 
value of –34.7° was determined for the (S)-configuration 17g.  (Weighted OR values 
instead of using IEFPCM-B3PW91/cc-pVTZ total energies or IEFPCM-B3LYP/6-
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31++G(2df,2pd)//IEFPCM-B3PW91/cc-pVTZ total energies were found to be –42.5° and 
–39.2°, respectively). 
As the measured optical rotation of 17g was found to be –34.54° (CHCl3 solvent, 
25 °C, c = 0.95), the absolute configuration of 17g is therefore assigned as (S), consistent 
with the configuration assigned using the VCD method. 
2.7.4.2 Determination of Absolute Configuration of 17a via VCD and OR 
Method 1 – Vibrational Circular Dichroism (VCD): 
Experimental Protocol.  A solution of 17a (55 mg/mL) was prepared in CDCl3 and 
loaded into a front-loading SL-4 cell (International Crystal Laboratories) possessing BaF2 
windows and 100 μm path length.   Infrared (IR) and VCD spectra were acquired on a 
BioTools ChiralIR-2X VCD spectrometer as a set of 30 one-hour blocks (30 blocks, 3120 
scans per block) in dual PEM mode.  A 15-minute acquisition of neat (-)-α-pinene control 
(separate 75 μm BaF2 cell) yielded a VCD spectrum in agreement with literature spectra.  
IR and VCD spectra were background-corrected using a 30-minute block IR acquisition 
of the empty instrument chamber under gentle N2 purge, and were solvent corrected using 
a 4-hour (4 blocks, 3120 scans per block) IR/VCD acquisition of CDCl3 in the same 100 
μm BaF2 cell as that used for sample acquisition.  The reported spectra represent the 
result of block averaging. 
Computational Protocol.  The arbitrarily chosen (R) enantiomer of compound 17a was 
subjected to an exhaustive initial molecular mechanics-based conformational search 
(MMFF94 force field, 0.08 Å geometric RMSD cutoff, and 30 kcal/mol energy window) 
as implemented in MOE 2019.0102 (Chemical Computing Group, Montreal, CA).  All 
conformers retained the (R) configuration.  All MMFF94 conformers under a 10 kcal/mol 
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energy window were then subjected to geometry optimization, harmonic frequency 
calculation, and VCD rotational strength evaluation using density functional theory.  All 
quantum mechanical calculations first utilized the B3LYP functional, small 6-31G* basis, 
and IEFPCM model (chloroform solvent) as an initial filter, followed by subsequent 
optimization using B3PW91 functional, cc-pVTZ basis, and implicit IEFPCM 
chloroform solvation model on all IEFPCM-B3LYP/6-31G* conformers below 3 
kcal/mol.   All calculations were performed with the Gaussian 16 program system (Rev. 
C.01; Frisch et al., Gaussian, Inc., Wallingford, CT).  Resultant IEFPCM-B3PW91/cc-
pVTZ harmonic frequencies were scaled by 0.98.	 All structurally unique conformers 
possessing all positive Hessian eigenvalues were Boltzmann weighted by relative free 
energy at 298.15 K.  The predicted IR and VCD frequencies and intensities of the 
retained conformers were convolved using Lorentzian line shapes (γ = 4 cm-1) and 
summed using the respective Boltzmann weights to yield the final predicted IR and VCD 
spectra of the (R) enantiomer of 17a.  The predicted VCD of the corresponding (S) 
enantiomer was generated by inversion of sign.  From the reasonable agreement between 
the predicted and measured IR and VCD spectra in the useful range (1050-1375 cm-1; see 
below), the absolute configuration of 17a is proposed, with moderate confidence, to 
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Figure 2.2 Experimental (left) and computed (right) IR and VCD spectra for 17a. 
	
(Attempted) Method 2 – Optical Rotation (OR): 
Computational Protocol.  The ensemble of unique IEFPCM-B3PW91/cc-pVTZ 
conformers of the (R) enantiomer of 17a  generated in Method 1 above were subjected to 
optical rotation calculation at 589.0 nm using the B3LYP hybrid density functional, the 
large and diffuse 6-311++G(2df,2pd) basis set, and the IEFPCM implicit chloroform 
solvent model.  Unlike the case of 17g, the geometric and energetic characteristics of 17a 
(including a preponderance of boat-like structures among the lowest energy conformers) 
give rise to individual, per-conformer optical rotations which fluctuate too greatly in sign 
to be confidently weighted and summed in order to compare with the experiment (for 
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which the measured value of +3.47° is also too close to zero to be compared to theory 
with any degree of confidence).  The individual relative energies, free energies, and 
optical rotational signatures of each conformer of 17a (again, not used for assignment of 
17a, but provided for transparency) are provided in the accompanying Microsoft Excel 
file. 
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Figure A3.3 13C NMR (125 MHz, CDCl3) of compound 14. 
 
Figure A3.2 Infrared spectrum (Thin Film, NaCl) of compound 14. 
 




















































































































 Figure A3.6 13C NMR (100 MHz, CDCl3) of compound 23. 
 
Figure A3.5 Infrared spectrum (Thin Film, NaCl) of compound 23. 
 























































































































 Figure A3.9 13C NMR (100 MHz, CDCl3) of compound 15. 
 
Figure A3.8 Infrared spectrum (Thin Film, NaCl) of compound 15. 
 

















































































































 Figure A3.12 13C NMR (100 MHz, CDCl3) of compound 16a. 
 
Figure A3.11 Infrared spectrum (Thin Film, NaCl) of compound 16a. 
 
























































































































 Figure A3.15 13C NMR (100 MHz, CDCl3) of compound 16b. 
 
Figure A3.14 Infrared spectrum (Thin Film, NaCl) of compound 16b. 
 
























































































































 Figure A3.18 13C NMR (100 MHz, CDCl3) of compound 16c. 
 
Figure A3.17 Infrared spectrum (Thin Film, NaCl) of compound 16c. 
 



















































Figure A3.19 19F NMR (282 MHz, CDCl3) of compound 16c. 
 
















































































































































 Figure A3.22 13C NMR (100 MHz, CDCl3) of compound 16d. 
 
Figure A3.21 Infrared spectrum (Thin Film, NaCl) of compound 16d. 
 























































































































 Figure A3.25 13C NMR (100 MHz, CDCl3) of compound 16e. 
 
Figure A3.24 Infrared spectrum (Thin Film, NaCl) of compound 16e. 
 

























































































































 Figure A3.28 13C NMR (100 MHz, CDCl3) of compound 16f. 
 
Figure A3.27 Infrared spectrum (Thin Film, NaCl) of compound 16f. 
 




















































































































 Figure A3.31 13C NMR (100 MHz, CDCl3) of compound 16g. 
 
Figure A3.30 Infrared spectrum (Thin Film, NaCl) of compound 16g. 
 





















































































































 Figure A3.34 13C NMR (100 MHz, CDCl3) of compound 16h. 
 
Figure A3.33 Infrared spectrum (Thin Film, NaCl) of compound 16h. 
 
















































































































Figure A3.37 13C NMR (100 MHz, CDCl3) of compound 16i. 
 
Figure A3.36 Infrared spectrum (Thin Film, NaCl) of compound 16i. 
 














































































































 Figure A3.40 13C NMR (100 MHz, CDCl3) of compound 17a. 
 
Figure A3.39 Infrared spectrum (Thin Film, NaCl) of compound 17a. 
 













































































































 Figure A3.43 13C NMR (100 MHz, CDCl3) of compound 17b. 
 
Figure A3.42 Infrared spectrum (Thin Film, NaCl) of compound 17b. 
 
















































































































Figure A3.46 13C NMR (100 MHz, CDCl3) of compound 17c. 
 
Figure A3.45 Infrared spectrum (Thin Film, NaCl) of compound 17c. 
 



















































Figure A3.47 19F NMR (282 MHz, CDCl3) of compound 17c. 
 


















































































































Figure A3.50 13C NMR (100 MHz, CDCl3) of compound 17d. 
 
Figure A3.49 Infrared spectrum (Thin Film, NaCl) of compound 17d. 
 
















































































































 Figure A3.53 13C NMR (100 MHz, CDCl3) of compound 17e. 
 
Figure A3.52 Infrared spectrum (Thin Film, NaCl) of compound 17e. 
 










































































































 Figure A3.56 13C NMR (100 MHz, CDCl3) of compound 17f. 
 
Figure A3.55 Infrared spectrum (Thin Film, NaCl) of compound 17f. 
 














































































































 Figure A3.59 13C NMR (100 MHz, CDCl3) of compound 17g. 
 
Figure A3.58 Infrared spectrum (Thin Film, NaCl) of compound 17g. 
 























































































































 Figure A3.62 13C NMR (100 MHz, CDCl3) of compound 17h. 
 
Figure A3.61 Infrared spectrum (Thin Film, NaCl) of compound 17h. 
 














































































































Figure A3.65  13C NMR (100 MHz, CDCl3) of compound 17i. 
 
Figure A3.64 Infrared spectrum (Thin Film, NaCl) of compound 17i. 
 














































































































 Figure A3.68 13C NMR (100 MHz, CDCl3) of compound 18. 
 
Figure A3.67 Infrared spectrum (Thin Film, NaCl) of compound 18. 
 















































































































Figure A3.71 13C NMR (100 MHz, CD3OD) of compound 19. 
 
Figure A3.70 Infrared spectrum (Thin Film, NaCl) of compound 19. 
 











































































































 Figure A3.74 13C NMR (100 MHz, CD3OD) of compound 20. 
 
Figure A3.73 Infrared spectrum (Thin Film, NaCl) of compound 20. 
 












































































































 Figure A3.77 13C NMR (100 MHz, CDCl3) of compound 21. 
 
Figure A3.76 Infrared spectrum (Thin Film, NaCl) of compound 21. 
 












































































































 Figure A3.80 13C NMR (100 MHz, CDCl3) of compound 22. 
 
Figure A3.79 Infrared spectrum (Thin Film, NaCl) of compound 22. 
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Cycloadditions of Oxacyclic Allenes and a Catalytic Asymmetric 
Entryway to Enantioenriched Cyclic Allenes † 
 
 
A4.1   INTRODUCTION 
As shown in Chapter 2, we have successfully developed the Pd-catalyzed 
enantioselective decarboxylative allylic alkylation of cyclic siloxyketones and 
demonstrated the utility of the resulting silicon-containing heterocycles for the 
synthesis of highly oxygenated acyclic quaternary building blocks. Along with 
these b-silylated substrates, we have also initiated the development of a Pd-
catalyzed allylic alkylation of a-silylated oxacyclic ketones in collaboration with 
	
	
†	This research was performed in collaboration with Michael M. Yamano, Rachel R. Knapp, and Melissa 
Ramirez. Portions of this chapter have been reproduced with permission from Yamano, M. M.; Knapp, R. 
R.; Ngamnithiporn, A.; Ramirez, M.; Houk, K. N.; Stoltz, B. M.; Garg, N. K. Angew. Chem. Int. Ed.. 2019, 
58, 5653–5657. ã 2019 Wiley-VCH. 
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the Garg lab at UCLA. We envisioned this motif to provide an entryway to 
enantioenriched cyclic allenes which could be subsequently employed in (4+2), 
(3+2), and (2+2) cycloaddition reactions, providing enantioselective access to a 
wide variety of complex heterocyclic scaffolds. 
Despite once being mere scientific curiosities, strained cyclic intermediates 
have become a popular arena for chemical discoveries. A notable breakthrough in 
the field was the discovery of benzyne (24), initially proposed by Wittig in 1942 
and validated by Roberts in 1953 (Figure A4.1).1 In the modern era, benzyne (24) 
and other cyclic alkynes are readily used to make natural products,2 medicinal 
agents,3 agrochemicals,4 materials,5 tools for chemical biology,6 and ligands for 
catalysis.7,8 The related intermediate 1,2-cyclohexadiene (25) has generally 
received less attention, despite being validated not long after benzyne (24) in 
1966.9 Historically, theoretical studies of 25 and its derivatives have been 
popular.10 However, only recently has 25 seen synthetic use in cycloadditions.11 
This is largely due to its ability to be accessed under mild fluoride-mediated 
conditions from silyl triflate 26.12,13 
One exciting opportunity in the field of strained cyclic intermediates is the 
ability to access heterocyclic allenes. Early efforts in this field relied on harsh 
reaction conditions;14,15 however, we recently demonstrated that azacyclic allenes 
27 (Figure A4.1) can be accessed using mild reaction conditions. Moreover, using 
chiral separation technology, enantioenriched 27 was intercepted (R=Cbz, R'=H, 
R''=Me), and its stereospecific trapping allowed for a unique approach to access 
enantioenriched cycloadducts.16 
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Figure A4.1 Highlights of benzyne and cyclic allene chemistry and cycloadditions of oxacyclic 
allenes described in this study. 
 
 
Given the potential for heterocyclic allenes to provide a facile means to rapidly 
assemble stereochemically-rich scaffolds,16 we questioned whether oxacyclic allenes 29 
could be employed efficiently in cycloadditions to access oxygen-containing 
heterocycles. 17  Oxygenated heterocycles are often seen in natural products and 
drugs 18 , 19 , 20 , 21  and are known bioisosteres for their nitrogen and sulfur-containing 
counterparts.22 A single report by Christl demonstrated that 29 (R'=H) could be generated 
using the Doering–Moore–Skattebøl rearrangement, however, this required harsh 
organolithium-based conditions.14 If 29 could be generated under mild conditions from 
silyl triflates 28, the untapped synthetic utility of this species could be unlocked. 
Additionally, we sought to establish a catalytic, asymmetric method to access 29 in 
enantioenriched form, ideally by preparing an enantioenriched precursor to the desired 
allene 29. By accessing enantioenriched 28, we could explore the possibility of 
transferring stereochemical information from allene precursor 28 to cycloadduct 30, via a 
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point chirality/axial chirality/point chirality transfer process. The results presented herein 
not only demonstrate the scope and utility of oxacyclic allene cycloadditions, but also 
showcase an exciting strategy that merges asymmetric catalysis with cyclic allene 
chemistry as a means to access enantioenriched scaffolds. 
 
A4.2   COMPUTATIONAL ANALYSIS OF OXACYCLIC ALLENE 31 
Density functional theory (DFT) calculations on the structure of heterocyclic 
allene 31 were performed using ωB97XD/6-31G(d) (Figure A4.2).10a,10c,10d,23 The C=C 
bond length of the allene is 1.32 Å, which is only slightly longer than the C=C bond 
length in a linear allene.16 Furthermore, the internal angle at the central allene carbon is 
133°, which is a significant deviation from the typical internal angle of 180° seen in 
linear allenes. The allene p orbitals in 31 are not perfectly orthogonal, resulting in the C–
H bonds being twisted out-of-plane (i.e., 38° and 41°). Thus, 31 is inherently chiral, 
analogous to linear allenes. The ground state geometry deviates from C2 symmetry 
because the molecule adopts an envelope shape; inversion of the envelope requires only 
0.8 kcal/mol. Interestingly, oxacyclic allene 31 is calculated to possess 31.0 kcal/mol of 
strain energy, which is nearly 4 kcal/mol more than the azacyclic variant we previously 
reported.16 This difference can be attributed to the smaller atomic radius of oxygen and 
the shorter C–O bond length relative to the C–N bond length in the azacyclic variant. The 
significant strain associated with oxacyclic allene 31 was expected to promote rapid 
cycloadditions. 
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A4.3   SUBSTRATE SYNTHESIS 
With the aim of accessing oxacyclic allene 31, we first targeted silyl triflate 35 
(Scheme A4.1), given the wide synthetic utility of silyl triflates as precursors to strained 
alkyne and allene intermediates.12,24 Bromoketone 32 (commercially available or readily 
synthesized from tetrahydro-4-pyranone) was converted to triethylsilyl enol ether 33 
upon treatment with DABCO and TESCl.25 Subsequent retro-Brook rearrangement 
furnished the desired a-silyl ketone 34. Lastly, triflation afforded silyl triflate 35.16 Our 
scalable,26 three step synthesis of 35 provides a new strategy to synthesize a-silyl ketones 
en route to cyclic allene precursors. Currently, a-silyl ketones are most commonly 
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Scheme A4.1 Synthesis of silyl triflate.  
 
 
A4.4   CYCLOADDITIONS OF OXACYCLIC ALLENE 
 With silyl triflate 35 in hand, we generated and trapped 31 in Diels–Alder, (3+2), 
and (2+2) cycloadditions. By simply employing a variety of dienes, a number of 
cycloadducts were prepared in good to excellent yields (Table A4.1, entries 1–5).28 In 
almost all cases, the reactions were performed at 23 °C, thus highlighting the mildness of 
the reaction conditions. Although the range of disastereoselectivities is variable, in all 
examples, the major diastereomer observed is the endo product. Furthermore, the 
observed selectivities are supported by computations as the endo transition states were 
found to be more energetically favorable compared to the exo transition states.26 It should 
be noted that in each case, the products formed are considerably complex from a 
structural perspective, each bearing three stereocenters, a bridged [2.2.1]-bicyclic 























i.  LDA, THF, –78 °C
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Table A4.1 Mild generation of oxacyclic allene 31 and its trapping in Diels–Alder 
cycloadditions.a 
 
[a] The major diastereomer is shown. [b] Yields reflect an average of two isolation experiments. [c] Diastereomeric ratios 
were determined by 1H NMR analysis of the crude reaction mixture. [d] The reaction was performed at 60 °C for 2.5 h using 
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Figure A4.3 (3+2) cycloadditions with nitrones. The major diastereomeric product is shown. 
Yields reflect an average of two isolation experiments. Diastereomeric ratios were 
determined by 1H NMR analysis of the crude reaction mixture. 
 
The results of the (3+2) and (2+2) cycloadditions are shown in Figure A4.3 and 
Table A4.2, respectively. The use of simple nitrones gave high yields of isoxazolidine 
products 50–52, whereas nitrones bearing either an indole or quinoline unit delivered 
cycloadducts 53 and 54. We also evaluated two cyclic nitrones where R'' and R''' of 48 
were tethered, which furnished fused tri-  and tetracyclic products 55 and 56. 
Additionally, a ketone-derived nitrone was utilized, ultimately giving rise to the 
heteroatom-rich trifluoromethylated product 57. Azomethine imines 60 and 62 were 
tested, giving rise to the corresponding pyrazolidines 61 and 63 in good to excellent 
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formation of isoxazoline 65 in 91% yield (entry 3). With regard to a (2+2) cycloaddition, 
the use of indene gave cyclobutane 67 in excellent yield and with high regioselectivity 
(entry 4). 
Table A4.2 Additional (3+2) and (2+2) cycloadditions.a 
 
[a] The major diastereomer is shown.[b] Yields reflect an average of two isolation experiments. [c] Diastereomeric ratios 
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Overall, silyl triflate 35 was elaborated to 17 different sp3-rich heterocyclic 
cycloadducts. Several of these bear a multitude of rings, stereocenters, and heteroatoms, 
thus showcasing the value of oxacyclic allenes for the rapid generation of complex 
scaffolds. Accordingly, this methodology should be especially valuable to those pursuing 
modern drug discovery efforts.17 
 
A4.5   CATALYTIC ASYMMETRIC APPROACH TO OXACYCLIC ALLENES 
AND EVALUATION OF ENANTIOSPECIFICITY 
As noted earlier, one of the most exciting opportunities regarding cyclic allene 
chemistry is the possibility of intercepting enantioenriched allenes for the synthesis of 
enantioenriched cycloadducts. In a seminal study, Christl and Engels generated 1-phenyl-
1,2-cyclohexadiene in enantioenriched form, as judged by the formation of an 
enantioenriched cycloadduct, albeit in low yield, likely owing to the necessary use of 
organolithium reagents.29 Our laboratory recently disclosed a mild, alternative strategy 
whereby silyl triflate precursors to the desired cyclic allenes could be employed in 
enantioenriched form.16 However, in both cases, the key substrates were only accessible 
via chiral separation technologies. A catalytic asymmetric strategy to access 
enantioenriched cyclic allene precursors has not yet been disclosed. 
Our efforts in this area are highlighted in Scheme A4.2. Enol carbonate 68 was 
formed by intercepting the enolate intermediate generated during the retro-Brook 
rearrangement of 33 (see Scheme A4.1). This set the stage for a Pd-catalyzed 
decarboxylative asymmetric allylic alkylation. Allylation was attractive, given that allyl 
groups serve as versatile handles for further manipulation.30 After extensive 
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experimentation,26 it was found that treatment of 68 with Pd(dmdba)2 and (S)-(CF3)3-tBu-
PHOX ligand (L28) in toluene at –10 °C gave the desired ketone 69 in 81% ee and 75% 
yield. This is the first example of a decarboxylative asymmetric allylic alkylation reaction 
being performed on an a-silyl-substituted enol carbonate. In fact, decarboxylative 
asymmetric allylic alkylations on substrates bearing a-heteroatoms are significantly 
underdeveloped.30,31 Ketone 69 was converted to silyl triflate 70 in one-step, thus 
establishing the first catalytic asymmetric strategy for the synthesis of enantioenriched 
cyclic allene precursors. 
Silylated enol triflate 70 was treated with trapping agent 72 or 42 in the presence 
of CsF in acetonitrile at 23 °C. Interestingly, the nitrone cycloadduct, isoxazolidine 73, 
was obtained in only 21% ee. On the other hand, the Diels–Alder cycloadduct, oxabicycle 
74, was obtained in 81% ee (>20:1 dr), reflective of complete transfer of stereochemical 
information. Given this latter result, we surmise that enantioenriched 71 is formed under 
the mild reaction conditions with complete transfer of stereochemical information. In the 
case of the nitrone trapping, previous computational studies have demonstrated that 
trapping may occur through either a stepwise or concerted pathway,11a which acounts for 
the partial loss of stereochemical information.32 However, in the case of the Diels–Alder 
reaction, it is likely that a concerted pathway is operative, based on our recent 
computational investigation of azacyclic allenes,16 thus leading to complete transfer of 
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Scheme A4.2 Catalytic asymmetric approach and cycloaddition results.  
 
The overall conversion of 70 to 71 to 74 deserves special attention. This is a 
scenario wherein the silyl-bearing stereocenter in 70 was ultimately accessed by 
asymmetric catalysis. The point chirality in 70 is then transferred to the axially chiral 
transient intermediate 71, which is then relayed to product 74, which possesses point 
chirality. Enantioenriched cycloadduct 74 contains three stereocenters, none of which 
were present in the starting material that bears only one stereocenter. The transformation 
occurs preferentially with the olefin more distal to the 2-phenyl allyl group undergoing 
Pd(dmdba)2 (10 mol %)
L28 (12.5 mol %)
toluene (0.005 M), –10 °C
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cycloaddition. This is presumably because of favorable electronic interactions in the 
transition state based on our prior studies,16 however, we cannot rule out the steric impact 
of the 2-Ph allyl chain as a contributor to the observed regioselectivity. 
 
A4.6   CONCLUSIONS 
We have discovered an efficient synthetic route to prepare a silyl triflate precursor 
to 3,4-oxacyclohexadiene, the first generation of an oxacyclic allene under mild 
conditions, and the in situ trapping of the oxacyclic allene in diastereo- and regioselective 
cycloadditions. These efforts collectively establish the synthetic utility of oxacyclic 
allenes for the rapid generation of complex heterocyclic scaffolds. In addition, we have 
uncovered the first catalytic, asymmetric approach to access an enantioenriched cyclic 
allene precursor. This relies on a Pd-catalyzed allylic allylation, performed for the first 
time on an a-silyl substituted substrate, ultimately permitting access to the necessary 
enantioenriched silyl triflate precursor. We show that trapping of the enantioenriched 
oxacyclic allene in a Diels–Alder reaction occurs with complete transfer of 
stereochemical information via a point chirality/axial chirality/point chirality transfer 
process. These results showcase an exciting strategy that merges asymmetric catalysis 
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A4.7  EXPERIMENTAL SECTION 
Supporting information, which includes detailed experimental procedures, 
spectroscopic data, and computational methods can be found under: 
https://onlinelibrary.wiley.com/doi/full/10.1002/anie.201900503 
A4.7.1  Additional Optimization Results for Asymmetric Allylic Alkylation 
Table A4.3 Effects of ligands, solvents, and temperatures.a 
 
[a] Conditions: enol carbonate 75 (0.05 mmol), Pd2(dba)3 (5 mol %), and ligand (12.5 mol %).[b] Conversion determined by 
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>95 589 L46 23toluene
>95 05 L43 23toluene
16 >95 70L28 –10toluene
>95 537 L44 23toluene
75 76
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Table A4.4 Substrate, temperature, and concentration optimization experiments.a 
 
[a] Reactions performed at 23°C utilized Pd2(dba)3 while reactions performed at –10 °C utilized Pd(dmdba)2).[b] Determined 
by chital SFC analysis . [c] Determined by chiral SFC analysis of isolated product. [c] Determined by 1H NMR of crude 
















































Pd2(dba)3 (5 mol %) or Pd(dmdba)2 (10 mol %)a
ligand (12.5 mol %)
toluene (conc.), temperature
SiR3 R’ temperature conc. (M) %eeb
23 °C 0.033 62
23 °C 0.033 58
23 °C 0.033 70
–10 °C 0.005 75
–10 °C 0.005 74
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Concise Total Syntheses of (–)-Jorunnamycin A and (–)-Jorumycin 
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3.1   INTRODUCTION 
The bis-tetrahydroisoquinoline (bis-THIQ) natural products have been 
studied intensively by chemists and biologists alike during the 40+ years since 
their initial discovery due to their intriguing chemical structures, potent biological 
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activities, and unique mechanisms of action.1,2 Jorumycin (77, Figure 3.1) and its 
congeners ecteinascidin 743 (Et 743, 78) and jorunnamycin A (79) possess a 
pentacyclic carbon skeleton, highly oxygenated ring termini, and a central pro-
iminium ion (manifested either as a carbinolamine or an a-aminonitrile motif). 
This latter functionality serves as an alkylating agent in vivo, resulting in covalent 
modification of DNA in a process that ultimately leads to cell death.3 The promise 
of these natural products as anticancer agents has been realized in the case of Et 
743 (Yondelis®, trabectedin), which has been approved in the United States, 
Europe, and elsewhere for the treatment of a variety of drug-resistant and 
unresectable soft-tissue sarcomas and ovarian cancer.3 Although 78 is available 
from nature, isolation of one gram of the drug would require more than one ton of 
biological material. For this reason, the successful application of 78 as an 
antitumor agent has necessitated its large-scale chemical synthesis, a 21-step 
process that begins with cyanosafracin A, a fermentable and fully functionalized 
bis-THIQ natural product.4 This has restricted medicinal chemistry endeavors 
through this route to the production of only compounds with a high degree of 
similarity to the natural products themselves. 
Although 77 and 79 possess quinone rings, these moieties are rapidly 
reduced in cells to their hydroquinone oxidation states, more closely resembling 
those of 78.5 These highly electron-rich functional groups are key components in 
the biosynthetic pathways of the bis-THIQ’s, which are forged by the action of 
Pictet–Spenglerase enzymes.6,7 Previously reported chemical syntheses of bis-
THIQ natural products feature elegant and creative application of electrophilic 
aromatic substitution (EAS) chemistry for the construction of one or more of the 
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THIQ motifs. Though highly enabling, this approach has also limited the synthesis 
of non-natural analogs to highly natural product-like derivatives. As a key 
example, despite the scores of analogs produced over the past few decades,8,9,10,11 
the majority of the derivatives focus on substitution of the heteroatom moiety 
appended to the B-ring (cf. structure 80, Figure 3.1), and only a select few possess 
significant structural and substitutional variation around the aromatic or quinone 
A- and E-rings.8–11 Furthermore, derivatives possessing electron-withdrawing 
groups on these rings are inaccessible using biomimetic approaches, as these 
would inhibit the EAS chemistry used to construct the THIQs. This latter point is 
significant, as studies have indicated that the smaller bis-THIQ natural products 
such as 77 and 79 are more susceptible to metabolic degradation than Et 743 and 
other larger bis-THIQs,12,13 and the installation of electron-withdrawing groups is a 
commonly employed strategy to improve a drug molecule’s metabolic stability.14 
Jorumycin has been the target of four total syntheses15,16,17,18 and two 
semisyntheses19,20 since its isolation in 2000,21 and jorunnamycin A has frequently 
been prepared en route. Jorumycin displays IC50’s of 0.24 nM vs. A549 lung 
cancer, 0.49 nM vs. DU145 prostate cancer, and 0.57 nM vs. HCT116 colon 
cancer,17,19,21 among others, thus offering immense therapeutic potential. 
Furthermore, jorumycin and jorunnamycin A are appealing targets for further 
synthetic elaboration: the oxygen substitution appended to the B-ring (cf. structure 
80, X = OH, Figure 3.1) could allow rapid diversification to the ecteinascidin, 
saframycin, safracin, and renieramycin scaffolds.1 To overcome the limitations of 
the current state of the art with respect to analog diversity, we sought an 
alternative, non-biomimetic route to these natural products. 
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Figure 3.1 Bis-tetrahydroisoquinoline natural products. 
 
 
3.2   GENERAL SYNTHETIC STRATEGY 
Specifically, we envisioned the retrosynthetic strategy shown in Scheme 3.1. We 
posited that a late stage oxygenation event to provide jorumycin (77) would greatly 
simplify the construction of the precursor, pentacycle 81. We then considered 
disconnection of the central C-ring (cf. Figure 3.1) through cleavage of the lactam moiety 
in 81, providing bis-THIQ compound 82. Critically, bis-THIQ structure 82 was 
recognized as a potential product of an enantioselective hydrogenation of bis-isoquinoline 
83. The central biaryl bond of 83 could be formed through a C–H cross-coupling 











































































Our Approach (this research):
Bis-Tetrahydroisoquinoline (bis-THIQ) natural products:  Alkaloids that display exceptional anticancer activity
A non-biomimetic approach will produce complementary analogs for bioactivity and medicinal chemistry studies
Pictet–Spengler, Bischler–Napieralski Cross Coupling/Reductive Cyclization
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synthetic challenge. As a key advantage, isoquinolines 84 and 85 could be prepared 
through the application of any known method, not limited only to those requiring highly 
electron-rich and p-nucleophilic species. Crucially, this approach would allow access to 
the natural products themselves, as well as derivatives featuring substantial structural 
and/or electronic variation. 
Scheme 3.1 Retrosynthesis of (–)-jorumycin. 
 
 
3.3   TOTAL SYNTHESIS OF JORUMYCIN 
As shown in Scheme 3.2, we initiated our synthetic studies with the Sonogashira 
coupling of aryl bromide 86 (available in two steps from 3,5-dimethoxybenzaldehyde, 
see Experimental Section) with tert-butyldimethylsilyl propargyl ether (87); simply 
adding solid hydroxylamine hydrochloride to the reaction mixture after the coupling 
provided oxime-bearing alkyne 88 in 99% yield. Catalytic silver(I) triflate activated the 
alkyne toward nucleophilic attack by the oxime, directly generating isoquinoline N-oxide 
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triflate 85 by using aryne-based methodology developed in our laboratories.23 Silyl aryl 
triflate 89 (available in 3 steps from 2,3-dimethoxytoluene, see Experimental Section) 
was treated with cesium fluoride to generate the corresponding aryne intermediate in situ 
(not shown), which underwent aryne acyl-alkylation with in situ condensation to provide 
3-hydroxy-isoquinoline 91 in 45% yield. Reaction with trifluoromethanesulfonic 
anhydride provided electrophilic coupling partner 85 in 94% yield.  
Scheme 3.2 Synthesis of isoquinoline monomers 84 and 85 and Fagnou coupling. 
 
With working routes to both isoquinoline monomers in hand, we turned our 
attention to the palladium-catalyzed cross-coupling reaction which would be used to 
construct the carbon skeleton of jorumycin. We were pleased to find that isoquinolines 84 
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Pd(OAc)2 (20 mol %)
P(t-Bu)2Me•HBF4 (50 mol %)
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workers to provide bis-isoquinoline 93 in 94% yield on a 7-gram scale.24 This large-scale 
application of C–H activation likely proceeds through a transition state similar to 92 and 
allows for the direct construction of 93 without the need for prefunctionalization.25 The 
excess of N-oxide 84 required to achieve maximum levels of efficiency appears to be 
only a kinetic factor, as all excess 84 was recovered after the reaction.  
At this stage, we sought to install the level of oxidation necessary to initiate our 
hydrogenation studies (Scheme 3.3). Specifically, this required selective oxidation of the 
nitrogen-adjacent methyl and methylene groups on the B- and D-rings, respectively. We 
attempted a double-Boekelheide rearrangement to transpose the N-oxidation to both C–
positions simultaneously, effecting formal C–H oxidation reactions.26 Unfortunately, 
after oxidation to intermediate bis-N-oxide 94, only the B-ring azine underwent 
rearrangement. Despite this setback, we found that it was possible to parlay this reactivity 
into a one-pot protocol by adding acetic anhydride upon complete oxidation, providing 
differentially protected diol 95 in 62% yield. N–O bond cleavage and oxyl-mediated 
oxidation provided bis-isoquinoline 83 in two additional steps. To date, we have 
produced more than 5 grams of bisisoquinoline 83. 
With a scaleable route to isoquinoline 83 in hand, we turned our attention to the 
key hydrogenation event. If successful, this strategic disconnection would add four molar 
equivalents of hydrogen, create four new stereocenters, and form the central C-ring 
lactam. Although the enantioselective hydrogenation of nitrogen-based heterocycles is a 
well-studied reaction, isoquinolines are possibly the most challenging and least 
investigated substrates.27 To our knowledge only four reports existed prior to our studies 
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that describe asymmetric isoquinoline hydrogenation, and only one appears to tolerate 
1,3-disubstitution patterns.28,29,30,31 
Scheme 3.3 Synthesis of hydrogenation precursor 83. 
 
We nonetheless noted that metal-catalyzed imine and carbonyl reduction is a 
comparatively successful and well-studied transformation.32,33 We were drawn to the 
iridium catalyst developed by scientists at Ciba-Geigy (now Syngenta) for asymmetric 
ether-directed imine reduction in the preparation of Metolachlor.34 Considering the 
positioning of the hydroxymethyl group appended to the B-ring of 83 and the electronic 
similarity of the adjacent C1–N p-bond to that of an imine, we posited that a similar 
catalytic system might be used to direct the initial reduction to this position (Scheme 3.4). 
Furthermore, the chelation mode was attractive as a scaffolding element to enable 
enantioselective Si-face reduction. In keeping with previous observations,28–31 we 
anticipated that full B-ring reduction would provide cis-mono-THIQ 97 as the major 
product. We believed that 97 would then act as a tridentate ligand for a metal ion 
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coordination environment of metal-bound 97•M would direct D-ring hydrogenation from 
the same face. Finally, the all-syn nature of 82 places the ester moiety in proximity to the 
B-ring secondary amine, and we expected lactamization to be rapid. If successful, this 
self-reinforcing diastereoselectivity model would allow for control over the four new 
stereocenters and produce the bis-THIQ core in a single step. 
Scheme 3.4 Stereochemical rationale for the hydrogenation of bis-isoquinoline 83. 
 
Upon beginning our enantioselective hydrogenation studies, we found that we 
could identify trace amounts of conversion to mono-THIQ product 97 by using the 
catalyst mixture developed at Ciba-Geigy,34 thus confirming the accelerating effects of 
the pendent hydroxy directing group. Under these general conditions, we then performed 
a broad evaluation of more than 60 chiral ligands commonly used in enantioselective 



































































•  directed Si-face reduction of 83 leads to enantioenriched generation of intermediate 97
•  three-dimensional structure of 97•M leads to substrate-reinforced diastereoselectivity
enantio- and diastereoselective
hydrogenation
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provided 97 in at least 80% enantiomeric excess (ee) and with uniformly excellent 
diastereoselectivity (all >20:1 diastereomeric ratio, dr): (S)-(CF3)-t-BuPHOX (L28, Table 
3.1, Entry 2, 22% yield, –82% ee), (S,S)-Et-FerroTANE (L47, Entry 3, 26% yield, –87% 
ee), and (S,RP)-Xyliphos (L48, Entry 4, 30% yield, 80% ee). After evaluating these 
ligand classes further, we identified (S,RP)-BTFM-Xyliphos (L49)35 as a strongly 
activating ligand that provided mono-THIQ 97 in 83% yield, >20:1 dr, and in a 
remarkable 94% ee (Entry 5). Moreover, we were elated to find that ligand L49 formed a 
catalyst that provided pentacycle 81 as a single diastereomer in 10% yield. Further 
evaluation of the reaction parameters revealed that increasing temperature provided 
higher levels of reactivity, albeit at the expense of enantioselectivity (Entry 6, 31% yield 
of 97, 87% ee, 43% yield of 81). The best results were achieved by performing the 
reaction at 60 °C for 18 hours, and then increasing the temperature to 80 °C for 24 hours. 
Under these conditions, 81 was isolated in 59% yield with >20:1 dr and 88% ee (Entry 
7).36 In the end, doubling the catalyst loading allowed us to isolate 81 in 83% yield, also 
with >20:1 dr and 88% ee (Entry 8) on greater than 1 mmol scale. bis-THIQ 81 could be 
easily accessed in enantiopure form (>99% ee by HPLC) by crystallization from a slowly 
evaporating acetonitrile solution, and we were able to confirm the relative and absolute 
stereochemistry by obtaining an x-ray crystal structure on corresponding 4-bromophenyl 
sulfonamide 98. In the context of this synthesis, the relatively high catalyst loading (20 
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Table 3.1 Optimization of the hydrogenation reaction.a 
 
[a] Reactions performed in 9:1 toluene:acetic acid (0.02 M) using a 1.2:1 ligand:metal ratio and a 3:1 iodide:metal 
ratio under a hydrogen atmosphere (60 bar) for 18 h. [b] Measured by UHPLC-MS UV absorption vs. 1,3,5-
trimethoxybenzene internal standard unless otherwise noted. [c] Measured by chiral HPLC analysis. [d] Measured 
by 1H-NMR analysis of the crude reaction mixture. [e] Reaction performed at 60 ºC for 18 h, then the temperature 
was raised to 80 ºC and maintained at that temperature for 24 h. [f] Yield of isolated product after column 
chromatography using 10.5 mol % L49 in entry 7 and 21 mol % L49 in entry 8. [g] After one recrystallization. 
 
At this stage, we were poised to investigate the third and final key disconnection 
from our retrosynthetic analysis, namely, late-stage C–H oxidation of the arenes (Scheme 
3.5). To set up this chemistry the piperazinone N–H of 81 was methylated under 
reductive amination conditions in quantitative yield. Despite numerous attempts to effect 
catalytic C–H oxidation on this advanced intermediate, we found that a two-step 



































1 5 mol % 23 ºC 0%2%
2 5 mol % 60 ºC 0% ----22%
3 5 mol % 60 ºC 0% ----26%
4 5 mol % 60 ºC 0% ----30%
5 5 mol % 60 ºC 10% >20:183%
6 5 mol % 80 ºC 43% >20:131%
8 10 mol % 60 ºC → 80 ºC e 83% f 88% (>99%) g>20:13%
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aromatic positions, providing bis-THIQ 99 in 68% yield. From here, we once again 
turned to catalysis, this time for the oxygenation of aryl halides. After extensive 
investigation, we found that Stradiotto and coworkers’ recently developed protocol for 
the hydroxylation of aryl halides was uniquely effective.37 Further optimization revealed 
that the combination of adamantyl BippyPhos ligand with Buchwald’s cyclometalated 
palladium(II) dimer was ideal,38 providing dihydroxylated bis-THIQ 100 in 46% yield, an 
impressive result for such a challenging coupling reaction on a sterically large, electron-
rich, and Lewis-basic substrate in the final stages of the synthesis. Partial lactam 
reduction with cyanide trapping proceeded in 50% yield, and oxidation of the phenols 
provided jorunnamycin A (79) in only 15 linear steps. We isolated hemiacetal 101 in 
33% yield, which was surprising given the generally low stability of acyclic hemiacetals.  





































































































(25 equiv), 45 °C
30 min
Pd G3 Dimer (50 mol %)
AdBippyPhos (200 mol %)
CsOH • H2O (10 equiv)
dioxane, 90 °C, 3 h
1) Li(EtO)2AlH2 (15 equiv)
THF, 0 °C, 45 min, then
AcOH, KCN, 50% yield
2)  DDQ (4 equiv), acetone, H2O
23 °C, 1 h
1)  aq. CH2O (1.85 equiv)
NaBH(OAc)3 (5 equiv)
DCE, 23 °C, 15 min
2) NCSac (2.1 equiv)
HFIP, 0 °C, 1 min
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Finally, we developed conditions for the conversion of jorunnamycin A into 
jorumycin in a single step, providing 77 in 68% yield in 16 linear steps (Scheme 3.4). 
Jorunnamycin A (79) and jorumycin (77) are produced in 0.24% and 0.17% yield, 
respectively, from commercially available materials, but key bis-THIQ 81, the branching 
point for derivative synthesis, is accessed over 10 steps in 5.0% overall yield on greater 
than 500 mg scale. These efforts are similar to Zhu and coworkers’ elegant synthesis of 
jorumycin with regard to brevity.16 
 
3.4   BIOLOGICAL EVALUATION OF BIS-THIQ ANALOGS 
Central to the anticancer activity of the bis-THIQ natural products is the capacity 
to alkylate DNA upon loss of water or cyanide from the central carbinolamine or a-
cyanoamine, respectively.39 After alkylation, compelling evidence suggests that 
formation of reactive oxygen species5 or DNA-protein cross-links8,40 leads to cell-cycle 
arrest or cell death. We therefore synthesized analogs 102–105, which feature the non-
oxygenated framework as well as all permutations of partial and full oxygenation. The 
activity of this series would allow us to determine the relative importance of the location 
and degree of oxygenation on the A- and E-rings, the structure-activity relationships of 
which have not previously been explored. 
With the backdrop that preclinical efficacy studies are complex and demanding, 
we conducted preliminary studies to probe the relative cytotoxicity of synthetic analogues 
102–105 and established that modifying one site on the scaffold greatly diminishes 
cytotoxicity, whereas other modifications conserved cytotoxicity. The cytostatic and 
cytotoxic properties of 102–105 were determined using long-term, growth-maximizing 
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assay conditions against 29 cancer cell lines known to be responsive in vitro to other 
general cytotoxics (Figure 3.2, also see section 3.6.6).41,42 Cells were routinely assessed 
for mycoplasma contamination using a multiplex PCR method and STR profiling for cell-
line authentication. This methodology differs markedly from the standard 72-hour, 
luminescence-based cytotoxicity assays employed most commonly for in vitro 
quantification of drug response. This approach was chosen as it is specifically well suited 
to determine the activity of compounds wherein anti-proliferative effects occur over a 
longer time period than standard cytotoxic agents. Perhaps not surprisingly, removal of 
both phenolic oxygens resulted in a complete loss in activity (i.e., 102, all IC50’s > 1 
µM), while fully oxygenated bis-THIQ 105 showed cytotoxicity. The most notable 
results were provided by 103 and 104, which possess A- and E-ring monohydroxylation, 
respectively. While compound 103, which is devoid of E-ring oxygenation, showed 
diminished activity, we were surprised to find that compound 104 featuring only E-ring 
oxygenation maintained a similar activity profile to fully oxygenated 105 (see section 
3.6.6). At the moment, we believe these data to be the result of general cytotoxicity, as 
opposed to cancer cell-specific activity. As a reference, three out of four previously 
known anticancer agents that function through general cytotoxicity showed similar levels 
of activity in our model. While more sophisticated studies are necessary to determine 
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Figure 3.2 Biological evaluation of non-natural analogs. 
 
 
3.5  CONCLUSIONS 
In conclusion, we have developed a synthesis of (–)-jorumycin (77) that is 
orthogonal to existing bis-THIQ syntheses, obviating the need for highly electron-rich 
and p-nucleophilic aromatic rings. The synthesis relies on an unprecedented combination 
of C–H cross-coupling assembly followed by asymmetric hydrogenation with self-
reinforcing diastereoselectivity to afford the skeleton of the bis-THIQ from relatively 
simple, achiral precursors. This will allow for the development of electron-deficient 
analogs that could be more metabolically stable than the natural products themselves. 
These analogs will have the potential to extend the still-largely untapped therapeutic 







































•  Cytotoxicity diminished upon E-ring deoxygenation  • •  Cytotoxicity maintained upon A-ring deoxygenation  •
102:  X = Y = H → both rings partially deoxygenated
103:  X = OH, Y = H → E-ring partially deoxygenated
104:  X = H, Y = OH → A-ring partially deoxygenated
105:  X = Y = OH → both rings fully oxygenated
Selective, partial oxygenation allows basic SAR development
MMAE
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3.6  EXPERIMENTAL SECTION 
3.6.1  MATERIALS AND METHODS 
Unless stated otherwise, reactions were performed at ambient temperature (23 °C) 
in flame-dried glassware under an argon atmosphere using dry, deoxygenated solvents 
(distilled or passed over a column of activated alumina).43 Commercially available 
reagents were used as received. Reactions requiring external heat were modulated to the 
specified temperatures using an IKAmag temperature controller. Thin-layer 
chromatography (TLC) was performed using E. Merck silica gel 60 F254 pre-coated 
plates (0.25 mm) and visualized by UV fluorescence quenching or potassium 
permanganate staining. Silicycle SiliaFlash P60 Academic Silica gel (particle size 40–63 
µm) was used for flash chromatography. Purified water was obtained using a Barnstead 
NANOpure Infinity UV/UF system. 1H and 13C NMR spectra were recorded on a Varian 
Inova 500 (500 MHz and 125 MHz, respectively) and a Bruker AV III HD spectrometer 
equipped with a Prodigy liquid nitrogen temperature cryoprobe (400 MHz and 100 MHz, 
respectively) and are reported in terms of chemical shift relative to CHCl3 (δ 7.26 and 
77.16, respectively). 19F and 31P NMR spectra were recorded on a Varian Inova 300 (282 
MHz and 121 MHz, respectively). Data for 1H NMR spectra are reported as follows: 
chemical shift (δ ppm) (multiplicity, coupling constant, integration). Infrared (IR) spectra 
were recorded on a Perkin Elmer Paragon 1000 Spectrometer and are reported in 
frequency of absorption (cm-1). Analytical chiral SFC was performed with a Mettler SFC 
supercritical CO2 analytical chromatography system with Chiralpak (AD-H) or Chiracel 
(OD-H) columns obtained from Daicel Chemical Industries, Ltd. High resolution mass 
spectra (HRMS) were obtained from the Caltech Center for Catalysis and Chemical 
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Synthesis using an Agilent 6200 series TOF with an Agilent G1978A Multimode source 
in mixed (Multimode ESI/APCI) ionization mode. Optical rotations were measured on a 
Jasco P-2000 polarimeter using a 100 mm path-length cell at 589 nm. For X-Ray 
structure determination (see Appendix 6), low-temperature diffraction data were collected 
on a Bruker AXS D8 VENTURE KAPPA diffractometer coupled to a PHOTON 100 
CMOS detector with K radiation ( = 1.54178 Å) from an IµS micro-source for the 
structure of compound P17208. The structure was solved by direct methods using 
SHELXS44 and refined against F2 on all data by full-matrix least squares with SHELXL-
201445 using established refinement techniques.46 All non-hydrogen atoms were refined 
anisotropically. All hydrogen atoms were included into the model at geometrically 
calculated positions and refined using a riding model. The isotropic displacement 
parameters of all hydrogen atoms were fixed to 1.2 times the U value of the atoms they 
are linked to (1.5 times for methyl groups). Unless otherwise noted, all disordered atoms 
were refined with the help of similarity restraints on the 1,2- and 1,3-distances and 
displacement parameters as well as rigid bond restraints for anisotropic displacement 
parameters. Compound P17208 crystallizes in the orthorhombic space group P21212 with 
one molecule in the asymmetric unit along with two molecules of isopropanol. The 
hydroxide group and both isopropanol molecules were disordered over two positions. The 
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3.6.2  EXPERIMENTAL PROCEDURES AND SPECTROSCOPIC DATA 
3.6.2.1 Synthesis of isoquinoline N-oxide  
 
Note: This procedure could be readily increased to 10 g scale with minimal loss in yield. 
3,5-dimethoxy-4-methylbenzaldehyde (107): The procedure was adapted from the 
method of Comins et al.47 N-methylpiperazine (670 µL, 6.6 mmol, 1.1 equiv) was 
dissolved in 20 mL THF and cooled to –20 ºC. n-Butyllithium (2.4 M, 2.65 mL, 6.3 
mmol, 1.05 equiv) was added in a dropwise fashion, resulting in an orange solution. The 
solution was stirred at this temperature 15 min before a solution of 3,5-
dimethoxybenzaldehyde (106, 1.00 g, 6.0 mmol, 1 equiv) in 3 mL THF was added in a 
dropwise fashion, causing a color change to yellow. The solution was stirred at this 
temperature 30 min before a second portion of n-butyllithium (2.4 M, 7.5 mL, 18.1 
mmol, 3 equiv) was added in a dropwise fashion. At this point, the flask was stored in a  
–20 ºC freezer for 24 h. The flask was re-submerged in a –20 ºC bath, and freshly 
distilled methyl iodide (2.25 mL, 36.1 mmol, 6 equiv) was added in a dropwise fashion, 
resulting in a mild exotherm. The solution was stirred 30 min at –20 ºC and was removed 
from its bath, warming to room temperature. After 30 min, the reaction was quenched by 
the addition of 20 mL 0.5 M HCl, and the solution was stirred 30 min open to air. The 
layers were separated and the aqueous phase was saturated with sodium chloride. The 
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product was purified by column chromatography (10% EtOAc/hex). Colorless solid, 1.03 
g, 5.72 mmol, 95% yield. NMR spectra were identical to the previously reported 
compound.47 1H NMR (400 MHz, CDCl3) δ 9.88 (s, 1H), 7.03 (s, 2H), 3.87 (s, 6H), 2.14 
(s, 3H); 13C NMR (100 MHz, CDCl3) δ 192.0, 158.7, 135.1, 122.5, 104.7, 55.9, 9.0.  
 
2-Bromo-3,5-dimethoxy-4-methylbenzaldehyde (86): Aldehyde 107 (8.62 g, 47.8 
mmol, 1 equiv) was dissolved in CH2Cl2 (100 mL, 0.5 M) and acetic acid (30 µL, 0.5 
mmol, 0.01 equiv) was added. The solution was cooled to 0 ºC before bromine was added 
in a slow, dropwise fashion. The solution was stirred 30 min after complete addition at  
0 ºC, at which time TLC (10% EtOAc/hex) showed complete conversion. The reaction 
was quenched by the addition of 10% aqueous sodium thiosulfate and saturated NaHCO3 
solution. The layers were separated and the aqueous phase was extracted with CHCl3. 
The combined organic phases were washed with water, dried over MgSO4 and 
concentrated. The product was purified by dissolving in ~50 mL boiling hexanes, under 
which conditions the trace amounts of dibromide are insoluble. The solution was filtered 
while boiling, providing the pure product. Colorless solid, 10.13 g, 39.1 mmol, 82% 
yield. NMR spectra were identical to the previously reported compound.48 1H NMR (400 
MHz, CDCl3) δ 10.33 (s, 1H), 7.21 (s, 1H), 3.87 (s, 3H), 3.81 (s, 3H), 2.25 (s, 3H); 13C 
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aldehyde oxime (88): Bromide 86 (19.4 g, 74.9 mmol, 1 equiv), (PPh3)2PdCl2 (2.6 g, 
3.70 mmol, 0.05 equiv), and CuI (714 mg, 3.75 mmol, 0.05 equiv) were slurried in 
diisopropylamine (300 mL, 0.25 M, freshly distilled from CaH2) in a 2 liter 3-necked 
roundbottom flask, and the orange suspension was sparged with N2 for 10 min. O-tert-
butyldimethylsilyl propargyl alcohol (87, 17.3 g, 101 mmol, 1.35 equiv)49 was added in 
one portion, causing the suspension to darken as the palladium catalyst was reduced. The 
suspension was sparged with N2 for a further 1 min, then heated to 70 ºC for 24 h. At this 
stage, TLC and LCMS indicated complete conversion of bromide 86, so the suspension 
was cooled to 50 ºC and 200 mL MeOH was added. Hydroxylamine hydrochloride (6.24 
g, 89.8 mmol, 1.2 equiv) was added in one portion and the solution was heated to reflux 
(85 ºC) for 2 h. At this stage, TLC and LCMS indicated complete conversion to the 
product. The solution was cooled to room temperature and celite (~100 g) was added. 
The suspension was filtered through a pad of celite, topped with sand, eluting with ethyl 
acetate. The filtrate was concentrated and purified by column chromatography (15% 
EtOAc/hex). Colorless solid, 26.9 g, 74.1 mmol, 99% yield. 1H NMR (500 MHz, CDCl3) 
δ 8.60 (s, 1H), 7.46 (s, 1H), 7.10 (s, 1H), 4.62 (s, 2H), 3.86 (s, 6H), 2.15 (s, 3H), 0.95 (s, 
9H), 0.18 (s, 6H); 13C NMR (125 MHz, CDCl3) δ 160.5, 158.8, 149.5, 132.8, 122.5, 





Me Br (PPh3)2PdCl2 (5 mol %)
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3270, 3093, 2997, 1954, 2932, 2896, 2857, 2221, 1611, 1592, 1560, 1464, 1403, 1384, 
1331, 1282, 1255, 1218, 1192, 1164, 1137, 1121, 110, 1080, 1035, 977, 904, 838, 780, 
722, 704; HRMS (ESI-TOF) calc’d for [M+] C19H29NO4Si = 363.1866, found 363.1939. 
 
3-(((tert-butyldimethylsilyl)oxy)methyl)-5,7-dimethoxy-6-methylisoquinoline-N-
oxide (84): Oxime 88 (15.92 g, 45.7 mmol, 1 equiv) was dissolved in CH2Cl2 (460 mL, 
0.1 M) and the flask was vacuum purged and refilled with nitrogen five times, then 
heated to reflux. AgOTf (235 mg, 0.91 mmol, 0.02 equiv) was added in one portion to the 
refluxing solution, resulting in a rapid and mildly exothermic reaction. The reaction flask 
was shielded from light and maintained at reflux for 15 min, at which time LCMS 
indicated full conversion to the product. The solution was filtered through a 1 inch pad of 
silica with 500 mL CH2Cl2 and 1 L 10% MeOH/EtOAc. Silica gel (40 mL) was added to 
the second portion of filtrate, which was then concentrated. The product was purified by 
column chromatography using a 6 inch pad of silica (30–50–100% EtOAc/CH2Cl2; then 
2–5–10–20% MeOH/EtOAc + 1% NEt3). Colorless solid, 12.27 g, 33.8 mmol, 77% yield. 
The product is initially isolated as a black solid that is spectroscopically pure, and can be 
recrystallized to a colorless solid from minimal boiling heptanes. Very little mass is lost 
during this process (less than 50 mg from a 12 g batch), indicating the presence of very 
minor yet highly colored impurities. 1H NMR (400 MHz, CDCl3) δ 8.65 (s, 1H), 8.02 (s, 
1H), 6.71 (s, 1H), 5.01 (d, J = 1.4 Hz, 2H), 3.92 (s, 3H), 3.87 (s, 3H), 2.27 (s, 3H), 1.00 
(s, 9H), 0.15 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 159.4, 153.7, 145.9, 135.2, 128.4, 
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123.6, 120.1, 115.0, 97.4, 61.7, 60.1, 55.9, 26.0, 18.4, 9.8, -5.3; IR (thin film, NaCl): 
3390, 3074, 2998, 2954, 2892, 2857, 1637, 1613, 1568, 1471, 1391, 1372, 1341, 1308, 
1254, 1210, 1185, 1148, 1116, 1021, 1007, 957, 900, 839, 808, 778, 702, 670, 638; 
HRMS (ESI-TOF) calc’d for [M+] C19H29NO4Si = 363.1866, found 363.1863. 
3.6.2.2 Synthesis of isoquinoline triflate 
 
3,4-Dimethoxy-5-methylphenyl isopropylcarbamate (109): In a nitrogen-filled 
glovebox, [Ir(cod)OMe]2 (22.3 mg, 0.034 mmol, 0.005 equiv) and 3,4,7,8-tetramethyl-
1,10-phenanthroline (15.9 mg, 0.067 mmol, 0.01 equiv) were dissolved in 5 mL THF and 
stirred 30 min. In the meantime, 2,3-dimethoxytoluene (108, 1.00 mL, 6.73 mmol, 1 
equiv) and B2Pin2 (1.28 g, 5.05 mmol, 0.75 equiv) were weighed into a 20 mL sealable 
microwave vial (also in the glovebox) with a teflon-coated stir bar and 5 mL THF was 
added. Upon complete dissolution, the catalyst solution was transferred to the microwave 
vial, which was sealed prior to removal from the glovebox. The vial was then placed in a 
preheated 80 ºC oil-bath and stirred for 48 h, at which time TLC (20% EtOAc/hex) 
revealed complete conversion to a single borylated product. The vial was cooled to room 
temperature and the cap was removed. N-methylmorpholine-N-oxide (2.37 g, 20.2 mmol, 
3 equiv) was added in a few small portions and the vial was resealed and returned to the 
80 ºC oil-bath for 3 h, at which time TLC (20% EtOAc/hex) indicated complete oxidation 
MeO then, NMO, 80 ºC
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to the intermediate phenol. Triethylamine (4.7 mL, 33.7 mmol, 5 equiv) and isopropyl 
isocyanate (2.6 mL, 26.9 mmol, 4 equiv) were added at 23 ºC and the solution was stirred 
for 16 h, at which time TLC (50% EtOAc/hex) indicated complete conversion to 
carbamate 109. The contents of the vial were transferred to a 100 mL roundbottom flask 
and 10% aq. Na2S2O3 was added to quench the remaining oxidant, and citric acid hydrate 
(4.5 g, >3 equiv) was added to chelate the boron. This solution was stirred for 1 h, and 
concentrated HCl was added 1 mL at a time until an acidic pH was achieved. The layers 
were separated and the aqueous phase was extracted with EtOAc. The combined organic 
phases were then washed with aqueous K2CO3, dried over MgSO4 and concentrated. The 
product was purified by column chromatography (25% EtOAc/hex). Colorless solid, 1.16 
g, 4.6 mmol, 68% yield. NMR spectra were identical to the previously reported 
compound.50 1H NMR (400 MHz, CDCl3) δ 6.55 (d, J = 2.6 Hz, 1H), 6.52 (d, J = 2.8 Hz, 
1H), 4.84 (d, J = 7.8 Hz, 1H), 3.88 (ddd, J = 16.1, 13.9, 7.6 Hz, 1H), 3.82 (s, 3H) 3.76 (s, 
3H), 2.24 (s, 3H), 1.23 (s, 3H), 1.21 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 154.0, 153.0, 
146.8, 144.7, 132.3, 115.4, 104.3, 60.3, 55.9, 43.6, 23.0, 16.0. 
 
3,4-Dimethoxy-5-methyl-2-(trimethylsilyl)phenyl isopropylcarbamate (110): 
Note: Vigorous stirring was required throughout the course of the reaction due to the 
formation of insoluble triflate salts. Carbamate 109 (17.30 g, 68.2 mmol, 1 equiv) was 
dissolved in Et2O (340 mL, 0.2 M), N,N,Nʹ,Nʹ-tetramethylethylenediamine (TMEDA, 
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tert-butyldimethylsilyl triflate (TBSOTf, 17.25 mL, 75.1 mmol, 1.1 equiv) was added in a 
slow stream. The solution was stirred 10 min at 0 ºC, removed from the ice bath and 
stirred at 23 ºC for 30 min. A second portion of TMEDA (41 mL, 273 mmol, 4 equiv) 
was added and the solution was cooled to –78 ºC. n-Butyllithium (2.4 M, 114 mL, 274 
mmol, 4 equiv) was added in a dropwise fashion through a flame-dried addition funnel 
over the course of 1 h, being sure to not let the temperature rise significantly. The 
resulting yellow suspension was stirred vigorously for 4 h at –78 ºC, taking care not to let 
the temperature rise. Trimethylsilyl chloride (61 mL, 478 mmol, 7 equiv) was then added 
dropwise via the addition funnel over the course of 30 min and the suspension was stirred 
at –78 ºC for 30 min, then was removed from the dry ice bath and stirred at 23 ºC for 16 
h. The reaction was quenched by the addition of 300 mL aqueous NH4Cl (30 mL 
saturated solution diluted to 300 mL) through an addition funnel, the first 50 mL of which 
were added dropwise, followed by the addition of the remainder in a slow stream. The 
aqueous phase was then further acidified by the addition of small portions of 
concentrated HCl until an acidic pH was achieved (~30 mL required). The layers were 
separated and the aqueous phase was extracted twice with Et2O. The combined organic 
phases were washed with saturated aqueous NH4Cl, dried over MgSO4 and concentrated. 
The product was purified by column chromatography (20–30% Et2O/hex). Colorless 
solid, 20.61 g, 63.3 mmol, 93% yield. NMR spectra were identical to the previously 
reported compound.50 1H NMR (300 MHz, CDCl3) δ 6.63 (s, 1H), 4.69 (d, J = 8.1 Hz, 
1H), 3.96–3.85 (m, 1H), 3.83 (s, 3H), 3.76 (s, 3H), 2.23 (s, 3H), 1.24 (s, 3H), 1.22 (s, 
3H), 0.30 (s, 9H); 157.9, 13C NMR (125 MHz, CDCl3) δ 157.9, 154.2, 150.5, 148.5, 
134.6, 123.0, 120.1, 60.5, 59.8, 43.5, 23.1, 16.1, 1.3. 
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3,4-Dimethoxy-5-methyl-2-(trimethylsilyl)phenyl trifluoromethanesulfonate (89): 
Note: Arene 89 can be isolated as a colorless oil, but undergoes decomposition and 
should be used within the day of its isolation. Carbamate 110 (8.08 g, 24.8 mmol, 1 
equiv) was dissolved in THF (100 mL, 0.25 M) and diethylamine (3.85 mL, 37.2 mmol, 
1.5 equiv) was added and the solution was cooled to –78 ºC. n-Butyllithium (2.5 M, 15 
mL, 37.5 mmol, 1.5 equiv) was added slowly over the course of 15 min. The solution was 
stirred at that temperature for 30 min, then removed from its bath and stirred at 23 ºC for 
30 min. N-Phenyl triflimide (10.6 g, 29.8 mmol, 1.2 equiv) was added in one portion and 
the solution was stirred 30 min. A second portion of diethylamine (4.6 mL, 44.7 mmol, 
1.8 equiv) was added and the solution was stirred 2 h. The solution was filtered through a 
1 inch pad of silica gel with 50% Et2O/hex and concentrated. The product was purified by 
column chromatography (10% Et2O/hex). Colorless oil, 9.15 g, 24.6 mmol, 99% yield. 
NMR spectra were identical to the previously reported compound.50 1H NMR (400 MHz, 
CDCl3) δ 6.87 (s, 1H), 3.87 (s, 3H), 3.78 (s, 3H), 2.28 (d, J = 0.7 Hz, 3H), 0.38 (s, 9H); 
13C NMR (100 MHz, CDCl3) δ 158.5, 150.4, 149.0, 135.6, 124.2, 118.7 (q, J = 320.6 















then, aq. NH4OH, 60 ºC
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7,8-Dimethoxy-1,6-dimethyl-3-hydroxyisoquinoline (91): Cesium fluoride (204 mg, 
1.34 mmol, 2.5 equiv) was dissolved in acetonitrile (5.4 mL, 0.1 M) in a 20 mL 
microwave vial and water (9.7 µL, 0.537 mmol, 1.0 equiv) and methyl acetoacetate (58 
µL, 0.537 mmol, 1.0 equiv) were added. Aryne precursor 89 (250 mg, 0.671 mmol, 1.25 
equiv) was added neat via syringe, and the vial was placed in a preheated 80 ºC oil bath. 
After 2 h, TLC revealed complete consumption of 89, so NH4OH (28–30%, 5.4 mL) was 
added in one portion. The vial was moved to a preheated 60 ºC oil bath and stirred for  
8 h. The solution was poured into brine inside a separatory funnel and the solution was 
extracted with EtOAc (2x 30 mL). The aqueous phase was brought to pH 7 by the 
addition of concentrated HCl and was extracted with EtOAc (2x 30 mL). The aqueous 
phase was discarded. The organic phase was then extracted with 2M HCl (5x 20 mL). 
The organic phase was checked by LCMS to confirm that all of product 91 had 
transferred to the aqueous phase and was subsequently discarded. The aqueous phase was 
then brought back to pH 7 by the addition of 100 mL 2M NaOH and was extracted with 
EtOAc (5x 20 mL). The combined organic phases were washed with brine, dried over 
Na2SO4 and concentrated, providing the product. Yellow solid, 56.9 mg, 0.243 mmol, 
45% yield. 1H NMR (300 MHz, CDCl3) δ 6.92 (d, J = 0.7 Hz, 1H), 6.51 (s, 1H), 3.90 (s, 
3H), 3.81 (s, 3H), 3.03 (d, J = 0.7 Hz, 3H), 2.28 (d, J = 1.0 Hz, 3H); 13C NMR (125 MHz, 
CDCl3) δ 161.8, 149.5, 145.9, 142.6, 140.4, 121.4, 113.1, 104.8, 60.5, 60.2, 21.1, 17.3; IR 
(thin film, NaCl): 3327, 2938, 2609, 1652, 1455, 1324, 1227, 1178, 1147, 1090, 1062, 
1035, 1001, 960, 938, 892, 862, 813, 724, 683, 662; HRMS (ESI-TOF) calc’d for [M+] 
C13H15NO3 = 233.1052, found 233.1057.  
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Note: When performed on multi-gram scale, this reaction proved highly variable due to 
unknown factors. Yields typically dropped into the 20–30% range. We have therefore 
developed the two-step procedure below that requires extensive column chromatography 
and generates significantly more organic waste, but that does provide 91 in higher 
overall yield. 
 
Methyl 2-(2-acetyl-3,4-dimethoxy-5-methylphenyl)acetate (111): Anhydrous 
potassium fluoride (7.0 g, 120.5 mmol, 3.3 equiv) and 18-crown-6 (31.0 g, 117.3 mmol, 
3.2 equiv) were weighed into a flame-dried 1L recovery flask inside a nitrogen-filled 
glovebox to minimize exposure to atmospheric water. The flask was removed from the 
glovebox, anhydrous THF (370 mL, 0.1 M in 89) was added, and the resulting slurry was 
heated to 50 °C in an oil bath. Aryne precursor 89 (13.67 g, 36.7 mmol, 1.0 equiv) was 
dissolved in anhydrous THF (30 mL) and added to the warm fluoride solution in a slow, 
dropwise fashion via cannula over 1 h, followed by a 10 mL rinse of the flask and 
cannula, added rapidly. After stirring 1 h at 50 °C, TLC revealed complete consumption 
of 89 and the appearance of at least five new products (the product has an Rf = 0.35 in 
20% EtOAc/hex, major middle spot). The crude reaction was filtered through a 1” pad of 
SiO2 using 1L of 30% EtOAc/hex and the filtrate was concentrated. The product was 
purified by column chromatography [4x10” SiO2, 2L 5% EtOAc/hex (collected in 
Erlenmeyer flasks)–1.5L 10%–1.5L 20%–1L 30%–600 mL 50% EtOAc/hex]. The 
product could not be completely purified from the reaction mixture, but using the above 
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conditions 111 could be obtained in roughly 80% purity as estimated by 1H NMR. 
Colorless oil, 6.70 g isolated, ~5.36 g 111 adjusted for purity, ~20.1 mmol, ~55% yield. 
NMR spectra were identical to the previously reported compound.50 Because of the low 
purity, only 1H NMR spectra were recorded for this compound. 1H NMR (500 MHz, 
CDCl3) δ 6.78 (q, J = 0.7 Hz, 1H), 3.87 (s, 3H), 3.82 (s, 4H), 3.68 (s, 3H), 3.62 (s, 2H), 
2.55 (s, 3H), 2.24 (d, J = 0.7 Hz, 3H). 
 
7,8-Dimethoxy-1,6-dimethyl-3-hydroxyisoquinoline (91): In a 250 mL flask equipped 
with a Kontes valve, arene 111 was dissolved in MeCN (15 mL) and NH4OH (28–30%, 
30 mL), the flask was sealed to prevent loss of gaseous ammonia, and was placed in a 
preheated 60 °C oil bath. Within 1 h, yellow 91 began to precipitate from the reaction 
solution. After stirring at 60 ºC for 18 h, the flask was cooled to room temperature, then 
placed in a –25 °C freezer for 3 h, after which time the suspension was filtered. The 
yellow filter cake was washed with cold (–25 °C) MeCN until the filtrate was no longer 
yellow. The filter cake was allowed to dry on the filter paper for 15 min, then was 
transferred to a vial and dried at high vacuum for 24 h to provide the analytically pure 
product. Yellow solid, 3.61 g, 15.5 mmol, 77% yield. 1H NMR (300 MHz, CDCl3) δ 6.92 
(d, J = 0.7 Hz, 1H), 6.51 (s, 1H), 3.90 (s, 3H), 3.81 (s, 3H), 3.03 (d, J = 0.7 Hz, 3H), 2.28 
(d, J = 1.0 Hz, 3H); 13C NMR (156 MHz, CDCl3) δ 161.8, 149.5, 145.9, 142.6, 140.4, 
121.4, 113.1, 104.8, 60.5, 60.2, 21.1, 17.3; IR (thin film, NaCl): 3327, 2938, 2609, 1652, 
aq. NH4OH, MeCN
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1455, 1324, 1227, 1178, 1147, 1090, 1062, 1035, 1001, 960, 938, 892, 862, 813, 724, 
683, 662; HRMS (ESI-TOF) calc’d for [M+] C13H15NO3 = 233.1052, found 233.1057. 
 
7,8-Dimethoxy-1,6-dimethyl-3-(trifluoromethanesulfonyloxy)isoquinoline (10): 
 Hydroxyisoquinoline 91 (2.60 g, 11.1 mmol, 1 equiv) was dissolved in CH2Cl2 (70 mL, 
0.16 M) and pyridine (11.4 mL, 140.6 mmol, 12.7 equiv) was added and the solution was 
cooled to 0 ºC. Trifluoromethanesulfonic anhydride (Tf2O, 3.00 mL, 17.8 mmol, 1.6 
equiv) was added dropwise, causing the yellow solution to turn dark red. After 30 min, 
TLC (10% EtOAc/hex) revealed complete conversion, so the reaction was quenched by 
the addition of saturated aqueous NaHCO3 (70 mL). The solution was stirred vigorously 
until bubbling ceased, at which time the layers were separated. The organic phase was 
extracted with CH2Cl2 and the combined organic phases were dried over Na2SO4 and 
concentrated. The product was purified by column chromatography (10% Et2O/hex). 
Yellow oil, 3.82 g, 10.5 mmol, 94% yield. 1H NMR (400 MHz, CDCl3) δ 7.39 (d, J = 1.0 
Hz, 1H), 7.21 (s, 1H), 3.98 (s, 3H), 3.93 (s, 3H), 3.07 (d, J = 0.7 Hz, 3H), 2.44 (d, J = 1.0 
Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 158.6, 151.0, 150.5, 149.9, 139.2, 136.8, 123.6, 
122.9, 118.8 (q, J = 320.5 Hz), 107.6, 60.8, 60.2, 26.7, 17.0; 19F NMR (282 MHz, 
CDCl3) δ –72.99; IR (thin film, NaCl): 3436, 2939, 1606, 1554, 1494, 1416, 1381, 1352, 
1333, 1249, 1209, 1134, 1097, 1060, 1010, 983, 966, 941, 892, 835, 768, 695, 649, 608; 
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3.6.2.3 Fagnou cross-coupling reaction 
 
3-(((tert-butyldimethylsilyl)oxy)methyl)-5,7,7',8'-tetramethoxy-1',6,6'-trimethyl-
[1,3'-biisoquinoline] 2-oxide (93): Palladium acetate (347 mg, 1.54 mmol, 0.20 equiv), 
di-tert-butyl (methyl)phosphonium tetrafluoroborate (957 mg, 3.86 mmol, 0.50 equiv), 
and cesium carbonate (1.26 g, 3.41 mmol, 0.50 equiv) were weighed into a 100 mL pear-
shaped flask and brought into a nitrogen-filled glovebox and cesium pivalate (CsOPiv, 
722 mg, 3.09 mmol, 0.40 equiv) was added to the flask. In the glovebox, degassed 
toluene (80 mL) was added, the flask was sealed with a rubber septum and removed from 
the glovebox, to be placed in a 60 ºC preheated oil bath, where it was stirred for 30 min 
and allowed to cool to room temperature. In the meantime, N-oxide 84 (8.42 g, 23.1 
mmol, 3 equiv) and cesium carbonate (7.54 g, 23.1 mmol, 3 equiv) were weighed into a 
250 mL sealable flask equipped with a Kontes valve, to which 50 mL toluene was added, 
and this suspension was sparge-degassed with nitrogen for 10 min. Isoquinoline triflate 
85 (2.77 g, 6.82 mmol, 1.00 equiv) was dissolved in 10 mL toluene, which was sparge-
degassed with nitrogen for 10 min. The solution of isoquinoline triflate 85 was then 
added via cannula to the cooled catalyst solution, rinsing the flask with 5 mL degassed 
toluene. The catalyst/triflate solution was then added via cannula to the 250 mL sealable 


















P(t-Bu)2Me•HBF4 (50 mol %)
CsOPiv (40 mol %)
Cs2CO3 (3.5 equiv)
PhMe, 130 ºC
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preheated oil bath for 4.5 h. The flask was then allowed to cool to room temperature and 
Celite (10 g) was added. This suspension was then filtered through a 1 inch pad of Celite 
that was topped with sand, rinsing with CH2Cl2 and acetone (500 mL each). The solution 
was concentrated, providing the crude product. 1H NMR of the crude reaction mixture 
showed a 2:1 mixture of bis-isoquinoline 93 and N-oxide 84 at this point, indicating 
complete conversion to product. The product was purified by column chromatography 
(10–20% EtOAc/hex, then 20–50–100% EtOAc/hex + 1% NEt3, then 10–20% 
MeOH/EtOAc + 1% NEt3. bis-Isoquinoline 93 elutes during the 50–100% EtOAc/hex 
portion, and the remaining N-oxide 84 elutes during the 10–20% MeOH/EtOAc portion). 
Colorless foam, 3.88 g, 6.70 mmol, 98% yield. An analogous coupling performed with 
2.39 g isoquinoline triflate 85 provided 3.30 g of product (87% yield), together providing 
7.18 g bis-isoquinoline 93 in 93% average yield. 1H NMR (400 MHz, CDCl3) δ 8.13 (d, J 
= 0.9 Hz, 1H), 7.81 (s, 1H), 7.42 (d, J = 1.1 Hz, 1H), 6.60 (s, 1H), 5.06 (d, J = 1.4 Hz, 
2H), 4.01 (s, 3H), 3.97 (s, 3H), 3.90 (s, 3H), 3.65 (s, 3H), 3.17 (s, 3H), 2.45 (d, J = 0.9 
Hz, 3H), 2.28 (s, 3H), 1.03 (s, 9H), 0.17 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 158.9, 
157.8, 153.8, 151.3, 149.6, 146.0, 143.7, 142.0, 137.6, 134.8, 128.2, 124.3, 122.7, 122.5, 
121.5, 120.4, 114.5, 98.6, 61.8, 60.9, 60.4, 60.3, 55.7, 27.2, 26.1, 18.5, 17.1, 9.7, –5.2; IR 
(thin film, NaCl): 3418, 2954, 2857, 1615, 1567, 1463, 1393, 1329, 1255, 1213, 1190, 
1139, 1118, 1089, 1057, 1008, 961, 937, 897, 839, 816, 778, 734, 702, 634; HRMS (ESI-
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3.6.2.4 First-generation synthesis of bis-isoquinoline 83 
 
3-(((Tert-butyldimethylsilyl)oxy)methyl)-5,7,7’,8'-tetramethoxy-1',6,6'-trimethyl-
1,3'-biisoquinoline (114): Bis-isoquinoline-N-oxide 93 (6.16 g, 10.6 mmol, 1.00 equiv) 
was dissolved in CH2Cl2 (210 mL, 0.05 M) and the solution was cooled to 0 ºC. Neat 
phosphorus trichloride (1.86 mL, 21.3 mmol, 2.00 equiv) was added at a dropwise pace 
over 5 minutes, causing the solution to immediately turn dark purple. After 30 min, TLC 
revealed complete conversion to the product, so the reaction was quenched with saturated 
aqueous K2CO3 and diluted with water. The layers were separated and the aqueous phase 
was extracted with EtOAc. The combined organic phases were dried over Na2SO4 and 
concentrated (note: a brine wash caused a significant emulsion regardless of extraction 
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1)  SeO2, dioxane, 110 ºC
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2) NaBH4, CH2Cl2/MeOH
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EtOAc/hex + 1% NEt3). Yellow solid, 5.44 g, 9.67 mmol, 91% yield). 1H NMR (400 
MHz, CDCl3) δ 8.03 (q, J = 1.1 Hz, 1H), 8.00 (s, 1H), 7.87 (s, 1H), 7.47 (d, J = 0.6 Hz, 
1H), 5.08 (d, J = 1.2 Hz, 2H), 4.02 (s, 3H), 3.98 (s, 3H), 3.92 (s, 3H), 3.85 (s, 3H), 3.21 
(s, 3H), 2.47 (d, J = 0.9 Hz, 3H), 2.36 (s, 3H), 1.04 (s, 9H), 0.18 (s, 6H); 13C NMR (100 
MHz, CDCl3) δ 157.4, 156.1, 155.5, 153.6, 152.2, 150.9, 150.6, 149.6, 137.4, 135.5, 
129.0, 125.9, 124.6, 124.2, 122.1, 119.8, 110.4, 101.2, 66.4, 61.6, 60.9, 60.4, 55.6, 27.2, 
26.2, 18.6, 17.1, 9.8, –5.2. 
 
5,7,7’,8’-Tetramethoxy-1',6,6'-trimethyl-[1,3'-biisoquinolin]-3-yl)methanol (112): 
Bis-isoquinoline 114 (5.44 g, 9.7 mmol, 1.00 equiv) was dissolved in acetic acid (40 mL, 
0.25 M) and solid potassium fluoride (2.81 g, 48.0 mmol, 5.00 equiv) was added in one 
portion. The solution was stirred 30 min at room temperature, at which time LCMS 
showed complete conversion to the product. The solution was diluted with CH2Cl2 and 
ice and the solution was stirred vigorously as a solution of sodium hydroxide (25 g, 0.625 
mol, 0.9 equiv relative to 40 mL AcOH) in 70 mL water was added slowly. The rest of 
the acetic acid was quenched by the addition of saturated aqueous K2CO3. The layers 
were separated and the aqueous phase was extracted with CH2Cl2. The combined organic 
phases were washed with brine, dried over Na2SO4, and concentrated. The product was 
purified by column chromatography (1–2–3–4–5% MeOH/CH2Cl2 + 1% NEt3). Colorless 
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1H), 7.79 (d, J = 0.9 Hz, 1H), 7.49 (d, J = 1.1 Hz, 1H), 4.94 (s, 2H), 4.03 (s, 3H), 3.97 (s, 
3H), 3.89 (s, 3H), 3.87 (s, 3H), 3.22 (s, 3H), 2.47 (d, J = 1.0 Hz, 3H), 2.35 (s, 4H); 13C 
NMR (100 MHz, CDCl3) δ 157.8, 156.0, 155.2, 153.5, 151.1, 150.3, 149.7, 149.6, 137.6, 
135.4, 129.0, 126.2, 124.7, 124.6, 122.2, 119.9, 111.3, 101.3, 65.0, 61.7, 60.9, 60.3, 55.6, 
27.2, 17.1, 9.9; IR (thin film, NaCl): 3352, 3129, 2937, 2855, 1620, 1594, 1557, 1484, 
1462, 1455, 1416, 1392, 1355, 1331, 1303, 1243, 1218, 1196, 1133, 1117, 1091, 1060, 
1008, 964, 906, 885, 841, 796, 733, 646; HRMS (ESI-TOF) calc’d for [M+] C26H28N2O5 
= 448.1998, found 448.1992. 
 
Methyl 5,7,7’,8’-tetramethoxy-1',6,6'-trimethyl-[1,3'-biisoquinoline]-3-carboxylate 
(113): bis-Isoquinoline 112 (1.50 g, 3.34 mmol, 1.00 equiv) and silver(I) oxide (3.88 g, 
16.7 mmol, 5.00 equiv) were slurried in MeOH (35 mL, 0.1 M). After 30 min, the 
solution appeared to be fully homogeneous and deep red in color. After 4 h, LCMS 
showed full conversion to a mixture of methyl ester 113 and the corresponding 
carboxylic acid. Thionyl chloride (1.21 mL, 16.7 mmol, 5.00 equiv) was added through 
the top of a reflux condenser, and following the complete addition, the solution was 
heated to reflux. After 1.5 h, LCMS showed complete conversion to methyl ester 113. 
The solution was cooled to room temperature and celite was added, and the solution was 
filtered through more celite, rinsing with EtOAc. The solution was concentrated, then 
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separated and the aqueous phase was extracted with CH2Cl2. The combined organic 
phases were washed with brine, dried over Na2SO4, and concentrated. The product was 
purified by column chromatography (25% EtOAc/hex + 1% NEt3). White solid, 1.40 g, 
2.94 mmol, 88% yield. 1H NMR (400 MHz, CDCl3) δ 8.75 (d, J = 0.9 Hz, 1H), 8.19 (s, 
1H), 8.13 (s, 1H), 7.52 (d, J = 1.1 Hz, 1H), 4.05 (s, 3H), 4.01 (s, 3H), 3.97 (s, 3H), 3.94 
(s, 3H), 3.90 (s, 3H), 3.20 (s, 3H), 2.46 (d, J = 1.0 Hz, 3H), 2.36 (s, 3H); 13C NMR (100 
MHz, CDCl3) δ 167.0, 160.0, 156.0, 155.8, 154.9, 151.1, 149.9, 149.5, 139.0, 137.5, 
135.6, 128.6, 128.0, 125.0, 124.7, 122.3, 120.5, 118.6, 101.9, 62.3, 60.9, 60.3, 55.8, 52.8, 
27.1, 17.1, 9.9; IR (thin film, NaCl): 3443, 2949, 1714, 1615, 1454, 1407, 1384, 1330, 
1305, 1270, 1226, 1137, 1089, 1057, 1008, 871, 786, 733; HRMS (ESI-TOF) calc’d for 
[M+] C27H28N2O6 = 476.1947, found 476.1952. 
 
Bis-isoquinoline aldehyde (115) hemiacetal (116). bis-Isoquinoline 113 (1.40 g, 2.94 
mmol, 1.00 equiv) and selenium dioxide (652 mg, 5.88 mmol, 2.00 equiv) were slurried 
in dioxane and the flask was fitted with a reflux condenser. The flask was vacuum 
purged/refilled with N2 five times, then heated to reflux. At about 80 ºC, the solution 
became fully homogeneous. After 1 h at reflux, the flask was cooled to room temperature 
and LCMS showed full conversion to aldehyde 115. Celite was added to the crude 
reaction and the resulting slurry was filtered through more celite, rinsing with EtOAc. 
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of the products, a mixture of MeOH and CH2Cl2 was required during purification by 
column chromatography (10% MeOH/DCM + 1% NEt3). During this process, the highly 
electrophilic aldehyde moiety is converted to the hemiacetal in a thermodynamic 85:15 
mixture favoring the hemiacetal. The two products can neither be interconverted nor 
separated, and as such, were characterized as a mixture. White solid, total mass = 1.47 g, 
85:15 molar ratio of 116:115 by 1H NMR, corresponding to 1.25 g hemiacetal 116 (2.39 
mmol, 82% yield) and 220 mg 115 (0.45 mmol, 15% yield), 2.84 mmol total, 97% 
combined yield. Aldehyde 115: 1H NMR (400 MHz, CDCl3) δ 10.92 (s, 1H), 8.78 (s, 1H), 
8.72 (s, 1H), 8.56 (s, 1H), 7.68 (d, J = 1.2 Hz, 1H), 4.07 (s, 3H), 4.04 (s, 3H), 4.02 (s, 
3H), 3.95 (s, 3H), 3.70 (s, 3H), 2.51 (d, J = 1.0 Hz, 3H), 2.37 (s, 3H); 13C NMR (101 
MHz, CDCl3) δ 193.4, 160.6, 154.8, 154.1, 151.8, 151.3, 151.0, 147.1, 139.2, 135.8, 
128.7, 128.1, 125.3, 125.0, 124.1, 121.6, 119.1, 102.0, 67.2, 60.7, 60.6, 56.3, 46.1, 17.4. 
Hemiacetal 116: 1H NMR (400 MHz, CDCl3) δ 8.78 (d, J = 0.8 Hz, 1H), 8.44 (s, 1H), 
7.97 (s, 1H), 7.61 (d, J = 1.1 Hz, 1H), 6.52 (d, J = 10.6 Hz, 1H), 6.41 (d, J = 10.6 Hz, 
1H), 4.10 (s, 3H), 4.06 (s, 3H), 3.98 (s, 3H), 3.98 (s, 3H), 3.92 (s, 3H), 3.63 (s, 3H), 2.48 
(d, J = 1.0 Hz, 3H), 2.37 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 166.8, 160.3, 155.2, 
154.9, 152.9, 151.5, 148.6, 148.2, 138.9, 138.6, 136.5, 128.5, 127.9, 125.2, 124.9, 123.4, 
120.1, 118.9, 101.5, 95.2, 62.3, 60.8, 60.3, 56.0, 55.2, 52.8, 17.3, 10.0. IR (thin film, 
NaCl): 3437, 2949, 2847, 1738, 1711, 1620, 1462, 1387, 1304, 1272, 1229, 1136, 1086.2, 
1002, 901, 734; HRMS (ESI-TOF) for aldehyde 115 calc’d for [M+] C27H26N2O7 = 
490.1740, found 490.1742; HRMS (ESI-TOF) for hemiacetal 116 calc’d for [M+] 
C28H30N2O8 = 522.2002, found 522.2005. 
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Bis-isoquinoline methyl ester dichloromethane solvate (83•CH2Cl2). Note: Aldehyde 
115 and hemiacetal 116 appear to be in thermal equilibrium at 23 ºC in a 4:1 v/v mixture 
of CH2Cl2:MeOH in a 1:3 ratio of 115:116. When excess NaBH4 was utilized, 
competitive reduction of the methyl ester was observed; however, when NaBH4 was 
employed in substoichiometric fashion, selective reduction of the aldehyde was observed. 
Presumably the reaction proceeds to completion as a manifestation of Le Châtelier’s 
principle. A mixture of bis-isoquinolines 115 and 116 (2.84 mmol in total, 1.00 equiv) 
was dissolved in CH2Cl2 (24 mL) and MeOH (6 mL, 0.1 M) and NaBH4 (36.0 mg, 0.946 
mmol, 0.33 equiv) was added. Gas evolution was observed for ~1 minute, then stopped. 5 
minutes after the addition of NaBH4, LCMS showed complete and selective reduction to 
product 83. The reaction was quenched by the addition of citric acid monohydrate (594 
mg, 2.84 mmol, 1.00 equiv) and water, and the solution was stirred at 1500 rpm for 10 
min, then was basified by the addition of saturated aqueous NaHCO3. The layers were 
separated and the aqueous phase was extracted with CH2Cl2. The combined organic 
phases were dried over Na2SO4 and concentrated. The product was purified by column 
chromatography using a 1:1 mixture of CH2Cl2:EtOAc as the polar solvent (20–30–40–
50–60–100% polar solvent/hex + 1% NEt3). Colorless solid, 1.55 g, 2.68 mmol, 98% 
yield. Note: A stoichiometric amount of dichloromethane could not be removed from the 
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the product is isolated as a stoichiometric dichloromethane monosolvate. 1H NMR (400 
MHz, CDCl3) δ 8.79 (d, J = 0.8 Hz, 1H), 8.30 (s, 1H), 7.90 (s, 1H), 7.59 (d, J = 0.5 Hz, 
1H), 5.55 (t, J = 3.5 Hz, 1H), 5.39 (d, J = 3.5 Hz, 2H), 5.30 [s, 2H (CH2Cl2)], 4.06 (s, 
3H), 4.06 (s, 3H), 3.99 (s, 3H), 3.96 (s, 3H), 3.90 (s, 3H), 2.49 (d, J = 0.9 Hz, 3H), 2.38 
(s, 3H); 13C NMR (100 MHz, CDCl3) δ 166.9, 160.2, 155.8, 155.6, 155.0, 151.1, 149.1, 
148.5, 139.0, 138.4, 135.5, 128.5, 127.9, 125.3, 124.8, 121.6, 120.3, 118.8, 101.3, 64.7, 
62.4, 60.9, 60.3, 56.1, 53.4, 52.9, 17.2, 10.0; IR (thin film, NaCl): 3365, 3130, 2930, 
2856, 1691, 1621, 1594, 1557, 1462, 1413, 1392, 1357, 1331, 1302, 1259, 1196, 1130, 
1089, 1059, 1010, 964, 886, 838, 802, 777; HRMS (ESI-TOF) calc’d for [M+] 
C27H28N2O7 = 492.1897, found 492.1894. 
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6,6'-dimethyl-[1,3'-biisoquinoline] 2-oxide (95): Note: Addition of the catalyst in a 
single portion resulted in rapid over-oxidation, but addition in 3 portions, at least 20 
minutes apart resulted in clean conversion. Furthermore, bis-N-oxide 94 was not stable 
to Na2SO4, MgSO4, or SiO2, and as such it was neither dried nor purified by column 
chromatography, but the clean reaction profile did not necessitate purification. Bis-
isoquinoline-N-oxide 93 (150 mg, 0.259 mmol, 1 equiv) and methyl trioxorhenium (1.3 
mg, 0.0052 mmol, 0.02 equiv) were dissolved in CH2Cl2 (2.6 mL, 0.1 M) and 35% 
aqueous hydrogen peroxide (40 µL, 0.454 mmol, 1.75 equiv) was added. The solution 
was stirred at 1300 rpm for 30 min, at which point a second portion of MeReO3 (1.3 mg, 
0.0052 mmol, 0.02 equiv) was added. After 30 min, a third and final portion of MeReO3 
(1.3 mg, 0.0052 mmol, 0.02 equiv) was added. After a further 30 min, LCMS showed 
complete consumption of the bis-isoquinoline-N-oxide, so acetic anhydride (0.122 ml, 
1.30 mmol, 5 equiv) was then added, and the reaction mixture was stirred at 23 °C. After 
12 hours, LCMS showed complete consumption of the bis-N-oxide. The reaction was 
quenched with water and basified with aqueous K2CO3. The layers were separated and 
the aqueous phase was extracted with CH2Cl2. The combined organic layers were dried 
over Na2SO4, filtered, concentrated, and azeotroped with benzene twice. The crude 
product was purified by column chromatography (35% EtOAc/hex + 1% NEt3). Yellow 
foam, 102.0 mg, 0.160 mmol, 62% yield. 1H NMR (400 MHz, CDCl3) δ 8.15 (s, 1H), 
8.05 (s, 1H), 7.49 (s, 1H), 6.64 (s, 1H), 5.85 (s, 2H), 5.05 (s, 2H), 4.04 (s, 3H), 3.96 (s, 
3H), 3.92 (s, 3H), 3.73 (s, 3H), 2.46 (s, 3H), 2.29 (s, 3H), 1.99 (s, 3H), 1.04 (s, 9H), 0.18 
(s, 6H); 13C NMR (100 MHz, CDCl3) δ 171.2, 159.1, 153.2, 145.8, 138.2, 134.9, 128.3, 
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124.4, 123.8, 122.9, 114.7, 98.8, 68.1, 61.8, 60.9, 60.4, 60.2, 55.8, 26.1, 21.1, 18.5, 17.1, 
9.8, –5.2. IR (thin film, NaCl): 2932, 2856, 1742, 1614, 1557, 1463, 1454, 1360, 1316, 
1236, 1137, 1090, 1006, 897, 839, 754; HRMS (ESI-TOF) calc’d for [M+H]+ 
C34H45N2O8Si = 637.2940, found 637.2944. 
 
(3-(hydroxymethyl)-5,7,7',8'-tetramethoxy-6,6'-dimethyl-[1,3'-biisoquinolin]-1'-
yl)methyl acetate (96): To a solution of bis-isoquinoline-N-oxide 95 (99.0 mg, 0.155 
mmol, 1 equiv) in acetic acid (1.6 mL), Fe powder (86.8 mg, 1.55 mmol, 10 equiv) was 
added at 23 °C. The reaction mixture was stirred at 50 °C for 3 hours, at which point the 
LCMS showed complete consumption of the starting material. The reaction mixture was 
then cooled to room temperature and KF (90.1 mg, 1.55 mmol, 10 equiv) was added. 
After 12 hours, LCMS showed complete consumption of the TBS-protected alcohol 
intermediate, so the reaction was diluted with CH2Cl2 and washed with aqueous K2CO3. 
The aqueous layer was separated and extracted with EtOAc twice. The combined organic 
layers were washed with brine, dried over Na2SO4, and concentrated. The crude was 
purified by column chromatography (50% EtOAc/CH2Cl2 + 1% Et3N). Pale yellow solid, 
48.1 mg, 0.095 mmol, 61% yield. 1H NMR (400 MHz, CDCl3) δ 8.13 (s, 1H), 7.85 (s, 
1H), 7.74 (d, J = 0.9 Hz, 1H), 7.47 (d, J = 1.1 Hz, 1H), 5.84 (s, 2H), 4.87 (d, J = 0.9 Hz, 
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(s, 3H), 1.98 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 171.2, 157.9, 155.1, 153.5, 151.6, 
151.0, 150.5, 149.5, 148.6, 138.1, 135.7, 129.0, 126.3, 124.8, 124.6, 121.5, 121.1, 111.5, 
101.3, 68.3, 64.9, 61.8, 60.9, 60.2, 55.8, 21.2, 17.1, 10.0; IR (thin film, NaCl): 3418, 
2939, 1738, 1595, 1557, 1455, 1418, 1303, 1238, 1131, 1091, 1006, 888, 755; HRMS 
(ESI-TOF) calc’d for [M+H]+ C28H31N2O7 = 507.2126, found 507.2130. 
 
Hydrogenation precursor (83): Alcohol 96 (29.5 mg, 0.058 mmol, 1 equiv), TEMPO 
(4.5 mg, 0.029 mmol, 0.5 equiv), N-hydroxysuccinimide (7.4 mg, 0.064 mmol, 1.1 
equiv), and (diacetoxyiodo)benzene (75.0 mg, 0.233 mmol, 4 equiv) were dissolved in 
CH2Cl2 (1.2 mL, 0.05 M) and stirred at room temperature. After 3 hours, LCMS showed 
complete consumption of the alcohol. Methanol (1.2 mL) and p-toluenesulfonic acid 
monohydrate (110.7 mg, 0.582 mmol, 10 equiv) were added and the reaction heated at 
reflux for 5 hours. The solution was concentrated, then redissolved in CH2Cl2 and was 
washed with dilute aqueous K2CO3 and brine. The layers were separated and the aqueous 
phase was extracted with CH2Cl2. The combined organic phases were dried over Na2SO4 
and concentrated. The product was purified by column chromatography using a 1:1 
mixture of CH2Cl2:EtOAc as the polar solvent (20–30–40–50–60–100% polar 
solvent/hex + 1% NEt3). Pale yellow solid, 18.6 mg, 0.038 mmol, 65% yield. 1H NMR 
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Hz, 1H), 5.55 (t, J = 3.5 Hz, 1H), 5.39 (d, J = 3.5 Hz, 2H), 4.06 (s, 3H), 4.06 (s, 3H), 3.99 
(s, 3H), 3.96 (s, 3H), 3.90 (s, 3H), 2.49 (d, J = 0.9 Hz, 3H), 2.38 (s, 3H); 13C NMR (100 
MHz, CDCl3) δ 166.9, 160.2, 155.8, 155.6, 155.0, 151.1, 149.1, 148.5, 139.0, 138.4, 
135.5, 128.5, 127.9, 125.3, 124.8, 121.6, 120.3, 118.8, 101.3, 64.7, 62.4, 60.9, 60.3, 56.1, 
53.4, 52.9, 17.2, 10.0; IR (thin film, NaCl): 3365, 3130, 2930, 2856, 1691, 1621, 1594, 
1557, 1462, 1413, 1392, 1357, 1331, 1302, 1259, 1196, 1131, 1089, 1059, 1010, 964, 
890, 838, 802, 777, 734; HRMS (ESI-TOF) calc’d for [M+] C27H28N2O7 = 492.1897, 
found 492.1894. 
3.6.2.6 Asymmetric hydrogenation of bis-isoquinoline 83 
 
Bis-THIQ pentacycle (81): Note: Due to the air-sensitivity of the phosphine ligand and 
the low-valent iridium complex, the preparation of the catalyst and the reaction mixture 
was performed inside a nitrogen-filled glovebox. The reaction was performed in a 100 
mL roundbottom flask with a teflon-coated, egg-shaped stir bar, which was placed inside 
a Parr bomb. Said bomb was also brought into the glovebox for reaction setup, with the 
exception of the pressure gauge. A piece of electrical tape was used to seal the bomb 
immediately upon its removal via the large antechamber, and care was taken to minimize 
the time between the removal of the tape and the replacement of the gauge. bis-











BTFM-Xyliphos (21 mol %)
60 ºC → 80 ºC














[Ir(cod)Cl]2 (10 mol %)
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roundbottom flask with a teflon-coated stir bar and the flask was brought into a nitrogen-
filled glovebox. Solid tetra-n-butylammonium iodide (238 mg, 0.644 mmol, 0.6 equiv, 3 
equiv relative to Ir) was added to the flask. [Ir(cod)Cl]2 (72.1 mg, 0.107 mmol, 0.1 equiv, 
20 mol% Ir) and BTFM-Xyliphos (a.k.a. SL-J008-2, 205 mg, 0.225 mmol, 0.21 equiv) 
were dissolved in 10 mL toluene in a scintillation vial and the resulting solution was 
allowed to stand for 10 min. 28.3 mL of toluene was added to the flask containing bis-
isoquinoline 83, followed by the addition of 5.4 mL AcOH, resulting in a yellow solution 
of protonated 83. The iridium-ligand solution was then added to the flask with two 5 mL 
rinses, bringing the final volume to 53.7 mL of 9:1 PhMe:AcOH (0.02 M in 83). The 
flask was sealed with a rubber septum that was then pierced with three 16 gauge (purple) 
needles, each bent at a 90º angle. The flask was placed inside the bomb, which was then 
sealed prior to removal from the glovebox via the large antechamber. At this stage, the 
tape was removed from the top of the bomb and the pressure gauge was quickly screwed 
in place and tightened. With 200 rpm stirring, the bomb was charged to 10 bar of H2 and 
slowly released. This process was repeated twice, before charging the bomb to 60 bar of 
H2, at which time it was placed in a preheated 60 ºC oil bath. The bath was maintained at 
this temperature for 18 h, then raised to 80 ºC for 24 h. At this time, the bomb was 
removed from the oil bath and the hydrogen pressure was vented. The flask was removed 
from the bomb and the solution was transferred to a 250 mL roundbottom flask and 
basified by the careful addition of saturated aqueous K2CO3 and water until pH > 7. The 
solution was transferred to a separatory funnel and the layers were separated. The 
aqueous phase was extracted 5x with EtOAc, and the combined organic phases were 
washed twice with water and once with brine, dried over Na2SO4, and concentrated. The 
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product was purified by column chromatography (15x1”, 1% MeOH/DCM + 1% NEt3). 
At this stage, 1H NMR determined the purity of the product to be 90% as a brown foam. 
469 mg, 422 mg adjusted for purity, 0.899 mmol, 83% yield, 88% ee. Enantiomeric 
excess was determined by chiral HPLC analysis [AD, 20% IPA, 280 nm, 1.0 mL/min: 
tR(minor) = 21.6 min, tR(minor) = 26.9 min]. The product could then be crystallized to 
analytical and optical purity (>99% ee) by dissolving the brown foam in acetonitrile and 
allowing the solution to slowly evaporate under a stream of N2. The crystals were washed 
3x with 500 µL portions of –40 ºC acetonitrile. The resulting crystals were dried in 
vacuo, providing 203 mg of enantiopure (>99% ee) bis-tetrahydroisoquinoline 81. The 
mother liquor could be purified by preparative SFC (AD-H, 20% IPA/CO2, 210 nm, flow 
rate = 40 mL/min, tR(minor) = 25.0 min, tR(major) = 30.0 min) to provide the remaining 
material in enantiopure fashion. The crystals isolated above were used to collect the 
following characterization data. 1H NMR (500 MHz, CDCl3) δ 6.73 (s, 1H), 6.35 (s, 1H), 
5.79 (dd, J = 6.7, 3.8 Hz, 1H), 4.12 – 4.10 (m, 2H), 3.93 (dt, J = 12.7, 2.9 Hz, 1H), 3.91 
(s, 3H), 3.83 (s, 3H), 3.78 (s, 3H), 3.70 (s, 3H), 3.43 (d, J = 10.6 Hz, 1H), 3.22 – 3.10 (m, 
3H), 3.03 (dd, J = 17.2, 6.6 Hz, 1H), 2.74 (dd, J = 14.5, 2.6 Hz, 1H), 2.67 – 2.60 (m, 1H), 
2.25 (s, 3H), 2.15 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 172.9, 157.7, 156.6, 150.0, 
149.7, 131.8, 131.2, 130.9, 125.0, 124.4, 119.8, 119.7, 106.1, 69.0, 61.7, 60.7, 60.4, 60.0, 
55.9, 55.0, 54.4, 52.8, 33.2, 30.1, 15.9, 9.2; IR (thin film, NaCl): 3302, 3053, 2940, 2859, 
2836, 1622, 1614, 1486, 1463, 1455, 1410, 1353, 1324, 1274, 1233, 1191, 1124, 1082.0, 
1001, 958, 926, 894, 849, 817, 789, 735, 703.; HRMS (ESI-TOF) calc’d for [M+] 
C26H32N2O6 = 468.2260, found 468.2255; [α]D = –56.9º (c = 0.5, CHCl3). 
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HPLC traces of racemic, enantioenriched, and enantiopure 81: 
Racemic 81:  
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3.6.2.7 Endgame synthesis of Jorumycin 
 
N–methyl bis-THIQ pentacycle (117): Enantiopure bis-tetrahydroisoquinoline 81 (120 
mg, 0.256 mmol, 1 equiv) was dissolved in 1,2-dichloroethane (1,2-DCE, 5.1 mL, 0.05 
M) and 37% aqueous formaldehyde (35 µL, 0.474 mmol, 1.85 equiv) was added. The 
solution was stirred at 800 rpm for 10 min before sodium triacetoxyborohydride (307 mg, 
1.45 mmol, 5 equiv) was added. This solution was stirred at 23 ºC for 15 min, at which 
time LCMS showed full conversion to the product. Citric acid monohydrate (404 mg, 
1.92 mmol, 7.5 equiv) was added to the solution, followed by 20 mL water. This solution 
was stirred for 10 min before the slow addition of saturated aqueous K2CO3 until pH > 7. 
The layers were separated and the aqueous phase was extracted with CH2Cl2. The 
combined organic phases were washed with brine, dried over Na2SO4 and concentrated. 
The product was purified by column chromatography (1% MeOH/DCM + 1% NEt3). 
Colorless solid, 123 mg, 0.255 mmol, quantitative yield. 1H NMR (500 MHz, CDCl3) δ 
6.72 (s, 1H), 6.34 (s, 1H), 5.77 (dd, J = 6.5, 3.8 Hz, 1H), 4.00 (dt, J = 12.4, 3.0 Hz, 1H), 
3.90 (s, 3H), 3.83 (s, 3H), 3.80 – 3.76 (m, 2H), 3.78 (s, 3H), 3.70 (s, 3H), 3.44 (ddd, J = 
8.6, 7.1, 6.0 Hz, 1H), 3.22 – 3.15 (m, 2H), 3.14 (dd, J = 17.6, 6.5 Hz, 1H), 2.96 (br s, 
1H), 2.94 (dd, J = 17.6, 1.2 Hz, 1H), 2.67 (dd, J = 14.5, 2.6 Hz, 1H), 2.62 – 2.53 (m, 1H), 
2.47 (s, 3H), 2.24 (s, 3H), 2.15 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 173.4, 157.4, 
156.7, 150.0, 149.7, 131.7, 131.5, 128.8, 125.0, 124.4, 119.7, 119.0, 106.9, 69.1, 61.4, 
aq. CH2O, NaBH(OAc)3
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60.7, 60.4, 60.3, 60.0, 58.4, 55.9, 52.8, 40.1, 33.0, 24.2, 15.9, 9.1; IR (thin film, NaCl): 
3383, 2938, 2862, 1633, 1608, 1485, 1463, 1446, 1410, 1360, 1325, 1272, 1233, 1190, 
1124, 1080, 1015, 1001, 963, 910, 848, 804, 646; HRMS (ESI-TOF) calc’d for [M+] 
C27H34N2O6 = 482.2417, found 482.2414; [α]D = –76.2º (c = 0.5, CHCl3). 
 
Dichlorinated bis-THIQ (99): bis-Tetrahydroisoquinoline 117 (179.9 mg, 0.372 mmol, 
1.0 equiv) was dissolved in HFIP (16.6 mL, 0.02 M after complete addition) and the 
solution was cooled to 0 ºC. N-Chlorosaccharine (170 mg, 0.782 mmol, 2.1 equiv) was 
dissolved in 2 mL HFIP and this solution was added at a slow dropwise pace, allowing 
the orange color to dispel after each addition, and the resulting yellow solution was 
stirred at 0 ºC. An LCMS sample taken 1 min after complete addition showed full 
conversion to the dichloride product, so the reaction was quenched by the addition of 
saturated aqueous Na2S2O3. The resulting mixture was transferred to a separatory funnel 
and diluted with CH2Cl2 and water, creating a triphasic system with HFIP on bottom, 
CH2Cl2 in the middle, and the aqueous phase on top. The bottom two phases were 
collected directly in a 250 mL roundbottom flask. The aqueous phase was basified with 
K2CO3 and extracted with CH2Cl2, draining the organic phase directly into the flask. The 
flask was concentrated and azeotropically dried twice with toluene. The product was then 
purified by column chromatography (1% MeOH/CH2Cl2 + 1% NEt3). White solid, 138.3 
mg, 0.251 mmol, 67% yield. 1H NMR (500 MHz, CDCl3) δ 5.85 (dd, J = 7.2, 4.1 Hz, 
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1H), 4.47 (dd, J = 3.7, 1.1 Hz, 1H), 4.04 (ddd, J = 12.8, 3.7, 2.6 Hz, 1H), 3.90 (s, 3H), 
3.82 (dd, J = 15.6, 2.6 Hz, 1H), 3.82 (s, 3H), 3.78 – 3.76 (m, 1H), 3.77 (s, 3H), 3.72 (s, 
3H), 3.42 (dt, J = 10.8, 4.8 Hz, 1H), 3.18 (dd, J = 7.0, 4.8 Hz, 1H), 3.13 (dd, J = 18.2, 6.7 
Hz, 1H), 3.13 – 3.08 (m, 1H), 3.00 (dd, J = 18.1, 1.3 Hz, 1H), 2.45 (s, 3H), 2.31 (s, 3H), 
2.27 (s, 3H), 2.17 (dd, J = 15.6, 12.8 Hz, 1H); 13C NMR (125 MHz, CDCl3)173.3, 156.1, 
153.8, 150.4, 148.3, 130.7, 129.8, 128.0, 127.9, 126.2, 125.6, 124.5, 123.9, 69.1, 60.9, 
60.5, 60.4, 60.4, 59.5, 58.8, 57.6, 52.1, 40.3, 29.5, 24.7, 13.8, 10.1; IR (thin film, NaCl): 
3418, 2940, 1644, 1634, 1462, 1455, 1404, 1361, 1330, 1272, 1236, 1224, 1191.6, 1147, 
1106, 1082, 1005, 951, 932, 833, 794; HRMS (ESI-TOF) calc’d for [M+] C27H32N2O6Cl2 
= 550.1637, found 550.1637; [α]D = –119.0º (c = 0.5, CHCl3). 
 
Dihydroxylated bis-THIQ (100). Note: If the reaction vessel is prematurely exposed to 
air at elevated temperatures, aerobic oxidation leads to the formation of quinones, which 
undergo hydrolysis of the vinylogous ester in the presence of CsOH. The solution must be 
fully cooled to room temperature prior to breaking the seal. The bisphenol product is 
otherwise not sensitive to aerobic oxidation, in the solid state or in solution. In a 
nitrogen-filled glovebox, (2′-Amino-1,1′-biphenyl-2-yl)methanesulfonatopalladium(II) 
dimer (Buchwald’s dimer, 33.5 mg, 0.0453 mmol, 0.500 equiv) and 5-[di(1-
adamantyl)phosphino]-1′,3′,5′-triphenyl-1′H-[1,4′]bipyrazole (AdBippyPhos, 120.2 mg, 
0.181 mmol, 2.00 equiv) were weighed into a scintillation vial and dioxane (8.1 mL) was 
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added. The vial was sealed with electrical tape and removed from the glovebox, sonicated 
briefly, and returned to the glovebox. The resulting tan solution was then transferred to a 
20 mL microwave vial containing bis-THIQ 99 (50.0 mg, 0.0907 mmol, 1.00 equiv) and 
CsOH•H2O (152.3 mg, 0.907 mmol, 10.0 equiv), followed by a 1 mL rinse (9.1 mL total 
volume, 0.01 M in 99). The vial was sealed, removed from the glovebox, and placed in a 
preheated 90 ºC oil bath. After 3 h, the vial was removed and allowed to cool fully to 
room temperature prior to removing the seal. Acetic acid (46.5 µL, 0.813 mmol, 9 equiv) 
was added to quench the remaining CsOH and the contents of the vial were transferred to 
a roundbottom flask, to which silica gel and solid KHCO3 (to quench excess acetic acid) 
were added directly to dry load the crude mixture onto a silica gel column. The solution 
was concentrated, and the product was purified by column chromatography (2–4–6–8–
10% MeOH + CH2Cl2: 200 mL portions, no NEt3 added, product elutes in the 6% 
portion). Tan solid, 21.4 mg, 0.0416 mmol, 46% yield. 1H NMR (500 MHz, CDCl3) δ 
5.80 (dd, J = 7.2, 4.2 Hz, 1H), 4.34 (d, J = 2.0 Hz, 1H), 3.96 (dt, J = 12.3, 2.5 Hz, 1H), 
3.81 (s, 3H), 3.80 (dd, J = 6.0, 1.0 Hz, 1H), 3.77 (s, 3H), 3.75 (s, 3H), 3.65 (s, 3H), 3.52 
(br s, 1H), 3.47 – 3.40 (m, 2H), 3.23 (dd, J = 10.8, 7.2 Hz, 1H), 3.14 (dd, J = 18.1, 6.7 
Hz, 1H), 3.02 (d, J = 18.0 Hz, 1H), 2.45 (s, 3H), 2.21 (s, 3H), 2.14 (s, 3H), 2.09 (dd, J = 
15.2, 12.2 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 173.6, 150.0, 149.7, 146.8, 144.1, 
143.5, 143.4, 124.6, 123.7, 122.6, 118.6, 118.3, 115.9, 69.2, 61.0, 60.9, 60.4, 60.3, 59.6, 
59.0, 55.3, 52.5, 40.1, 25.2, 24.5, 9.7, 9.3; IR (thin film, NaCl): 3332, 2937, 1613, 1462, 
1453, 1414, 1353, 1302, 1191, 1109, 1068, 1006, 910, 836, 806, 731; HRMS (ESI-TOF) 
calc’d for [M+] C27H34N2O8 = 514.2315, found 514.2311; [α]D = –91.6º (c = 0.5, CHCl3). 
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Dihydroxylated bis-THIQ aminonitrile (105): In an oven-dried vial, LiAlH4 solution 
(1.0 M in THF, 2 mL, 2.0 mmol) was cooled to 0 ºC. A solution of ethyl acetate (230 µL, 
2.35 mmol) in 2 mL THF was added slowly, and the resulting solution was stirred 30 min 
at 0 ºC, providing a 0.47 M solution of Li(EtO)2AlH2 in THF. bis-THIQ 100 (49.0 mg, 
0.095 mmol, 1.0 equiv) was dissolved in THF (4.8 mL, 0.02 M) and the resulting solution 
was cooled to 0 ºC. A solution of Li(EtO)2AlH2 (0.47 M in THF, 3.0 mL, 1.43 mmol, 
15.0 equiv) was added slowly, resulting in extensive evolution of H2. After stirring 50 
min, the reaction was quenched with acetic acid (115 µL, 2.00 mmol, 21 equiv) and 
aqueous potassium cyanide (4.8 M, 120 µL, 0.571 mmol, 6.0 equiv) was added, followed 
by celite and anhydrous Na2SO4 (roughly 1 g each). The solution was diluted with 8 mL 
THF and stirred 10 h, warming to room temperature. More celite was added, and the 
suspension was filtered through celite, rinsing with EtOAc. The filtrate was transferred to 
a roundbottom flask and was concentrated. At this stage, LCMS revealed a ~4:1 mixture 
of product 105 and starting material 100, so the crude mixture was resubjected to the 
reduction conditions, using 3 mL THF as the reaction solvent and 1 mL of freshly 
prepared Li(EtO)2AlH2 solution. After 10 min, LCMS showed minimal conversion of the 
remaining starting material, with some over-reduced product (m/z = 501). The reaction 
mixture was quenched and worked up as described above. The product was purified by 
column chromatography (50–75–100% EtOAc/hex, 200 mL each; product elutes in the 
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75% portion). Colorless solid, 25.2 mg, 47.9 µmol, 50% yield. 1H NMR (400 MHz, 
CDCl3) δ 4.19 (dD, J = 2.7, 1.1 Hz, 1H), 4.00 – 4.05 (m, 2H), 3.81 (s, 3H), 3.751 (s, 3H), 
3.749 (s, 3H), 3.70 (s, 3H), 3.56 (dd, J = 10.9, 4.4 Hz, 1H), 3.40 (ddd, J = 7.5, 2.5, 1.2 
Hz, 1H), 3.31 (dt, J = 12.1, 2.7 Hz, 1H), 3.18 (d, J = 9.4 Hz, 1H), 3.13 (dd, J = 15.6, 2.7 
Hz, 1H), 3.10 (dd, J = 18.6, 7.8 Hz, 1H), 2.51 (d, J = 18.6 Hz, 1H), 2.34 (s, 3H), 2.22 (s, 
3H), 2.09 (s, 3H), 1.85 (dd, J = 15.6, 12.0 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 149.6, 
148.7, 146.6, 143.7, 143.4, 143.1, 125.4, 123.5, 122.7, 118.1, 118.0, 117.1, 116.7, 66.2, 
61.2, 61.0, 60.8, 60.4, 60.2, 58.5, 57.1, 56.7, 55.2, 41.9, 25.4, 21.7, 9.8, 9.0; IR (thin film, 
NaCl): 3428, 2936, 2833, 2228, 1607, 1463, 1412, 1385, 1350, 1320, 1301, 1251, 1218.1, 
1191, 1151, 1108, 1070, 1002, 982, 908, 875, 830, 754; HRMS (ESI-TOF) calc’d for 
[M+] C28H35N3O7 = 525.2475, found 525.2471; [α]D = +22.9º (c = 0.5, CHCl3). 
 
(–)-Jorunnamycin A (79): bis-Tetrahydroisoquinoline 105 (22.0 mg, 41.9 µmol, 1.0 
equiv) and DDQ (38.0 mg, 167 µmol, 4.0 equiv) were weighed into a roundbottom flask 
and 8.4 mL of a 9:1 mixture of acetone and water was added (0.005 M). The purple 
solution gradually turned blood red. After 1 h, the reaction was quenched with saturated 
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aqueous NaHCO3. The phases were separated and the aqueous phase was extracted with 
ethyl acetate. The combined organic phases were washed with brine, dried over Na2SO4, 
and concentrated. The product was purified using reverse-phase (C18) preparative HPLC 
(MeCN/0.4% acetic acid in water, 5.0 mL/min, monitor wavelength = 254 nm, 20–70% 
MeCN over 5 min, hold at 70% for 3 min, hold at 95% for 3 min. Product 3 has tR = 7.2 
min). Yellow film, 6.6 mg, 13.4 µmol, 32% yield. 1H NMR (500 MHz, CDCl3) δ 4.11 (d, 
J = 2.6 Hz, 1H), 4.08 (dd, J = 3.0, 1.0 Hz, 1H), 4.03 (s, 3H), 3.99 (s, 3H), 3.90 (app q, J = 
3.1 Hz, 1H), 3.71 (dd, J = 11.3, 3.4 Hz, 1H), 3.50 (br s, 1H), 3.42 (ddd, J = 7.4, 2.6, 1.5 
Hz, 1H), 3.18 (dt, J = 11.4, 2.9 Hz, 1H), 2.93 (ddd, J = 17.4, 2.8, 0.9 Hz, 1H), 2.83 (dd, J 
= 21.0, 7.5 Hz, 1H), 2.31 (s, 3H), 2.26 (d, J = 21.0 Hz, 1H), 1.95 (s, 3H), 1.94 (s, 3H), 
1.41 (ddd, J = 17.5, 11.5, 2.7 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 186.4, 185.6, 
182.4, 181.5, 155.6, 155.5, 141.8, 141.5, 136.2, 135.8, 129.1, 128.8, 117.0, 64., 61.3, 
61.3, 59.1, 58.1, 54.6, 54.4, 54.4, 41.8, 25.5, 21.6, 9.0, 8.9; IR (thin film, NaCl): 3508.5, 
2943.0, 2226.8, 1651.8, 1620.8, 1447.2, 1373.6, 1310.6, 1277.4, 1236.0, 1190.6, 1151.1, 
1098.1, 1077.8, 963.7, 886.8, 775.3; HRMS (ESI-TOF) calc’d for [M+] C26H27N3O7 = 
493.1849, found 493.1848; [α]D = –94.3º (c = 0.35, CHCl3). 
 
Hemiacetal (101): Product 101 was also isolated from the preparative HPLC method 
described above, with tR = 9.3 min. Yellow film, 7.3 mg, 13.9 µmol, 33% yield. The 
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and HMBC correlations (C13 to C14 but not C9, C1 to C15 and C5, C4 to C15 and C5). 
1H NMR (400 MHz, CDCl3) δ 4.54 (t, J = 7.7 Hz, 1H), 4.16 (dd, J = 3.8, 1.5 Hz, 1H), 
4.08 (s, 3H), 4.00 (s, 3H), 3.74 (dd, J = 7.8, 5.8 Hz, 1H), 3.66 (d, J = 2.6 Hz, 1H), 3.43 
(ddd, J = 7.8, 2.8, 1.7 Hz, 1H), 3.29 (dt, J = 10.8, 4.2 Hz, 1H), 3.13 (s, 3H), 2.82 (dd, J = 
20.9, 7.8 Hz, 1H), 2.62 (ddd, J = 18.6, 4.6, 3.0 Hz, 1H), 2.28 (s, 3H), 2.13 (d, J = 20.9 
Hz, 1H), 1.93 (s, 3H), 1.75 (s, 3H), 1.68 (br s, 1H, OH), 1.52 (ddd, J = 18.5, 10.7, 3.1 Hz, 
1H); 13C NMR (400 MHz, CDCl3) δ 186.6, 185.2, 182.7, 160.4, 155.9, 143.2, 141.2, 
136.2, 128.5, 127.7, 117.9, 116.0, 99.0, 74.2, 61.2, 60.5, 59.1, 56.0, 55.6, 54.6, 53.9, 51.8, 
41.9, 26.0, 21.5, 8.8, 7.9; IR (thin film, NaCl): 3446, 3014, 2953, 2854, 2226, 1644, 
1615, 1455, 1413, 1373, 1318, 1272, 1248, 1189, 1154, 1092, 1061, 1026, 991, 973, 950, 
896, 878, 759, 721; HRMS (ESI-TOF) calc’d for [M–OH]+ C27H29N3O7 = 493.1849, 
found 493.1848; [α]D = –94.3º (c = 0.35, CHCl3). 
 
(–)-Jorumycin (77): In a 1-dram vial, Jorunnamycin A (79, 6.6 mg, 13.4 µmol, 1.0 
equiv) and DMAP (4.9 mg, 40.1 µmol, 3.0 equiv) were dissolved in acetonitrile (400 µL, 
0.03 M) and acetic anhydride (3.8 µL, 40.1 µmol, 3.0 equiv) was added neat. The brown 
solution immediately turned yellow. After 30 minutes, LCMS showed complete 
conversion to the acetylated intermediate. At this stage, silver nitrate (57.0 mg, 334 µmol, 
25.0 equiv) and water (260 µL) were added in rapid succession. The vial was resealed 
and placed in a preheated 45 ºC heating block, then protected from light with aluminum 
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foil. After 30 minutes, LCMS showed complete conversion to (–)-jorumycin (77), so the 
solution was filtered to remove AgCN and silver black, and the crude reaction mixture 
was purified directly using preparative HPLC (MeCN/0.4% acetic acid in water, 5.0 
mL/min, monitor wavelength = 265 nm, 10–55% MeCN over 7 min, ramp to 95% MeCN 
over 0.2 min, hold at 95% for 1.8 min for a total run time of 9 min. Product has tR = 6.6 
min). Yellow film, 4.8 mg, 9.12 µmol, 68% yield. 1H NMR (500 MHz, CDCl3) δ 4.44 
(dd, J = 11.2, 3.5 Hz, 1H), 4.44 (br s, 1H), 4.37 (d, J = 3.1 Hz, 1H), 4.01 (s, 3H), 3.99 (s, 
3H), 3.92 (br s, 1H), 3.82 (dd, J = 11.3, 3.4 Hz, 1H), 3.21 – 3.16 (m, 1H), 3.14 (dd, J = 
7.3, 4.7 Hz, 1H), 2.84 (dd, J = 16.6, 2.4 Hz, 1H), 2.66 (dd, J = 21.1, 7.6 Hz, 1H), 2.27 (s, 
3H), 2.23 (d, J = 21.0 Hz, 1H), 1.96 (s, 3H), 1.94 (s, 3H), 1.76 (s, 3H), 1.24 (ddd, J = 
16.6, 11.3, 2.6 Hz, 1H); 13C NMR (125 MHz, CDCl3) δ 186.0, 181.4, 170.2, 155.8, 155.4, 
142.1, 142.0, 137.4, 128.9, 128.5, 83.1, 64.4, 61.19, 61.17, 57.6, 54.4, 52.9, 51.1, 41.6, 
25.7, 20.74, 20.69, 8.9, 8.8; IR (thin film, NaCl): 3478, 2924, 28501, 1738, 1652, 1621, 
1449, 1374, 1309, 1260, 1234, 1189, 1150, 1096, 1083, 1013, 902, 872, 840, 801, 730; 
HRMS (ESI-TOF) calc’d for [M+] C27H30N2O9 = 526.1951, found 526.1956; [α]D = –
86.8º (c = 0.1, CHCl3). Note: After purification via the method described above 
(preparative HPLC using MeCN and 0.4% AcOH in H2O with lyophilization of the 
product-containing fractions), we obtained jorumycin as a yellow solid in high purity as 
determined from the following LCMS trace (TIC): 
 
Following this method of purification, a sample was prepared for NMR spectroscopy 
using CDCl3 that had been freshly distilled from flame-dried K2CO3, and a 1H spectrum 
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was recorded within minutes of preparing the sample. Despite all of our precautions, 
significant impurities were present in the spectrum at 1.25 ppm, 2–2.25 ppm, and 5–6 
ppm. The sample was immediately tested for purity using the same LCMS method as 
above and provided the following chromatogram (TIC): 
 
Many attempts to repurify our samples were made, including repurification via the 
method described above, preparative HPLC with MeCN and H2O in the absence of 
AcOH, column chromatography with 1% MeOH in CH2Cl2 in the presence or absence of 
NEt3, and column chromatography on SiO2 or basic alumina with EtOAc in the absence 
of NEt3. In all cases, spectra containing the impurities described above were obtained, 
independent of the method of purification. This leads us to conclude that jorumycin is not 
stable in chloroform; this is also consistent to observations made in the isolation report.21 
The optical rotation listed above was measured by repurifying the product as originally 
described and dissolving the sample in CHCl3 that had been freshly distilled from flame-
dried K2CO3 immediately prior to recording its optical rotation to minimize 
decomposition, and this method provided a value in good agreement with previous 
literature;15–20 however, a 1H NMR spectrum of this sample showed the same impurities 
described above. We therefore conclude that future synthetic endeavors should avoid the 
use of chloroform as a solvent for analytical characterization.51,52 We are currently 
working to obtain the requisite data in a solvent such as benzene or acetonitrile. 
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carbonitrile (102). In an oven-dried vial, LiAlH4 solution (1.0 M in THF, 2 mL, 2.0 
mmol) was cooled to 0 ºC. A solution of ethyl acetate (230 µL, 2.35 mmol) in 2 mL THF 
was added slowly, and the resulting solution was stirred 30 min at 0 ºC, providing a 0.47 
M solution of Li(EtO)2AlH2 in THF. bis-Tetrahydroisoquinoline 117 (8.0 mg, 16.6 µmol, 
1.0 equiv) was dissolved in THF (0.75 mL, 0.02 M) and the resulting solution was cooled 
to 0 ºC. A solution of Li(EtO)2AlH2 (0.47 M in THF, 0.47 mL, 0.21 mmol, 15.0 equiv) 
was added slowly, resulting in extensive evolution of H2. After stirring for 45 min, the 
reaction was quenched with acetic acid (17.7 µL, 0.31 mmol, 21 equiv) and aqueous 
potassium cyanide (4.8 M, 18.4 µL, 88.4 µmol, 6.0 equiv) was added, followed by celite 
and anhydrous Na2SO4 (roughly 300 mg each). The solution was diluted with 1 mL THF 
and stirred 10 h, warming to room temperature. More celite was added, and the 
suspension was filtered through celite, rinsed with EtOAc, and concentrated. The product 
was purified by preparative HPLC (MeCN/0.4% acetic acid in water, 5.0 mL/min, 
monitor wavelength = 230 nm, 35–95% MeCN over 8 min, hold at 95% for 1 min for a 
total run time of 9 min. Product 102 has tR = 6.5 min). Colorless solid, 3.9 mg, 7.9 µmol, 
48% yield. 1H NMR (400 MHz, CDCl3) δ 6.57 (s, 1H), 6.23 (s, 1H), 4.02 (d, J = 2.4 Hz, 
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1H), 3.99 (t, J = 4.4 Hz, 1H), 3.80 (s, 3H), 3.75 (s, 3H), 3.69 (s, 3H), 3.66 (s, 3H), 3.55 – 
3.51 (m, 1H), 3.48 (d, J = 10.4 Hz, 1H), 3.36 (d, J = 7.7 Hz, 1H), 3.25 (dt, J = 12.1, 2.6 
Hz, 1H), 3.13 – 3.07 (m, 1H), 3.05 (dd, J = 18.4, 7.8 Hz, 1H), 2.49 – 2.39 (m, 2H), 2.31 
(s, 3H), 2.25 – 2.16 (m, 1H), 2.13 (s, 3H), 2.06 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 
155.4, 148.5, 148.1, 130.0, 129.2, 124.9, 124.2, 123.5, 118.1, 117.7, 116.9, 107.3, 106.2, 
64.9, 62.4, 61.3, 60.1, 59.3, 58.9, 57.5, 55.5, 54.8, 54.6, 40.7, 31.8, 20.6, 14.7, 8.0; IR 
(thin film, NaCl): 3441, 2961, 2928, 2855, 1607, 1456, 1410, 1326, 1261, 1190, 1123, 
1082, 1030, 912, 865, 801, 734; HRMS (ESI-TOF) calc’d for [M+] C28H35N3O5 = 
493.2577, found 493.2579; [α]D = –43.3º (c = 0.05, CHCl3). 
 
 
Monochlorinated bis-THIQ pentacycles (118 and 119): bis-THIQ 117 (112.0 mg, 
0.232 mmol, 1.0 equiv) was dissolved in HFIP (11.6 mL, 0.02 M after complete addition) 
and the solution was cooled to 0 ºC. N-Chlorosaccharine (55.6 mg, 0.255 mmol, 1.1 
equiv) was dissolved in 1.6 mL HFIP and this solution was added at a slow dropwise 
pace, allowing the orange color to dispel after each addition, and the resulting yellow 
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solution was stirred at 0 ºC. An LCMS sample taken 1 min after complete addition 
showed a 2.5:1.7:1.0:1.5 mixture of starting material 117:118:119:product 99. The 
reaction was quenched by the addition of saturated aqueous Na2S2O3 and transferred to a 
separatory funnel with CH2Cl2 and water, creating a triphasic system with HFIP on 
bottom, CH2Cl2 in the middle, and the aqueous phase on top. The bottom two phases 
were collected. The aqueous phase was basified with K2CO3 and extracted with CH2Cl2. 
The combined organic phases were concentrated and azeotropically dried twice with 
benzene. Products 118 and 119 were isolated using preparative HPLC (MeCN/0.4% 
acetic acid in water, 5.0 mL/min, monitor wavelength = 235 nm, 50–80% MeCN over 10 
min, ramp to 95% MeCN over 0.5 min, hold at 95% for 2.5 min for a total run time of 13 
min. Starting material 117, product 118, and 119 has tR = 3.1, 5.1, and 6.7 min, 
respectively). Starting material 117 was recovered as a colorless solid, 24.3 mg, 0.050 
mmol, 22% yield. 118 was isolated as a white solid, 25.2 mg, 0.049 mmol, 21% yield, 
and 27% yield based on recovered starting material. 119 is a white solid, 13.7 mg, 0.026 
mmol, 11% yield, 15% yield based on recovered starting material. The structures of 118 
and 119 were assigned using diagnostic nOe correlations (highlighted -OMe or -Me). 
 
Product 118: 1H NMR (400 MHz, CDCl3) δ 6.42 (s, 1H), 5.75 (dd, J = 6.4, 4.0 Hz, 1H), 
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(s, 3H), 3.69 (s, 3H), 3.40 (dd, J = 11.0, 4.0 Hz, 1H), 3.26 (dd, J = 15.2, 2.5 Hz, 1H), 3.18 
(dd, J = 10.9, 6.4 Hz, 2H), 3.12 (d, J = 6.6 Hz, 1H), 2.94 (dd, J = 17.7, 1.3 Hz, 1H), 2.47 
(s, 3H), 2.41 (dd, J = 15.2, 12.6 Hz, 1H), 2.31 (s, 3H), 2.14 (s, 3H); 13C NMR (100 MHz, 
CDCl3) δ 173.1, 157.4, 156.8, 150.4, 148.5, 130.6, 129.7, 128.5, 127.5, 126.2, 119.8, 
118.7, 107.0, 68.8, 61.1, 60.9, 60.4, 60.4, 60.1, 57.6, 55.9, 52.7, 40.0, 30.6, 24.0, 13.8, 
9.1; IR (thin film, NaCl): 3388, 2938, 1634, 1456, 1407, 1330, 1123, 1081, 1013, 754; 
HRMS (ESI-TOF) calc’d for [M+H]+ C27H34ClN2O6 = 517.2100, found 517.2082; [α]D = 
–73.6º (c = 0.89, CHCl3). 
Product 119: 1H NMR (400 MHz, CDCl3) δ 6.73 (s, 1H), 5.85 (dd, J = 7.5, 4.2 Hz, 1H), 
4.46 – 4.39 (m, 1H), 4.08 (dt, J = 12.9, 2.9 Hz, 1H), 3.90 (s, 3H), 3.80 (s, 3H), 3.77 (s, 
4H), 3.71 (s, 4H), 3.44 (dd, J = 10.8, 4.2 Hz, 1H), 3.22 – 3.06 (m, 3H), 3.00 (dd, J = 18.1, 
1.3 Hz, 1H), 2.43 (s, 3H), 2.39 – 2.29 (m, 1H), 2.26 (s, 3H), 2.23 (s, 3H); 13C NMR (100 
MHz, CDCl3) δ 173.3, 156.0, 153.6, 149.8, 149.4, 131.7, 131.3, 127.8, 126.1, 124.8, 
124.4, 124.2, 123.5, 69.0, 60.6, 60.4, 60.3, 59.9, 59.3, 59.2, 57.6, 52.0, 40.1, 31.7, 24.8, 
15.7, 10.0; IR (thin film, NaCl): 3418, 2939, 2870, 1644, 1634, 1455, 1446, 1326, 1224, 
1106, 1081, 1005, 932, 755; HRMS (ESI-TOF) calc’d for [M+H]+ C27H34ClN2O6 = 
517.2100, found 517.2101; [α]D = –114.0º (c = 0.86, CHCl3). 
 
Monohydroxy(A-ring) bis-THIQ (120): In a nitrogen-filled glovebox, Buchwald’s 
dimer (16.4 mg, 0.022 mmol, 0.50 equiv) and 5-[di(1-adamantyl)phosphino]-1′,3′,5′-


































Chapter 3 – Concise Total Syntheses of (–)-Jorunnamycin A and (–)-Jorumycin  
Enabled by Asymmetric Catalysis 
  
308 
triphenyl-1′H-[1,4′]bipyrazole (AdBippyPhos, 58.9 mg, 0.089 mmol, 2.00 equiv) were 
weighed into a scintillation vial and dioxane (4.0 mL) was added. The vial was sealed 
with electrical tape and removed from the glovebox, sonicated briefly, and returned to the 
glovebox. The resulting tan solution was then transferred to a scintillation vial containing 
bis-tetrahydroisoquinoline 118 (23.0 mg, 0.045 mmol, 1.00 equiv) and CsOH•H2O (74.7 
mg, 0.045 mmol, 10.0 equiv), followed by a 0.5 mL rinse (4.5 mL total volume, 0.01 M). 
The vial was sealed, removed from the glovebox, and placed in a preheated 90 ºC oil 
bath. After 3 h, the vial was removed and allowed to cool fully to room temperature prior 
to removing the seal. Acetic acid (23 µL, 0.401 mmol, 9 equiv) was added to quench the 
remaining CsOH and the contents of the vial were transferred to a roundbottom flask, to 
which silica gel was added directly to dry load the crude mixture onto a silica gel column. 
The solution was concentrated, and the product was purified by column chromatography 
(2–4–6–8% MeOH + CH2Cl2: no NEt3 added). Colorless solid, 14.4 mg, 0.029 mmol, 
65% yield. Note: Based on the 1H NMR spectrum of the isolated product, there is 
approximately 20% of an additional side product. 1H NMR (500 MHz, CDCl3) δ 6.55 (s, 
1H), 5.85 (dd, J = 6.7, 4.1 Hz, 1H), 4.15 – 3.98 (m, 2H), 3.94 (d, J = 2.5 Hz, 7H), 3.89 (s, 
4H), 3.81 (s, 4H), 3.50 (dd, J = 11.0, 4.2 Hz, 1H), 3.34 – 3.22 (m, 3H), 3.07 (dd, J = 17.6, 
1.2 Hz, 1H), 2.60 (s, 3H), 2.37 (dd, J = 14.9, 12.6 Hz, 1H), 2.28 (s, 3H), 2.26 (s, 3H); 13C 
NMR (100 MHz, CDCl3) δ 173.3, 157.3, 156.8, 150.0, 146.3, 143.7, 128.7, 125.3, 119.8, 
118.8, 118.3, 117.4, 107.2, 69.1, 61.3, 60.9, 60.4, 60.2, 60.2, 58.1, 56.0, 52.6, 40.0, 29.8, 
26.1, 24.0, 9.1; IR (thin film, NaCl): 3318, 2935, 1622, 1608, 1587, 1463, 1456, 1355, 
1272, 1123, 1069, 755; HRMS (ESI-TOF) calc’d for [M+H]+ C27H35N2O7 =499.2439, 
found 499.2449; [α]D = –87.2º (c = 1.03, CHCl3). 
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Monohydroxy(A-ring) bis-THIQ aminonitrile (103): In an oven-dried 1-dram vial, 
LiAlH4 solution (1.0 M in THF, 1 mL, 1.0 mmol) was cooled to 0 ºC. A solution of ethyl 
acetate (115 µL, 1.18 mmol) in 1 mL THF was added slowly, and the resulting solution 
was stirred 30 min at 0 ºC, providing a 0.47 M solution of Li(EtO)2AlH2 in THF. bis-
THIQ 120 (14.4 mg, 28.9 µmol, 1.0 equiv) was dissolved in THF (1.5 mL, 0.02 M) and 
the resulting solution was cooled to 0 ºC. A solution of Li(EtO)2AlH2 (0.47 M in THF, 
0.92 mL, 0.43 mmol, 15.0 equiv) was added slowly, resulting in extensive evolution of 
H2. After stirring 20 min, LCMS showed complete consumption of 120, so the reaction 
was quenched with acetic acid (34.7 µL, 0.607 mmol, 21 equiv) and aqueous potassium 
cyanide (4.8 M, 36.1 µL, 0.173 mmol, 6.0 equiv) was added, followed by celite and 
anhydrous Na2SO4 (roughly 500 mg each). The solution was diluted with 3 mL THF and 
stirred for 12 h, warming to room temperature. At this stage, LCMS revealed some 
unreacted starting material, so the reaction was stirred at 50°C for an additional 3 hours. 
~1 g of K2CO3 was added, followed by celite. The suspension was filtered through celite, 
rinsed with EtOAc, and concentrated. The product was purified by preparative HPLC 
(MeCN/0.4% acetic acid in water, 5.0 mL/min, monitor wavelength = 230 nm, 40–60% 
MeCN over 7 min, ramp to 95% MeCN over 0.5 min, hold at 95% for 2.5 min for a total 
run time of 10 min. Product 103 has tR = 5.1 min). Colorless solid, 5.1 mg, 10.0 µmol, 
35% yield. 1H NMR (600 MHz, CDCl3) δ 6.37 (s, 1H), 4.09 (d, J = 2.4 Hz, 1H), 4.07 (t, J 
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= 4.6 Hz, 1H), 3.83 (s, 3H), 3.81 (s, 3H), 3.77 (s, 3H), 3.73 (s, 3H), 3.65 – 3.62 (m, 1H), 
3.53 (dd, J = 10.9, 4.5 Hz, 1H), 3.43 (dt, J = 7.8, 1.5 Hz, 1H), 3.27 (dt, J = 12.0, 2.7 Hz, 
1H), 3.16 – 3.09 (m, 2H), 2.94 (dd, J = 15.1, 2.7 Hz, 1H), 2.50 (d, J = 18.2 Hz, 1H), 2.39 
(s, 3H), 2.13 (s, 3H), 2.12 (s, 3H), 2.10 (d, J = 12.3 Hz, 1H), 1.99 (dd, J = 15.1, 12.1 Hz, 
1H); 13C NMR (101 MHz, CDCl3) δ 156.6, 156.1, 149.6, 146.3, 143.3, 130.4, 125.8, 
119.3, 118.9, 118.1, 117.8, 116.1, 107.6, 66.2, 63.6, 61.4, 60.8, 60.5, 60.1, 58.5, 56.4, 
55.9, 55.8, 41.9, 26.1, 21.8, 9.2, 8.9; IR (thin film, NaCl): 3444, 2937, 2359, 1606, 1463, 
1418, 1354, 1263, 1191, 1122, 1070, 983, 911, 733; HRMS (ESI-TOF) calc’d for [M+] 
C28H36N3O6 = 510.2599, found 510.2589; [α]D = +36.4º (c = 0.36, CHCl3). 
 
Monohydroxy(E-ring) bis-THIQ (121). In a nitrogen-filled glovebox, Buchwald’s 
dimer (6.8 mg, 9.2 µmol, 0.50 equiv) and 5-[di(1-adamantyl)phosphino]-1′,3′,5′-
triphenyl-1′H-[1,4′]bipyrazole (AdBippyPhos, 24.4 mg, 0.037 mmol, 2.00 equiv) were 
weighed into a scintillation vial and dioxane (1.6 mL) was added. The vial was sealed 
with electrical tape and removed from the glovebox, sonicated briefly, and returned to the 
glovebox. The resulting tan solution was then transferred to a 1-dram vial containing bis-
tetrahydroisoquinoline 119 (9.5 mg, 0.018 mmol, 1.00 equiv) and CsOH•H2O (30.9 mg, 
0.184 mmol, 10.0 equiv), followed by a 0.2 mL rinse (1.8 mL total volume, 0.01 M). The 
vial was sealed, removed from the glovebox, and placed in a preheated 90 ºC oil bath. 
After 3 h, the vial was removed and allowed to cool fully to room temperature prior to 
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removing the seal. Acetic acid (9.5 µL, 0.166 mmol, 9 equiv) was added to quench the 
remaining CsOH and the contents of the vial were transferred to a scintillation vial, to 
which silica gel was added directly to dry load the crude mixture onto a silica gel column. 
The solution was concentrated, and the product was purified by column chromatography 
(2–4–6–8% MeOH + CH2Cl2: no NEt3 added). Due to a significant amount of impurities 
present in the sample, the isolated product was repurified using preparative HPLC 
(MeCN/0.4% acetic acid in water, 5.0 mL/min, monitor wavelength = 235 nm, 25–55% 
MeCN over 10 min, ramp to 95% MeCN over 0.5 min, hold at 95% for 2.5 min for a total 
run time of 13 min. Product 121 has tR = 5.1 min). White solid, 1.7 mg, 3.41 µmol, 19% 
yield. 1H NMR (400 MHz, CDCl3) δ 6.72 (s, 1H), 5.81 (dd, J = 7.2, 3.6 Hz, 1H), 5.65 (s, 
1H), 4.27 (dd, J = 3.7, 1.3 Hz, 1H), 4.02 (dt, J = 12.7, 2.9 Hz, 1H), 3.90 (s, 3H), 3.78 (s, 
3H), 3.77 (s, 3H), 3.76–3.73 (m, 1H), 3.68 (s, 3H), 3.45 (dd, J = 11.0, 4.1 Hz, 1H), 3.22 
(dd, J = 10.6, 7.2 Hz, 1H), 3.13 (dd, J = 18.0, 6.7 Hz, 1H), 3.07 – 2.93 (m, 2H), 2.47 – 
2.32 (m, 4H), 2.24 (s, 3H), 2.23 – 2.20 (m, 4H); 13C NMR (100 MHz, CDCl3) δ 173.6, 
149.9, 149.8, 149.6, 143.7, 143.0, 132.2, 131.7, 124.8, 124.7, 123.4, 123.0, 115.9, 69.4, 
61.1, 60.7, 60.5, 60.0, 59.7, 59.2, 55.2, 52.7, 40.2, 31.8, 24.8, 15.9, 9.8; IR (thin film, 
NaCl): 3424, 2936, 1628, 1439, 1412, 1326, 1260, 1236, 1109, 1080, 1052, 1006, 731; 
HRMS (ESI-TOF) calc’d for [M+H]+ C27H35N2O7 =499.2439, found 499.2439; [α]D =  
–45.8º (c = 0.10, CHCl3). 
Note: In addition to the desired product 121, we were also able to isolate and assign the 
structure of side product 122. 122 presumably arises from palladium-mediate oxidative 
deformylation. Similar byproducts have been identified by LCMS in other runs, but have 
neither been isolated nor quantified. 
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Oxidative deformylated byproduct (122). Isolated from preparative HPLC as described 
above. Product 122 has tR = 11.3 min. Colorless solid, 0.9 mg, 1.99 µmol, 11% yield. 1H 
NMR (400 MHz, CDCl3) δ 6.67 (s, 1H), 6.38 (s, 1H), 4.66 (d, J = 18.7 Hz, 1H), 4.55 (d, 
J = 18.7 Hz, 1H), 4.05 (ddd, J = 12.2, 4.8, 2.7 Hz, 1H), 3.87 (dd, J = 4.7, 1.2 Hz, 1H), 
3.85 (s, 3H), 3.82 (s, 4H), 3.78 (s, 3H), 3.70 (s, 3H), 3.10 (dd, J = 17.9, 7.1 Hz, 1H), 2.97 
– 2.88 (m, 1H), 2.69 (dd, J = 15.0, 2.7 Hz, 1H), 2.48 (s, 3H), 2.45 – 2.34 (m, 1H), 2.21 (s, 
3H), 2.13 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 171.0, 157.3, 156.6, 149.7, 130.6, 
129.5, 129.1, 124.7, 123.4, 119.6, 119.1, 107.0, 60.7, 60.2, 59.5, 55.9, 55.8, 40.6, 40.1, 
33.7, 22.8, 15.8, 9.1; IR (thin film, NaCl): 2935, 2858, 2362, 2344, 1654, 1638, 1610, 
1458, 1448, 1413, 1327, 1124, 1078, 1001, 731; HRMS (ESI-TOF) calc’d for [M+H]+ 
C26H33N2O5 =453.2384, found 453.2379; [α]D = –123.4º (c = 0.06, CHCl3). 
 
Monohydroxy(E-ring) bis-THIQ aminonitrile (104). In an oven-dried 1-dram vial, 
LiAlH4 solution (1.0 M in THF, 1 mL, 1.0 mmol) was cooled to 0 ºC. A solution of ethyl 
acetate (115 µL, 1.18 mmol) in 1 mL THF was added slowly, and the resulting solution 
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THIQ 121 (2.2 mg, 4.41 µmol, 1.0 equiv) was dissolved in THF (0.2 mL, 0.02 M) and 
the resulting solution was cooled to 0 ºC. A solution of Li(EtO)2AlH2 (0.47 M in THF, 
141 µL, 66.2 µmol, 15.0 equiv) was added slowly, resulting in extensive evolution of H2. 
After stirring for 20 min, LCMS showed complete consumption of 121, so the reaction 
was quenched with acetic acid (5.3 µL, 92.7 µmol, 21 equiv). Aqueous KCN (4.8 M, 5.5 
µL, 26.5 µmol, 6.0 equiv) was added, followed by celite, anhydrous Na2SO4 (ca. 100 mg 
each), and 0.4 mL of THF. The reaction was warmed to room temperature and stirred for 
12 h. ~150 mg of K2CO3 and celite were added. The suspension was filtered through 
celite, rinsed with EtOAc, and concentrated. The product was purified by preparative 
HPLC (MeCN/0.4% acetic acid in water, 5.0 mL/min, monitor wavelength = 230 nm, 
40–70% MeCN over 10 min, ramp to 95% MeCN over 0.5 min, hold at 95% for 2.5 min 
for a total run time of 13 min. Product 104 has tR = 4.7 min). Colorless solid, 0.7 mg, 1.4 
µmol, 31% yield. 1H NMR (400 MHz, CDCl3) δ 6.65 (s, 1H), 5.52 (s, 1H), 4.15 (s, 1H), 
4.07 (d, J = 3.0 Hz, 2H), 3.87 (s, 3H), 3.75 (t, J = 0.9 Hz, 7H), 3.70 (s, 3H), 3.56 (d, J = 
8.6 Hz, 2H), 3.43 – 3.31 (m, 2H), 3.10 (dd, J = 18.5, 7.8 Hz, 1H), 2.80 (dd, J = 15.4, 2.5 
Hz, 1H), 2.50 (d, J = 18.5 Hz, 1H), 2.34 (s, 3H), 2.23 (s, 3H), 2.20 (s, 4H); 13C NMR 
(100 MHz, CDCl3) δ 155.5, 149.2, 148.7, 143.6, 143.3, 142.1, 131.8, 131.2, 125.2, 124.9, 
123.5, 118.1, 116.9, 66.0, 61.1, 61.1, 60.5, 60.2, 60.1, 58.7, 57.5, 56.6, 55.3, 41.9, 32.0, 
21.8, 15.8, 9.8; IR (thin film, NaCl): 3400, 2930, 2859, 2351, 2250, 1664, 1458, 1412, 
1327, 1308, 1261, 1106, 1080, 1057, 1010, 911, 801, 733; HRMS (ESI-TOF) calc’d for 
[M+] C28H36N3O6 = 510.2599, found 510.2596; [α]D = –21.8º (c = 0.05, CHCl3).  
Dihydroxylated bis-THIQ aminonitrile (105): See page 298 for experimental 
procedure and characterization data. 
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3.6.2.9 Preparation of 98 for crystal structure analysis 
 
Sulfonamide (98): Bis-THIQ 81 (45 mg, 0.096 mmol, 1.0 equiv, 88% ee), 4-
dimethylaminopyridine (DMAP, 1.2 mg, 0.0096 mmol, 0.10 equiv), and p-
bromophenylsulfonyl chloride (27 mg, 0.105 mmol, 1.10 equiv) were dissolved in 
CH2Cl2 (2 mL, 0.05 M) and diisopropylethylamine (DIPEA, 33 µL, 0.192 mmol, 2.0 
equiv) was added. The solution was stirred 2 h, at which time LCMS revealed full 
conversion to product 98. The reaction was quenched by the addition of 1M HCl. The 
layers were separated and the aqueous phase was extracted with CH2Cl2. The combined 
organic phases were washed with brine, dried over Na2SO4, and concentrated. The 
product was purified by column chromatography (1% MeOH/CH2Cl2 + 1% NEt3). 
Colorless solid, 61.0 mg, 0.089 mmol, 92% yield. 1H NMR (400 MHz, CDCl3) δ 7.55 (d, 
J = 8.7 Hz, 2H), 7.47 (d, J = 8.8 Hz, 2H), 6.73 (s, 1H), 6.35 (s, 1H), 5.70 (dd, J = 6.3, 4.3 
Hz, 1H), 5.07 (dd, J = 3.5, 1.6 Hz, 1H), 4.74 (dt, J = 7.0, 1.3 Hz, 1H), 4.01 (dt, J = 12.7, 
2.9 Hz, 1H), 3.90 (s, 3H), 3.84 (s, 3H), 3.77 (s, 3H), 3.49 (s, 3H), 3.41 (dt, J = 10.4, 4.9 
Hz, 1H), 3.19 (dt, J = 11.2, 5.6 Hz, 1H), 3.03 (dd, J = 17.6, 1.3 Hz, 1H), 2.77 (dd, J = 
14.4, 2.6 Hz, 1H), 2.71 (dd, J = 17.6, 6.9 Hz, 1H), 2.62 (t, J = 13.4 Hz, 1H), 2.49 (t, J = 
5.6 Hz, 1H), 2.24 (s, 3H), 2.09 (s, 3H).  
 
p-BrPhSO2Cl, DIPEA
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3.6.3 COMPARISON OF NMR DATA TO KNOWN SAMPLES 
Table 3.2 Tabulated NMR data for (–)-jorunnamycin A (79). 
Synthetic Jorunnamycin A (79) 
1H NMR 






4.11 (d, J = 2.6 Hz, 1H) 4.08 (d, J = 2.3 Hz, 1H) 186.4 186.5 
4.08 (dd, J = 3.0, 1.0 Hz, 1H) 4.06 (app d, J = 2.1 Hz, 1H) 185.6 185.7 
4.03 (s, 3H) 4.01 (s, 3H) 182.4 182.5 
3.99 (s, 3H) 3.97 (s, 3H) 181.5 181.6 
3.90 (app q, J = 3.1 Hz, 1H) 3.87 (ddd, J = 5.8, 3.0, 3.0 Hz, 1H) 155.6 155.7 
3.71 (dd, J = 11.3, 3.4 Hz, 1H) 3.69 (dt, J = 11.5, 2.8 Hz, 1H) 155.5 155.6 
3.50 (br s, 1H) 3.48 (m, 1H) 141.8 141.8 
3.42 (ddd, J = 7.4, 2.6, 1.5 Hz, 1H) 3.39 (app d, J = 7.5 Hz, 1H) 141.5 141.6 
3.18 (dt, J = 11.4, 2.9 Hz, 1H) 3.15 (dt, J = 11.5, 2.8 Hz, 1H) 136.2 136.3 
2.93 (ddd, J = 17.4, 2.8, 0.9 Hz, 
1H) 2.91 (dd, J = 17.5, 2.6 Hz, 1H) 135.8 135.8 
2.83 (dd, J = 21.0, 7.5 Hz, 1H) 2.81 (dd, J = 20.9, 7.5 Hz, 1H) 129.1 129.1 
2.31 (s, 3H) 2.28 (s, 3H) 128.8 128.8 
2.26 (d, J = 21.0 Hz, 1H) 2.23 (d, J = 21.1 Hz, 1H) 117.0 117.0 
1.95 (s, 3H) 1.93 (s, 3H) 64.1 64.2 
1.94 (s, 3H) 1.92 (s, 3H) 61.3 61.3 
1.41 (ddd, J = 17.5, 11.5, 2.7 Hz, 
1H) 
1.38 (ddd, J = 17.3, 11.5, 2.6 Hz, 
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Table 3.3 Tabulated NMR data for (–)-jorunnamycin (77). 
Synthetic Jorumycin (77) 
1H NMR 








4.47 – 4.41 (m, 1H) 4.41 (dd, J = 11.1, 3.4 Hz, 1H),  186.7 186.8 
4.44 (dd, J = 11.2, 3.5 Hz, 1H) 4.41 (d, J = 11.1 Hz, 1H),  186.0 186.1 
4.36 (q, J = 3.6, 3.2 Hz, 1H) 4.35 (ddd, J = 5.5, 2.8, 2.8 Hz, 1H),  186.7 182.8 
4.00 (s, 3H) 3.98 (s, 3H),  181.5 181.6 
3.98 (s, 3H) 3.96 (s, 3H),  170.2 170.3 
3.90 (app d, J = 2.5 Hz, 1H) 3.88 (app d, J = 2.7 Hz, 1H),  155.8 155.9 
3.88 (br s, 1H, C21-OH) 3.86 (d, J = 10.9 Hz, 1H, C21-OH),  155.4 155.5 
3.81 (dd, J = 11.2, 3.3 Hz, 1H) 3.80 (dd, J = 11.1, 3.2 Hz, 1H),  142.1 142.2 
3.20 – 3.12 (m, 2H) 3.16 (m, 1H),  142.0 142.1 
 3.14 (m, 1H),  137.4 137.5 
2.84 (dd, J = 16.7, 2.2 Hz, 1H) 2.82 (dd, J = 16.8, 2.3 Hz, 1H),  134.6 134.7 
2.65 (dd, J = 21.0, 7.5 Hz, 1H) 2.63 (dd, J = 21.1, 7.5 Hz, 1H),  128.9 129.0 
2.26 (s, 3H) 2.24 (s, 3H),  128.5 128.6 
2.23 (d, J = 18.8 Hz, 1H) 2.22 (d, J = 20.0 Hz, 1H),  83.2 83.2 
1.96 (s, 3H) 1.94 (s, 3H),  64.3 64.4 
1.93 (s, 3H) 1.91 (s, 3H),  61.2 61.2 
1.76 (s, 3H) 1.74 (s, 3H),  61.2 61.2 
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3.6.4  OPTIMIZATION OF THE ENANTIOSELECTIVE HYDROGENATION 









































60 °C, 18 h
(R = CO2Me)
yield and ee of 97Josiphos lig. R1 R2
--L50:  SL-J001-1 Ph Cy
L51:  SL-J002-1 Ph t-Bu
26%, 80% eeL48:  SL-J005-2 Ph Xyl
--L52:  SL-J216-1 1-Nap t-Bu
68%, –15% eeL53:  SL-J404-1 1-Nap Xyl
--L54:  SL-J006-1 BTFM Cy
83%, 94% eeL49:  SL-J008-1 BTFM Xyl
--L55:  SL-J007-1 DMM-Ph Cy
--L56:  SL-J013-1 DMM-Ph t-Bu
30%, –77% eeL57:  SL-J418-1 DMM-Ph Xyl
--L58:  SL-J212-1 2-fur t-Bu
22%, –16% eeL59:  SL-J015-1 2-fur Xyl
L60:  SL-J003-2 Cy Cy
--L61:  SL-J009-1 Cy t-Bu
--L62:  SL-J004-1 Cy Ph
--L63:  SL-J502-1 t-Bu Ph






Josiphos framework (-1 enantiomer)
--
yield and ee of 22Walphos lig. R1 R2
--L31:  SL-W002-1 Ph Ph
L65:  SL-W006-1 Ph Xyl
2%, ee NDL66:  SL-W001-1 Ph BTFM
6%, ee NDL67:  SL-W005-1 DMM-Ph BTFM
4%, ee NDL68:  SL-W003-1 Ph Cy
2%, ee NDL69:  SL-W008-1 Cy BTFM
--L70:  SL-W009-1 Xyl Xyl
--L71:  SL-W022-1 Ph norbornyl
--
Fe








































L1:  BINAP L5:  DTB-MeOBIPHEP L6:  DTBM-MeOBIPHEP L3:  SEGPHOS
-- <1 %, ee ND -- -- <1 %, ee ND
L72:  MeO-BIBOP
Chapter 3 – Concise Total Syntheses of (–)-Jorunnamycin A and (–)-Jorumycin  










































L30:  DM-SEGPHOS L8:  C3-TunePhos L9:  Difluorphos
L32:  SL-M001-2 L73:  SL-M012-2
-- -- 14%, 62% ee --




























































L35:  QUINAP L21:  Me-BPE L76:  Et-BPE L22:  i-Pr-BPE
L23:  Me-DUPHOS L77:  Et-DUPHOS
6%, ee ND 30%, 26% ee 31%, 16% ee 2%, ee ND
L74:  SL-M003-2 L33:  SL-T001-1 L75:  SL-T002-1 L29:  SL-N004-1
L41:  t-Bu-PHOX L28:  (CF3)-t-Bu-PHOX
55%, –27% ee 88%, –17% ee <1%, ee ND --
1%, ee ND 22%, –82% ee
L30:  DuanPhos L25:  catASium MNXyl(S) L78:  catASium MNXylF(S)
L47:  Et-FerroTANE L26:  Me-Ferrocelane L79:  i-Pr-Ferrocelane
3%, ee ND 36%, 0% ee 12%, ee ND
26%, –87% ee < 1%, ee ND --
L11:  SolPhos
L4:  P-Phos




31%, 10% ee 15%, 58% ee 4%, ee ND
L15:  Chiraphos
L18:  catASium D
L19:  BPPM L20:  NorPhos
--
48%, 13% ee
8%, ee ND 20%, 47% ee























































































11%, ee ND 12%, ee ND
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3.6.5  EXPLANATION OF SELECTIVITY DIFFERENCES  
Of all the ligands tested, only BTFM-Xyliphos (L49) enables the further 
reduction of 97 to 81 following lactamization. Intriguingly, the product 97 shows a 94% 
ee, while product 81 only shows 87% ee (Scheme 3.6). We propose that the discrepancy 
in enantioenrichment of the products is due to competitive D-ring reduction with lower 
enantioselectivity than that observed when the B-ring is reduced first. Because no other 
diastereomers are observed, global reduction via this route also appears to be fully 
diastereoselective. 
Scheme 3.6 Observed discrepancy in enantioenrichment of products 97 and 81. 
 
We believe that Path A is faster than Path B for all ligands to such an extent that 
Path B is only observed when the most activating ligand, BTFM-Xyliphos, is used. Both 
partially reduced intermediates are expected to form tridentate chelates to the metal to 
form 97•M and 123•M (with M not necessarily being the catalytically active metal), with 




































60 ºC, 18 h
(R = CO2Me)
excess Ac2O added












97 was found to be unstable
to isolation, presumably due to
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diastereomer (Scheme 3.7). Furthermore, because B-ring reduction appears to be faster 
than D-ring reduction in all cases, intermediate 97 can be isolated (after N-protection) 
while intermediate 123 has never been directly observed. The discrepancy in 
enantiomeric excess between intermediate 97 and fully hydrogenated intermediate 82 (as 
manifested by the enantiomeric excess of 123 and bis-THIQ 81, respectively) can be 
explained if the enantioselectivity of Path B is significantly lower than that of Path A. As 
the two paths converge onto the same product, the enantiopurity of 81 would be expected 
to be less than that of 97. 
Scheme 3.7 Possible reaction pathways to generate pentacycle 81 . 
 
3.6.6  BIOLOGICAL EVALUATION OF NON-NATURAL ANALOGS 
3.6.6.1 Cell Culture and Proliferation Assays 
Cell lines, cell culture, and reagents: A panel of 29 cell lines, representing 4 major 
cancer types (lung, colon, breast, and ovarian), was assayed for response to THIQ agents. 
Cells were cultured in appropriate culture media (e.g., RPMI 1640, DMEM, L-15) 





















































(second reduction is slow)
Ester group
shields top face
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glutamine, and 1% penicillin G-streptomycin-fungizone solution (PSF, Irvine Scientific) 
as previously described.41 Cells were routinely assessed for mycoplasma contamination 
using a multiplex PCR method, and STR profiling by the GenePrint 10 System 
(Promega) was used for cell-line authentication.  
In vitro proliferation assays: Response to THIQ agents was measured by a six-day 
proliferation assay. Stock solutions of THIQ agents were prepared at 10 mM in DMSO. 
Cells were seeded in 48-well plates at a seeding density previously determined to 
maximize growth over a 6-day treatment window. After 24 h, the cells were treated with 
six 1:10 (105) or 1:5 (101–104) dilutions of inhibitor starting at 1 µM. Control wells were 
imaged at this time for baseline cell counts. After 6 days of treatment, cells were counted 
on a custom automation platform designed by Tecan. This robotic system trypsinizes 
adherent cells, centrifuges cells to the bottom of the wells, and counts cells via brightfield 
image segmentation on a Synentec Cellavista imaging system. IC50 values for each 
molecule were calculated by fitting curves to data points from each dose–response assay 
using the Proc NLIN function in SAS for Windows version 9.2 (SAS Institute, Inc.). 
3.6.6.2 Biological Activity of Non-Natural Analogs 
Table 3.5 Geometric mean of IC50 values and their statistics. 
 
Compound Geometric Mean Median Maximum Minimum
Carfilzomib .004 .005 .020 .001
Cisplatin .202 .199 .799 .028
MK8745 .360 .380 1.000 0.079
MMAE .438 3.978 .077
.807 1.000 1.000 .225
1.000 1.000 1.000 1.000
.708 .891 1.000 .256
.233 .213 .787 .120







IC50 Statistics (all numbers in µM)
Chapter 3 – Concise Total Syntheses of (–)-Jorunnamycin A and (–)-Jorumycin  
Enabled by Asymmetric Catalysis 
  
322 








Biological Evaluati n of Non-Natural Analogs 
Table S12.  IC50’s (nM) of compounds 30–34 (all data in µM; data listed as 1000 µM are  
≥1000 µM). 
S59
101 102 103 104 105
H810 Lung 260 ND 260 210 110
A427 Lung 660 1000 880 210 340
H1836 Lung 470 1000 700 280 490
H226 Lung 1000 ND 770 210 660
H441 Lung 1000 ND 980 270 740
H1437 Lung 1000 ND 1000 740 760
H647 Lung 1000 1000 1000 540 770
NCIH747 Colon 1000 1000 290 150 120
SW837 Colon 910 1000 890 140 230
SW480 Colon 1000 ND 720 190 370
LS174t Colon 1000 1000 1000 260 610
SNUC1 Colon 1000 ND 820 500 730
SKCO1 Colon 1000 1000 1000 790 780
SW48 Colon 1000 1000 720 120 810
OVCAR3 Ovarian 1000 1000 1000 150 120
ES2 Ovarian 1000 1000 410 200 170
OV207 Ovarian 1000 1000 970 250 170
OVTOKO Ovarian 1000 1000 860 210 420
RMG1 Ovarian 1000 1000 990 200 520
RMUGS Ovarian 1000 1000 1000 300 550
OVCAR5 Ovarian 1000 ND 310 220 650
EFO21 Ovarian 1000 1000 1000 240 780
MB468 Breast 1000 ND 470 140 210
ZR751 Breast 1000 ND 330 180 230
EFM19 Breast 460 ND 1000 140 230
MB453 Breast 260 ND 1000 250 350
HCC1806 Breast 1000 ND 560 190 380
T47D Breast 1000 ND 1000 210 540
COLO824 Breast 230 ND 260 200 790
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Scheme A5.1 Synthesis of isoquinoline N-oxide 84.  
 
 







(PPh3)2PdCl2 (5 mol %)
i-Pr2NH, 70 ºC, 18 h















































OMe then, aq. NH4OH
















































then, NMO, 80 ºC
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(66% yield, 2 steps)
1)  aq. CH2O (1.85 equiv)
NaBH(OAc)3 (5 equiv)
DCE, 23 °C, 15 min
2) NCSac (2.1 equiv)






















































(25 equiv), 45 °C
30 min
Pd G3 Dimer (50 mol %)
AdBippyPhos (200 mol %)
CsOH • H2O (10 equiv)
dioxane, 90 °C, 3 h
1) Li(EtO)2AlH2 (15 equiv)
THF, 0 °C, 45 min, then
AcOH, KCN, 50% yield
2)  DDQ (4 equiv), acetone, H2O
23 °C, 1 h
(93% yield)
Pd(OAc)2 (20 mol %)
P(t-Bu)2Me•HBF4 (50 mol %)
CsOPiv (40 mol %)
Cs2CO3 (3.5 equiv)
PhMe, 130 ºC
MeReO3 (6 mol %)
aq. H2O2, CH2Cl2
23 °C, 1 h




AcOH, 50 ºC, 3 h
then, KF (10 equiv)
23 ºC, 12 h
TEMPO
NHS, PhI(OAc)2
CH2Cl2, 23 ºC, 3 h
then, p-TsOH•H2O
MeOH, 65 ºC, 5 h
[Ir(cod)Cl]2 (10 mol %)
L49 (21 mol %)
TBAI, 60 mol %
9:1 PhMe/AcOH
60 ºC → 80 ºC
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 Figure A6.5 13C NMR (125 MHz, CDCl3) of compound 88. 
 
























































































































Figure A6.8 13C NMR (100 MHz, CDCl3) of compound 84. 
 
Figure A6.7 Infrared spectrum (Thin Film, NaCl) of compound 84. 
 































































































































































































































































































































































Figure A6.14 13C NMR (125 MHz, CDCl3) of compound 91. 
 
Figure A6.13 Infrared spectrum (Thin Film, NaCl) of compound 91. 
 










































































































































































































 Figure A6.18 13C NMR (100 MHz, CDCl3) of compound 85. 
 
Figure A6.17 Infrared spectrum (Thin Film, NaCl) of compound 85. 
 





Figure A6.19 19F NMR (282 MHz, CDCl3) of compound 85. 




























































































































 Figure A6.22 13C NMR (100 MHz, CDCl3) of compound 93. 
 
Figure A6.21 Infrared spectrum (Thin Film, NaCl) of compound 93. 
 






























































































































Figure A6.24 13C NMR (100 MHz, CDCl3) of compound 114. 
 
 


























































































































Figure A6.27 13C NMR (100 MHz, CDCl3) of compound 112. 
 
Figure A6.26 Infrared spectrum (Thin Film, NaCl) of compound 112. 
 





























































































































Figure A6.30 13C NMR (100 MHz, CDCl3) of compound 113. 
 
Figure A6.29 Infrared spectrum (Thin Film, NaCl) of compound 113. 
 





























































































































































Figure A6.33 13C NMR (100 MHz, CDCl3) of compounds 115 and 116. 
 
Figure A6.32 Infrared spectrum (Thin Film, NaCl) of compounds 115 and 116. 
 






































































































































Figure A6.36 13C NMR (100 MHz, CDCl3) of compound 83 • DCM. 
 
Figure A6.35 Infrared spectrum (Thin Film, NaCl) of compound 83 • DCM. 
 















































































































































Figure A6.39 13C NMR (100 MHz, CDCl3) of compound 95. 
 
Figure A6.38 Infrared spectrum (Thin Film, NaCl) of compound 95. 
 




























































































































 Figure A6.42 13C NMR (100 MHz, CDCl3) of compound 96. 
 
Figure A6.41 Infrared spectrum (Thin Film, NaCl) of compound 96. 
 



























































































































Figure A6.45 13C NMR (125 MHz, CDCl3) of compound 81. 
 
Figure A6.44 Infrared spectrum (Thin Film, NaCl) of compound 81. 
 































































































































 Figure A6.48 13C NMR (125 MHz, CDCl3) of compound 117. 
 
Figure A6.47 Infrared spectrum (Thin Film, NaCl) of compound 117. 
 






































































































































Figure A6.51 13C NMR (125 MHz, CDCl3) of compound 99. 
 
Figure A6.50 Infrared spectrum (Thin Film, NaCl) of compound 99. 
 



































































































































Figure A6.54 13C NMR (125 MHz, CDCl3) of compound 100. 
 
Figure A6.53 Infrared spectrum (Thin Film, NaCl) of compound 100. 
 

































































































































Figure A6.57 13C NMR (100 MHz, CDCl3) of compound 105. 
 
Figure A6.56 Infrared spectrum (Thin Film, NaCl) of compound 105. 
 




























































































































Figure A6.60 13C NMR (125 MHz, CDCl3) of compound 79. 
 
Figure A6.59 Infrared spectrum (Thin Film, NaCl) of compound 79. 
 
































































































































Figure A6.63 13C NMR (100 MHz, CDCl3) of compound 101. 
 
Figure A6.62 Infrared spectrum (Thin Film, NaCl) of compound 101. 
 





























































































































Figure A6.66 13C NMR (100 MHz, CDCl3) of compound 77. 
 
Figure A6.65 Infrared spectrum (Thin Film, NaCl) of compound 77. 
 

































































































































Figure A6.69 13C NMR (100 MHz, CDCl3) of compound 102. 
 
Figure A6.68 Infrared spectrum (Thin Film, NaCl) of compound 102. 
 
































































































































Figure A6.72 13C NMR (100 MHz, CDCl3) of compound 118. 
 
Figure A6.71 Infrared spectrum (Thin Film, NaCl) of compound 118. 
 
















































































































































































































































Figure A6.76 13C NMR (100 MHz, CDCl3) of compound 119. 
 
Figure A6.75 Infrared spectrum (Thin Film, NaCl) of compound 119. 
 


























































































































































































































































Figure A6.80 13C NMR (100 MHz, CDCl3) of compound 120. 
 
Figure A6.79 Infrared spectrum (Thin Film, NaCl) of compound 120. 
 

































































































































Figure A6.83 13C NMR (100 MHz, CDCl3) of compound 103. 
 
Figure A6.82 Infrared spectrum (Thin Film, NaCl) of compound 103. 
 
































































































































Figure A6.86 13C NMR (100 MHz, CDCl3) of compound 121. 
 
Figure A6.85 Infrared spectrum (Thin Film, NaCl) of compound 121. 
 
































































































































 Figure A6.89 13C NMR (100 MHz, CDCl3) of compound 122. 
 
Figure A6.88 Infrared spectrum (Thin Film, NaCl) of compound 122. 
 
























































































































































































































































































Figure A6.92 13C NMR (100 MHz, CDCl3) of compound 104. 
 
Figure A6.91 Infrared spectrum (Thin Film, NaCl) of compound 104. 
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A7.1   GENERAL EXPERIMENTAL 
Low-temperature diffraction data were collected on a Bruker AXS D8 VENTURE 
KAPPA diffractometer coupled to a PHOTON 100 CMOS detector with K radiation ( = 
1.54178 Å) from an IμS micro-source for the structure of compound P17208 (98). The 
structure was solved by direct methods using SHELXS and refined against F2 on all data 
by full-matrix least squares with SHELXL-2014 using established refinement techniques. 
All non-hydrogen atoms were refined anisotropically. All hydrogen atoms were included 
into the model at geometrically calculated positions and refined using a riding model. The 
isotropic displacement parameters of all hydrogen atoms were fixed to 1.2 times the U 
value of the atoms they are linked to (1.5 times for methyl groups). Unless otherwise 
noted, all disordered atoms were refined with the help of similarity restraints on the 1,2- 
and 1,3-distances and displacement parameters as well as rigid bond restraints for 
anisotropic displacement parameters. Compound P17208 crystallizes in the orthorhombic 
space group P21212 with one molecule in the asymmetric unit along with two molecules 
of isopropanol. The hydroxide group and both isopropanol molecules were disordered 
over two positions. The Flack parameter refines to be 0.138(9). 
A7.2  X-RAY CRYSTAL STRUCTURE ANALYSIS OF SULFONAMIDE 98 
 
 
X-ray quality crystals were obtained by allowing the slow evaporation of an 
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Table A7.1 Crystal data and structure refinement for product 98. 
 
Identification code  P17208 
Empirical formula  C38 H51 Br N2 O10 S 
Formula weight  807.77 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Orthorhombic 
Space group  P21212 
Unit cell dimensions a = 29.7321(15) Å a= 90°. 
 b = 10.3172(5) Å b= 90°. 
 c = 12.6857(5) Å g = 90°. 
Volume 3891.4(3) Å3 
Z 4 
Density (calculated) 1.379 Mg/m3 
Absorption coefficient 2.426 mm-1 
F(000) 1696 
Crystal size 0.250 x 0.150 x 0.050 mm3 
Theta range for data collection 2.972 to 74.895°. 
Index ranges -37<=h<=37, -12<=k<=12, -15<=l<=13 
Reflections collected 45084 
Independent reflections 7959 [R(int) = 0.0739] 
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Completeness to theta = 67.679° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7538 and 0.5857 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 7959 / 402 / 569 
Goodness-of-fit on F2 1.115 
Final R indices [I>2sigma(I)] R1 = 0.0767, wR2 = 0.1896 
R indices (all data) R1 = 0.0827, wR2 = 0.1932 
Absolute structure parameter 0.138(9) 
Extinction coefficient n/a 
Largest diff. peak and hole 1.066 and -0.843 e.Å-3 
 
Table A7.2 Atomic coordinates (x 10
4





) for 98. U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
___________________________________________________________________ 
S(1) 7330(1) 9529(2) 5282(1) 21(1) 
O(1) 7382(2) 10830(5) 5676(4) 26(1) 
O(2) 7712(2) 8714(5) 5193(5) 25(1) 
C(1) 7091(3) 9659(7) 4003(6) 20(2) 
C(2) 7040(3) 8533(8) 3407(6) 24(2) 
C(3) 6848(3) 8611(9) 2430(7) 30(2) 
C(4) 6721(3) 9829(8) 2046(6) 27(2) 
Br(1) 6463(1) 9894(1) 672(1) 44(1) 
C(5) 6777(3) 10919(8) 2608(7) 26(2) 
C(6) 6959(3) 10842(8) 3625(6) 23(2) 
N(1) 6986(2) 8806(6) 6076(5) 19(1) 
N(2) 6545(2) 7601(7) 7718(5) 23(1) 
C(7) 6601(3) 9510(8) 6531(6) 23(2) 
C(8) 6441(3) 8857(8) 7564(6) 27(2) 
O(3) 6207(3) 9498(7) 8157(5) 43(2) 
C(9) 6354(3) 7011(9) 8688(7) 34(2) 
Appendix 7 – X-Ray Crystallography Reports Relevant to Chapter 3 
 
401 
C(26) 5842(6) 6970(30) 8740(20) 51(5) 
O(4) 5736(5) 5946(19) 8061(14) 52(4) 
C(26A) 5876(5) 6590(20) 8358(17) 41(5) 
O(4A) 5608(5) 5980(20) 9140(14) 65(5) 
C(10) 6605(3) 5795(8) 8993(6) 24(2) 
C(11) 6654(3) 5434(8) 10053(6) 25(2) 
O(5) 6497(2) 6289(6) 10816(5) 33(1) 
C(27) 6132(4) 5865(12) 11453(9) 49(3) 
C(12) 6877(3) 4311(9) 10335(6) 27(2) 
O(6) 6899(2) 3954(6) 11394(5) 34(1) 
C(28) 7254(4) 4587(12) 11946(7) 45(3) 
C(13) 7070(3) 3513(8) 9578(7) 30(2) 
C(29) 7346(4) 2355(10) 9889(8) 45(3) 
C(14) 7012(3) 3866(8) 8530(7) 26(2) 
C(15) 6786(3) 4969(8) 8237(5) 21(1) 
C(16) 6749(3) 5418(7) 7107(6) 22(2) 
C(17) 6862(3) 6871(7) 7060(5) 18(1) 
C(18) 6872(3) 7419(7) 5938(6) 18(2) 
C(19) 6439(3) 7261(7) 5311(6) 20(1) 
C(20) 6360(3) 6056(7) 4816(6) 20(2) 
C(21) 5970(3) 5890(7) 4228(6) 20(2) 
O(7) 5852(2) 4737(6) 3772(4) 26(1) 
C(30) 6156(4) 3681(9) 3839(9) 40(2) 
C(22) 5658(3) 6909(9) 4089(7) 28(2) 
C(31) 5241(3) 6720(10) 3457(8) 35(2) 
C(23) 5756(3) 8094(8) 4567(6) 23(2) 
O(8) 5462(2) 9120(6) 4435(5) 31(1) 
C(32) 5585(3) 9946(9) 3576(7) 34(2) 
C(24) 6140(3) 8272(7) 5196(6) 21(2) 
C(25) 6208(3) 9569(8) 5748(6) 24(2) 
O(1S) 5417(12) 4360(30) 9650(30) 149(9) 
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C(11S) 5442(14) 2970(30) 9740(30) 160(9) 
C(12S) 5879(16) 2530(40) 9240(40) 146(12) 
C(13S) 5430(20) 2650(50) 10910(40) 160(10) 
O(2S) 5258(14) 3230(30) 9460(30) 167(9) 
C(21S) 5190(13) 2300(40) 10310(30) 169(9) 
C(22S) 5170(20) 960(30) 9810(40) 189(14) 
C(23S) 5592(19) 2450(50) 11050(40) 163(11) 
O(3S) 5234(9) 3630(30) 7350(30) 164(9) 
C(31S) 5499(8) 3070(30) 6520(30) 131(7) 
C(32S) 5967(7) 2713(15) 6970(20) 60(6) 
C(33S) 5231(9) 1900(30) 6140(30) 98(7) 
O(4S) 4896(10) 3880(30) 6440(30) 141(8) 
C(41S) 5176(10) 2810(30) 6170(30) 128(7) 
C(42S) 5669(10) 3150(40) 6160(40) 117(8) 
C(43S) 5065(12) 1590(30) 6760(30) 106(9) 
______________________________________________________________________ 
 
Table A7.3 Bond lengths [Å] and angles [°] for 98. 
_____________________________________________________  
S(1)-O(2)  1.418(6) 
S(1)-O(1)  1.440(6) 
S(1)-N(1)  1.618(7) 
S(1)-C(1)  1.777(7) 
C(1)-C(6)  1.368(11) 
C(1)-C(2)  1.394(11) 
C(2)-C(3)  1.365(12) 
C(2)-H(2)  0.9500 
C(3)-C(4)  1.400(13) 
C(3)-H(3)  0.9500 
C(4)-C(5)  1.343(12) 
C(4)-Br(1)  1.906(7) 
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C(5)-C(6)  1.401(11) 
C(5)-H(5)  0.9500 
C(6)-H(6)  0.9500 
N(1)-C(7)  1.473(10) 
N(1)-C(18)  1.481(9) 
N(2)-C(8)  1.347(10) 
N(2)-C(17)  1.466(10) 
N(2)-C(9)  1.486(10) 
C(7)-C(25)  1.535(11) 
C(7)-C(8)  1.549(11) 
C(7)-H(7)  1.0000 
C(8)-O(3)  1.220(11) 
C(9)-C(10)  1.511(11) 
C(9)-C(26)  1.523(19) 
C(9)-C(26A)  1.544(19) 
C(9)-H(9A)  1.0000 
C(9)-H(9B)  1.0000 
C(26)-O(4)  1.40(2) 
C(26)-H(26A)  0.9900 
C(26)-H(26B)  0.9900 
O(4)-H(4)  0.8400 
C(26A)-O(4A)  1.42(2) 
C(26A)-H(26C)  0.9900 
C(26A)-H(26D)  0.9900 
O(4A)-H(4A)  0.8400 
C(10)-C(15)  1.390(11) 
C(10)-C(11)  1.404(10) 
C(11)-C(12)  1.383(12) 
C(11)-O(5)  1.390(10) 
O(5)-C(27)  1.422(12) 
C(27)-H(27A)  0.9800 
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C(27)-H(27B)  0.9800 
C(27)-H(27C)  0.9800 
C(12)-C(13)  1.389(13) 
C(12)-O(6)  1.395(10) 
O(6)-C(28)  1.423(12) 
C(28)-H(28A)  0.9800 
C(28)-H(28B)  0.9800 
C(28)-H(28C)  0.9800 
C(13)-C(14)  1.389(12) 
C(13)-C(29)  1.500(12) 
C(29)-H(29A)  0.9800 
C(29)-H(29B)  0.9800 
C(29)-H(29C)  0.9800 
C(14)-C(15)  1.374(11) 
C(14)-H(14)  0.9500 
C(15)-C(16)  1.511(10) 
C(16)-C(17)  1.537(10) 
C(16)-H(16A)  0.9900 
C(16)-H(16B)  0.9900 
C(17)-C(18)  1.531(10) 
C(17)-H(17)  1.0000 
C(18)-C(19)  1.523(11) 
C(18)-H(18)  1.0000 
C(19)-C(24)  1.379(11) 
C(19)-C(20)  1.412(10) 
C(20)-C(21)  1.390(10) 
C(20)-H(20)  0.9500 
C(21)-O(7)  1.368(9) 
C(21)-C(22)  1.413(12) 
O(7)-C(30)  1.417(12) 
C(30)-H(30A)  0.9800 
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C(30)-H(30B)  0.9800 
C(30)-H(30C)  0.9800 
C(22)-C(23)  1.396(12) 
C(22)-C(31)  1.489(11) 
C(31)-H(31A)  0.9800 
C(31)-H(31B)  0.9800 
C(31)-H(31C)  0.9800 
C(23)-O(8)  1.382(9) 
C(23)-C(24)  1.405(11) 
O(8)-C(32)  1.431(11) 
C(32)-H(32A)  0.9800 
C(32)-H(32B)  0.9800 
C(32)-H(32C)  0.9800 
C(24)-C(25)  1.523(11) 
C(25)-H(25A)  0.9900 
C(25)-H(25B)  0.9900 
O(1S)-C(11S)  1.442(19) 
O(1S)-H(1S)  0.8400 
C(11S)-C(12S)  1.516(17) 
C(11S)-C(13S)  1.521(17) 
C(11S)-H(11S)  1.0000 
C(12S)-H(12A)  0.9800 
C(12S)-H(12B)  0.9800 
C(12S)-H(12C)  0.9800 
C(13S)-H(13A)  0.9800 
C(13S)-H(13B)  0.9800 
C(13S)-H(13C)  0.9800 
O(2S)-C(21S)  1.450(19) 
O(2S)-H(2S)  0.8400 
C(21S)-C(22S)  1.520(17) 
C(21S)-C(23S)  1.529(17) 
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C(21S)-H(21S)  1.0000 
C(22S)-H(22A)  0.9800 
C(22S)-H(22B)  0.9800 
C(22S)-H(22C)  0.9800 
C(23S)-H(23A)  0.9800 
C(23S)-H(23B)  0.9800 
C(23S)-H(23C)  0.9800 
O(3S)-C(31S)  1.438(19) 
O(3S)-H(3S)  0.8400 
C(31S)-C(33S)  1.525(17) 
C(31S)-C(32S)  1.547(17) 
C(31S)-H(31S)  1.0000 
C(32S)-H(32D)  0.9800 
C(32S)-H(32E)  0.9800 
C(32S)-H(32F)  0.9800 
C(33S)-H(33A)  0.9800 
C(33S)-H(33B)  0.9800 
C(33S)-H(33C)  0.9800 
O(4S)-C(41S)  1.426(18) 
O(4S)-H(4S)  0.8400 
C(41S)-C(43S)  1.494(17) 
C(41S)-C(42S)  1.511(17) 
C(41S)-H(41S)  1.0000 
C(42S)-H(42A)  0.9800 
C(42S)-H(42B)  0.9800 
C(42S)-H(42C)  0.9800 
C(43S)-H(43A)  0.9800 
C(43S)-H(43B)  0.9800 
C(43S)-H(43C)  0.9800 
 
 














































































































































































































































































) for 98. The anisotropic displacement 
factor exponent takes the form: -2p2 [ h2 a*2U11 + ... + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
_________________________________________________________________  
S(1) 27(1)  21(1) 16(1)  3(1) -5(1)  -3(1) 
O(1) 42(3)  23(3) 13(2)  1(2) -3(2)  -8(2) 
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O(2) 28(3)  19(3) 28(3)  2(2) -7(2)  -3(2) 
C(1) 26(4)  17(4) 18(3)  0(3) -3(3)  0(3) 
C(2) 33(4)  15(4) 23(4)  2(3) -1(3)  -2(3) 
C(3) 35(5)  28(4) 27(4)  -6(4) -5(4)  -1(4) 
C(4) 37(4)  26(4) 18(3)  -1(3) -9(3)  -1(4) 
Br(1) 66(1)  39(1) 26(1)  3(1) -18(1)  6(1) 
C(5) 34(4)  21(4) 24(4)  4(3) -3(3)  3(3) 
C(6) 28(4)  21(4) 21(4)  6(3) -5(3)  0(3) 
N(1) 26(3)  13(3) 18(3)  -5(2) -4(3)  0(2) 
N(2) 26(4)  25(3) 18(3)  -5(3) 1(3)  2(3) 
C(7) 32(4)  18(3) 19(4)  -5(3) -4(3)  4(3) 
C(8) 35(4)  27(4) 20(4)  -1(3) -7(3)  6(4) 
O(3) 68(5)  38(4) 22(3)  4(3) 14(3)  23(3) 
C(9) 43(5)  34(4) 25(4)  17(3) 12(3)  17(4) 
C(26) 41(8)  58(11) 52(11)  15(9) 17(7)  13(7) 
O(4) 31(8)  71(10) 52(9)  13(8) 11(6)  4(7) 
C(26A) 37(7)  41(11) 44(10)  20(8) 19(7)  19(7) 
O(4A) 40(7)  102(13) 53(9)  41(9) 2(6)  -11(8) 
C(10) 27(4)  24(4) 19(4)  0(3) -5(3)  1(3) 
C(11) 34(4)  32(4) 9(3)  10(3) -1(3)  2(3) 
O(5) 45(4)  34(3) 19(3)  1(2) 2(3)  1(3) 
C(27) 55(6)  58(7) 33(5)  3(5) 16(5)  4(5) 
C(12) 29(4)  33(4) 19(4)  7(3) -3(3)  -4(3) 
O(6) 49(4)  35(3) 17(3)  13(3) -5(3)  0(3) 
C(28) 49(6)  62(7) 26(5)  13(5) -15(4)  -1(5) 
C(13) 36(5)  27(4) 25(4)  6(3) 3(3)  2(3) 
C(29) 65(7)  35(5) 34(5)  19(4) 4(5)  16(5) 
C(14) 35(5)  19(4) 25(4)  1(3) 5(3)  3(3) 
C(15) 31(4)  17(3) 14(3)  4(3) -2(3)  -3(3) 
C(16) 36(4)  14(3) 15(3)  -2(3) -3(3)  -2(3) 
C(17) 27(4)  16(3) 12(3)  -4(3) -1(3)  -3(3) 
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C(18) 29(4)  14(3) 12(3)  1(3) -2(3)  3(3) 
C(19) 28(4)  17(3) 14(3)  3(3) 1(3)  -4(3) 
C(20) 26(4)  20(3) 14(3)  0(3) -5(3)  -2(3) 
C(21) 28(4)  19(3) 14(3)  -2(3) -6(3)  -3(3) 
O(7) 28(3)  30(3) 22(3)  -4(2) -4(2)  -8(2) 
C(30) 50(6)  25(5) 45(6)  -1(4) -10(5)  -1(4) 
C(22) 21(4)  35(4) 26(4)  4(3) -2(3)  -2(3) 
C(31) 31(5)  38(5) 36(5)  -7(4) -10(4)  -3(4) 
C(23) 23(4)  19(4) 27(4)  7(3) 3(3)  4(3) 
O(8) 23(3)  29(3) 40(4)  7(3) -2(2)  6(2) 
C(32) 35(4)  22(4) 45(5)  0(4) -7(4)  7(4) 
C(24) 24(4)  21(4) 18(4)  8(3) -2(3)  1(3) 
C(25) 29(4)  25(4) 19(3)  -1(3) 1(3)  4(3) 
O(1S) 140(20)  126(16) 180(20)  60(15) 22(18)  -2(15) 
C(11S) 150(20)  134(15) 190(20)  52(15) 7(16)  -3(15) 
C(12S) 140(20)  120(20) 180(30)  47(19) -10(20)  1(18) 
C(13S) 160(20)  130(18) 190(20)  50(15) 13(17)  -2(17) 
O(2S) 160(20)  141(17) 200(20)  38(16) 7(17)  -2(16) 
C(21S) 160(20)  145(16) 200(20)  49(15) 4(16)  -2(16) 
C(22S) 180(30)  152(19) 230(30)  38(18) -20(20)  3(18) 
C(23S) 150(20)  137(19) 200(20)  40(17) 10(18)  5(18) 
O(3S) 156(16)  154(15) 183(18)  -26(14) -10(13)  32(12) 
C(31S) 122(13)  122(12) 149(15)  -14(11) -34(11)  24(10) 
C(32S) 95(13)  2(7) 82(14)  2(8) -20(10)  -7(7) 
C(33S) 71(13)  96(13) 128(17)  -19(13) -42(12)  49(10) 
O(4S) 132(15)  143(14) 147(18)  -21(14) -23(14)  44(12) 
C(41S) 111(13)  126(12) 147(16)  -14(12) -25(12)  28(10) 
C(42S) 112(14)  110(14) 129(18)  -14(14) -11(12)  25(11) 
C(43S) 67(15)  115(14) 140(20)  -21(14) -35(15)  35(12) 
_________________________________________________________________ 
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Table A7.5 Hydrogen coordinates (x 10
4




) for 98. 
_______________________________________________________________________________  
 x  y  z  U(eq) 
__________________________________________________________________ 
H(2) 7137 7722 3677 28 
H(3) 6803 7852 2020 36 
H(5) 6695 11735 2320 31 
H(6) 6991 11598 4046 28 
H(7) 6698 10416 6695 28 
H(9A) 6437 7642 9254 41 
H(9B) 6345 7648 9282 41 
H(26A) 5736 6798 9464 61 
H(26B) 5709 7796 8486 61 
H(4) 5940 5386 8087 77 
H(26C) 5713 7361 8100 49 
H(26D) 5904 5980 7757 49 
H(4A) 5335 6139 9021 98 
H(27A) 5865 5742 11011 73 
H(27B) 6069 6519 11993 73 
H(27C) 6211 5043 11793 73 
H(28A) 7542 4365 11620 68 
H(28B) 7254 4304 12684 68 
H(28C) 7209 5527 11915 68 
H(29A) 7320 1685 9345 67 
H(29B) 7236 2014 10562 67 
H(29C) 7662 2611 9963 67 
H(14) 7133 3323 7996 32 
H(16A) 6441 5267 6841 26 
H(16B) 6961 4924 6659 26 
H(17) 7168 6987 7368 22 
H(18) 7122 6989 5542 22 
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H(20) 6570 5369 4884 24 
H(30A) 6440 3916 3499 60 
H(30B) 6026 2925 3483 60 
H(30C) 6211 3473 4581 60 
H(31A) 5089 7555 3363 52 
H(31B) 5040 6120 3827 52 
H(31C) 5319 6360 2766 52 
H(32A) 5892 10264 3681 51 
H(32B) 5378 10683 3544 51 
H(32C) 5569 9458 2915 51 
H(25A) 5929 9808 6128 29 
H(25B) 6268 10247 5214 29 
H(1S) 5541 4593 9081 224 
H(11S) 5181 2560 9376 192 
H(12A) 5905 1590 9293 219 
H(12B) 5880 2787 8493 219 
H(12C) 6133 2944 9599 219 
H(13A) 5444 1710 11008 240 
H(13B) 5682 3063 11270 240 
H(13C) 5145 2975 11216 240 
H(2S) 5363 3915 9711 250 
H(21S) 4904 2491 10689 203 
H(22A) 5123 307 10363 283 
H(22B) 4918 924 9309 283 
H(22C) 5451 780 9440 283 
H(23A) 5561 1835 11637 244 
H(23B) 5870 2262 10663 244 
H(23C) 5601 3333 11322 244 
H(3S) 5021 4060 7084 246 
H(31S) 5534 3702 5931 157 
H(32D) 6151 2325 6413 89 
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H(32E) 6115 3498 7234 89 
H(32F) 5931 2091 7548 89 
H(33A) 5395 1464 5572 148 
H(33B) 5188 1291 6728 148 
H(33C) 4937 2185 5881 148 
H(4S) 5029 4573 6291 211 
H(41S) 5101 2610 5419 154 
H(42A) 5847 2388 5971 176 
H(42B) 5722 3843 5643 176 
H(42C) 5759 3457 6862 176 
H(43A) 5268 898 6537 159 
H(43B) 5100 1746 7517 159 
H(43C) 4753 1343 6609 159 
__________________________________________________________________________ 
 









































































































































Table A7.7 Hydrogen bonds for 98 [Å and °]. 
________________________________________________________________________ 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
________________________________________________________________________  
 C(2)-H(2)...O(1)#1 0.95 2.56 3.477(10) 163.6 
 C(3)-H(3)...O(5)#2 0.95 2.40 3.320(11) 163.2 
 C(5)-H(5)...O(6)#3 0.95 2.64 3.508(10) 151.5 
 C(6)-H(6)...O(2)#4 0.95 2.55 3.462(10) 162.2 
 C(9)-H(9B)...Br(1)#5 1.00 2.93 3.910(10) 165.6 
 C(26)-H(26B)...O(3) 0.99 2.33 2.92(3) 116.8 
 C(26A)-H(26C)...O(3) 0.99 2.65 3.17(2) 113.0 
 O(4A)-H(4A)...O(2S)#6 0.84 1.96 2.73(4) 151.5 
 C(27)-H(27A)...O(4A) 0.98 2.51 3.32(2) 140.9 
 C(27)-H(27A)...O(1S) 0.98 2.61 3.49(4) 149.8 
 C(27)-H(27C)...O(6) 0.98 2.39 3.016(14) 121.3 
 C(28)-H(28B)...S(1)#7 0.98 2.87 3.729(9) 146.5 
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 C(28)-H(28C)...O(5) 0.98 2.65 3.193(12) 115.0 
 C(18)-H(18)...O(1)#1 1.00 2.45 3.435(9) 168.8 
 O(1S)-H(1S)...O(4) 0.84 1.99 2.76(4) 151.8 
 O(1S)-H(1S)...O(3S) 0.84 2.58 3.06(5) 117.6 
 C(12S)-H(12A)...Br(1)#8 0.98 2.98 3.71(4) 132.1 
 C(12S)-H(12B)...O(3S) 0.98 2.56 3.27(6) 129.3 
 O(2S)-H(2S)...O(4A) 0.84 2.37 3.06(4) 139.8 
 C(23S)-H(23B)...Br(1)#8 0.98 3.01 3.72(6) 130.4 
 O(3S)-H(3S)...O(4)#6 0.84 2.57 3.05(3) 117.7 
 O(3S)-H(3S)...O(3S)#6 0.84 2.52 3.14(6) 131.9 
 C(33S)-H(33C)...O(8)#6 0.98 2.57 3.17(2) 119.6 
 C(42S)-H(42B)...O(7) 0.98 2.58 3.48(5) 154.3 
________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
#1 -x+3/2,y-1/2,-z+1    #2 x,y,z-1    #3 x,y+1,z-1       
#4 -x+3/2,y+1/2,-z+1    #5 x,y,z+1    #6 -x+1,-y+1,z       
#7 -x+3/2,y-1/2,-z+2    #8 x,y-1,z+1 








Progress Toward the Syntheses of  
bis-Tetrahydroisoquinoline Analogs † 
 
  
A8.1   INTRODUCTION 
As shown in Chapter 3, we have successfully developed a modular 
synthesis of (–)-jorumycin (77) and (–)-jorunamycin A (79). With the remarkable 
biological activity conserved across the bis-tetrahydroisoquinoline (bis-THIQ) 
family of natural products,1 we aim to further utilized the general synthetic strategy 
developed for the total synthesis of jorumycin to prepare non-natural bis-THIQ 
analogs for biological evaluation.  
Of particular interest is the syntheses of electron-deficient bis-THIQ 
analogs. Since previous synthetic efforts have focused on the use of electrophilic 
aromatic substitution chemistry to access the core THIQ structure,2 electron-
deficient analogs have thus far been inaccessible, and consequently, their cytotoxic 
	
	
†	This research was performed in collaboration with Dr. Eric Welin and Dr. Gerit Pototschnig. 
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activities are not known. Additionally, studies have shown that metabolic stability 
(as measured by in vivo half-lives) varies greatly with different bis-THIQ 
molecules (Figure A8.1),3 and oxidative degradation is reported to be a major 
metabolic pathway.4 As a result, we believe that incorporation of electron-
withdrawing atoms, particularly fluorine,5 might be able to improve the metabolic 
stability of these non-natural analogs (124 and 125). Our synthetic strategy, which 
exploits the tandem cross-coupling/hydrogenation approach outlined in Chapter 3, 
should allow for the introduction of a wide range of functionality regardless of 
their electronic nature. Overall, this research aims to generate bis-THIQ analog 
with simplified structure, while maintaining or improving both potency and 
metabolic stability. 
Figure A8.1 Non-natural bis-THIQ analogs with their corresponding in vivo half-lives. 
 
 
A8.2  APPROACH 
Our initial efforts focused on the syntheses of polyfluorinated bis-THIQ analogs 
126–128 (Scheme A8.1). These included all possible combinations of “natural” (84 and 
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Fagnou reaction. Subsequently, we envisioned accessing the bis-THIQ pentacyclic cores 
129–131 via the enantioselective hydrogenation developed in Chapter 3. At this stage, we 
hoped to probe the substrate tolerance of the previously established hydrogenation 
technology. 
Scheme A8.1 Targeted polyfluorinated bis-THIQ analogs 126–128. 
 
With the pentacyclic cores in hand, we planned to oxidize one of the termini (i.e., 
A- or E-rings) to the quinone oxidation state. We envisioned that the electronic 
differentiation between the A- and E-rings in bis-THIQs 130 and 131 should allow for the 
selective functionalization of the more electron-rich ring, leaving the difluorinated arene 
intact. This sequence would produce analogs 127–128, which will allow us to 
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both rings improves metabolic stability. The general cytotoxicity of these analogs will 
also be evaluated against a range of cancer cell lines.  
A8.2.1  Synthesis of Difluorinated isoquinolines 132 and 133 
 We commenced our synthetic studies with the preparation of isoquinoline N-oxide 
132 and isoquinoline triflate 133. N-oxide 132 was synthesized via a 3-step protocol from 
commercially available 4,5-difluoro-2-bromobenzaldehyde (134). Sonogashira coupling 
of aryl bromide 134 with TBS-protected propagyl alcohol (87) provided an alkyne 
intermediate (not shown) in 89% yield. Condensation with hydroxylamine afforded 
oxime-bearing alkyne 135 in 84% yield, which was subsequently subjected to a silver-
catalyzed 6-endo-dig cyclization to furnish 6,7-difluoroisoquinoline N-oxide 132 in 63% 
yield. 
Scheme A8.2 Synthesis of isoquinoline N-oxide 132 and isoquinoline triflate 133. 
 
 For the preparation of the isoquinoline triflate (133), we performed the aryne 
acyl-alkylation of ortho-silyl triflate 1366 with in situ condensation to deliver 3-
hydroxyisoquinoline 137 in 36% yield (Scheme A8.2). Attempt to further improve the 
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2. NH2OH•HCl
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(see section 3.6.2.2) proved unsuccessful, providing isoquinoline 137 in only 15–25% 
yield over 2 steps. Finally, triflation of the resulting hydroxyisoquinoline 137 with triflic 
anhydride provided isoquinoline triflate 133 in 92% yield. 
A8.2.2  Fagnou Coupling 
As shown in Scheme A8.1, we envisioned employing the Fagnou coupling for the 
preparation of the bis-isoquinolines (bis-IQs). To our delight, we found that the 
developed reaction conditions (see Chapter 3) were amenable to the production of 138–
140 (Scheme A8.3). Tetrafluorinated bis-IQ 138 was synthesized in 70% yield, and the 
excess N-oxide 132 could be recovered quantitatively. Furthermore, difluorinated bis-IQs 
139 and 140 were also prepared in 72% yield and 84% yield, respectively, thus 
highlighting the modularity and flexibility of our developed synthetic strategy. 
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A8.2.3  Preparation of the Hydrogenation Precursors 
The general sequence to access the hydrogenation precursors consists of 
deoxygenation, alcohol deprotection, oxidation of the benzyl alcohol to the methyl ester, 
and installation of the hydroxy group at the benzylic position of the western isoquinoline 
fragment. Tetrafluorinated bis-IQ N-oxide 138 smoothly underwent deoxygenation with 
phosphorus trichloride to provide bis-IQ 141 in 98% yield (Scheme A8.4). Unfortunately, 
upon the removal of the TBS group, the desired alcohol was only slightly soluble in 
organic solvents, resulting in difficulties in product purification. The subsequent 
oxidation using silver(I) oxide previously utilized in the total synthesis of jorumycin also 
failed to deliver the desired bis-IQ ester 142 in a synthetically useful yield. 
Scheme A8.4 Attempt to prepare bis-IQ methylester 142. 
 
To circumvent these problems, we elected to exploit Jones reagent for the in situ 
cleavage of the TBS ether and oxidation of the resulting alcohol to the carboxylic acid 
oxidation state. Attempts to simultaneously esterify the carboxylic acid via Fischer 
esterification in the same pot proved unsuccessful, thus the crude carboxylic acid was 
converted to the methyl ester through the acid chloride intermediate (Scheme A8.5). With 
the bis-IQ ester 142 in hand, we next performed a selenium dioxide-mediated oxidation, 
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Scheme A8.5 Synthetic route to access tetrafluorinated bis-IQ hydrogenation precursor 144. 
 
 We took a similar approach to prepare the difluorinated hydrogenation precursors. 
From difluorinated bis-IQ 139, we were able to reduce the N–oxide, affording bis-IQ 145 
in quantitative yield (Scheme A8.6). However, unexpectedly, the deprotection-oxidation 
of bis-IQ 145 via Jones reagent was sluggish, and increasing the temperature with 
prolonged reaction time did not improve the results (Table A8.1, entry 1). After 2 days, 
we still observed a mixture of deprotected alcohol, aldehyde, and carboxylic acid.  
We next elected to remove the TBS protecting group and survey different 
oxidation conditions on alcohol 146. Silver(I) oxidation afforded trace amounts of desired 
ester 149, with the majority of the mass balance being unreacted starting material 146 
(Table A8.1, entry 2). TEMPO oxidation, which was successfully employed in the total 
synthesis of jorumycin, resulted only in aldehyde 147 (entry 3). Lastly, N-heterocyclic 
carbene-catalyzed oxidation in methanol7 provided 2:1 mixture of aldehyde 147 and 
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The clean reaction profile from TEMPO oxidation (Table A8.1, entry 3) prompted 
us to subject the aldehyde product (147) to a subsequent Corey-Gillman-Ganem 
oxidation8 (entry 5). We were pleased to find that the desired methyl ester 149 was 
formed in 85% yield. Attempt to perform MnO2 double oxidation directly on alcohol 146, 
however, resulted in only 50% yield of the desired ester (entry 6).  
Table A8.1 Optimization of the alcohol oxidation to access bis-IQ 149. 
 
 With the oxidation conditions identified, we subsequently installed the hydroxyl 
group at the benzylic position in bis-IQ 149 by performing selenium dioxide-mediated 
oxidation, followed by NaBH4 reduction of the resulting aldehyde to the corresponding 
alcohol. The modified sequence to access difluorinated hydrogenation precursor 151 is 



















entry conditions 146 147
1
148
used 145 instead of 146 as SM
side pdt m/z = 431 (≈ 35%)
TEMPO, PhI(OAc)2
NHSIa, DCM, 23 °C



















bNHC cat =aNHSI =
NO O
OH
Ag2O, MeOH, 23 °C2 major – no change at 60 °Ctrace
Jones reagent, acetone







147: X = H
148: X = OH
149: X = OMe
major
≈ 65%
145: R = TBS







6 – –≈ 50 % reaction stalled after 18 hours≈ 50 %
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Scheme A8.6 Synthetic route to access difluorinated bis-IQ hydrogenation precursor 151. 
 
Scheme A8.7 Synthetic route to access difluorinated bis-IQ hydrogenation precursor 155. 
 
Difluorinated hydrogenation precursor 155, having the difluorinated isoquinoline 
on the eastern side of the molecule, was prepared via the same sequence developed for 
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tetrafluorinated system, and difluorinated hydrogenation precursor 155 was obtained in 
36% yield over 5 steps from bis-IQ 140 (Scheme A8.7). 
A8.2.4  Ir-Catalyzed Enantioselective Hydrogenation 
 With polyfluorinated hydrogenation precursors 144, 151, and 155 in hand, we 
were able to examine the substrate tolerance of the developed enantioselective 
hydrogenation (Scheme A8.8). To our delight, tetrafluorinated bis-IQ 144 was 
hydrogenated, and in situ lactamization proceeded to deliver tetrafluorinated pentacycle 
129 in 40–50% yield,9 with >20:1 dr and 80% ee. These results highlight the versatility of 
our key asymmetric hydrogenation as electronic variations have little impact on the 
reduction efficiency. 
































































[Ir(cod)Cl]2 (10 mol %)
L49 (BTFM-xyliphos)
TBAI, 9:1 PhMe/AcOH
60 to 80 °C
40–50% yield
>20:1 dr, 80% ee
[Ir(cod)Cl]2 (10 mol %)
L49 (BTFM-xyliphos)
TBAI, 9:1 PhMe/AcOH
60 to 80 °C
49% yield
>20:1 dr, 17% ee
[Ir(cod)Cl]2 (10 mol %)
L49 (BTFM-xyliphos)
TBAI, 9:1 PhMe/AcOH
60 to 80 °C
>20:1 dr, 60% ee
OMe
OMe
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Intriguingly, however, isolated difluorinated pentacycles 130 and 131 were 
obtained in only 17% ee and 60% ee, respectively. Although additional experiments are 
required to fully understand the mode of enantioinduction, we currently attribute the 
observed loss in enantioselectivity to the less selective, competitive D-ring reduction (see 
Chapter 3, Scheme 3.7, Path B). 
A8.2.5  End-route toward bis-THIQ analogs 126-128 
The final sequence in the synthesis of bis-THIQ analog 126 includes reductive 
amination and partial lactam reduction with cyanide trapping (Scheme A8.9). Reductive 
amination of 129 with aqueous formaldehyde and sodium triacetoxyborohydride (STAB) 
proceeded with quantitative yield. Finally, the partial reduction of lactam, followed by 
cyanide trapping provided the desired tetrafluorinated bis-THIQ analog (126) in 68% 
yield. We also synthesized two additional analogs in the tetrafluorinated series by 1) 
acylating the free alcohol in 126 to generate analog 157, and 2) performing the 
Mitsunobu reaction to replace the alcohol with phthalimide (158).10 
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Along the synthetic route to access difluorinated bis-THIQ 127 with fluorines in 
the western fragment (Scheme A8.10), we found that the electronic differentiation 
between the A- and E-rings was sufficient to selectively chlorinate only the more 
electron-rich E-ring, providing monochlorinated bis-THIQ 160 in 94% yield. 
Unfortunately, the Pd-catalyzed hydroxylation from the jorumycin synthesis failed to 
deliver the desired hydroxylated product 161; we only observed protodechlorinated 
product 162 and oxidative deformylated-protodechlorinated product 163.11 
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A8.3   CONCLUSIONS AND FUTURE DIRECTIONS 
 In conclusion, we have completed the syntheses of tetrafluorinated bis-
THIQ analogs 126, 157, and 158 by exploiting the Fagnou coupling/hydrogenation 
strategy developed for the total synthesis of jorumycin. These non-natural analogs, 
which can be obtained in reasonable yields and with good enantioselectivity, 
highlight the flexibility of our developed synthetic strategy and represent the first 
set of electron-deficient bis-THIQ analogs produced to date. Studies to evaluate 
their biological activity by our collaborators at the UCLA Translational Oncology 
Research Laboratories are currently underway. 
Given the difficulty in the Pd-catalyzed hydroxylation reaction encountered 
en route to difluorinated bis-THIQ 127, one strategy moving forward is the use of 
different phenol protecting group such as p-methoxybenzyl, instead of methyl, on 
the eastern isoquinoline fragment (cf. 164, Scheme A8.11). Upon removal of the 
PMB group in 168, we envisioned that phenol oxidation by salcomine/O212 should 
directly provide analog 127, thus bypassing the requirement of the challenging C–
O coupling reaction. Initial efforts to access bis-IQ 167 demonstrated that the 
Fagnou coupling between IQ-triflate 133 and IQ N-oxide 16413 delivered bis-IQ 
product 165 in 60% yield. Deoxygenation, desilylation, followed by oxidation of 
165 generated 166 in 23% yield over 3 steps. Lastly, PMB-protected bis-IQ 
hydrogenation precursor 167 was prepared in 60% yield from the selenium 
oxidation-sodium borohydride reduction sequence. 
Should the subsequent steps in this strategy fail to deliver the desired bis-IQ 
analog 127, future directions of this research will focus on exploring different 
conditions for late-stage hydroxylation. The lithiation/borylation/oxidation 
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sequence14 and the direct aromatic C–H oxygenation developed by Ritter15 are of 
interest. Furthermore, a collaboration with the Arnold lab, exploiting the power of 
biocatalysis for this oxidation, also represents an alternative strategy. 
Scheme A8.11 Alternative strategy to access difluorinated bis-THIQ analog 127. 
 
Finally, we still have not yet been successful in obtaining difluorinated bis-IQ 
analog 128. However, based on the results observed in the preparation of mono-
hydroxylated analogs 103 and 104 (see Chapter 3), we expect the Pd-catalyzed C–O 
coupling to be more facile on the A-ring. The remaining steps to access this analog (128) 
is shown in A8.12. Once we have these additional difluorinated bis-THIQ analogs in 
hand, a systematic investigation into the effects of electronic variations of the A- and E- 
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pharmacokinetic (DMPK) studies, we aim to design the next generation of bis-THIQ 
analogs with improved biological properties and metabolic stability. 
Scheme A8.12 End-route toward difluorinated bis-THIQ analog 128. 
 
  
A8.4  EXPERIMENTAL SECTION 
A8.4.1  MATERIALS AND METHODS 
Unless stated otherwise, reactions were performed at ambient temperature (23 °C) 
in flame-dried glassware under an argon atmosphere using dry, deoxygenated solvents 
(distilled or passed over a column of activated alumina).16 Commercially available 
reagents were used as received. Reactions requiring external heat were modulated to the 
specified temperatures using an IKAmag temperature controller. Thin-layer 
chromatography (TLC) was performed using E. Merck silica gel 60 F254 pre-coated 
plates (0.25 mm) and visualized by UV fluorescence quenching or potassium 
permanganate staining. Silicycle SiliaFlash P60 Academic Silica gel (particle size 40–63 
µm) was used for flash chromatography. Purified water was obtained using a Barnstead 
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Inova 500 (500 MHz and 125 MHz, respectively) and a Bruker AV III HD spectrometer 
equipped with a Prodigy liquid nitrogen temperature cryoprobe (400 MHz and 100 MHz, 
respectively), and are reported in terms of chemical shift relative to CHCl3 (δ 7.26 and 
77.16, respectively). 19F and 31P NMR spectra were recorded on a Varian Inova 300 (282 
MHz and 121 MHz, respectively). Data for 1H NMR spectra are reported as follows: 
chemical shift (δ ppm) (multiplicity, coupling constant, integration). Infrared (IR) spectra 
were recorded on a Perkin Elmer Paragon 1000 Spectrometer and are reported in 
frequency of absorption (cm-1). Analytical chiral HPLC was performed with an Agilent 
1100 Series HPLC utilizing Chiralpak (AD) or Chiralcel (OJ) columns (4.6 mm x 25 cm) 
obtained from Daicel Chemical Industries, Ltd. High resolution mass spectra (HRMS) 
were obtained from the Caltech Center for Catalysis and Chemical Synthesis using an 
Agilent 6200 series TOF with an Agilent G1978A Multimode source in mixed 
(Multimode ESI/APCI) ionization mode. Optical rotations were measured on a Jasco P-
2000 polarimeter using a 100 mm path-length cell at 589 nm. 
A8.4.2  EXPERIMENTAL PROCEDURES AND SPECTROSCOPIC DATA 
A8.4.2.1 Synthesis of difluorinated isoquinoline N-oxide 132 
 
Sonogashira product 171: 2-bromide-4,5-difluorobenzaldehyde (134) (9.00 g, 40.7 
mmol, 1 equiv), (PPh3)2PdCl2 (1.43 g, 2.04 mmol, 0.05 equiv), and CuI (388 mg, 2.04 
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from CaH2), and the suspension was sparged with N2 for 10 min. O-tert-
butyldimethylsilyl propargyl alcohol (87, 8.32 g, 48.9 mmol, 1.35 equiv)17 was added in 
one portion, causing the suspension to darken as the palladium catalyst was reduced, and 
the reaction mixture was heated to 70 ºC. After 2 hours, TLC indicated complete 
conversion of bromide 134, so the suspension was cooled to room temperature and celite 
was added. The mixture was filtered through a pad of celite and eluted with Et2O. The 
filtrate was concentrated and purified by column chromatography (5% Et2O/hexanes) to 
afford 171 as a colorless solid (11.30 g, 89% yield); 1H NMR (500 MHz, CDCl3) δ 10.38 
(d, J = 3.2 Hz, 1H), 7.72 (dd, J = 10.0, 8.2 Hz, 1H), 7.34 (dd, J = 10.1, 7.1 Hz, 1H), 4.58 
(s, 2H), 0.94 (s, 9H), 0.16 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 189.3, 153.8 (dd, J = 
259.6, 13.8 Hz), 151.0 (dd, J = 255.6, 13.1 Hz), 133.7 (dd, J = 4.5, 3.3 Hz), 124.0 (dd, J 
= 8.9, 3.8 Hz), 122.1 (d, J = 19.3 Hz), 116.3 (dd, J = 18.5, 2.4 Hz), 96.1 (d, J = 2.0 Hz), 
78.4 (t, J = 1.9 Hz), 52.19, 25.91, 18.47, –5.00.	
 
Difluorinated oxime 135: Aldehyde 171 (11.30 g, 36.4 mmol, 1.0 equiv) was dissolved 
in MeOH (75 mL, 0.5 M), and to the solution was added NaOAc (6.57 g, 80.1 mmol, 2.2 
equiv). The solution was then stirred at room temperature for 5 minutes. Hydroxylamine 
hydrochloride (2.78 g, 40.0 mmol, 1.1 equiv) was added in one portion and NaCl began 
to precipitate immediately. After 20 minutes, TLC revealed complete consumption of the 
starting material, so the reaction was quenched with saturated aqueous NaHCO3 and 











23 °C, 20 min
(84% yield)
OTBS
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CH2Cl2 three times. The combined organic phases were washed with brine, dried over 
Na2SO4, and concentrated. The crude material was purified by column chromatography 
(10% Et2O/hexanes) to provide 135 (10.00 g, 84% yield) as a colorless solid. 1H NMR 
indicates 10:1 mixture of E:Z isomers; 1H NMR of (E)-isomer (300 MHz, CDCl3) δ 8.51 
(d, J = 1.7 Hz, 1H), 7.63 (dd, J = 11.1, 8.2 Hz, 1H), 7.25 – 7.18 (m, 1H), 4.56 (s, 2H), 
0.94 (s, 9H), 0.17 (s, 6H). 
 
Difluorinated isoquinoline N-oxide 132: Oxime 135 (10.0 g, 30.7 mmol, 1 equiv) was 
dissolved in CH2Cl2 (300 mL, 0.1 M) and the flask was vacuum purged and refilled with 
nitrogen five times, then heated to reflux. AgOTf (158 mg, 0.61 mmol, 0.02 equiv) was 
added in one portion to the refluxing solution, resulting in a rapid and mildly exothermic 
reaction. The reaction flask was shielded from light and maintained at reflux for 15 min, 
at which time LCMS indicated full consumption of the starting material. The solution 
was filtered through a pad of silica with CH2Cl2 and 10% MeOH/EtOAc, then 
concentrated. The crude material was purified by column chromatography (20–50–100% 
EtOAc/hexanes + 1% NEt3 ; then 10% MeOH/EtOAc + 1% NEt3) to afford N-oxide 132 
(6.30g, 63% yield) as a colorless solid.; 1H NMR (300 MHz, CDCl3) δ 8.72 (s, 1H), 7.84 
(s, 1H), 7.59 (dd, J = 10.0, 7.5 Hz, 1H), 7.47 (dd, J = 9.8, 7.7 Hz, 1H), 5.00 (s, 2H), 1.00 
(s, 9H), 0.19 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 151.9 (dd, J = 256.2, 15.8 Hz), 
151.8 (dd, J = 255.0, 16.0 Hz), 149.2–149.3 (m), 135.4 – 135.3 (m), 126.5 (dd, J = 8.0, 
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111.0 (d, J = 18.7 Hz), 60.2, 26.2, 18.6, –5.1; 19F NMR (282 MHz, CDCl3) δ –131.01 –  
–131.19 (m), –131.73 – –131.92 (m). 
A8.4.2.2 Synthesis of difluorinated isoquinoline triflate 133 
 
6,7-Difluoro-1-methyl-3-hydroxyisoquinoline (137):18 Cesium fluoride (2.64 g, 17.4  
mmol, 2.5 equiv) was dissolved in acetonitrile (35 mL, 0.2 M based on methyl 
acetoacetate) in a Schlenk flask and methyl acetoacetate (0.75 mL, 6.94 mmol, 1.0 equiv) 
was added. Aryne precursor 1366 (2.90 g, 8.67 mmol, 1.25 equiv) was added neat via 
syringe dropwise, and the flask was placed in a preheated 80 ºC oil bath. After 2 h, TLC 
revealed complete consumption of 136, so aqueous NH4OH (28–30%, 35 mL) was added 
in one portion. The flask was then capped, moved to a preheated 60 ºC oil bath and 
stirred for 12 h. The solution was poured into brine inside a separatory funnel and the 
solution was extracted with EtOAc three times. The aqueous phase was brought to pH 7 
by the addition of 2M HCl and was extracted with EtOAc twice. The aqueous phase was 
discarded. The organic phase was then extracted with 2M HCl three times. The organic 
phase was analyzed by LCMS to confirm that all of product 137 had transferred to the 
aqueous phase, and was subsequently discarded. The aqueous phase was then brought 
back to pH 7 by the addition of 5M NaOH and was extracted with EtOAc (5x 20 mL). 
The combined organic phases were washed with brine, dried over MgSO4 and 
















60 ºC, 12 h
90
(36% yield)
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product is not soluble in CDCl3. Characterization data match those reported in the 
literature.18  
 
Difluoroisoquinoline triflate 133: Hydroxyisoquinoline 137 (43.6 mg, 0.223 mmol, 1.0 
equiv) was dissolved in CH2Cl2 (1.1 mL, 0.2 M) and pyridine (0.18 mL, 2.23 mmol, 10 
equiv) was added and the solution was cooled to 0 ºC. Trifluoromethanesulfonic 
anhydride (Tf2O, 75 µL, 0.446 mmol, 2.0 equiv) was added dropwise, causing the yellow 
solution to turn dark red. After 30 minutes, TLC (30% EtOAc/hexanes) revealed 
complete consumption of 133, so the reaction was quenched by the addition of saturated 
aqueous NaHCO3. The solution was stirred vigorously until bubbling ceased, at which 
time the layers were separated. The organic phase was extracted with CH2Cl2 and the 
combined organic phases were washed with brine, dried over Na2SO4, and concentrated. 
The crude product was purified by column chromatography (15% EtOAc/hexanes) to 
provide 133 (70.1 mg, 96% yield) as a pale yellow oil; 1H NMR (500 MHz, CDCl3) δ 
7.94 – 7.86 (m, 1H), 7.63 (dd, J = 9.9, 7.5 Hz, 1H), 7.37 (s, 1H), 2.92 (s, 3H). 
A8.4.2.3 Fagnou coupling 
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Tetrafluorinated bis-isoquinoline N-oxide 138: Palladium acetate (48.7 mg, 0.217 
mmol, 0.2 equiv), di-tert-butyl (methyl)phosphonium tetrafluoroborate (135 mg, 0.543 
mmol, 0.5 equiv), and cesium carbonate (141 mg, 0.434 mmol, 0.4 equiv) were weighed 
into a pear-shaped flask and brought into a nitrogen-filled glovebox. Cesium pivalate 
(CsOPiv, 102 mg, 0.434 mmol, 0.4 equiv) was added to the flask. In the glovebox, 
degassed toluene (5 mL) was added to the flask, and it was sealed with a rubber septum 
and removed from the glovebox. The flask was placed in a 60 ºC preheated oil bath, 
where it was stirred for 30 min after which the reaction mixture turned from orange to 
golden yellow. In the meantime, N-oxide 132 (1.06 g, 3.26 mmol, 3 equiv) and cesium 
carbonate (0.92 g, 2.82 mmol, 2.6 equiv) were weighed into a sealable flask equipped 
with a Kontes valve, to which 15 mL toluene was added, and this suspension was sparge-
degassed with nitrogen for 10 min. Isoquinoline triflate 133 (355 mg, 1.09 mmol, 1.0 
equiv) was dissolved in 2.5 mL toluene, which was sparge-degassed with nitrogen for 10 
min. The solution of isoquinoline triflate 85 was then added via cannula to the catalyst 
solution while at 60 °C, and the flask was rinsed with 2 mL degassed toluene. The 
catalyst/triflate solution was then added via cannula to the N-oxide solution and rinsed 
with 2 mL degassed toluene. The flask was sealed and placed in a 130 ºC preheated oil 
bath. After 12 h, TLC and LCMS indicated full consumption of isoquinoline triflate 133, 
so the flask was allowed to cool to room temperature and Celite (2 g) was added. This 
suspension was then filtered through a pad of Celite that was topped with sand and rinsed 
with CH2Cl2 and acetone. The solution was concentrated and subsequently purified by 
column chromatography (20–50–100% EtOAc/hex, then 10–20% MeOH/EtOAc + Et3N) 
to afford bis-Isoquinoline 138 as a colorless foam (382 mg, 70% yield). Excess 
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isoquinoline N-oxide 132 was obtained after 10–20% MeOH/EtOAc flush, and recovered 
quantitatively (706 mg, 2.17 mmol); 1H NMR (300 MHz, CDCl3) δ 8.02 – 7.89 (m, 3H), 
7.63 (dd, J = 10.0, 7.7 Hz, 2H), 7.25 (dd, J = 11.4, 7.7 Hz, 1H), 5.03 (s, 2H), 3.00 (s, 3H), 
1.01 (s, 9H), 0.19 (s, 6H); 19F NMR (282 MHz, CDCl3) δ –129.11 – –129.66 (m), –
130.73 – –131.26 (m), –131.66 – –132.03 (m), –132.17 – –132.68 (m). Due to an overlap 
of a product peak with a residual CHCl3 solvent peak, we also obtained 1H spectra in 
CD2Cl2;	1H NMR (400 MHz, CD2Cl2) δ 8.00 (dd, J = 11.0, 7.8 Hz, 1H), 7.96 – 7.89 (m, 
2H), 7.67 (ddd, J = 12.9, 10.3, 7.8 Hz, 2H), 7.23 (dd, J = 11.7, 7.9 Hz, 1H), 4.98 (s, 2H), 
2.97 (s, 3H), 1.03 (s, 9H), 0.21 (s, 6H). Multiple 13C–19F couplings in product 138 
resulted in complicated 13C spectra. The multiplicities and coupling constants of the 
following signals have not been assigned: 13C NMR (100 MHz, CD2Cl2) δ 154.7, 154.5, 
152.7, 152.7, 152.6, 152.5, 152.4, 152.1, 152.0, 150.2, 150.2, 150.1, 150.0, 150.0, 149.9. 
We expect these signals to correspond to the four carbons adjacent to the four fluorine 
atoms. The rest of the 13C signals are assigned as follows: 13C NMR (100 MHz, CD2Cl2) 
δ 159.4 (dd, J = 5.4, 1.6 Hz), 149.7 – 149.5 (m), 143.7 (dd, J = 5.8, 2.9 Hz), 143.3 (d, J = 
2.7 Hz), 134.2 (dd, J = 8.8, 1.3 Hz), 126.6 (dd, J = 8.1, 1.3 Hz), 126.0 (dd, J = 8.3, 1.3 
Hz), 124.8 (d, J = 5.4 Hz), 122.8 – 120.7 (m), 120.2 – 118.4 (m), 114.3 (d, J = 17.0 Hz), 
113.7 (d, J = 17.2 Hz), 113.0 (dd, J = 17.4, 1.3 Hz), 112.0 (d, J = 20.0 Hz), 60.6, 26.1, 
22.9, 18.7, –5.2.	Note: Future characterization efforts should focus on simplifying the 
data by obtaining 13C spectrum with simultaneous 1H and 19F decoupled (13C-{1H, 19F}).	
 
 




Difluorinated bis-isoquinoline N-oxide 139: Prepared according to General Procedure 1 
using N-Oxide 84 (1.82 g, 5.00 mmol, 3.0 equiv) and isoquinoline triflate 133 (545 mg, 
1.65 mmol, 1.0 equiv). Reaction completed after 5 hours. The crude material was purified 
by column chromatography (30–40–50–60–70–100% EtOAc/hex, then 10% 
MeOH/EtOAc + 1% Et3N) to afford bis-Isoquinoline 139 as a white solid (647 mg, 72% 
yield); 1H NMR (400 MHz, CDCl3) δ 8.17 – 8.05 (m, 1H), 8.00 – 7.89 (m, 2H), 7.62 (dd, 
J = 10.2, 7.8 Hz, 1H), 6.49 (s, 1H), 5.06 (d, J = 1.3 Hz, 2H), 3.91 (s, 3H), 3.64 (s, 3H), 
2.99 (s, 3H), 2.29 (s, 3H), 1.03 (s, 9H), 0.18 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 
159.17, 158.75 (dd, J = 5.4, 1.5 Hz), 153.87, 153.20 (dd, J = 219.2, 15.6 Hz), 150.66 (dd, 
J = 216.6, 15.7 Hz), 146.06, 143.94 (d, J = 2.7 Hz), 143.11, 134.05 (dd, J = 8.6, 1.1 Hz), 
128.08, 124.33 (dd, J = 6.3, 1.3 Hz), 123.02, 120.50, 114.88, 113.94 (d, J = 16.8 Hz), 
112.60 (dd, J = 17.4, 1.3 Hz), 98.07, 61.81, 60.33, 55.62, 26.03, 22.76, 18.46, 9.72, –
5.21; 19F NMR (282 MHz, CDCl3) δ –129.98 (dt, J = 23.4, 8.8 Hz), –131.28 – –132.39 
(m); IR (thin film, NaCl): 2952, 2856, 161, 1516, 1464, 1430, 1326, 1250, 1188, 1136, 
1117, 858, 838, 845, 777, 756; HRMS (ESI-TOF) calc’d for [M+H+] C29H35F2N2O4Si = 
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Difluorinated bis-isoquinoline N-oxide 140: Prepared according to General Procedure 1 
using N-Oxide 132 (2.44 g, 7.50 mmol, 3.0 equiv) and isoquinoline triflate 85 (913 mg, 
2.50 mmol, 1.0 equiv). Reaction completed after 5 hours. The crude material was purified 
by column chromatography (20–30–50% EtOAc/hex, then 10% MeOH/EtOAc + 1% 
Et3N) to afford bis-Isoquinoline 140 as a colorless solid (1.14 g, 84% yield); 1H NMR 
(300 MHz, CDCl3) δ 7.88 (s, 1H), 7.80 (s, 1H), 7.60 (dd, J = 10.0, 7.7 Hz, 1H), 7.42 (s, 
1H), 7.31 (dd, J = 11.5, 7.8 Hz, 1H), 5.03 (s, 2H), 4.02 (s, 3H), 3.98 (s, 3H), 3.17 (s, 3H), 
2.46 (s, 3H), 1.01 (s, 9H), 0.18 (s, 6H); 19F NMR (282 MHz, CDCl3) δ –132.48 (ddd, J = 
19.5, 11.5, 7.7 Hz), –132.99 (ddd, J = 20.6, 10.0, 7.9 Hz). 
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General Procedure 2: Deoxygenation 
 
Tetrafluoro bis-isoquionline alcohol 141: Bis-isoquinoline-N-oxide 138 (79 mg, 0.157 
mmol, 1.0 equiv) was dissolved in CH2Cl2 (3.0 mL, 0.05 M) and the solution was cooled 
to 0 ºC. Neat phosphorus trichloride (28 µL, 0.314 mmol, 2.0 equiv) was added dropwise. 
After 15 min, TLC revealed complete consumption of 138, so the reaction was quenched 
with saturated aqueous K2CO3 at 0 °C and diluted with water. The biphasic mixture was 
allowed to warm to room temperature, and the layers were separated. The aqueous phase 
was extracted with EtOAc. The combined organic phases were dried over Na2SO4 and 
concentrated (note: a brine wash caused a significant emulsion regardless of extraction 
solvent, and was avoided). The crude material (75 mg, 98% yield) was obtained as a 
colorless solid and crude 1H NMR showed >95% purity. Note: Attempt to perform this 
reaction on a larger scale (382 mg, 0.76 mmol) led to a formation of byproducts, thus 
requiring column purification (7% EtOAc/hexanes + 1% Et3N). On larger scale, after 
purification, the product was obtained as a colorless solid (188 mg, 51% yield); 1H NMR 
(400 MHz, CDCl3) δ 8.55 (dd, J = 12.1, 8.3 Hz, 1H), 8.17 (s, 1H), 7.94 (dd, J = 10.4, 7.8 
Hz, 1H), 7.85 – 7.75 (m, 1H), 7.65 (ddd, J = 19.9, 10.4, 7.8 Hz, 2H), 5.07 (s, 2H), 3.04 (s, 
3H), 1.02 (s, 9H), 0.19 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 157.38 (dd, J = 5.5, 1.7 
Hz), 155.91 (dd, J = 5.7, 1.8 Hz), 154.85 (d, J = 2.2 Hz), 153.18 (dd, J = 238.2, 15.7 Hz), 
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150.10 (dd, J = 250.4, 15.2 Hz), 136.69 – 135.19 (m), 134.56 (dd, J = 8.6, 1.3 Hz), 
124.18 (dd, J = 6.4, 1.3 Hz), 122.88 (dd, J = 7.3, 1.1 Hz), 120.13 (dd, J = 4.9, 2.3 Hz), 
115.71 (dd, J = 4.9, 2.0 Hz), 115.15 – 114.53 (m), 114.48 – 113.66 (m), 112.92 (d, J = 
16.9 Hz), 112.52 (dd, J = 17.3, 1.6 Hz), 66.08, 26.16, 22.90, 18.65, –5.12; 19F NMR (282 
MHz, CDCl3) δ –129.97 (ddd, J = 20.3, 10.3, 7.8 Hz), –130.63 (ddd, J = 20.9, 10.5, 8.3 
Hz), –131.80 (ddd, J = 20.3, 10.8, 7.8 Hz), –134.20 (ddd, J = 20.4, 12.1, 7.9 Hz); IR (thin 
film, NaCl): 2954, 2930, 2886, 2858, 1511, 1432, 1247, 1125, 1101, 894, 858, 838, 776; 
HRMS (ESI-TOF) calc’d for [M+H+] C26H27F4N2OSi = 487.1823, found 487.1805.	
General Procedure 3: Jones oxidation/esterification 
 
Tetrafluoro bis-isoquinoline ester 142: Bis-isoquinoline TBS-protected alcohol 141 (68 
mg, 0.14 mmol, 1.0 equiv) was dissolved in acetone (2.2 mL, 0.065 M) and cooled to 0 
ºC. Jones reagent (25 g CrO3 in 25 mL conc. HCl and 75 mL H2O, ca. 0.12 mL) was 
added. After 1 hour, LCMS showed complete conversion to the carboxylic acid, so the 
reaction mixture was filtered through celite and rinsed with MeOH. The filtrate was 
concentrated, redissolved in distilled MeOH (2.2 mL, 0.065 M), and SOCl2 (0.1 mL, 1.40 
mmol, 10 equiv) was added dropwise at room temperature. The solution was heated to 
reflux and stirred for 1 hour, at which time the LCMS revealed complete consumption of 
the carboxylic acid. The solution was cooled to room temperature, concentrated, and 
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ester 142 as a colorless solid (48 mg, 85% yield); 1H NMR (300 MHz, CDCl3) δ 8.82 (dd, 
J = 12.0, 8.1 Hz, 1H), 8.57 (s, 1H), 8.37 (s, 1H), 7.94 (dd, J = 10.7, 7.7 Hz, 1H), 7.75 
(ddd, J = 12.6, 10.1, 7.8 Hz, 2H), 4.07 (s, 3H), 3.04 (s, 3H). 
General Procedure 4: SeO2 oxidation/NaBH4 reduction 
 
Tetrafluorinated hydrogenation precursor 144: To bis-isoquinoline ester 142 (290 mg, 
0.724 mmol, 1.0 equiv) in a pressure tube was added dioxane (14 mL, 0.05 M) and SeO2 
(161 mg, 1.449 mmol, 2.0 equiv) at room temperature. After heating the reaction mixture 
to reflux, the reaction became homogeneous. The solution was kept at reflux for an 
additional 4 hours, at which point LCMS revealed complete consumption of starting 
material 142,  so the reaction was cooled to room temperature. Celite was added and the 
resulting slurry was filtered through more celite, rinsing with EtOAc and CH2Cl2. The 
filtrate was concentrated to afford aldehyde 143. Attempt to purify this crude material 
resulted in poor mass recovery, thus we elected to use the crude product in the subsequent 
step without further purification. 
To a scintillation vial containing aldehyde 143 was added CH2Cl2, MeOH (4:1 
CH2Cl2/MeOH, 7.5 mL, 0.1 M), and NaBH4 (9.0 mg, 0.239 mmol, 0.33 equiv). Gas 
evolution was observed for ~1 minute, then stopped. After stirring at room temperature 
for 10 minutes, LCMS indicated the presence of aldehyde 143, so additional NaBH4 (9.0 
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complete consumption of aldehyde 143. The reaction was quenched by the addition of 
citric acid monohydrate (300 mg) and water, and the solution was stirred for 5 min, then 
was basified by the addition of saturated aqueous NaHCO3. The layers were separated 
and the aqueous phase was extracted with CH2Cl2. The combined organic phases were 
dried over Na2SO4 and concentrated. The product was purified by column 
chromatography (20–30–40–50% EtOAc/CH2Cl2 + 1% NEt3) to afford hydrogenation 
precursor 144 as a colorless solid (170 mg, 56% yield); 1H NMR (300 MHz, CDCl3) δ 
8.61 (s, 1H), 8.49 (dd, J = 11.2, 8.2 Hz, 1H), 8.41 (s, 1H), 7.86 – 7.75 (m, 3H), 5.29 (s, 
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Difluorinated bis-isoquinoline alcohol 146: Deoxygenation of 139 (647 mg, 1.20 
mmol) was performed according to General Procedure 2 to quantitatively provide 
deoxygenated product 145 as a tan solid. The crude material was >95% pure by 1H NMR 
and can be used in the next step without further purification; 1H NMR (500 MHz, CDCl3) 
δ 8.15 (s, 1H), 8.10 – 8.02 (m, 1H), 7.92 (dd, J = 10.7, 7.7 Hz, 1H), 7.78 (s, 1H), 7.67 
(dd, J = 10.3, 7.8 Hz, 1H), 5.08 (d, J = 1.0 Hz, 2H), 3.92 (s, 3H), 3.84 (s, 3H), 3.03 (s, 
3H), 2.35 (s, 3H), 1.03 (s, 9H), 0.17 (s, 6H); IR (thin film, NaCl): 2930, 2856, 1596, 
1513, 1462, 1429, 1393, 1300, 1250, 1200, 1127, 1023, 891, 857, 838, 776; HRMS (ESI-
TOF) calc’d for [M+H+] C29H35F2N2O3Si = 525.2380, found 525.2383. Note: In some 
experiments where byproducts were detected in >10%, the crude material could be 
purified by column chromatography (15% EtOAc/hexanes + 1% Et3N), albeit with 
modest mass recovery (ca. 70%). 
The deoxygenated bis-isoquinoline intermediate (145, 113.5 mg, 0.216 mmol, 1.0 
equiv) was dissolved in acetic acid (0.9 mL, 0.25 M), and solid potassium fluoride (25.2 
mg, 0.433 mmol, 2.0 equiv) was added in one portion. The solution was stirred for 4 h at 
room temperature, at which time LCMS showed complete consumption of 145. The 
solution was diluted with CH2Cl2 and ice, then stirred vigorously as a solution of sodium 
hydroxide (565 mg, 14.1 mmol, 0.9 equiv relative to 0.9 mL AcOH) in 1.5 mL water was 
added slowly. The rest of the acetic acid was quenched by the addition of saturated 
aqueous K2CO3. The layers were separated and the aqueous phase was extracted with 
CH2Cl2. The combined organic phases were washed with brine, dried over Na2SO4, and 
concentrated to afford 146 as a colorless solid (86.7 mg, 98% yield). The crude 1H NMR 
showed >95% purity; 1H NMR (300 MHz, CDCl3) δ 8.22 (s, 1H), 8.01 – 7.87 (m, 2H), 
Appendix 8 – Progress toward the Syntheses of bis-Tetrahydroisoquinoline Analogs 
  
454	
7.87 – 7.80 (m, 1H), 7.69 (dd, J = 10.3, 7.8 Hz, 1H), 4.97 (d, J = 4.8 Hz, 2H), 3.91 (s, 
3H), 3.87 (s, 3H), 3.04 (s, 3H), 2.36 (s, 3H); 19F NMR (282 MHz, CDCl3) δ –130.27 
(ddd, J = 20.4, 10.2, 7.8 Hz), –132.29 (ddd, J = 20.3, 10.9, 7.8 Hz); IR (thin film, NaCl): 
3196, 2926, 1594, 1511, 1453, 1433, 1399, 1308, 1248, 1133, 1118, 1024, 886, 858, 839, 
726; HRMS (ESI-TOF) calc’d for [M+H+] C23H21F2N2O3 = 411.1515, found 411.1500.	
	
Difluoro bis-isoquinoline ester 149: Alcohol 146 (261 mg, 0.64 mmol, 1.00 equiv), 
TEMPO (79.7 mg, 0.51 mmol, 0.80 equiv), N-hydroxysuccinimide (NHSI, 127.7 mg, 
1.11 mmol, 1.75 equiv), and (diacetoxyiodo)benzene (1.30 g, 4.04 mmol, 6.35 equiv) 
were dissolved in CH2Cl2 (20 mL, 0.032 M) and stirred at room temperature. The white 
heterogeneous mixture gradually turned to a homogeneous orange solution. After 3 
hours, LCMS showed complete consumption of the alcohol, affording the aldehyde as the 
major product, so the reaction was quenched with saturated aqueous K2CO3. The aqueous 
layer was extracted with CH2Cl2 three times. The combined organic phases were dried 
over Na2SO4 and concentrated. Note: Oxidation to the carboxylic acid was not observed 
even with higher temperature and prolonged reaction time. Since the oxidation stops at 
the aldehyde oxidation state, this experiment can be performed without NHSI. 
To the aldehyde intermediate (147, 0.636 mmol) was added MnO2 (1.32 g, 15.2 
mmol, 24 equiv), NaCN (49.5 mg, 1.01 mmol, 1.6 equiv), and THF (10 ml, 0.06 M), 
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the reaction was heated to reflux. After 12 hours, the reaction mixture was cooled to 
room temperature and filtered through celite, before rinsing with CH2Cl2, and 
concentrated. The filtrate was redissolved in CH2Cl2, washed with water, and back-
extracted with CH2Cl2 twice. The combined organic phases were dried over MgSO4, 
concentrated, and purified by column chromatography (10–20% EtOAc/CH2Cl2 + 1% 
NEt3) to provide 149 as a colorless solid (153 mg, 55% yield over 2 steps); 1H NMR (400 
MHz, CDCl3) δ 8.78 (d, J = 0.7 Hz, 1H), 8.33 (s, 1H), 8.03 (s, 1H), 7.92 (dd, J = 10.6, 7.6 
Hz, 1H), 7.70 (dd, J = 10.3, 7.8 Hz, 1H), 4.05 (s, 3H), 3.95 (s, 3H), 3.90 (s, 3H), 3.01 (s, 
3H), 2.37 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 166.8, 160.2, 156.7 (dd, J = 5.5, 1.6 
Hz), 155.4, 155.0, 153.4 (ddd, J = 256.7, 15.7, 0.0 Hz), 151.8 (d, J = 2.8 Hz), 150.7 (dd, J 
= 254.1, 15.6 Hz), 139.0, 134.8 (dd, J = 8.6, 1.2 Hz), 128.5, 128.1, 125.3, 124.1 (dd, J = 
6.3, 1.3 Hz), 120.6 (dd, J = 4.9, 2.3 Hz), 119.0, 114.3 (d, J = 16.4 Hz), 112.4 (dd, J = 
17.3, 1.5 Hz), 101.4, 62.3, 55.8, 52.9, 22.7, 9.9; 19F NMR (282 MHz, CDCl3) δ –130.23 
(ddd, J = 20.3, 10.3, 7.8 Hz), –132.14 (ddd, J = 20.3, 10.9, 7.8 Hz); IR (thin film, NaCl): 
2926, 1708, 1620, 1515, 1455, 1434, 1396, 1311, 1278, 1248, 1233, 1217, 1140, 1118, 
996, 893, 858; HRMS (ESI-TOF) calc’d for [M+H+] C24H21F2N2O4 = 439.1464, found 
439.1463. 
 
Difluorinated hydrogenation precursor 151: Compound 151 was prepared from bis-
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required only 0.33 equiv of NaBH4. The crude product was purified by column 
chromatography (20–40–50% EtOAc/CH2Cl2 + 1% NEt3) to afford 151 as a colorless 
solid (105 mg, 56% yield); 1H NMR (400 MHz, CDCl3) δ 8.82 (d, J = 0.7 Hz, 1H), 8.46 
(s, 1H), 7.87 (s, 1H), 7.77 (ddd, J = 21.1, 10.2, 7.7 Hz, 2H), 5.26 (s, 2H), 4.07 (s, 3H), 
3.99 (s, 3H), 3.89 (s, 3H), 2.39 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 166.7, 160.5, 
155.8 (dd, J = 5.7, 1.6 Hz), 155.1, 154.9, 150.7 (d, J = 2.3 Hz), 139.0, 135.2 (dd, J = 8.7, 
1.2 Hz), 128.5, 128.1, 125.6, 121.8 (dd, J = 4.8, 2.1 Hz), 121.6 (d, J = 6.5 Hz), 119.3, 
114.8 (d, J = 16.4 Hz), 110.2 (dd, J = 17.6, 1.4 Hz), 100.9, 62.4, 61.9, 56.1, 52.9, 10.0; 
19F NMR (282 MHz, CDCl3) δ –128.41 (ddd, J = 20.3, 10.2, 7.7 Hz), –130.36 (ddd, J = 
20.1, 10.3, 7.7 Hz). Note: Due to the poor signal-to-noise ratio in 13C spectrum, we were 
not able to confidently pick peaks that correspond to the two carbons adjacent to the 

































































Difluorinated bis-isoquinoline TBS-protected alcohol 152: Deoxygenation of 140 
(1.14 g, 2.11 mmol) was performed according to General Procedure 2. The crude material 
was purified by column chromatography (10% EtOAc/hexanes) to afford the desired 
product (152) as a colorless solid (932 mg, 84% yield); 1H NMR (500 MHz, CDCl3) δ 
8.58 (dd, J = 12.2, 8.3 Hz, 1H), 8.00 (s, 1H), 7.78 (d, J = 0.9 Hz, 1H), 7.60 (dd, J = 10.6, 
7.9 Hz, 1H), 7.51 – 7.44 (m, 1H), 5.07 (s, 2H), 4.02 (s, 3H), 3.98 (s, 3H), 3.30 – 3.10 (m, 
3H), 2.46 (d, J = 0.9 Hz, 3H), 1.02 (s, 9H), 0.18 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 
156.6, 156.6 (dd, J = 5.6, 1.7 Hz), 154.8 (d, J = 2.1 Hz), 152.9 (dd, J = 256.4, 16.2 Hz), 
151.3, 149.9 (dd, J = 250.2, 15.5 Hz), 149.6, 149.3, 137.7, 136.0 (d, J = 7.9 Hz), 135.3, 
124.6, 123.0 (dd, J = 7.3, 1.1 Hz), 122.4, 120.1, 115.2 (d, J = 17.7 Hz), 115.2 (dd, J = 
4.8, 1.8 Hz), 112.7 (d, J = 16.7 Hz), 66.1, 60.9, 60.4, 27.4, 26.2, 18.6, 17.1, –5.1. 
 
Difluorinated bis-isoquinoline ester 153: Compound 153 was prepared according to 
General Procedure 3 from 152 (900 mg, 1.72 mmol). The crude material was purified by 
column chromatography using a 1:1 mixture of CH2Cl2:EtOAc as the polar solvent (40% 
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(437 mg, 57% yield); 1H NMR (400 MHz, CDCl3) δ 8.89 (dd, J = 12.1, 8.3 Hz, 1H), 8.53 
– 8.43 (m, 1H), 8.20 (s, 1H), 7.72 (dd, J = 10.0, 7.9 Hz, 1H), 7.59 – 7.45 (m, 1H), 4.06 (s, 
3H), 4.02 (s, 3H), 3.98 (s, 3H), 3.20 (s, 3H), 2.46 (d, J = 0.8 Hz, 3H); 13C NMR (100 
MHz, CDCl3) δ 166.3, 157.3 (dd, J = 5.5, 1.7 Hz), 156.5, 153.1 (dd, J = 265.2, 21.6 Hz), 
151.6 (dd, J = 252.0, 12.7 Hz), 151.5, 149.6, 148.7, 141.4 (d, J = 2.5 Hz), 137.8, 135.3, 
135.2 (dd, J = 8.7, 1.0 Hz), 125.8 (dd, J = 7.9, 1.4 Hz), 124.8, 123.0 (dd, J = 4.8, 2.1 Hz), 
122.5, 120.8, 116.2 (dd, J = 19.4, 1.2 Hz), 114.2 (d, J = 17.2 Hz), 60.9, 60.3, 53.1, 27.3, 
17.1; 19F NMR (282 MHz, CDCl3) δ –129.10 (ddd, J = 20.9, 9.9, 8.5 Hz), –129.50 (ddd, J 
= 20.7, 12.1, 7.8 Hz).	
 
Difluorinated hydrogenation precursor 155: Compound 155 was prepared according 
to General Procedure 4 from 153 (415 mg, 0.95 mmol). The crude material was purified 
by column chromatography using a 1:1 mixture of CH2Cl2:EtOAc as the polar solvent 
(40% polar solvent/hexanes + 1% NEt3) to afford the desired product (155) as a white 
solid (376 mg, 76% yield over 2 steps); 1H NMR (400 MHz, CDCl3) δ 8.56 – 8.53 (m, 
1H), 8.51 – 8.43 (m, 1H), 8.22 (s, 1H), 7.76 (t, J = 8.8 Hz, 1H), 7.62 – 7.53 (m, 1H), 5.38 
(d, J = 4.2 Hz, 2H), 5.27 (t, J = 4.4 Hz, 1H, OH), 4.06 (s, 3H), 4.05 (s, 3H), 3.96 (s, 3H), 
2.48 (d, J = 0.8 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 166.1, 157.3 (d, J = 3.4 Hz), 




















154: R = CHO
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141.4 (d, J = 1.6 Hz), 138.8, 135.1, 134.9 (dd, J = 6.5, 3.6 Hz), 125.7 (dd, J = 6.0, 3.1 
Hz), 124.7, 123.2 (d, J = 2.8 Hz), 121.9, 120.5, 115.3 (dd, J = 16.3, 4.5 Hz), 114.4 (t, J = 
9.2 Hz), 64.7, 60.92, 60.3, 53.1, 17.2; 19F NMR (282 MHz, CDCl3) δ –128.44 –  
–128.58 (m). 
A8.4.2.5 Ir-catalyzed enantioselective hydrogenation 
General Procedure 5: Hydrogenation 
 
Tetrafluorinated bis-THIQ pentacycle (129): A flame-dried 100-mL roundbottom 
flask with a teflon-coated stir bar and bis-IQ hydrogenation precursor 144 (169 mg, 0.407 
mmol, 1.00 equiv) was placed into a Parr bomb and brought in to a nitrogen-filled 
glovebox, with the exception of the pressure gauge. A layer of plastic wrap and a rubber 
band were also brought in to seal the top of the bomb. In a nitrogen-filled glovebox, a 
solution of L49 (BTFM-xyliphos) (89.0 mg, 0.098 mmol, 0.24 equiv) and [Ir(cod)Cl]2 
(27.34 mg, 0.041 mmol, 0.10 equiv) in toluene (10 mL) was prepared and allowed to 
stand for 10 minutes. Meanwhile, TBAI (90.2 mg, 0.244 mmol, 0.60 equiv) and AcOH (2 
mL) were added to the flask containing bis-isoquinoline 144. Afterwards, the 
homogeneous iridium-ligand solution was transferred to the flask with two 4 mL toluene 
rinses, bringing the final volume to 20 mL of 9:1 PhMe:AcOH (0.02 M of 129). After 
sealing the flask with a rubber septum that was pierced with three 16 gauge (purple) 





















[Ir(cod)Cl]2 (10 mol %)
L49 (BTFM-xyliphos)
TBAI, 9:1 PhMe/AcOH
60 to 80 °C
40–50% yield
>20:1 dr, 80% ee
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covered tightly with plastic wrap secured by a rubber band. The bomb was then removed 
from the glovebox, and the pressure gauge was quickly screwed in place and tightened. 
The bomb was charged to 5-10 bar H2 and slowly released. This process was repeated 
twice, before charging the bomb to 60 bar of H2, at which time it was placed in a 
preheated 60 ºC oil bath. The bath was maintained at this temperature for 18 h, then 
raised to 80 ºC. After 24 h, the bomb was removed from the oil bath and the hydrogen 
pressure was vented. The flask was removed from the bomb and the solution was 
transferred to a 250 mL roundbottom flask and basified by the careful addition of 
saturated aqueous K2CO3 and water until pH > 7. The solution was transferred to a 
separatory funnel and the layers were separated. The aqueous phase was extracted with 
EtOAc, and the combined organic phases were washed with water, then brine, dried over 
Na2SO4, and concentrated. The product was purified using reverse-phase (C18) 
preparative HPLC (MeCN/0.05% TFA in water, 35.0 mL/min, monitor wavelength = 210 
nm, 20–38% MeCN over 6.2 min, ramp to 100% for 0.1 min, hold at 100% for 2 min; tR 
= 5.7 min) to furnish pentacycle 129 as a white solid (63 mg, 40% yield); 78% ee; [α]D25 
–26.4 (c 0.97, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.06 – 6.93 (m, 3H), 6.89 (dd, J = 
10.4, 7.8 Hz, 1H), 5.17 (t, J = 5.6 Hz, 1H), 4.12 (d, J = 3.0 Hz, 1H), 3.99 (d, J = 6.1 Hz, 
1H), 3.90 (dt, J = 12.6, 2.6 Hz, 1H), 3.31 (dd, J = 10.8, 5.2 Hz, 1H), 3.20 – 3.10 (m, 1H), 
3.08 (dd, J = 10.8, 6.2 Hz, 1H), 3.00 (d, J = 17.1 Hz, 1H), 2.82 – 2.74 (m, 2H, overlapped 
with NH), 2.53 (t, J = 13.5 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 171.1, 149.9 (dd, J = 
249.6, 12.7 Hz), 149.5 (dd, J = 247.9, 11.6 Hz), 149.3 (dd, J = 247.0, 12.1 Hz), 148.2 
(dd, J = 248.1, 13.1 Hz), 131.5 (dd, J = 6.1, 3.8 Hz), 130.8 (dd, J = 5.9, 3.8 Hz), 130.3 
(dd, J = 5.9, 3.8 Hz), 128.4 (t, J = 4.1 Hz), 118.1 (d, J = 16.9 Hz), 117.2 (d, J = 18.0 Hz), 
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116.7 (d, J = 17.1 Hz), 116.5 (d, J = 17.6 Hz), 66.8, 60.6, 57.2, 53.8, 53.6, 33.9, 32.6; 19F 
NMR (282 MHz, CDCl3) δ –137.75 (ddd, J = 21.6, 10.7, 7.8 Hz), –138.85 (ddd, J = 21.4, 
10.2, 7.6 Hz), –139.29 – –139.71 (m), –139.99 – –140.57 (m); IR (Neat Film, NaCl) 
3288, 2928, 1633, 1514, 1433, 1413, 1312, 1296, 1214, 1120, 1052, 879, 807, 755 cm-1; 
HRMS (MM:ESI-APCI+) m/z calc’d for C20H17F4N2O2 [M+H]+: 393.1221, found 
393.1204; HPLC conditions: 40% IPA/hexanes, 1.0 mL/min, Chiralpak AD-H column, λ 
= 210 nm, tR (min): minor = 8.3, major = 10.4.	
 
Difluorinated bis-THIQ pentacycle 130: Prepared according to General Procedure 5 
using bis-IQ 151 (25.0 mg, 0.055 mmol) as the starting material. The product was 
purified using reverse-phase (C18) preparative HPLC (MeCN/0.4% acetic acid in water, 
5.0 mL/min, monitor wavelength = 225 nm, 15.0–40.5% MeCN over 8.50 min, ramp to 
95% MeCN over 0.5 min, and hold at 95% for 4 min; tR = 6.9 min) to furnish pentacycle 
130 as a white solid (11.5 mg, 49% yield); 17% ee; 1H NMR (400 MHz, CDCl3) δ 7.02 
(ddd, J = 10.9, 7.6, 3.3 Hz, 2H), 6.33 (s, 1H), 5.31 (t, J = 5.5 Hz, 1H), 4.13 (d, J = 3.3 Hz, 
1H), 4.10 (d, J = 5.6 Hz, 1H), 3.95 (dt, J = 12.5, 2.9 Hz, 1H), 3.83 (s, 3H), 3.68 (s, 3H), 
3.29 (d, J = 5.5 Hz, 2H), 3.13 (dd, J = 17.4, 1.5 Hz, 1H), 3.02 (dd, J = 17.4, 6.4 Hz, 1H), 
2.80 (dd, J = 14.7, 2.6 Hz, 1H), 2.73 – 2.54 (m, 3H, overlapped with OH and NH), 2.14 
(s, 3H); 13C NMR (100 MHz, CDCl3) δ 172.3, 157.8, 156.8, 149.6 (dd, J = 243.6, 7.3 






















[Ir(cod)Cl]2 (10 mol %)
L49 (BTFM-xyliphos)
TBAI, 9:1 PhMe/AcOH
60 to 80 °C
49% yield
>20:1 dr, 17% ee
OMe
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(m), 120.1, 119.7, 117.1 (d, J = 17.8 Hz), 116.6 (d, J = 17.4 Hz), 106.1, 68.2, 61.0, 60.5, 
57.5, 56.0, 54.9, 54.3, 33.0, 30.0, 9.3; 19F NMR (282 MHz, CDCl3) δ –138.67 – –139.26 
(m), –139.30 – –139.75 (m); IR (Neat Film, NaCl) 3288, 2941, 1634, 1608, 1513, 1455, 
1407, 1371, 1335, 1310, 1296, 1274, 1214, 1125, 1061, 753 cm-1; HRMS (MM:ESI-
APCI+) m/z calc’d for C23H25F2N2O2 [M+H]+: 431.1777, found 431.1774; HPLC 
conditions: 10% IPA/hexanes, 1.0 mL/min, Chiralcel OD-H column, λ = 220 nm,  
tR (min): major = 67.3, minor = 77.7.	
 
Difluorinated bis-THIQ pentacycle 131: Prepared according to General Procedure 5 
using bis-IQ 155 (10.0 mg, 0.022 mmol) as the starting material to furnish pentacycle 
131; 60% ee;	1H NMR (400 MHz, CDCl3) δ 7.01 (dd, J = 10.7, 7.8 Hz, 1H), 6.92 (dd, J = 
10.6, 7.7 Hz, 1H), 6.72 (s, 1H), 5.77 (dd, J = 6.8, 3.9 Hz, 1H), 4.12 (d, J = 3.4 Hz, 1H), 
4.05 (dd, J = 6.2, 1.8 Hz, 1H), 3.95 – 3.87 (m, 1H), 3.91 (s, 3H), 3.7 (s, 3H), 3.44 (dd, J = 
11.0, 4.0 Hz, 1H), 3.20 (dd, J = 11.0, 6.8 Hz, 1H), 3.17 – 3.05 (m, 2H), 2.71 (dd, J = 
14.4, 2.4 Hz, 1H), 2.60 – 2.47 (m, 1H), 2.24 (s, 4H, overlapped with NH proton); 13C 
NMR (100 MHz, CDCl3) δ 172.2, 150.1, 149.9 (dd, J = 249.4, 12.7 Hz), 149.7, 148.3 
(dd, J = 247.7, 13.1 Hz), 132.0, 131.0 – 130.9 (m), 130.8, 128.8 (t, J = 4.2 Hz), 124.7, 
124.5, 118.2 (d, J = 17.0 Hz), 116.8 (d, J = 17.0 Hz), 68.9, 61.5, 60.7, 60.0, 54.1, 53.9, 
52.9, 34.3, 33.0, 15.9; HPLC conditions: 20% IPA, 1.0 mL/min, Chiralcel OD-H column, 





















[Ir(cod)Cl]2 (10 mol %)
L49 (BTFM-xyliphos)
TBAI, 9:1 PhMe/AcOH
60 to 80 °C
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A8.4.2.6 Completion of bis-THIQ analogs 
 
General Procedure 6: Reductive amination 
 
N-methyl tetrafluorinated bis-THIQ 156: bis-tetrahydroisoquinoline 129 (48 mg, 0.122 
mmol, 1.00 equiv) was dissolved in 1,2-dichloroethane (1,2-DCE, 2.5 mL, 0.05 M) and 
37% aqueous formaldehyde (17 µL, 0.226 mmol, 1.85 equiv) was added. The solution 
was stirred for 10 min before sodium triacetoxyborohydride (130 mg, 0.612 mmol, 5 
equiv) was added. This solution was stirred at 23 ºC for 30 min, at which time LCMS 
showed complete consumption of 129. Citric acid monohydrate (193 mg, 0.917 mmol, 
7.5 equiv) was added to the solution, followed by 5 mL water. This solution was stirred 
for 10 min before the slow addition of saturated aqueous K2CO3 until pH > 7. The layers 
were separated and the aqueous phase was extracted with CH2Cl2. The combined organic 
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(68% yield)
126: R = OH
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mg, quantitative yield) with >95% purity; [α]D25 –53.3 (c 1.203, CHCl3); 1H NMR (400 
MHz, CDCl3) δ 7.09 – 6.95 (m, 3H), 6.91 (dd, J = 10.3, 7.8 Hz, 1H), 5.27 (t, J = 4.6 Hz, 
1H), 4.01 (dt, J = 12.6, 2.8 Hz, 1H), 3.79 (d, J = 3.3 Hz, 1H), 3.73 (d, J = 6.5 Hz, 1H), 
3.34 – 3.21 (m, 3H), 2.86 (d, J = 17.5 Hz, 1H), 2.72 (dd, J = 14.6, 2.4 Hz, 1H), 2.54 (t, J 
= 13.6 Hz, 1H), 2.46 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 171.9, 149.9 (dd, J = 249.6, 
12.7 Hz), 149.6 (dd, J = 246.3, 9.8 Hz), 149.4 (dd, J = 246.8, 11.7 Hz), 148.5 (dd, J = 
248.4, 12.9 Hz), 131.9 (dd, J = 6.0, 3.8 Hz), 130.4 – 130.2 (m), 130.3 – 130.1 (m), 126.6 
(t, J = 4.1 Hz), 117.8 (d, J = 17.0 Hz), 117.6 (d, J = 17.4 Hz), 117.1 (d, J = 17.9 Hz), 
116.6 (d, J = 17.6 Hz), 68.2 – 65.7 (m), 60.3, 59.7, 57.6, 57.4, 40.0, 32.6, 28.1; 19F NMR 
(282 MHz, CDCl3) δ –137.47 – –137.89 (m), –138.68 (ddd, J = 21.3, 10.1, 7.6 Hz),  
–138.93 – –139.28 (m), –139.58 – –139.93 (m); IR (Neat Film, NaCl) 3288, 2930, 1639, 
1513, 1438, 1419, 1364, 1338, 1312, 1213, 1178, 1140, 1109, 1059, 909, 880, 794, 733 
cm-1; HRMS (MM:ESI-APCI+) m/z calc’d for C21H19F4N2O2 [M+H]+: 407.1377, found 
407.1386.	
	
Tetrafluorinated bis-THIQ aminonitrile 126: In an oven-dried vial, LiAlH4 solution 
(1.0 M in THF, 2 mL, 2.0 mmol) was cooled to 0 ºC. A solution of ethyl acetate (230 µL, 
2.35 mmol) in 2 mL THF was added slowly, and the resulting solution was stirred 30 min 
at 0 ºC, providing a 0.47 M solution of Li(EtO)2AlH2 in THF. bis-THIQ 156 (49.7 mg, 
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was cooled to 0 ºC. A solution of Li(EtO)2AlH2 (0.47 M in THF, 3.9 mL, 1.83 mmol, 
15.0 equiv) was added slowly, resulting in extensive evolution of H2. After stirring for 30 
min, the LCMS indicated full consumption of the starting material, so the reaction was 
quenched with acetic acid (150 µL, 2.56 mmol, 21 equiv) and aqueous potassium cyanide 
(4.8 M, 153 µL, 0.732 mmol, 6.0 equiv) was added, followed by celite and anhydrous 
Na2SO4 (roughly 1 g each). The solution was diluted with 12 mL THF and stirred at 50 
°C for 16 h. At this stage, LCMS revealed full consumption of the iminium, thus celite 
and K2CO3 (4 g) were added, and the suspension was filtered through celite, rinsing with 
EtOAc and CH2Cl2. The filtrate was transferred to a roundbottom flask and was 
concentrated. The product was purified using reverse-phase (C18) preparative HPLC 
(MeCN/0.4% acetic acid in water, 5.0 mL/min, monitor wavelength = 270 nm, 50–80% 
MeCN over 10 min, ramp to 95% over 0.5 min, hold at 95% for 2.4 min; tR = 7.3 min) to 
furnish amino nitrile 126 as a white powder (34.4 mg, 68% yield); [α]D25 –57.3 (c 1.012, 
CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.00 – 6.81 (m, 4H), 4.11 (d, J = 2.5 Hz, 1H), 
3.82 (t, J = 4.7 Hz, 1H), 3.62 (dd, J = 2.8, 1.2 Hz, 1H), 3.55 (dd, J = 11.2, 4.2 Hz, 1H), 
3.41 (ddd, J = 7.5, 2.6, 1.3 Hz, 1H), 3.35 (dt, J = 12.1, 2.7 Hz, 1H), 3.20 (dd, J = 11.2, 5.2 
Hz, 1H), 3.18 – 3.10 (m, 1H), 2.63 – 2.52 (m, 2H), 2.36 (s, 3H), 2.28 – 2.17 (m, 1H); 13C 
NMR (100 MHz, CDCl3) δ 149.6 (dd, J = 248.6, 12.7 Hz), 149.2 (dd, J = 252.8, 16.9 
Hz), 149.2 (dd, J = 241.9, 7.6 Hz), 148.2 (dd, J = 248.3, 12.9 Hz), 131.2 (dd, J = 6.0, 3.6 
Hz), 130.9 (dd, J = 5.7, 3.8 Hz), 129.9 (dd, J = 5.4, 3.7 Hz), 128.0 (t, J = 3.9 Hz), 117.9 
(d, J = 16.5 Hz), 117.5, 116.5 (d, J = 9.3 Hz), 116.3 (d, J = 9.1 Hz), 116.0 (d, J = 17.7 
Hz), 67.4, 62.5 (d, J = 1.5 Hz), 62.4, 60.7, 56.0, 55.2, 41.7, 32.4, 25.7; 19F NMR (282 
MHz, CDCl3) δ –138.81 (ddd, J = 21.3, 10.9, 7.9 Hz), –139.65 (ddd, J = 21.5, 10.4, 7.6 
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Hz), –139.84 – –140.35 (m), –140.64 (ddd, J = 21.3, 10.0, 7.8 Hz); IR (Neat Film, NaCl) 
3477, 2938, 1614, 1515, 1435, 1354, 1320, 1268, 1216, 1144, 1100, 1054, 912, 890, 762 
cm-1; HRMS (MM:ESI-APCI+) m/z calc’d for C22H20F4N3O [M+H]+: 418.1537, found 
418.1544.	
 
Tetrafluorinated Acylated bis-THIQ aminonitrile 157: In a 1-dram vial, bis-THIQ 
126 (6.0 mg, 0.015 mmol, 1.0 equiv) and DMAP (4.8 mg, 0.043 mmol, 3.0 equiv) were 
dissolved in acetonitrile (300 µL, 0.05 M), and acetic anhydride (4.1 µL, 0.043 µmol, 3.0 
equiv) was added neat. After 30 minutes, LCMS showed complete consumption of 126. 
The reaction was concentrated and the crude material was purified using reverse-phase 
(C18) preparative HPLC (MeCN/0.4% acetic acid in water, 5.0 mL/min, monitor 
wavelength = 260 nm, 60–84% MeCN over 8 min, ramp to 95 over 0.5 min, hold at 95% 
for 1.5 min; tR = 7.2 min) to afford acylated bis-THIQ analog 157 as a colorless solid (6.0 
mg, >99% yield); [α]D25 +55.3 (c 0.400, CHCl3); 1H NMR (400 MHz, CDCl3) δ 6.98 – 
6.87 (m, 3H), 6.83 (dd, J = 10.2, 7.8 Hz, 1H), 4.28 (dd, J = 11.3, 4.6 Hz, 1H), 4.07 (d, J = 
2.5 Hz, 1H), 3.89 (t, J = 4.4 Hz, 1H), 3.61 (dd, J = 11.3, 4.1 Hz, 1H), 3.58 – 3.56 (m, 
1H), 3.39 (ddd, J = 7.6, 2.6, 1.3 Hz, 1H), 3.28 (dt, J = 11.9, 2.6 Hz, 1H), 3.08 (dd, J = 
18.1, 8.0 Hz, 1H), 2.67 – 2.51 (m, 2H), 2.34 (s, 3H), 2.25 – 2.13 (m, 1H), 1.70 (s, 3H); 
13C NMR (100 MHz, CDCl3) δ 170.3, 149.6 (dd, J = 247.9, 12.6 Hz), 149.4 (dd, J = 
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(dd, J = 6.1, 3.6 Hz), 131.5 (dd, J = 5.9, 3.8 Hz), 129.4 (dd, J = 5.5, 3.8 Hz), 127.99 – 
127.71 (m), 117.7 (d, J = 16.2 Hz), 117.6, 116.7 – 116.3 (m, 2 carbons), 116.1 (d, J = 
17.9 Hz), 66.7, 62.3, 60.7, 60.4, 56.0, 55.2, 41.8, 32.7, 25.3, 20.6; 19F NMR (282 MHz, 
CDCl3) δ –139.32 (ddd, J = 21.4, 10.3, 7.8 Hz), –139.51 – –140.17 (m), –141.34 – –
141.90 (m); HRMS (MM:ESI-APCI+) m/z calc’d for C24H22F4N3O2 [M+H]+: 460.1643, 
found 460.1627.	
 
Tetrafluorinated Phthalimido bis-THIQ aminonitrile 158: In a 1-dram vial, bis-THIQ 
126 (6.0 mg, 0.015 mmol, 1.0 equiv), phthalimide (4.2 mg, 0.029 mmol, 2.0 equiv), and 
triphenylphosphine (7.5 mg, 0.029 mmol, 2.0 equiv) were dissolved in THF (300 µL, 
0.05 M). DIAD (5.7 µL, 0.029 mmol, 2.0 equiv) was added. After 2 hours, LCMS 
showed complete consumption of starting material 126, so the reaction was quenched 
with H2O. The layers were separated, and the aqueous phase was extracted with CH2Cl2. 
The organic phases were combined, concentrated, and the crude material was purified 
using reverse-phase (C18) preparative HPLC (MeCN/0.4% acetic acid in water, 5.0 
mL/min, monitor wavelength = 230 nm, 65–95% MeCN over 10 min, hold at 95% for 2 
min; tR = 6.7 min) to afford phthalimide analog 158 as a colorless solid (6.4 mg, 
quantitative yield); [α]D25 +48.6 (c 0.367, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.73 (s, 
4H), 6.88 (ddd, J = 23.1, 10.0, 7.6 Hz, 2H), 6.71 (dd, J = 10.5, 7.8 Hz, 2H), 4.16 – 4.08 
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14.1, 4.7 Hz, 1H), 3.36 (dt, J = 8.0, 1.6 Hz, 1H), 3.22 (dt, J = 12.0, 2.5 Hz, 1H), 3.10 – 
2.93 (m, 1H), 2.62 – 2.49 (m, 2H), 2.31 (s, 3H), 2.20 – 2.06 (m, 1H); 13C NMR (100 
MHz, CDCl3) δ 167.7, [signals for 4 carbons adjacent to fluorines: 150.7, 150.6, 150.5, 
150.4, 149.2, 149.1, 148.3, 148.1, 148.1, 148.0, 146.7, 146.6], 134.3, 131.8 (dd, J = 6.0, 
3.7 Hz), 131.5, 131.1 (dd, J = 5.8, 3.8 Hz), 130.6 (dd, J = 5.4, 3.9 Hz), 127.7 (t, J = 3.9 
Hz), 123.6, 117.7, 117.3 (d, J = 16.5 Hz), 116.6 (d, J = 17.1 Hz, 2 carbons), 116.3 (d, J = 
18.1 Hz), 62.2, 60.5, 60.5, 57.3, 55.3, 43.9, 41.6, 32.8, 25.3; 19F NMR (282 MHz, cdcl3) δ 
–139.13 (dd, J = 20.0, 9.9 Hz), –139.49 (dt, J = 19.6, 9.4 Hz), –139.84 – –140.56 (m), –
141.13 – –142.10 (m); HRMS (MM:ESI-APCI+) m/z calc’d for C30H23F4N4O2 [M+H]+: 
547.1752, found 547.1740. 
	
N-methyl tetrafluorinated bis-THIQ 159: Prepared according to General Procedure 6 
using pentacycle 130 as the starting material (11.5 mg, 0.027 mmol). The crude product 
of 159 was obtained as a colorless solid (11.4 mg, 96% yield) and 1H NMR indicated 
>95% purity; 1H NMR (400 MHz, CDCl3) δ 7.02 (dt, J = 10.1, 7.4 Hz, 2H), 6.33 (s, 1H), 
5.32 (t, J = 5.5 Hz, 1H), 4.01 (dt, J = 12.4, 3.0 Hz, 1H), 3.84 (s, 3H), 3.79 (dd, J = 6.5, 
1.5 Hz, 2H), 3.69 (s, 3H), 3.33 (dd, J = 11.1, 5.0 Hz, 1H), 3.27 (dd, J = 11.1, 6.0 Hz, 1H), 
3.13 (dd, J = 17.8, 6.7 Hz, 1H), 2.96 – 2.84 (m, 1H), 2.73 (dd, J = 14.7, 2.7 Hz, 1H), 2.61 
(t, J = 13.5 Hz, 1H), 2.46 (s, 3H), 2.14 (s, 3H); 19F NMR (282 MHz, CDCl3) δ –139.12 






























Difluorinated monochlorinated bis-THIQ 160: bis-THIQ 159 (5.9 mg, 0.013 mmol, 
1.0 equiv) was dissolved in HFIP (0.65 mL, 0.02 M) and the solution was cooled to 0 ºC. 
N-Chlorosaccharine (3.0 mg, 0.014 mmol, 1.05 equiv) was added, after which the cloudy 
white mixture turned yellow and became homogeneous. After complete addition, the 
LCMS showed complete consumption of 159, so the reaction was quenched by the 
addition of saturated aqueous Na2S2O3. The resulting mixture was transferred to a 
separatory funnel and diluted with CH2Cl2 and water, creating a triphasic system with 
HFIP on the bottom, CH2Cl2 in the middle, and the aqueous phase on top. The bottom 
two phases were collected. The aqueous phase was basified with saturated aqueous 
K2CO3 solution and extracted with CH2Cl2. The organic phases were combined, 
concentrated, and azeotropically dried twice with benzene to afford the crude material 
with >95% purity as a yellow solid (6.0 mg, 94% yield); 1H NMR (500 MHz, CDCl3) δ 
7.01 (ddd, J = 10.4, 7.6, 4.3 Hz, 2H), 5.37 (t, J = 5.9 Hz, 1H), 4.44 (d, J = 3.7 Hz, 1H), 
4.35 (br s, 1H, OH), 4.09 (dt, J = 12.7, 3.0 Hz, 1H), 3.82 (s, 3H), 3.76 (d, J = 6.8 Hz, 1H), 
3.71 (s, 3H), 3.43 – 3.19 (m, 3H), 3.12 (dd, J = 18.1, 6.9 Hz, 1H), 2.96 (d, J = 18.1 Hz, 
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A8.4.2.7 Preparation of PMB-protected bis-isoquinoline 
 
2-bromo-3-hydroxy-5-methoxy-4-methylbenzaldehyde (173): Aldehyde 17219 (3.97 g, 
23.9 mmol, 1.00 equiv) was dissolved in CH2Cl2 (48 mL, 0.5 M), and acetic acid (14 µL, 
0.24 mmol, 0.01 equiv) was added. The solution was cooled to 0 ºC before bromine (1.35 
mL, 26.3 mmol, 1.10 equiv) was added in a slow, dropwise fashion. The solution was 
stirred 30 min after complete addition at 0 ºC, at which time TLC (20% EtOAc/hex) 
showed complete consumption of starting material 172. The reaction was quenched by 
the addition of saturated aqueous sodium thiosulfate and saturated NaHCO3 solution. The 
layers were separated and the aqueous phase was extracted with CH2Cl2 and EtOAc. The 
combined organic phases were washed with water, dried over MgSO4 and concentrated. 
The crude residue (brown solid, 5.17 mg, 88% yield) was sufficiently pure by 1H NMR 
and was used in the subsequent step without further purification; 1H NMR (500 MHz, 
CDCl3) δ 10.24 (s, 1H), 7.08 (s, 1H), 5.88 (s, 1H), 3.88 (s, 3H), 2.25 (s, 3H). 
 
2-bromo-5-methoxy-3-((4-methoxybenzyl)oxy)-4-methylbenzaldehyde (174): To a 
solution of alcohol 173 (245 mg, 1.0 mmol, 1.0 equiv) in DMF (5 mL, 0.2 M) was added 
4-methoxybencyl chloride (PMBCl, 0.15 ml, 1.1 mmol, 1.1 equiv)  and K2CO3 (166 mg, 
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ambient temperature, and quenched with ice and water. The layers were separated, and 
the aqueous phase was extracted with EtOAc. The combined organic phases were washed 
with brine, dried over Na2SO4, and concentrated. The crude residue was purified by 
column chromatography (10% EtOAc/hexanes) to furnish PMB-protected alcohol 174 as 
a white solid (298 mg, 82% yield); 1H NMR (400 MHz, CDCl3) δ 10.37 (s, 1H), 7.47 (d, 
J = 8.6 Hz, 2H), 7.25 (s, 1H), 6.94 (d, J = 8.7 Hz, 2H), 4.87 (s, 2H), 3.88 (s, 3H), 3.84 (s, 
3H), 2.23 (s, 3H). 
 
Oxime 175: Bromide 174 (5.73 g, 15.69 mmol, 1 equiv), (PPh3)2PdCl2 (550 mg, 0.784 
mmol, 0.05 equiv), and CuI (149 mg, 0.784 mmol, 0.05 equiv) were slurried in 
diisopropylamine (60 mL, 0.25 M, freshly distilled from CaH2), and the yellow 
suspension was sparged with N2 for 10 min. O-tert-butyldimethylsilyl propargyl alcohol20 
(87, 3.61 g, 21.18 mmol, 4.35 equiv) was added in one portion, causing the suspension to 
darken. The suspension was sparged with N2 for a further 1 min, then heated to 70 ºC for 
24 h. At this stage, TLC and LCMS indicated complete consumption of bromide 86, so 
the brown suspension was cooled to 50 ºC and 40 mL of distilled MeOH was added. 
Hydroxylamine hydrochloride (1.31 g, 18.85 mmol, 1.2 equiv) was added in one portion 
and the solution was heated to reflux (85 ºC). After 2 h, TLC and LCMS indicated 
complete consumption of the intermediate aldehyde. The solution was cooled to room 









(PPh3)2PdCl2 (5 mol %)
CuI (5 mol %), i-Pr2NH
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celite, topped with sand, eluting with ethyl acetate. The filtrate was concentrated and 
purified by column chromatography (20–25–50–100% EtOAc/hexanes) to afford 175 as a 
brown solid (5.19 g, 70% yield); 1H NMR (300 MHz, CDCl3) δ 8.64 (s, 1H), 7.42 (d, J = 
8.7 Hz, 2H), 7.12 (s, 1H), 6.90 (d, J = 8.7 Hz, 2H), 4.96 (s, 2H), 4.61 (s, 2H), 3.85 (s, 
3H), 3.82 (s, 3H), 2.07 (s, 3H), 0.93 (s, 9H), 0.15 (s, 6H).	
 
Isoquinoline N-oxide 164: Oxime 175 (5.19 g, 11.05 mmol, 1 equiv) was dissolved in 
CH2Cl2 (110 mL, 0.1 M) and the flask was vacuum purged and refilled with nitrogen five 
times, then heated to reflux. AgOTf (57 mg, 0.22 mmol, 0.02 equiv) was added in one 
portion to the refluxing solution, resulting in a rapid and mildly exothermic reaction. The 
reaction flask was shielded from light and maintained at reflux for 15 min, at which time 
TLC indicated partial conversion to the product. No significant change was observed 
after another 25 minutes at reflux, so additional AgOTf (57 mg, 0.22 mmol, 0.0 equiv) 
was added to the reaction. After 15 minutes, complete consumption of the oxime was 
observed by LCMS, so the solution was filtered through a pad of silica with CH2Cl2 and 
5–10% MeOH/EtOAc + 1% Et3N. The crude residue was purified by column 
chromatography (50–100% EtOAc/hexanes + 1% Et3N; then 5–10–20% MeOH/EtOAc + 
1% NEt3) to  afford N-oxide 164 as a colorless solid (3.43 g, 66% yield); 1H NMR (300 
MHz, CDCl3) δ 8.69 (s, 1H), 8.09 (s, 1H), 7.41 (d, J = 8.5 Hz, 2H), 6.93 (d, J = 8.7 Hz, 
2H), 6.76 (s, 1H), 5.03 (s, 2H), 4.91 (s, 2H), 3.95 (s, 3H), 3.84 (s, 3H), 2.27 (s, 3H), 0.97 






















Difluorinated PMB bis-IQ N-oxide 165: Prepared according to General Procedure 1 
using isoquinoline triflate 133 (424 mg, 1.295 mmol) and isoquinoline N-oxide 164 (1.83 
g, 3.886 mmol). Reaction completed after 17 hours. The crude material was purified by 
column chromatography (30–50–100% EtOAc/hex + 1% Et3N, then 10–20% 
MeOH/EtOAc + 1% Et3N) to afford bis-isoquinoline 165 as a white solid (388 mg, 60% 
yield). This isolated product is ca. 90% pure by NMR; 1H NMR (400 MHz, CDCl3) δ 
8.23 (s, 1H), 8.01 – 7.91 (m, 2H), 7.63 (dd, J = 10.2, 7.8 Hz, 1H), 7.45 (d, J = 8.7 Hz, 
2H), 6.95 (d, J = 8.7 Hz, 2H), 6.51 (s, 1H), 5.06 (d, J = 1.2 Hz, 2H), 4.93 (s, 2H), 3.85 (s, 
3H), 3.66 (s, 3H), 3.01 (s, 3H), 2.26 (s, 3H), 0.98 (s, 9H), 0.17 (s, 6H). 
 
Difluorinated PMB bis-IQ 176: Prepared according to General Procedure 2 using N-
oxide 165 (388 mg, 0.60 mmol) as the starting material. Reaction stalled after 1 h, so 
additional PCl3 (0.1 mL, 1.2 mmol, 2.0 equiv) was added  and stirred at 0 °C for another 
30 minutes. The crude material was purified by column chromatography (10% 
EtOAc/hex + 1% Et3N) to afford bis-isoquinoline 176 as a white solid (218 mg, 57% 
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(s, 1H), 7.67 (dd, J = 10.2, 7.9 Hz, 1H), 7.49 (d, J = 8.6 Hz, 2H), 6.96 (d, J = 8.6 Hz, 2H), 
5.09 (s, 2H), 4.94 (s, 2H), 3.86 (s, 3H), 3.85 (s, 3H), 3.04 (s, 3H), 2.32 (s, 3H), 1.00 (s, 
9H), 0.18 (s, 6H). Note: The reaction profile was very clean according to TLC and 
LCMS, but low yield was obtained as a result of poor mass recovery after column 
purification. This is consistent with what was observed in previous deoxygenation 
reactions. 
	
Difluorinated PMB bis-IQ 177: Bis-isoquinoline 176 (218 mg, 0.345 mmol, 1.0 equiv) 
was dissolved in acetic acid (7.0 mL, 0.05 M) and solid potassium fluoride (40.1 mg, 
0.689 mmol, 2.0 equiv) was added in one portion. The solution was stirred for 2 h at 
room temperature, at which point TLC showed complete conversion to the product. The 
reaction mixture was dilute with CH2Cl2, and ice and the solution was stirred vigorously 
as a solution of sodium hydroxide (4.4 g, 0.11 mol, 0.9 equiv relative to 7 mL AcOH) in 
12 mL water was added slowly. The rest of the acetic acid was quenched by the addition 
of saturated aqueous K2CO3. The layers were separated and the aqueous phase was 
extracted with CH2Cl2. The combined organic phases were washed with brine, dried over 
Na2SO4, and concentrated to afford crude 177 as a white solid (208 mg, >99 yield). Crude 
1H NMR (500 MHz, CDCl3) δ 8.25 (d, J = 2.7 Hz, 1H), 7.98 – 7.90 (m, 2H), 7.82 (s, 1H), 
7.76 – 7.67 (m, 1H), 7.44 (d, J = 8.3 Hz, 2H), 6.97 (d, J = 8.0 Hz, 2H), 4.94 (s, 2H), 4.93 
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crude material in the subsequent step without further purification due to its poor 
solubility in organic solvents.	
 
Difluorinated PMB bis-IQ ester 166: To a solution of desilylated bis-isoquinoline 177 
(167 mg, 0.325 mmol, 1.0 equiv) in THF (7.6 mL, 0.04 M) was added MnO2 (988 mg, 
11.4 mmol, 35 equiv), NaCN (18.6 mg, 0.379 mmol, 1.2 equiv), and MeOH (77 µL, 
1.895 mmol, 5.8 equiv). The reaction mixture was stirred for 18 hours at reflux, after 
which time a ca. 1:1 mixture of aldehyde/ester was observed by LCMS. At this stage, 
additional NaCN (18.6 mg, 0.379 mmol, 1.2 equiv) and MeOH (77 µL, 1.895 mmol, 5.8 
equiv) were added, and the reaction mixture was stirred at reflux for another 18 hours. 
The reaction mixture was cooled to room temperature and filtered through celite, rinsing 
with CH2Cl2 and MeOH. The filtrate was concentrated, then redissolved in CH2Cl2, 
washed with water, dried over Na2SO4, and concentrated. The crude residue was purified 
by column chromatography  using a 1:1 mixture of CH2Cl2:EtOAc as the polar solvent 
(30–50% polar solvent/hexanes + 1% NEt3) to provide 166 as a colorless solid (71 mg, 
40% yield). Note: The Rf difference between the aldehyde and the ester is very small. The 
isolated product still contains ca. 10% aldehyde; 1H NMR (500 MHz, CDCl3) δ 8.80 (s, 
1H), 8.34 (s, 1H), 8.02 (s, 1H), 7.94 (dd, J = 10.5, 7.8 Hz, 1H), 7.77 – 7.65 (m, 1H), 7.47 
(d, J = 8.5 Hz, 2H), 6.97 (d, J = 8.5 Hz, 2H), 4.99 (s, 2H), 4.05 (s, 3H), 3.91 (s, 3H), 3.86 





























Difluorinated PMB bis-IQ hydrogenation precursor 167: Prepared according to 
General Procedure 4 using bis-isoquinoline ester 166 (9.3 mg, 0.017 mmol) as the 
starting material. The reduction required only 0.33 mmol of NaBH4. The crude material 
was purified by preparative TLC (50% EtOAC/hexanes) to afford hydrogenation 
precursor 167 as a white solid (5.8 mg, 60% yield over 2 steps); 1H NMR (500 MHz, 
CDCl3) δ 8.81 (s, 1H), 8.46 (s, 1H), 7.88 (s, 1H), 7.84 – 7.64 (m, 2H), 7.47 (d, J = 8.5 Hz, 
2H), 6.98 (d, J = 8.5 Hz, 2H), 5.27 (s, 2H), 5.02 (s, 2H), 4.06 (s, 3H), 3.90 (s, 3H), 3.86 
(s, 3H), 2.36 (s, 3H).  
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Scheme A9.1 Syntheses of isoquinoline N-oxide 132 and isoquinoline triflate 133.  
 
 







































60 ºC, 12 h
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(36% yield) (92% yield)








 1. Pd(PPh3)2Cl2, CuI
i-Pr2NH, 70 °C, 2 h;
2. NH2OH•HCl
NaOAc, MeOH
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[Ir(cod)Cl]2 (10 mol %)
L49 (BTFM-xyliphos)
TBAI, 9:1 PhMe/AcOH
60 to 80 °C
40–50% yield
>20:1 dr, 80% ee
(98% yield)
(85% yield) (56% yield, 2 steps)
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Scheme A9.3 Syntheses of tetrafluorinated analog 126 and its derivatives 157–158.  
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(68% yield)
126: R = OH
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[Ir(cod)Cl]2 (10 mol %)
L49 (21 mol %)
TBAI, 9:1 PhMe/AcOH
60 to 80 °C
49% yield
>20:1 dr, 17% ee
151
Appendix 9 – Synthetic Summary of Appendix 8 
  
483	
Scheme A9.5 Synthetic route toward analog 127.  
 
 



































































































































Pd(OAC)2 (20 mol %)
P(t-Bu)2Me•HBF4 (50 mol %)
CsOPiv, Cs2CO3
PhMe, 130 °C
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Scheme A9.7 Construction of difluorinated bis-THIQ core 131. 
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[Ir(cod)Cl]2 (10 mol %)
L49 (BTFM-xyliphos)
TBAI, 9:1 PhMe/AcOH
60 to 80 °C


































Me 1. C–O coupling
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 Figure A10.6 19F NMR (282 MHz, CDCl3) of compound 132. 
 
Figure A10.5 13C NMR (100 MHz, CDCl3) of compound 132. 
 
 





























































































































































































Figure A10.9 13C NMR (100 MHz, CD2Cl2) of compound 138. 
 
 























































































































Figure A10.13 13C NMR (100 MHz, CDCl3) of compound 139. 
 
Figure A10.12 Infrared spectrum (Thin Film, NaCl) of compound 139. 
 



















































Figure A10.14 19F NMR (282 MHz, CDCl3) of compound 139. 
 
 























































































































Figure A10.16 19F NMR (282 MHz, CDCl3) of compound 140. 
 
 


















































































































Figure A10.19 13C NMR (100 MHz, CDCl3) of compound 141. 
 
Figure A10.18 Infrared spectrum (Thin Film, NaCl) of compound 141. 
 





















































Figure A10.20 19F NMR (282 MHz, CDCl3) of compound 141. 
 
 












































































































































































































































































 Figure A10.25 19F NMR (282 MHz, CDCl3) of compound 146. 
 
Figure A10.24 Infrared spectrum (Thin Film, NaCl) of compound 146. 
 













































































































































 Figure A10.28 13C NMR (100 MHz, CDCl3) of compound 149. 
 
Figure A10.27 Infrared spectrum (Thin Film, NaCl) of compound 149. 
 




















































Figure A10.29 19F NMR (282 MHz, CDCl3) of compound 149. 
 
 



















































































































































Figure A10.31 13C NMR (100 MHz, CDCl3) of compound 151. 
 
 



































































































































































Figure A10.34 13C NMR (100 MHz, CDCl3) of compound 152. 
 
 
























































































































Figure A10.37 19F NMR (282 MHz, CDCl3) of compound 153. 
 
Figure A10.36 13C NMR (100 MHz, CDCl3) of compound 153. 
 
 





























































































































Figure A10.40 19F NMR (282 MHz, CDCl3) of compound 155. 
 
Figure A10.39 13C NMR (100 MHz, CDCl3) of compound 155. 
 
 




































































































































Figure A10.43 13C NMR (100 MHz, CDCl3) of compound 129. 
 
Figure A10.42 Infrared spectrum (Thin Film, NaCl) of compound 129. 
 





















































Figure A10.44 19F NMR (282 MHz, CDCl3) of compound 129. 
 
 







































































































































 Figure A10.47 13C NMR (100 MHz, CDCl3) of compound 130. 
 
Figure A10.46 Infrared spectrum (Thin Film, NaCl) of compound 130. 
 




















































Figure A10.48 19F NMR (282 MHz, CDCl3) of compound 130. 
 
 


















































































































Figure A10.50 13C NMR (100 MHz, CDCl3) of compound 131. 
 
 















































































































Figure A10.53 13C NMR (100 MHz, CDCl3) of compound 156. 
 
Figure A10.52 Infrared spectrum (Thin Film, NaCl) of compound 156. 
 




















































Figure A10.54 19F NMR (282 MHz, CDCl3) of compound 156. 
 
 

















































































































Figure A10.57 13C NMR (100 MHz, CDCl3) of compound 126. 
 
Figure A10.56 Infrared spectrum (Thin Film, NaCl) of compound 126. 
 





















































Figure A10.58 19F NMR (282 MHz, CDCl3) of compound 126. 
 





















































































































 Figure A10.61 19F NMR (100 MHz, CDCl3) of compound 157. 
 
Figure A10.60 13C NMR (100 MHz, CDCl3) of compound 157. 
 
 























































































































Figure A10.64 19F NMR (100 MHz, CDCl3) of compound 158. 
 
Figure A10.63 13C NMR (100 MHz, CDCl3) of compound 158. 
 
 





















































































































Figure A10.66 19F NMR (100 MHz, CDCl3) of compound 159. 
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Iridium-Catalyzed Enantioselective and Diastereoselective 
Hydrogenation of 1,3-Disubstituted Isoquinolines† 
 
 
4.1   INTRODUCTION 
The stereocontrolled synthesis of nitrogen-containing heterocycles remains a 
challenge of great importance, as it provides direct access to chiral compounds that are 
prevalent structural motifs in many biologically active molecules. 1  As a result, the 
asymmetric hydrogenation of various hetero-aromatic compounds has been extensively 
explored as a direct, efficient synthesis of enantiopure cyclic amines.2 Despite recent 
progress made toward the asymmetric hydrogenation of N-heterocycles such as 
 
 
† This research was performed in collaboration with Alexia N. Kim, Dr. Eric Welin, Martin T. Daiger, 
Christian U. Grünanger, Dr. Michael D. Bartberger, and Dr. Scott C. Virgil. Portions of this chapter have 
been reproduced with permission from Kim, A. N.; Ngamnithiporn, A.; Welin, E. R.; Daiger, M. T.; 
Grünanger, C. U.; Bartberger, M. D.; Virgil, S. C.; Stoltz, B. M. ACS Catal. 2020, 10, 3241–3248 ã 2020 
American Chemical Society. 
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quinolines, quinoxalines, and pyridines, the synthesis of 1,2,3,4-tetrahydroisoquinolines 
(THIQs) from isoquinolines remains significantly under-developed (Figure 4.1A).2 This 
is due in part to the stronger basicity and coordinating ability of the THIQ products 
compared to those of other heterocycles (e.g., quinolines), leading to catalyst deactivation, 
as well as the overall lower reactivity of isoquinoline substrates. 3  Although a few 
effective strategies toward the asymmetric hydrogenation of substituted isoquinolines 
have been reported, these typically require preparation of the isoquinolinium salt, 
substrate activation with halogenides, and harsher hydrogenation reaction conditions 
(Figure 4.1B).4  Furthermore, previous to our research, there were only two catalytic 
systems describing efficient methods to access chiral 1,3-disubstituted tetrahydro 
isoquinolines,4c,e,g a more complex and sterically challenging system that generates two 
stereogenic centers. In addition, the limited substrate scope from these reports 
demonstrates the low tolerance of additional Lewis basic functionalities, such as alcohols 
or heteroaryl-substituted isoquinolines, which limit the applicability of these 
methodologies in synthesis. Since 1,3-disubstituted tetrahydroisoquinolines with Lewis 
basic moieties are ubiquitous motifs present in a wide range of natural products, such as 
the saframycin, naphthyridinomycin, and quinocarcin families,5  a general method for 
highly enantioselective and diastereoselective hydrogenation of neutral disubstituted 
isoquinolines under mild reaction conditions would be a significant advancement toward 
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Figure 4.1 A) Limitations in enantioselective hydrogenation of N-heterocycles. B) Previous examples 
of iridium-catalyzed enantioselective and diastereoselective hydrogenation of mono- and di-
substituted isoquinolines. 
 
Recently, our group has successfully completed the total synthesis of jorumycin 
(77) and jorunnamycin A (79), two bis-tetrahydroisoquinoline natural products that 
exhibit potent antiproliferative activity, as well as strong Gram-positive and Gram-
negative antibiotic character (see Chapter 3).6 Through an unprecedented, nonbiomimetic 
synthetic route, we were successful in harnessing catalysis to allow expedient access to 
these natural products, as well as a diverse range of non-natural analogs that are 
otherwise inaccessible using prior biomimetic synthetic approaches. One of the key steps  
a) Substrate Activation via Isoquinolinium Salts
• 4 reports with only 1 report describing 1,3-disubstituted isoquinolines
• Requires prior formation of the salt for activation













b) in situ and Transient Activation
• 3 reports with only 1 report describing 1,3-disubstituted isoquinolines
• Requires high temperature & pressure
















B. Prior Art in Ir-Catalyzed Asymmetric Hydrogenation of Isoquinolines:





>50 reports >20 reports >20 reports <10 reports
R1, R2 = alkyl, aryl
R1, R2 = alkyl, aryl
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Figure 4.2 Our research on iridium-catalyzed enantioselective and diastereoselective hydrogenation 
of 1,3-disubstituted isoquinolines. 
 
of this synthesis involves a catalytic enantioselective hydrogenation of bis-isoquinoline 
83 to afford the THIQ motif, a crucial intermediate that forms the pentacyclic carbon 
skeleton 81 in one step by further hydrogenation of the second isoquinoline and eventual 
amide ring closure (Figure 4.2). Considering the ubiquity of the hydroxymethyl group at 
the C1 position, and the amino alcohol functionality in a large number of natural 
products, we envision that this synthetic method could access a wide variety of THIQs as 
well as chiral amino alcohols, both highly valuable pharmacophores. Following the 
N











CO2Me H2 (60 bar), TBAI
60 °C, 18 h













• No need for prior activation
• Mild reaction conditions











Jorumycin Synthesis: A Key Enantioselective Hydrogenation Step
X X
























• 30 examples of 1,3-disubstituted isoquinolines
• General method for a variety of substitution patterns
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successful development of our asymmetric hydrogenation technology for bis-
isoquinolines, herein we disclose a mild, general method for the enantioselective and 
diastereoselective hydrogenation of 1,3-disubstituted isoquinolines. 
 
4.2   SUBSTRATE SYNTHESES 
Due to a limited number of methods for the syntheses of 1,3-disubstituted 
isoquinolines,7 we first established a simple and divergent sequence to access a wide 
variety of 1 (hydroxymethyl)-3-arylisoquinoline substrates (i.e., 182, Scheme 4.1). 
Utilizing Pd-catalyzed arylation of ester enolates reported by Donohoe and coworkers,8 
monoarylated tert-butyl acetate 179 was isolated in an excellent 92% yield. Cyclization 
to isoquinoline triflate 180 was then achieved via hydrolysis of the ketal, followed by 
isoquinoline annulation with aqueous ammonium hydroxide, and alcohol triflation.9 At 
this stage, different aryl or heteroaryl groups could be coupled with intermediate 180 
using Suzuki coupling conditions to deliver a wide range of 1,3-disubstituted 
isoquinolines (i.e., 181), highlighting the divergency of our synthetic route. Finally, SeO2 
oxidation to the aldehyde and subsequent NaBH4 reduction provided our desired 
isoquinoline starting materials 182a–r. It is worth noting that this sequence allows for an 
introduction of various aryl and heteroaryl groups at the C3-position of isoquinolines, as 
well as different substituents with varied electronics on the isoquinoline carbocycle (e.g., 
184a–f, vide infra, Scheme 4.4). Currently in the literature, the 1,3-disubstituted 
isoquinoline motif is typically accessed via transition-metal-catalyzed tandem C–H 
activation/annulation of arenes with alkynes.10 These methods have shown limited 
success in producing C3-heteroaryl isoquinolines.11 
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Scheme 4.1 Syntheses of 1-(hydroxymethyl)-3-aryl isoquinoline substrates. 
 
 
4.3   REACTION OPTIMIZATION 
With a divergent sequence to access 1,3-disubstituted isoquinolines, we began our 
hydrogenation studies with 1-(hydroxymethyl)-3-phenylisoquinoline (182a) as our model 
substrate, using slightly modified conditions from our previously reported hydrogenation 
on the bis-isoquinoline system (Table 4.1). An initial experiment, employing 1.25 mol % 
[Ir(cod)Cl]2 and 3 mol % of the BTFM-xyliphos ligand (L1), gave high conversion of the  
substrate but surprisingly modest enantioselectivity (49% ee, entry 1). Seeking to 
improve the ee, we surveyed a wide variety of chiral ligand scaffolds (see Table 4.2, 
Section 4.7.3) and found the xyliphos ligand framework to be optimal. By exploring 
different electronics of this ligand scaffold, we observed that replacing the 3,5 
bistrifluoromethylphenyl (BTFM) with more electron-rich aryl groups provided the 
product with both excellent conversion and higher enantio-selectivity (entries 1–5). 
Ligand L57, which features 4-methoxy-3,5-dimethylphenyl (DMM) substituted 



































4:1 CH2Cl2/MeOH, 23 °C
(75–97% yield)
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diastereoselectivity (entry 5). Interestingly, a background reaction was observed in the 
absence of the chiral ligand, providing the product in excellent conversion and 
diastereoselectivity (entry 6). From this finding, we obtained all racemic hydrogenated 
products by simply performing the hydrogenation in the absence of ligand, affording the 
cis-product as a single diastereomer. 
Table 4.1 Optimization of the enantioselective hydrogenation of isoquinolines to afford THIQs.a 
 
[a] Reactions conditions: 0.04 mmol of 182a, 1.25 mol % [Ir(cod)Cl]2, 3 mol % ligand, 7.5 mol % TBAI, 60 bar H2 in 2.0 mL 
9:1 solvent:AcOH. [b] Determined from crude 1H NMR using 1,3,5-trimethoxybenzene as a standard. [c] Determined by 
chiral SFC analysis of Cbz-protected product. [d] Opposite enantiomer of ligand used. [e] Reaction performed on a 0.2 mmol 
scale at 23 °C, 20 bar H2, and 0.1 M concentration of 182a. 
 
Investigation of different solvents with L57 as the optimal ligand reveals that 




[Ir(cod)Cl]2 (1.25 mol %)
ligand (3 mol %)
H2 (60 bar), TBAI (7.5 mol %)
solvent (0.02 M)








entry solvent cis:transbligand % conversionb % ee of cisc
1 L49 >95 –49dPhMe:AcOH
2 L48 >95 84PhMe:AcOH
3 L53 66 63PhMe:AcOH
4 L59 92 3PhMe:AcOH
5 L57 >95 89PhMe:AcOH
6 – >95 0PhMe:AcOH
7 L57 >95 84CH2Cl2:AcOH
8 L57 66 87dioxane:AcOH
9 L57 >95 90THF:AcOH











11 L57 >95 902-MeTHF:AcOH 9.5:1
L49: Ar = BTFMd
L48: Ar = Ph
L53: Ar = 1-naphthyl
L59: Ar = furyl
L57: Ar = DMM
182a 183a
12e L57 >95 92THF:AcOH 15.7:1
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diastereoselectivity could be improved with the use of ethereal solvents (entries 8–11).  
Although bulkier ethereal solvents proved to worsen conversion (entries 8 and 10), we 
were delighted to find that THF and the more sustainable solvent 2-MeTHF delivered the 
product in excellent conversion with high levels of diastereoselectivity and 
enantioselectivity (entries 9 and 11). The absence of AcOH resulted in low conversion,12 
while further exploration of different additives (e.g., LiI, NaI, KI, etc.) demonstrated that 
TBAI is the optimal additive (see Table 4.3, Section 4.7.3). Finally, we were excited to 
observe that lowering the temperature to 23 °C and H2 pressure to 20 bar maintained 
excellent levels of conversion, diastereo-selectivity, and enantioselectivity (entry 12). To 
the best of our knowledge, these are the mildest reaction conditions reported for 
isoquinoline hydrogenation to afford chiral THIQs to date.4 
 
4.4   SUBSTRATE SCOPE 
With optimized reaction conditions identified, we explored the general substrate 
scope for this transformation (Scheme 4.2). Gratifyingly, a wide variety of aryl 
substituents at the 3-position of the isoquinoline are well tolerated under the mild reaction 
conditions of 20 bar H2 at ambient temperature. Substitution at the para-position of the 3-
aryl ring delivered the hydrogenated products 183a–g in consistently high yields and 
enantioselectivity. Electron-rich substrates such as the 3-(p-tert-butylphenyl)isoquinoline 
(182b) and the p-methoxyphenyl (182d) afforded chiral THIQs with excellent yields, 
diastereoselectivity, and enantioselectivity, similarly to 182a. Interestingly, however, a 
general trend of lower diastereoselectivity was observed with electron-withdrawing 
substituents both at the para- and meta- positions (182f–i). We envision that the observed 
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lower diastereoselectivity arises from the weaker coordinating ability of the nitrogen to 
the iridium catalyst in electron-poor substrates, discouraging coordination to the catalyst 
in a bidentate fashion,13 and thus resulting in poorer facial selectivity in the second 
hydride addition step. However, at this time, we still cannot rule out the possibility that 
epimerization in situ also influences the trend seen in diastereoselectivity.14 Investigation 
of steric effects revealed that more sterically encumbered isoquinolines such as the 3-
napthyl and 3-xylyl substrates furnished the products (183j–k) in excellent isolated yields 
with similarly high enantioselectivity (95% and 92% ee, respectively) as a single 
diastereomer. The most sterically demanding substrate 182m, bearing an ortho-tolyl 
substituent, provided product 183m in a modest 64% yield with lower enantioselectivity 
(49% ee), albeit still with a high 10.1:1 diastereoselectivity. Additionally, we were 
pleased to find that the nitrile and nitro functional groups as well as the naphthyl 
substituent were not reduced (183g, 183h, and 183j), highlighting the chemoselectivity of 
this catalytic process. 
Pleased to find the reaction tolerable to a range of 3-aryl substituted isoquinolines, 
we sought to further extend the scope of the transformation by exploring heteroaryl-
substituted isoquinolines (Scheme 4.3). Although performing the hydrogenation at 23 °C 
and 20 bar H2 resulted in lower conversion, partially due to solubility issues, we found 
that heterocyclic substituents including furan, thiophene, pyrazole, and pyridine were 
well tolerated at 60 °C and under higher pressure of 60 bar H2, producing THIQs 183n–r. 
We also observed that the substitution pattern on the heteroaryl groups strongly affects 
the reaction conversion. For instance, an isoquinoline with a 3-substituted thiophene 
proceeded with a significantly lower conversion than the 2-thiophene substrate (183o and 
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Scheme 4.2 Substrate scope of different aryl substituents.a 
 
[a] Reactions performed on a 0.2 mmol scale. [b] Reaction performed at 60 °C and 60 bar H2. [c] CH2Cl2 cosolvent used to 
improve substrate solubility. 
 
183p). Similarly, no conversion was observed with 3- and 4-pyridyl substrates, whereas 
2-pyridyl THIQ 183r was isolated in 48% yield under the same reaction conditions. We 
speculate that this may be due to the competitive binding of the catalyst by the more 
distal heteroatom of 3- and 4-substituted heterocycles that inhibits directed hydrogenation 






Ar[Ir(cod)Cl]2 (1.25 mol %)
L57 (3 mol %)
H2 (20 bar), TBAI (7.5 mol %)
9:1 THF:AcOH (0.1 M)












>20:1 dr, 92% ee
183j
87% yield























183a 95H 15.7:1 92
183b 87t-Bu 13.3:1 91
183c 79Ph 9.0:1 92
183d 75OMe 13.3:1 92
183e 99F 10.1:1 93
183f 81CF3 4.6:1 92





10.1:1 dr, 49% ee
Me
98% yield
>20:1 dr, 88% ee
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crystal structure to confirm the relative and absolute stereochemistry of our 
hydrogenation product. 
Scheme 4.3 Substrate scope of heteroaryl substituents.a 
 
 
[a] Reactions performed on a 0.2 mmol scale. 
 
Furthermore, we were interested in exploring the substrate scope of isoquinolines 
with different electronics and substitution patterns on the isoquinoline carbocycle 
(Scheme 4.4). Electron-poor fluorinated isoquinolines with varied electronics at the 3-
position provided THIQs in high yields (77–94%) with high diastereoselectivity and 
enantioselectivity under our standard conditions (185a–c). It should be noted that these 
electron-poor THIQs would be difficult to access utilizing electrophilic aromatic 






Het[Ir(cod)Cl]2 (1.25 mol %)
L57 (3 mol %)
H2 (60 bar), TBAI (7.5 mol %)
9:1 THF:AcOH (0.1 M)
















7.3:1 dr, 89% ee
183n
74% yield
3.0:1 dr, 92% ee
183o
94% yield








2.5:1 dr, 85% ee
183q
98% yield
2.9:1 dr, 87% ee X-ray of 183p
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the electron-rich dioxolane-appended isoquinolines (184d–e) afforded lowered 
conversion under the same reaction conditions, due in part to the poor solubility of the 
substrates in THF. Nevertheless, executing the reaction at 60 °C and 60 bar H2 with 
CH2Cl2 as cosolvent improved the solubility and conversion to yield products 185d–e 
with high diastereoselectivity.15 Interestingly, we observed significantly lower 
enantioselectivity for the dioxolane THIQs, which is observed in other reports as well.4a,g 
Finally, the naphthyl-fused THIQ (185f) was obtained with high diastereoselectivity and 
enantioselectivity, despite its extended aromatic system and larger steric hindrance. 
Although we observed modest conversion for these highly decorated isoquinolines, we 
were pleased to see that we were able to isolate unreacted starting material after column 
chromatography to obtain 80%, 99%, and 79% yield, respectively, of 185d–f based on 
recovered starting material. Consistent with our results for THIQs 183j and 183r, only 
the ring with the least degree of aromatic stabilization was reduced for 185f. 
Having demonstrated that this transformation is general for a wide variety of 1,3-
disubstituted isoquinolines, we then turned our attention to investigate the effects of 
different “directing” groups at the C1-position (Scheme 4.5). Isoquinolines bearing other 
polar groups such as an ester (186a), ethers (186b–c), and a Boc-protected amine (186d) 
delivered the products in lower yields than the hydroxy-directed substrate at 23 °C and 20 
bar H2. However, to our delight, by increasing the temperature and H2 pressure, these 
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Scheme 4.4 Substrate scope of IQ backbone substituents.a 
 
[a] Reactions performed on a 0.2 mmol scale. [b] Reaction performed at 60 °C and 60 bar H2. [c] CH2Cl2 cosolvent used to 
improve substrate solubility. 
 
Additionally, we found that aldehyde 186f was reduced to the alcohol in situ, 
affording the hydroxymethyl THIQ 187a in comparable yield, enantioselectivity, and 
diastereoselectivity to that of the hydroxy-directing substrate 183a (vide supra).  
Interestingly, an isoquinoline lacking a potential directing group (187e) also afforded 
chiral THIQs with no erosion of enantioselectivity (90% ee),16 although elevated 
temperature and pressure are needed to obtain a synthetically useful yield (64%). While 
the hydroxy-directing aspect is the enabling feature in the context of our total synthesis of 
jorumycin, we are pleased to find that we can obviate this requirement in our developed 






Ar[Ir(cod)Cl]2 (1.25 mol %)
L57 (3 mol %)
H2 (20 bar), TBAI (7.5 mol %)
9:1 THF:AcOH (0.1 M)





















>20:1 dr, 90% ee
185c
77% yield
6.7:1 dr, 94% ee
185a
94% yield











4.9:1 dr, 58% ee
41% yield
>20:1 dr, 54% ee
43% yield
15.7:1 dr, 82% ee
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demonstrates the importance of a functional group for directed hydrogenation, with the 
hydroxy functionality acting as the best directing group for mild and efficient asymmetric 
hydrogenation. Notably, this is the first asymmetric hydrogenation method of 
isoquinolines in which additional Lewis basic functionalities are tolerated. It is also the 
first report investigating the effects of different directing groups in enantioselective 
hydrogenation of isoquinolines. 
Scheme 4.5 Substrate scope of different directing groups.a 
 
[a] Reactions performed on a 0.2 mmol scale. [b] Reaction performed at 60 °C and 60 bar H2. [c] Relative and absolute 
stereochemistry determined by experimental and computed VCD and optical rotation, see Supporting Information.16 
 
4.5  SYNTHETIC UTILITY 
Overall, the broad application of our hydrogenation technology to afford chiral 


















Ph[Ir(cod)Cl]2 (1.25 mol %)
L57 (3 mol %)
H2 (20 bar), TBAI (7.5 mol %)
9:1 THF:AcOH (0.1 M)
23 °C, 18 h
186a–f 187a–e
81% yield
19:1 dr, 92% ee
80% yield




>20:1 dr, 88% ee
71% yield
9.0:1 dr, 90% ee
56% yield
>20:1 dr, 86% ee
187a
187e b,c
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biomimetic approaches (e.g., Pictet-Spengler, Bischler-Napieralski). These often require 
electron-rich substrates to undergo cyclization (eq 1).17 
 
With the scope of the transformation established, we sought to demonstrate the 
synthetic utility of the produced chiral THIQs toward more complex scaffolds that could 
be applicable to natural products. Additionally, we envisioned taking advantage of the 
chiral β-amino alcohol that is generated in our product as a building block to forge more 
complex enantioenriched heterocyclic scaffolds (Scheme 4.6).18 
Scheme 4.6 Derivatization of a hydrogenated product. 
 
Prior to our investigation into the synthetic utilitiy of THIQ products, we 
performed the hydrogenation of isoquinoline 182l on a larger scale (1 mmol). We were 
pleased to find that the hydrogenated product 183l was still obtained in good yield (91% 
isolated yield) with excellent selectivity (>20:1 dr, 88% ee). With an ample amount of 








R2R = electron-donating substituents
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the tricyclic 1,2-fused oxazolidine THIQ 188 was formed rapidly via the cyclization of 
the alcohol onto the iminium generated in situ. Furthermore, the reaction of amino 
alcohol 183l with carbonyldiimidazole (CDI) afforded oxazolidinone-fused THIQ 189 in 
84% yield.19 To our delight, we found that these 6,6,5-tricyclic systems are conserved 
structural motifs in a number of natural products such as quinocarcin, tetrazomine, and 
bioxalomycin.5 Lastly, a different tricyclic scaffold containing fused morpholinone (190) 
can be isolated in 41%  yield by the addition of excess glyoxal to 183l at room 
temperature.20 Being able to access a variety of complex heterocyclic scaffolds in one step 
from our hydrogenated THIQs further highlights the advantages of the hydroxymethyl 
functionality at the C1 position, beyond directing hydrogenation. 
In addition to the tricyclic scaffold, we were pleased to find that an analog of 
tetrahydroprotoberberine alkaloids, a family of natural products with a tetracyclic bis-
THIQ core,21 can be synthesized via a 2-step sequence. First, reaction of 183l with 
glyoxal dimethyl acetal delivered the oxazolidine-fused intermediate with a dimethoxy 
acetal substituent at the carbinol-amine carbon. Subsequently, exploration of both 
Brønsted and Lewis acid-mediated Pomeranz-Fritsch reaction revealed that the use of 
Eaton’s reagent22 delivered pentacyclic THIQ 191 in 38% yield as a single diastereomer. 
This complex scaffold could be of medicinal interest, as previous studies have shown that 
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4.6  CONCLUSIONS 
We have developed a general, efficient enantioselective hydrogenation reaction of 
1,3-disubstituted isoquinolines toward the syntheses of chiral THIQs. Key to the success 
of this reaction is the installation of a directing group at the C1-position that facilitates 
hydrogenation to reduce a variety of isoquinolines under mild reaction conditions. The  
developed m ethod affords chiral T H IQ s in  good yields, w ith  high levels of 
diastereoselectivity and enantioselectivity. The reaction conditions tolerate a wide range 
of substitution on the 1-, 3-, 6-, 7-, and 8-position of the isoquinoline core. To date, this 
report represents the broadest scope and highest tolerance of Lewis-basic functionality of 
any asymmetric isoquinoline reduction technology currently known. Furthermore, this 
method is amenable to the production of electron-deficient THIQs that are difficult to 
obtain through the classical Pictet-Spengler approach. In order to demonstrate the  
synthetic utility of the hydrogenated products, we utilize the hydroxyl directing group as 
a functional handle for further synthetic manipulations. As a result, we have completed 
the syntheses of various tricyclic and pentacyclic skeletons that are of potential medicinal 
interest. Further exploration of the mechanism and other applications of this technology 
are currently underway. 
 
4.7  EXPERIMENTAL SECTION 
4.7.1  MATERIALS AND METHODS 
Unless otherwise stated, reactions were performed in flame-dried glassware under 
an argon or nitrogen atmosphere using dry, deoxygenated solvents.24  Solvents were dried 
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by passage through an activated alumina column under argon. Reaction progress was 
monitored by thin-layer chromatography (TLC) or Agilent 1290 UHPLC-MS.  TLC was 
performed using E. Merck silica gel 60 F254 precoated glass plates (0.25 mm) and 
visualized by UV fluorescence quenching, p-anisaldehyde, or KMnO4 staining.  Silicycle 
SiliaFlash® P60 Academic Silica gel (particle size 40–63 nm) was used for flash 
chromatography.  1H NMR spectra were recorded on Bruker 400 MHz or Varian Mercury 
300 MHz spectrometers and are reported relative to residual CHCl3 (δ 7.26 ppm).  13C 
NMR spectra were recorded on Bruker 400 MHz spectrometer (100 MHz) and are 
reported relative to CHCl3 (δ 77.16 ppm). 19F NMR spectra were recorded on Varian 
Mercury 300 MHz spectrometer (282 MHz). Data for 1H NMR are reported as follows: 
chemical shift (δ ppm) (multiplicity, coupling constant (Hz), integration).  Multiplicities 
are reported as follows: s = singlet, d = doublet, t = triplet, q = quartet, p = pentet, sept = 
septuplet, m = multiplet, br s = broad singlet, br d = broad doublet, app = apparent.  Data 
for 13C NMR are reported in terms of chemical shifts (δ ppm).  IR spectra were obtained 
using Perkin Elmer Spectrum BXII spectrometer or Nicolet 6700 FTIR spectrometer 
using thin films deposited on NaCl plates and reported in frequency of absorption (cm–1).  
Optical rotations were measured with a Jasco P-2000 polarimeter operating on the 
sodium D-line (589 nm), using a 100 mm path-length cell and are reported as: [a]DT 
(concentration in 10 mg/1 mL, solvent). Analytical SFC was performed with a Mettler 
SFC supercritical CO2 analytical chromatography system utilizing Chiralpak (AD-H, AS-
H or IC) or Chiralcel (OD-H, OJ-H, or OB-H) columns (4.6 mm x 25 cm) obtained from 
Daicel Chemical Industries, Ltd. High resolution mass spectra (HRMS) were obtained 
from Agilent 6200 Series TOF with an Agilent G1978A Multimode source in 
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electrospray ionization (ESI+), atmospheric pressure chemical ionization (APCI+), or 
mixed ionization mode (MM: ESI-APCI+), or obtained from Caltech mass spectrometry 
laboratory. 
4.7.2  EXPERIMENTAL PROCEDURES AND SPECTROSCOPIC DATA 
4.7.2.1 Syntheses of hydroxymethyl 1,3-disubstituted isoquinolines 
General sequence: 
 
General procedure 1: Enolate alkylation of aryl bromide 
 
 
tert-butyl 2-(2-(2-methyl-1,3-dioxolan-2-yl)phenyl)acetate (179a): This procedure has 
been adapted from a previous report.8 In a Schlenk flask was added P(t-Bu)3•HBF4 (119 


































t-butyl acetate, LiHMDS, 
Pd2(dba)3 (5 mol %)
P(t-Bu)3•HBF4 (10 mol %)
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methyl-1,3-dioxolane (178a) (1.0 g, 4.1 mmol, 0.42 M), and tert-Butyl acetate (0.95 g, 
8.2 mmol), respectively. The reaction mixture was cooled to –78 °C and sparged with 
nitrogen for 15 minutes. A degassed solution of LiHMDS (1.72 g, 10.25 mmol, 1 M in 
toluene) was then added via syringe. The reaction mixture was degassed for an additional 
15 minutes at –78 °C, and allowed to slowly warm to room temperature. The reaction 
was stirred at room temperature for 18 hours, and then quenched with saturated aqueous 
NaHCO3. The aqueous layer was extracted with Et2O twice. The combined organic 
phases were dried over MgSO4, filtered, and the solvent was removed in vacuo. The 
crude product was purified by silica gel flash chromatography (5% EtOAc in hexanes) to 
afford 179a as a yellow oil (1.05 g, 92% yield): 1H NMR (400 MHz, CDCl3) δ 7.53 – 
7.45 (m, 1H), 7.20 – 7.06 (m, 3H), 3.96 – 3.83 (m, 2H), 3.71 (s, 2H), 3.68 – 3.55 (m, 2H), 
1.60 (s, 3H), 1.39 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 171.6, 141.1, 132.6, 132.3, 
128.2, 127.1, 126.4, 109.2, 80.4, 64.3, 40.4, 28.2, 28.2, 27.6; IR (Neat Film, NaCl) 3454, 
3062, 2977, 2936, 2893, 1731, 1484, 1455, 1392, 1368, 1218, 1196, 1168, 1037, 952, 
869, 763, 706 cm-1; HRMS (MM:ESI-APCI+) m/z calc’d for C16H23O4 [M+H]+: 
279.1591, found 279.1589. 
 
tert-butyl 2-(4-fluoro-2-(2-methyl-1,3-dioxolan-2-yl)phenyl)acetate (179b): 
Compound 179b was prepared from aryl bromide (2-(2-bromo-5-fluorophenyl)-2-
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chromatography (10% EtOAc in hexanes) to afford 179b with impurities. The compound 
was then subjected to the second column chromatography (15% Et2O in hexanes) to 
obtain 179b as a colorless solid (74 mg, 61% yield); 1H NMR (400 MHz, CDCl3) δ 7.28 
(dd, J = 10.3, 2.8 Hz, 1H), 7.15 (dd, J = 8.4, 5.7 Hz, 1H), 6.94 (td, J = 8.2, 2.9 Hz, 1H), 
4.06 – 3.90 (m, 2H), 3.74 (s, 2H), 3.72 – 3.69 (m, 2H), 1.65 (s, 3H), 1.45 (s, 9H); 13C 
NMR (100 MHz, CDCl3) δ 171.5, 161.9 (d, J = 245.1 Hz), 143.9 (d, J = 6.2 Hz), 134.2 
(d, J = 7.8 Hz), 127.9 (d, J = 3.3 Hz), 114.9 (d, J = 21.1 Hz), 113.5 (d, J = 23.0 Hz), 
108.6, 80.6, 64.4, 39.6, 28.2, 27.3; 19F NMR (282 MHz, CDCl3) δ –115.6 (ddd, J = 10.3, 
8.0, 5.8 Hz); IR (Neat Film, NaCl) 2980, 1732, 1613, 1493, 1412, 1392, 1368, 1340, 
1256, 1200, 1179, 1147, 1037, 947, 878 cm-1; HRMS (MM:ESI-APCI+) m/z calc’d for 
C16H22FO4 [M+H]+: 297.1497, found 297.1494. 
 
tert-butyl 2-(6-(2-methyl-1,3-dioxolan-2-yl)benzo[d][1,3]dioxol-5-yl)acetate (179c): 
Compound 179c was prepared from aryl bromide (5-bromo-6-(2-methyl-1,3-dioxolan-2-
yl)benzo[d][1,3]dioxole)  (178c) using general procedure 1, and purified by column 
chromatography (5% to 15% EtOAc in hexanes) to afford 179c as a pale yellow oil (83.4 
mg, 63% yield): 1H NMR (400 MHz, CDCl3) δ 7.07 (s, 1H), 6.66 (s, 1H), 5.93 (s, 2H), 
3.95 – 3.93 (m, 2H), 3.72 – 3.69 (m, 2H), 3.62 (s, 2H), 1.64 (s, 3H), 1.46 (s, 9H); 13C 
NMR (100 MHz, CDCl3) δ 171.7, 147.2, 146.7, 135.2, 125.9, 112.3, 109.1, 107.0, 101.3, 
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1332, 1259, 1197, 1166, 1142, 1041, 929, 869, 935 cm-1; HRMS (MM:ESI-APCI+) m/z 
calc’d for C17H23O6 [M+H]+: 323.1489, found 323.1501. 
 
tert-butyl 2-(2-(2-methyl-1,3-dioxolan-2-yl)naphthalen-1-yl)acetate (179d): 
Compound 179d was prepared from aryl bromide (2-(1-bromonaphthalen-2-yl)-2-
methyl-1,3-dioxolane) (178d) using general procedure 1, and purified by column 
chromatography (0% to 5% EtOAc in hexanes) to afford 179d as a pale yellow oil (2.15 
g, 98% yield): 1H NMR (400 MHz, CDCl3) δ 7.93 (d, J = 8.0 Hz, 1H), 7.82 (d, J = 8.0 
Hz, 1H), 7.76 (s, 2H), 7.48 (ddd, J = 7.9, 6.7, 1.4 Hz, 2H), 4.38 (s, 2H), 4.04 – 4.00 (m, 
2H), 3.79 – 3.73 (m, 2H), 1.78 (s, 3H), 1.45 (s, 9H);  13C NMR (100 MHz, CDCl3) δ 
171.4, 139.3, 133.6, 128.7, 128.6, 127.8, 126.5, 125.8, 124.3, 124.1, 109.7, 80.7, 64.4, 
36.2, 28.2, 27.8. IR (Neat Film, NaCl) 2980, 2890, 1732, 1454, 1368, 1336, 1142, 1100, 
1037, 951, 884, 870, 822, 750 cm-1; HRMS (MM:ESI-APCI+) m/z calc’d for C20H25O4 
[M+H]+: 329.1747, found 329.1739. 















1. 33% TFA in DCM
23 °C
2. NH4OH, MeCN
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1-methylisoquinolin-3-yl trifluoromethanesulfonate (180a): This procedure has been 
adapted from a previous report.9 In a RBF were added ester 179a (2.78 g, 10.0 mmol), 
anhydrous CH2Cl2 (75 mL, 0.13 M), and TFA (25 mL, 33% volume of CH2Cl2), 
respectively. The reaction was stirred at room temperature for 2 hours, and then 
concentrated in vacuo. The crude was transferred to a Schlenk tube, dissolved in MeCN 
(10 mL, 1 M), and aqueous NH4OH (28–30%, 20 mL, 200% volume of MeCN). The tube 
was sealed with Kontes valve to prevent loss of gaseous ammonia and stirred at 70 °C. 
Within 1 hour, the yellow solid of the 3-hydroxyisoquinoline began to precipitate from 
the reaction solution. After stirring for 18 hours at 70 °C, the reaction was cooled to room 
temperature, then placed in a –20 °C freezer, and the yellow solid was collected via 
vacuum filtration. This yellow powder was then washed with cold MeCN and dried under 
high vacuum to provide 3-hydroxyisoquinoline intermediate (0.70 g, 4.39 mmol). If any 
starting material remains, the filtrate could be transferred to a flask and concentrated in 
vacuo to undergo a second condensation reaction.  
To a separate flame-dried RBF containing CH2Cl2 (22 mL, 0.2 M) and distilled 
pyridine (3.6 mL, 44 mmol), the collected yellow powder (0.70 g, 4.39 mmol) was added, 
and the resulting mixture was cooled to 0 °C. Trifluoromethanesulfonic anhydride (1.5 
mL, 8.8 mmol) was then added dropwise at 0 °C, and the reaction was stirred at 0 °C for 
1 hour. The reaction was then quenched with saturated aqueous NaHCO3 at 0 °C, and 
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over Na2SO4, and concentrated in vacuo. The crude product was purified by column 
chromatography (10% EtOAc in hexanes) to afford 180a as a pale yellow oil (1.11 g, 
38% yield over 3 steps): 1H NMR (400 MHz, CDCl3) δ 8.17 (dd, J = 8.5, 1.0 Hz, 1H), 
7.88 (dt, J = 8.3, 1.0 Hz, 1H), 7.76 (ddd, J = 8.2, 6.9, 1.2 Hz, 1H), 7.67 (ddd, J = 8.3, 6.9, 
1.3 Hz, 1H), 7.42 (s, 1H), 2.97 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 160.3, 151.3, 
138.6, 131.5, 128.1, 127.8, 127.6, 126.1, 118.9 (q, J = 320.5 Hz), 109.0, 22.1; 19F NMR 
(282 MHz, CDCl3) δ –73.0 IR (Neat Film, NaCl) 1624, 1600, 1563, 1422, 1327, 1213, 
1138, 1116, 987, 958, 891, 832, 742, 616 cm-1; HRMS (MM:ESI-APCI+) m/z calc’d for 
C11H9F3NO3S [M+H]+: 292.0250, found 292.0253. 
 
7-fluoro-1-methylisoquinolin-3-yl trifluoromethanesulfonate (180b): Compound 180b 
was prepared from ester 179b using general procedure 2 and purified by column 
chromatography (10% EtOAc in hexanes) to provide a pale brown oil (384 mg, 31% 
yield over 3 steps): 1H NMR (400 MHz, CDCl3) δ 7.90 (dd, J = 9.0, 5.3 Hz, 1H), 7.76 
(dd, J = 9.6, 2.5 Hz, 1H), 7.56 (ddd, J = 8.9, 8.0, 2.5 Hz, 1H), 7.43 (s, 1H), 2.92 (s, 3H); 
13C NMR (100 MHz, CDCl3) δ 161.4 (d, J = 251.1 Hz), 159.4 (d, J = 6.1 Hz), 151.1 (d, J 
= 3.3 Hz), 135.5, 130.3 (d, J = 8.7 Hz), 128.5 (d, J = 8.3 Hz), 122.2 (d, J = 25.6 Hz), 
118.9 (q, J = 320.5 Hz), 109.8 (d, J = 21.8 Hz), 108.9, 22.1; 19F NMR (282 MHz, CDCl3) 
δ –73.0, –109.0 (ddd, J = 9.5, 8.0, 5.4 Hz); IR (Neat Film, NaCl) 1598, 1573, 1516, 1416, 
1209, 1136, 1114, 986, 960, 933, 875, 805, 764 cm-1; HRMS (MM:ESI-APCI+) m/z 
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5-methyl-[1,3]dioxolo[4,5-g]isoquinolin-7-yl trifluoromethanesulfonate (180c): 
Compound 180c was prepared from ester 179c using general procedure 2 and purified by 
column chromatography (10 to 20% EtOAc in hexanes) to provide a white solid (608 mg, 
58% yield over 3 steps): 1H NMR (400 MHz, CDCl3) δ 7.35 (s, 1H), 7.23 (s, 1H), 7.10 (s, 
1H), 6.15 (s, 2H), 2.82 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 156.9, 151.9, 150.9, 
149.2, 137.3, 124.8, 118.8 (q, J = 321.2 Hz), 108.4, 103.3, 102.2, 101.8, 22.2; 19F NMR 
(282 MHz, CDCl3) δ –73.0; IR (Neat Film, NaCl) 2918, 1584, 1504, 1464, 1416, 1223, 
1134, 1038, 964, 940, 873, 840 cm-1; HRMS (MM:ESI-APCI+) m/z calc’d for 
C12H9F3NO5S [M+H]+: 336.0148, found 336.0146. 
 
4-methylbenzo[f]isoquinolin-2-yl trifluoromethanesulfonate (180d): Compound 180d 
was prepared from ester 179d using general procedure 2 and purified by column 
chromatography (5 to 10% EtOAc in hexanes) to provide a white solid (497 mg, 65% 
yield over 3 steps): 1H NMR (400 MHz, CDCl3) δ 8.63 – 8.57 (m, 1H), 8.15 (s, 1H), 8.01 
– 7.95 (m, 2H), 7.90 (d, J = 9.2 Hz, 1H), 7.81 – 7.73 (m, 2H), 3.01 (s, 3H); 13C NMR 
(100 MHz, CDCl3) δ 158.8, 152.5, 138.6, 133.3, 129.6, 129.1, 128.9, 128.6, 127.8, 125.8, 
123.6, 122.2, 118.8 (q, J = 321.2 Hz), 105.1, 22.4; 19F NMR (282 MHz, CDCl3) δ –78.3; 
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HRMS (MM:ESI-APCI+) m/z calc’d for C15H11F3NO3S [M+H]+: 342.0406, found 
342.0399. 
General procedure 3: Suzuki cross-coupling 
 
 
1-methyl-3-phenylisoquinoline (181a): This procedure has been adapted from a 
previous report.25 To a flame-dried 20-mL scintillation vial capped with a PTFE-lined 
septum was added XPhos Pd G3 (11.63 mg, 0.014 mmol) and phenyl boronic acid (126 
mg, 1.03 mmol). The reaction vial was then evacuated and backfilled with N2 three times. 
The isoquinoline triflate 180a (200 mg, 0.687 mmol) in degassed THF (2 mL, 0.3 M) was 
then added to the vial, followed by degassed 0.5 M K3PO4 solution (4 mL, 0.2 M). The 
reaction was then stirred at 40 °C for 2 hours. Afterwards, the reaction was diluted with 
water and the aqueous layer was extracted with Et2O. The combined organic phases were 
dried over Na2SO4, concentrated in vacuo, and purified by column chromatography (5% 
EtOAc in hexanes) to afford 181a as a white solid (138 mg, 92% yield): 1H NMR (400 
MHz, CDCl3) δ 8.15 – 8.13 (m, 3H), 7.93 (s, 1H), 7.86 (dt, J = 8.3, 1.0 Hz, 1H), 7.67 
(ddd, J = 8.2, 6.9, 1.2 Hz, 1H), 7.57 (ddd, J = 8.2, 6.8, 1.3 Hz, 1H), 7.52 – 7.48 (m, 2H), 
7.42 – 7.38 (m, 1H), 3.05 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 158.7, 150.2, 140.0, 










2:1 K3PO4(0.5 M aq):THF
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NaCl) 3060, 1621, 1589, 1571, 1501, 1440, 1390, 1332, 1030, 902, 880, 786, 765, 692 
cm-1; HRMS (MM:ESI-APCI+) m/z calc’d for C16H14N [M+H]+: 220.1121, found 
220.1129. 
 
3-(4-(tert-butyl)phenyl)-1-methylisoquinoline (181b): Compound 181b was prepared 
from triflate 180a using general procedure 3 and purified by column chromatography 
(5% EtOAc in hexanes) to provide a pale yellow oil (177 mg, 93% yield); 1H NMR (400 
MHz, CDCl3) δ 8.12 (d, J = 8.4 Hz, 1H) 8.06 (d, J = 8.5 Hz, 2H), 7.90 (s, 1H), 7.85 (d, J 
= 8.2 Hz, 1H), 7.66 (ddd, J = 8.1, 6.8, 1.2 Hz, 1H), 7.57 – 7.52 (m, 3H), 3.04 (s, 3H), 
1.38 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 158.6, 151.5, 150.3, 137.3, 136.9, 130.1, 
127.7, 126.8, 126.7, 126.6, 125.8, 125.8, 115.0, 34.8, 31.5, 22.8; IR (Neat Film, NaCl) 
2961, 1622, 1591, 1568, 1515, 1442, 1390, 1362, 1333, 1268, 1112, 1017, 837, 754, 743, 
685 cm-1; HRMS (MM:ESI-APCI+) m/z calc’d for C20H22N [M+H]+: 276.1747, found 
276.1749. 
 
3-([1,1'-biphenyl]-4-yl)-1-methylisoquinoline (181c): Compound 181c was prepared 
from triflate 180a using general procedure 3 and purified by column chromatography 
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MHz, CDCl3) δ 8.24 – 8.22 (m, 2H), 8.14 (d, J = 8.4 Hz, 1H), 7.98 (s, 1H), 7.88 (d, J = 
8.1 Hz, 1H), 7.75 – 7.73 (m, 2H), 7.70 – 7.67 (m, 3H), 7.58 (ddd, J = 8.3, 6.9, 1.3 Hz, 
1H), 7.50 – 7.46 (m, 2H), 7.39 – 7.37 (m, 1H), 3.06 (s, 3H); 13C NMR (100 MHz, CDCl3) 
δ 158.8, 149.7, 141.2, 141.0, 138.9, 136.9, 130.2, 128.9, 127.8, 127.6, 127.5, 127.5, 
127.2, 126.9, 126.8, 125.8, 115.2, 22.9; IR (Neat Film, NaCl) 3028, 1621, 1568, 1488, 
1440, 1389, 1334, 842, 766, 730, 696 cm-1; HRMS (MM:ESI-APCI+) m/z calc’d for 
C22H18N [M+H]+: 296.1434, found 296.1426. 
 
3-(4-methoxyphenyl)-1-methylisoquinoline (181d): Compound 181d was prepared 
from triflate 180a using general procedure 3 and purified by column chromatography 
(5% EtOAc in hexanes) to afford a white solid (79 mg, 93% yield): 1H NMR (400 MHz, 
CDCl3) 1H NMR (400 MHz, CDCl3) δ 8.14 – 8.07 (m, 3H), 7.84 (s, 1H), 7.81 (d, J = 8.5, 
1H), 7.64 (ddd, J = 8.2, 6.8, 1.2 Hz, 1H), 7.53 (ddd, J = 8.2, 6.8, 1.3 Hz, 1H), 7.06 – 7.01 
(m, 2H), 3.88 (s, 3H), 3.03 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 160.0, 158.4, 149.8, 
136.9, 132.6, 130.0, 128.2, 127.5, 126.4, 126.3, 125.7, 114.1, 114.1, 55.4, 22.7; IR (Neat 
Film, NaCl) 3060, 2955, 2835, 1608, 1568, 1514, 1439, 1390, 1290, 1249, 1174, 1034, 
833, 751, 730 cm-1; HRMS (MM:ESI-APCI+) m/z calc’d for C17H16NO [M+H]+: 
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3-(4-fluorophenyl)-1-methylisoquinoline (181e): Compound 181e was prepared from 
triflate 180a using general procedure 3 and purified by column chromatography (10% 
EtOAc in hexanes) to provide a white solid (155 mg, 95% yield); 1H NMR (400 MHz, 
CDCl3) δ 8.17 – 8.07 (m, 3H), 7.89 – 7.81 (m, 2H), 7.68 (ddd, J = 8.2, 6.9, 1.2 Hz, 1H), 
7.58 (ddd, J = 8.2, 6.8, 1.3 Hz, 1H), 7.20 – 7.16 (m, 2H), 3.04 (s, 3H); 13C NMR (100 
MHz, CDCl3) δ 163.3 (d, J = 247.3 Hz), 158.8, 149.1, 136.9, 136.0 (d, J = 3.3 Hz), 130.3, 
128.8 (d, J = 8.2 Hz), 127.7, 127.0, 126.6, 125.8, 115.7 (d, J = 21.4 Hz), 115.1, 22.8; 19F 
NMR (282 MHz, CDCl3) δ –114.2; IR (Neat Film, NaCl) 1605, 1570, 1510, 1440, 1390, 
1332, 1231, 1156, 836, 749, 723 cm-1; HRMS (MM:ESI-APCI+) m/z calc’d for 
C16H13FN [M+H]+: 238.1027, found 238.1030. 
 
1-methyl-3-(4-(trifluoromethyl)phenyl)isoquinoline (181f): Compound 181f was 
prepared from triflate 180a using general procedure 3 and purified by column 
chromatography (2% to 3% EtOAc in hexanes) to afford a white solid (89 mg, 91% 
yield): 1H NMR (400 MHz, CDCl3) δ 8.26 (d, J = 8.1 Hz, 2H), 8.15 (d, J = 8.4, 1H), 7.96 
(s, 1H), 7.88 (d, J = 8.2 Hz, 1H), 7.78 – 7.73 (m, 2H), 7.73 – 7.67 (m, 1H), 7.63 – 7.59 
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130.2 (q, J = 32.5 Hz), 127.9, 127.5, 127.3, 127.1, 125.8, 125.7 (q, J = 3.8 Hz), 124.4 (q, 
J = 271.9 Hz), 116.1, 22.8; 19F NMR (282 MHz, CDCl3) δ –62.4; IR (Neat Film, NaCl) 
3070, 2357, 1622, 1573, 1418, 1390, 1324, 1162, 1122, 1066, 1015, 842, 754, 742, 682 
cm-1; HRMS (MM:ESI-APCI+) m/z calc’d for C17H13F3N [M+H]+: 288.0995, found 
288.0988. 
 
4-(1-methylisoquinolin-3-yl)benzonitrile (181g): Compound 181g was prepared from 
triflate 180a using general procedure 3 and purified by column chromatography (10% to 
20% EtOAc in hexanes) to provide a white solid (144 mg, 86% yield); 1H NMR (400 
MHz, CDCl3) δ 8.38 – 8.22 (m, 2H), 8.16 (d, J = 8.3 Hz, 1H), 7.99 (s, 1H), 7.89 (d, J = 
8.3, 1H), 7.82 – 7.75 (m, 2H), 7.73 (ddd, J = 8.1, 6.9, 1.2 Hz, 1H), 7.64 (ddd, J = 8.2, 6.9, 
1.3 Hz, 1H), 3.05 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 159.3, 147.6, 144.0, 136.6, 
132.7, 130.7, 128.0, 127.9, 127.6, 127.3, 125.9, 119.3, 116.6, 111.8, 22.8; IR (Neat Film, 
NaCl) 2224, 1618, 1570, 1508, 1441, 1390, 1334, 878, 844, 748, 731 cm-1; HRMS 
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1-methyl-3-(3-nitrophenyl)isoquinoline (181h): Compound 181h was prepared from 
triflate 180a using general procedure 3 and purified by column chromatography (10% 
EtOAc in hexanes) to provide a white solid (139 mg, 77% yield); 1H NMR (400 MHz, 
CDCl3) δ 9.01 (t, J = 2.0 Hz, 1H), 8.51 (ddd, J = 7.8, 1.8, 1.1 Hz, 1H), 8.24 (ddd, J = 8.2, 
2.3, 1.1 Hz, 1H), 8.16 (dd, J = 8.3, 1.0 Hz, 1H), 8.01 (s, 1H), 7.90 (dd, J = 8.1, 0.7 Hz, 
1H), 7.72 (ddd, J = 8.1, 6.9, 1.2 Hz, 1H), 7.72 – 7.59 (m, 2H), 3.05 (s, 3H); 13C NMR 
(100 MHz, CDCl3) δ 159.3, 149.0, 147.3, 141.7, 136.6, 132.8, 130.6, 129.7, 127.9, 127.8, 
127.2, 125.9, 123.0, 121.9, 116.0, 22.8; IR (Neat Film, NaCl) 1619, 1568, 1524, 1442, 
1390, 1350, 880, 806, 749, 692 cm-1; HRMS (MM:ESI-APCI+) m/z calc’d for 
C16H13N2O2 [M+H]+: 265.0972, found 265.0974. 
 
1-methyl-3-(3,4,5-trifluorophenyl)isoquinoline (181i): Compound 181i was prepared 
from triflate 180a using general procedure 3 and purified by column chromatography 
(5% EtOAc in hexanes) to afford a white solid (103 mg, 87% yield): 1H NMR (400 MHz, 
CDCl3) δ 8.13 (d, J = 8.4, 1H), 7.86 – 7.78 (m, 4H), 7.72 – 7.68 (m, 1H), 7.65 – 7.58 (m, 
1H), 3.02 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 159.1, 151.6 (ddd, J = 248.4, 10.1, 4.1 
Hz), 146.5, 140.0 (dt, J = 252.6, 15.7 Hz), 136.6, 136.0 (td, J = 7.5, 4.5 Hz), 130.6, 127.8, 
127.7, 127.1, 125.8, 115.4, 110.9 – 110.7 (m), 22.7; 19F NMR (282 MHz, CDCl3) δ –
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1526, 1446, 1392, 1352, 1237, 1034, 879, 847, 753 cm-1; HRMS (MM:ESI-APCI+) m/z 
calc’d for C16H11F3N [M+H]+: 274.0838, found 274.0841. 
 
1-methyl-3-(naphthalen-2-yl)isoquinoline (181j): Compound 181j was prepared from 
triflate 180a using general procedure 3 and purified by column chromatography (5% 
EtOAc in hexanes) to provide a white solid (159 mg, 86% yield); 1H NMR (400 MHz, 
CDCl3) δ 8.68 (s, 1H), 8.27 (dd, J = 8.6, 1.8 Hz, 1H), 8.16 (dq, J = 8.3, 1.0 Hz, 1H), 8.07 
(s, 1H), 8.00 – 7.96 (m, 2H), 7.91 – 7.86 (m, 2H), 7.70 (ddd, J = 8.2, 6.8, 1.2 Hz, 1H), 
7.59 (ddd, J = 8.2, 6.8, 1.3 Hz, 1H), 7.56 – 7.46 (m, 2H), 3.09 (s, 3H); 13C NMR (100 
MHz, CDCl3) δ 158.9, 149.9, 137.2, 137.0, 133.9, 133.5, 130.2, 128.9, 128.5, 127.8, 
127.8, 127.0, 126.8, 126.3, 126.3, 125.8, 124.9, 115.7, 22.9; IR (Neat Film, NaCl) 3059, 
1621, 1585, 1567, 1508, 1439, 1390, 879, 848, 816, 744 cm-1; HRMS (MM:ESI-APCI+) 
m/z calc’d for C20H16N [M+H]+: 270.1277, found 270.1270. 
 
3-(3,5-dimethylphenyl)-1-methylisoquinoline (181k): Compound 181k was prepared 
from triflate 180a using general procedure 3 and purified by column chromatography to 
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8.4, 1.1 Hz, 1H), 7.90 (s, 1H), 7.85 (dd, J = 8.2, 0.7 Hz, 1H), 7.75 (s, 2H), 7.66 (ddd, J = 
8.2, 6.8, 1.2 Hz, 1H), 7.56 (ddd, J = 8.2, 6.9, 1.3 Hz, 1H), 7.05 (s, 1H), 3.05 (s, 3H), 2.43 
(s, 6H); 13C NMR (100 MHz, CDCl3) δ 158.6, 150.5, 139.9, 138.3, 136.9, 130.2, 130.1, 
127.7, 126.8, 126.7, 125.8, 125.0, 115.4, 22.8, 21.7; IR (Neat Film, NaCl) 2919, 2358, 
1622, 1582, 1568, 1443, 1391, 1335, 874, 846, 786, 750, 711 cm-1; HRMS (MM:ESI-
APCI+) m/z calc’d for C18H18N [M+H]+: 248.1434, found 248.1434. 
 
3-(3,4-dimethoxyphenyl)-1-methylisoquinoline (181l): Compound 181l was prepared 
from triflate 180a using general procedure 3 and purified by column chromatography 
(20% EtOAc in hexanes) to provide a white solid (195 mg, 99% yield); 1H NMR (400 
MHz, CDCl3) δ 8.11 (d, J = 8.4, 1H), 7.89 – 7.81 (m, 2H), 7.77 (d, J = 2.1 Hz, 1H), 7.71 
– 7.61 (m, 2H), 7.55 (ddd, J = 8.3, 6.9, 1.3 Hz, 1H), 6.99 (d, J = 8.4 Hz, 1H), 4.04 (s, 
3H), 3.95 (s, 3H), 3.04 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 158.6, 149.8, 149.6, 
149.3, 137.0, 132.9, 130.2, 127.6, 126.7, 126.5, 125.8, 119.5, 114.5, 111.4, 110.3, 56.1, 
22.8; IR (Neat Film, NaCl) 2936, 2833, 1568, 1516, 1454, 1436, 1317, 1259, 1236, 1170, 
1026, 874, 817, 751 cm-1; HRMS (MM:ESI-APCI+) m/z calc’d for C18H18NO2 [M+H]+: 











Chapter 4 – Iridium-Catalyzed Enantioselective and Diastereoselective  
Hydrogenation of 1,3-Disubstituted Isoquinolines 
  
580 
1-methyl-3-(o-tolyl)isoquinoline (181m): Compound 181m was prepared from triflate 
180a using general procedure 3 and purified by column chromatography (10% EtOAc in 
hexanes) to provide a white solid (153 mg, 96% yield); 1H NMR (400 MHz, CDCl3) δ 
8.17 (d, J = 8.4, 1H), 7.84 (d, J = 8.3, 1H), 7.70 (ddd, J = 8.2, 6.8, 1.3 Hz, 1H), 7.65 – 
7.57 (m, 2H), 7.53 – 7.45 (m, 1H), 7.32 – 7.30 (m, 3H), 3.04 (s, 3H), 2.43 (s, 3H); 13C 
NMR (100 MHz, CDCl3) δ 158.1, 152.7, 140.9, 136.5, 136.3, 130.9, 130.1, 130.1, 128.1, 
127.5, 127.0, 126.2, 126.0, 125.7, 118.9, 22.6, 20.6; IR (Neat Film, NaCl) 3053, 2950, 
2920, 2355, 1622, 1584, 1567, 1498, 1446, 1392, 1360, 1330, 1144, 1033, 969, 906, 884, 
763, 752, 726 cm-1; HRMS (MM:ESI-APCI+) m/z calc’d for C17H16N [M+H]+: 234.1277, 
found 234.1286. 
 
3-(furan-2-yl)-1-methylisoquinoline (181n): Compound 181n was prepared from 
triflate 180a using general procedure 3 and purified by column chromatography (5% 
EtOAc in hexanes) to provide a white solid (106 mg, 99% yield): 1H NMR (400 MHz, 
CDCl3) δ 8.06 (d, J = 8.4 Hz, 1H), 7.86 (s, 1H), 7.80 (dd, J = 8.4 Hz, 1H), 7.67 – 7.59 (m, 
1H), 7.57 – 7.49 (m, 2H), 7.13 (dd, J = 3.4, 0.8 Hz, 1H), 6.56 (dd, J = 3.4, 1.8 Hz, 1H), 
2.99 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 159.0, 154.4, 142.9, 142.3, 136.5, 130.2, 
127.6, 126.7, 126.6, 125.8, 113.0, 112.0, 108.1, 22.6; IR (Neat Film, NaCl) 3067, 1622, 
1568, 1488, 1447, 1390, 1325, 1288, 1216, 1157, 1007, 970, 883, 814, 736 cm-1; HRMS 
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1-methyl-3-(thiophen-2-yl)isoquinoline (181o): Compound 181o was prepared from 
triflate 180a using general procedure 3 and purified by column chromatography (3% 
EtOAc in hexanes) to provide a white solid (103 mg, 92% yield): 1H NMR (400 MHz, 
CDCl3) δ 8.07 (dt, J = 8.4 Hz, 1H), 7.82 (s, 1H), 7.79 (dd, J = 8.2 Hz, 1H), 7.69 (dd, J = 
3.6, 1.1 Hz, 1H), 7.64 (ddd, J = 8.1, 6.8, 1.2 Hz, 1H), 7.52 (ddd, J = 8.2, 6.8, 1.2 Hz, 1H), 
7.38 (dd, J = 5.1, 1.1 Hz, 1H), 7.14 (dd, J = 5.0, 3.6 Hz, 1H), 2.99 (s, 3H); 13C NMR (100 
MHz, CDCl3) δ 158.8, 145.5, 145.4, 136.6, 130.2, 128.1, 127.4, 126.7, 126.6, 125.8, 
123.8, 113.1, 22.5; IR (Neat Film, NaCl) 3068, 1620, 1586, 1568, 1446, 1387, 1330, 
1238, 1194, 1036, 876, 820, 748, 704 cm-1; HRMS (MM:ESI-APCI+) m/z calc’d for 
C14H12NS [M+H]+: 226.0685, found 226.0680. 
 
1-methyl-3-(thiophen-3-yl)isoquinoline (181p): Compound 181p was prepared from 
triflate 180a using general procedure 3 and purified by column chromatography (5% 
EtOAc in hexanes) to provide a white solid (148 mg, 95% yield); 1H NMR (400 MHz, 
CDCl3) δ 8.10 (dd, J = 8.4, 1.0 Hz, 1H), 8.04 (dd, J = 3.1, 1.3 Hz, 1H), 7.81 (dt, J = 8.2, 
0.9 Hz, 1H), 7.79 (s, 1H), 7.73 (dd, J = 5.0, 1.3 Hz, 1H), 7.65 (ddd, J = 8.2, 6.8, 1.2 Hz, 
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NMR (100 MHz, CDCl3) δ 158.8, 146.4, 142.7, 136.9, 130.2, 127.6, 126.7, 126.6, 126.3, 
126.2, 125.8, 123.2, 114.7, 22.8; IR (Neat Film, NaCl) 3056, 2920, 1622, 1591, 1568, 
1496, 1446, 1388, 1317, 874, 842, 795, 749, 696 cm-1; HRMS (MM:ESI-APCI+) m/z 
calc’d for C14H12NS [M+H]+: 226.0685, found 226.0687. 
 
1-methyl-3-(1-methyl-1H-pyrazol-4-yl)isoquinoline (181q): Compound 181q was 
prepared from triflate 180a using general procedure 3 and purified by column 
chromatography (50% to 60% EtOAc in hexanes) to provide a white solid (112 mg, 99% 
yield): 1H NMR (400 MHz, CDCl3) δ 8.07 (d, J = 8.4 Hz, 1H), 8.04 – 8.00 (m, 2H), 7.77 
(dd, J = 8.2, 1.1 Hz, 1H), 7.67 – 7.60 (m, 2H), 7.54 – 7.47 (m, 1H), 3.98 (s, 3H), 2.97 (s, 
3H); 13C NMR (100 MHz, CDCl3) δ 158.8, 137.4, 136.8, 130.1, 128.9, 127.1, 126.2, 
126.1, 125.7, 113.3, 39.1, 22.6; IR (Neat Film, NaCl) 2940, 2351, 1620, 1601, 1568, 
1556, 1493, 1416, 1182, 983, 840, 750, 702 cm-1; HRMS (MM:ESI-APCI+) m/z calc’d 
for C14H14N3 [M+H]+: 224.1182, found 224.1176. 
 
1-methyl-3-(pyridin-2-yl)isoquinoline (181r): Compound 181r was prepared from 
triflate 180a using a procedure adapted from a previous report.6 To a microwave vial was 
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Bu)3•HBF4 (15 mg, 0.052 mmol), and the N-oxide (147 mg, 1.55 mmol). The vial was 
then evacuated and backfilled with argon three times. A solution of 180a (150 mg, 0.52 
mmol) in toluene (2 mL, 0.3 M) was then added, and the reaction was stirred at 130 °C 
overnight. The reaction was then cooled to room temperature, filtered through celite, and 
dissolved in CH2Cl2 (10 mL, 0.05 M). The reaction flask was then cooled to 0 °C and 
PCl3 (0.27 mL, 3.1 mmol) was added dropwise, then the reaction stirred for 30 minutes at 
0 °C. The reaction was then quenched with saturated aqueous K2CO3, extracted with 
EtOAc, and dried over Na2SO4. The crude product was purified by column 
chromatography (30% EtOAc in hexanes + 1% NEt3) to provide a pale yellow solid (56 
mg, 50% yield over 2 steps); 1H NMR (400 MHz, CDCl3) δ 8.72 (dd, J = 4.8, 1.9 Hz, 
1H), 8.62 (s, 1H), 8.56 (dd, J = 8.0, 1.1 Hz, 1H), 8.14 (dd, J = 8.3, 1.0 Hz, 1H), 7.95 (dt, 
J = 8.2, 1.0 Hz, 1H), 7.84 (td, J = 7.7, 1.8 Hz, 1H), 7.68 (ddd, J = 8.1, 6.8, 1.2 Hz, 1H), 
7.60 (ddd, J = 8.2, 6.9, 1.4 Hz, 1H), 7.29 (ddd, J = 7.5, 4.8, 1.2 Hz, 1H), 3.05 (s, 3H); 13C 
NMR (100 MHz, CDCl3) δ 158.5, 156.9, 149.4, 148.7, 137.1, 136.9, 130.2, 128.6, 127.7, 
127.5, 125.8, 123.3, 121.4, 116.5, 22.9; IR (Neat Film, NaCl) 3053, 3004, 2916, 1621, 
1580, 1568, 1474, 1443, 1426, 1391, 1335, 1142, 891, 796, 742, 681, 624 cm-1; HRMS 
(MM:ESI-APCI+) m/z calc’d for C15H13N2 [M+H]+: 221.1073, found 221.1076. 
 
7-fluoro-1-methyl-3-phenylisoquinoline (192a): Compound 192a was prepared from 
triflate 180b using general procedure 3 and purified by column chromatography (5% 
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CDCl3) δ 8.14 – 8.11 (m, 2H), 7.90 (s, 1H), 7.85 (dd, J = 9.2, 5.7 Hz, 1H), 7.73 – 7.68 
(m, 1H), 7.54 – 7.48 (m, 2H), 7.48 – 7.38 (m, 2H), 2.99 (s, 3H); 13C NMR (100 MHz, 
CDCl3) δ 160.7 (d, J = 248.3 Hz), 158.0 (d, J = 5.8 Hz), 149.8 (d, J = 2.8 Hz), 139.7, 
133.9, 130.3 (d, J = 8.5 Hz), 128.9, 128.5, 127.3 (d, J = 7.8 Hz), 127.0, 120.6 (d, J = 25.3 
Hz), 114.9 (d, J = 1.7 Hz), 109.4 (d, J = 21.0 Hz), 22.8; 19F NMR (282 MHz, CDCl3) δ –
109.7 – –111.8 (m);  IR (Neat Film, NaCl) 3031, 2358, 1576, 1506, 1446, 1393, 1372, 
1313, 1230, 1183, 1028, 972, 922, 904, 881, 822, 777, 764, 704 cm-1; HRMS (MM:ESI-
APCI+) m/z calc’d for C16H13FN [M+H]+: 238.1027, found 238.1027. 
 
7-fluoro-3-(4-methoxyphenyl)-1-methylisoquinoline (192b): Compound 192b was 
prepared from triflate 180b using general procedure 3 and purified by column 
chromatography (5% EtOAc in hexanes) to provide a white solid (110 mg, 99% yield): 
1H NMR (400 MHz, CDCl3) δ 8.10 – 8.04 (m, 2H), 7.87 – 7.81 (m, 2H), 7.70 (dd, J = 
9.9, 2.6 Hz, 1H), 7.44 (ddd, J = 9.0, 8.3, 2.5 Hz, 1H), 7.06 – 6.99 (m, 2H), 3.88 (s, 3H), 
2.98 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 160.4 (d, J = 248.5 Hz), 160.1, 157.7 (d, J = 
5.7 Hz), 149.4 (d, J = 2.8 Hz), 133.9, 132.2, 130.0 (d, J = 8.5 Hz), 128.1, 126.7 (d, J = 
7.7 Hz), 120.5 (d, J = 25.3 Hz), 114.2, 113.7 (d, J = 1.8 Hz), 109.3 (d, J = 20.9 Hz), 55.4, 
22.7; 19F NMR (282 MHz, CDCl3) δ –111.9 (ddd, J = 9.3, 9.1, 5.7 Hz); IR (Neat Film, 
NaCl) 1608, 1514, 1443, 1393, 1288, 1252, 1186, 1029, 878, 863, 836, 821 cm-1; HRMS 
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7-fluoro-1-methyl-3-(4-(trifluoromethyl)phenyl)isoquinoline (192c): Compound 192c 
was prepared from triflate 180b using general procedure 3 and purified by column 
chromatography (5% EtOAc in hexanes) to provide a white solid (150 mg, 98% yield): 
1H NMR (400 MHz, CDCl3) δ 8.22 (d, J = 8.0 Hz, 2H), 7.94 (s, 1H), 7.90 – 7.85 (m, 1H), 
7.74 (d, J = 8.0 Hz, 2H), 7.71 – 7.69 (m, 1H), 7.53 – 7.43 (m, 1H), 2.99 (s, 3H); 13C 
NMR (100 MHz, CDCl3) δ 161.1 (d, J = 249.4 Hz), 158.4 (d, J = 6.2 Hz), 148.1, 143.0, 
133.7, 130.4 (d, J = 8.5 Hz), 130.2 (q, J = 32.4 Hz), 127.8 (d, J = 8.1 Hz), 127.2, 125.8 
(q, J = 3.8 Hz), 124.5 (q, J = 272.7 Hz), 120.9 (d, J = 24.9 Hz), 115.6, 109.5 (d, J = 21.4 
Hz), 22.8 ; 19F NMR (282 MHz, CDCl3) δ –62.5, –110.2 (ddd, J = 9.9, 8.2, 5.5 Hz); IR 
(Neat Film, NaCl) 1592, 1418, 1393, 1330, 1157, 1126, 1107, 1067, 880, 868, 847, 816 
cm-1; HRMS (MM:ESI-APCI+) m/z calc’d for C17H12NF4 [M+H]+: 306.0900, found 
306.0895. 
 
5-methyl-7-phenyl-[1,3]dioxolo[4,5-g]isoquinoline (192d): Compound 192d was 
prepared from triflate 180c using general procedure 3 and purified by column 
chromatography (10% EtOAc in hexanes) to provide a white solid (153 mg, 97% yield): 
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7.41 – 7.32 (m, 2H), 7.11 (s, 1H), 6.10 (s, 2H), 2.92 (s, 3H); 13C NMR (100 MHz, 
CDCl3) δ 156.4, 150.5, 149.5 148.1, 140.0, 135.1, 128.7, 128.1, 126.8, 123.5, 115.1, 
103.4, 101.9, 101.6, 23.0; IR (Neat Film, NaCl) 2914, 1591, 1486, 1462, 1232, 1189, 
1039, 945, 878, 846, 695, 684 cm-1; HRMS (MM:ESI-APCI+) m/z calc’d for C17H14NO2 
[M+H]+: 264.1019, found 264.1021. 
 
7-(3,4-dimethoxyphenyl)-5-methyl-[1,3]dioxolo[4,5-g]isoquinoline (192e): Compound 
192e was prepared from triflate 180c using general procedure 3 at 65 °C and purified by 
column chromatography via dry loading (40% EtOAc in hexanes) to provide a white 
solid (202 mg, 82% yield); 1H NMR (400 MHz, CDCl3) δ 7.72 (d, J = 2.1 Hz, 1H), 7.69 
(s, 1H), 7.60 (dd, J = 8.3, 2.0 Hz, 1H), 7.34 (s, 1H), 7.09 (s, 1H), 6.96 (d, J = 8.4 Hz, 1H), 
6.09 (s, 2H), 4.02 (s, 3H), 3.94 (s, 3H), 2.91 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 
156.2, 150.5, 149.3, 149.2, 147.9, 135.2, 134.3, 133.0, 123.2, 119.1, 114.3, 111.2, 110.0, 
103.3, 101.8, 101.5, 56.0, 56.0, 23.0; IR (Neat Film, NaCl) 2935, 1591, 1517, 1462, 
1267, 1230, 1165, 1143, 1024, 872, 731 cm-1; HRMS (MM:ESI-APCI+) m/z calc’d for 
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4-methyl-2-phenylbenzo[f]isoquinoline (192f): Compound 192f was prepared from 
triflate 180d using general procedure 3 and the product was collected via vacuum 
filtration to provide a white solid (246 mg, 63% yield); 1H NMR (400 MHz, CDCl3) δ 
8.55 – 8.40 (m, 2H), 7.96 – 7.88 (m, 2H), 7.73 (t, J = 8.7 Hz, 1H), 7.69 – 7.61 (m, 1H), 
7.54 (t, J = 8.3 Hz, 1H), 7.45 – 7.42 (m, 2H), 7.26 (td, J = 7.6, 1.7 Hz, 2H), 7.16 (td, J = 
7.3, 1.7 Hz, 1H), 2.81 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 157.9, 152.0, 140.3, 135.6, 
133.4, 129.3, 128.8, 128.7, 128.5, 128.4, 127.7, 127.2, 127.1, 124.4, 123.4, 122.9, 111.0, 
23.1; IR (Neat Film, NaCl) 2342, 1574, 1506, 1483, 1444, 1386, 1242, 1028, 876, 824, 
760, 725, 692 cm-1; HRMS (MM:ESI-APCI+) m/z calc’d for C20H16N [M+H]+: 270.1277, 
found 270.1289. 




(3-phenylisoquinolin-1-yl)methanol (182a): This procedure has been adapted from a 
previous report.4 To a 20-mL microwave vial containing a stir bar was added SeO2 (140 
mg, 1.26 mmol), isoquinoline 181a (138 mg, 0.63 mmol), and 1,4-dioxane (13 mL, 0.05 
M). The reaction vial was then sealed and heated to 110 °C while stirring for 2 hours. The 
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EtOAc. The filtrate was then concentrated in vacuo to afford the aldehyde intermediate, 
which was used in the next step without further purification.  
A scintillation vial containing the crude in 4:1 DCM:MeOH (0.1 M) was added 
sodium borohydride (24 mg, 0.63 mmol) at room temperature. The reaction was stirred 
until no starting material remained by TLC, and then quenched by the addition of citric 
acid monohydrate (132 mg, 0.63 mmol). The reaction was stirred for an additional 10 
minutes, then basified by the addition of saturated aqueous NaHCO3. The layers were 
separated and the aqueous phase was extracted with CH2Cl2. The combined organic 
phases were dried over Na2SO4 and concentrated in vacuo. The crude product was 
purified by column chromatography (20% acetone in hexanes) to afford 182a as a white 
solid (100 mg, 68% yield over 2 steps): 1H NMR (400 MHz, CDCl3) δ 8.18 – 8.15 (d, J = 
7.0 Hz, 2H), 8.03 (s, 1H), 7.94 – 7.92 (m, 2H), 7.73 (ddd, J = 8.3, 6.9, 1.1 Hz, 1H), 7.61 
(ddd, J = 8.1, 6.9, 1.2 Hz, 1H), 7.53 (t, J = 7.6 Hz, 2H), 7.46 – 7.42 (m, 1H), 5.31 (s, 2H), 
5.26 (br s, 1H, OH); 13C NMR (100 MHz, CDCl3) δ 157.4, 148.7, 138.9, 137.1, 130.9, 
129.0, 128.9, 128.0, 127.5, 127.0, 124.2, 123.3, 116.3, 61.6; IR (Neat Film, NaCl) 3378, 
3060, 2867, 1624, 1574, 1502, 1461, 1443, 1370, 1331, 1304, 1088, 1072, 1024, 1009, 
882, 782, 766, 693 cm-1; HRMS (MM:ESI-APCI+) m/z calc’d for C16H14NO [M+H]+: 
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((3-(4-(tert-butyl)phenyl)isoquinolin-1-yl)methanol (182b): Compound 182b was 
prepared from isoquinoline 181b using general procedure 4 and purified by column 
chromatography (20% EtOAc in hexanes) to provide a white solid (162 mg, 95% yield); 
1H NMR (400 MHz, CDCl3) δ 8.20 – 8.06 (m, 2H), 8.00 (s, 1H), 7.97 – 7.85 (m, 2H), 
7.72 (ddd, J = 8.4, 6.9, 1.2 Hz, 1H), 7.62 – 7.58 (m, 1H), 7.58 – 7.52 (m, 2H), 5.30 (s, 
3H), 1.40 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 157.2, 152.1, 148.7, 137.1, 136.2, 
130.8, 127.9, 127.3, 126.7, 125.9, 124.1, 123.3, 115.9, 61.5, 34.9, 31.5; IR (Neat Film, 
NaCl) 3385, 2958, 1626, 1574, 1514, 1446, 1416, 1360, 1333, 1265, 1088, 1014, 841, 
744, 680 cm-1; HRMS (MM:ESI-APCI+) m/z calc’d for C20H22NO [M+H]+: 292.1696, 
found 292.1696. 
 
(3-([1,1'-biphenyl]-4-yl)isoquinolin-1-yl)methanol (182c): Compound 182c was 
prepared from isoquinoline 181c using general procedure 4 and purified by column 
chromatography (20% EtOAc in hexanes) to provide a colorless solid (181 mg, 92% 
yield); 1H NMR (400 MHz, CDCl3) δ 8.30 – 8.20 (m, 2H), 8.07 (s, 1H), 7.98 – 7.88 (m, 
2H), 7.81 – 7.66 (m, 5H), 7.62 (ddd, J = 8.4, 6.9, 1.2 Hz, 1H), 7.49 (dd, J = 8.2, 6.8 Hz, 
2H), 7.43 – 7.34 (m, 1H), 5.32 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 157.4, 148.3, 
141.7, 140.7, 137.8, 137.1, 130.9, 129.0, 128.0, 127.7, 127.7, 127.6, 127.3, 127.2, 124.2, 
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1412, 1374, 1334, 1088, 1006, 840, 766, 729, 697 cm-1; HRMS (MM:ESI-APCI+) m/z 
calc’d for C22H18NO [M+H]+: 312.1382, found 312.1383. 
 
(3-(4-methoxyphenyl)isoquinolin-1-yl)methanol (182d): Compound 182d was 
prepared from isoquinoline 181d using general procedure 4 and purified by column 
chromatography (20% EtOAc in hexanes) to provide a white solid (48 mg, 73% yield): 
1H NMR (400 MHz, CDCl3) δ 8.14 – 8.07 (m, 2H), 7.93 (s, 1H), 7.91 – 7.85 (m, 2H), 
7.69 (ddd, J = 8.2, 6.9, 1.1 Hz, 1H), 7.56 (ddd, J = 8.2, 6.9, 1.2 Hz, 1H), 7.06 – 7.03 (m, 
2H), 5.28 (s, 3H), 3.89 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 160.3, 157.0, 148.3, 
137.1, 131.4, 130.7, 128.1, 127.7, 127.0, 123.7, 123.1, 115.0, 114.2, 61.4, 55.4; IR (Neat 
Film, NaCl) 3376, 2928, 2836, 1608, 1573, 1515, 1442, 1372, 1334, 1287, 1250, 1175, 
1087, 1032, 1010, 832, 750, 730 cm-1; HRMS (MM:ESI-APCI+) m/z calc’d for 
C17H16NO2 [M+H]+: 266.1176, found 266.1185. 
 
(3-(4-fluorophenyl)isoquinolin-1-yl)methanol (182e): Compound 182e was prepared 
from isoquinoline 181e using general procedure 4 and purified by column 
chromatography (20% EtOAc in hexanes) to provide a colorless solid (149 mg, 95% 
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7.89 (m, 2H), 7.73 (ddd, J = 8.3, 6.9, 1.1 Hz, 1H), 7.61 (ddd, J = 8.1, 6.9, 1.2 Hz, 1H), 
7.21 (dd, J = 8.9, 8.5 Hz, 2H), 5.30 (s, 2H), 5.17 (br s, 1H, OH); 13C NMR (100 MHz, 
CDCl3) δ 163.5 (d, J = 248.3 Hz), 157.5, 147.8, 137.0, 135.1 (d, J = 3.2 Hz), 131.0, 128.7 
(d, J = 8.2 Hz), 127.9, 127.6, 124.1, 123.3, 116.0, 115.8, 61.6; 19F NMR (282 MHz, 
CDCl3) δ –113.3 – –113.4 (m); IR (Neat Film, NaCl) 3382, 3059, 2354, 1622, 1604, 
1574, 1512, 1446, 1331, 1230, 1157, 1087, 1011, 837, 750, 725 cm-1; HRMS (MM:ESI-
APCI+) m/z calc’d for C16H13FNO [M+H]+: 254.0974, found 254.0976. 
 
(3-(4-(trifluoromethyl)phenyl)isoquinolin-1-yl)methanol (182f): Compound 182f was 
prepared from isoquinoline 181f using general procedure 4 and purified by column 
chromatography (10% to 20% EtOAc in hexanes) to provide a white solid (23 mg, 25% 
yield); 1H NMR (400 MHz, CDCl3) δ 8.26 (d, J = 7.8 Hz, 2H), 8.07 (s, 1H), 8.00 – 7.92 
(m, 2H), 7.82 – 7.73 (m, 3H), 7.70 – 7.61 (m, 1H), 5.32 (s, 2H), 5.10 (br s, 1H, OH); 13C 
NMR (100 MHz, CDCl3) δ 157.9, 147.1, 142.3, 136.8, 131.2, 130.7 (q, J = 32.5 Hz), 
128.2, 128.1, 127.2, 125.9 (q, J = 3.8 Hz), 124.6, 124.4 (q, J = 273.7 Hz), 123.4, 117.2, 
61.6; 19F NMR (282 MHz, CDCl3) δ –62.5; IR (Neat Film, NaCl) 3408, 1623, 1574, 
1418, 1324, 1166, 1111, 1075, 1014, 842, 753, 682 cm-1; HRMS (MM:ESI-APCI+) m/z 





Chapter 4 – Iridium-Catalyzed Enantioselective and Diastereoselective  




4-(1-(hydroxymethyl)isoquinolin-3-yl)benzonitrile (182g): Compound 182g was 
prepared from isoquinoline 181g using general procedure 4 and purified by column 
chromatography (30% EtOAc in hexanes) to provide a white solid (138 mg, 92% yield); 
1H NMR (400 MHz, CDCl3) δ 8.31 – 8.18 (m, 2H), 8.09 (s, 1H), 7.97 (m, 2H), 7.86 – 
7.74 (m, 3H), 7.68 (ddd, J = 8.2, 6.9, 1.2 Hz, 1H), 5.32 (s, 2H), 4.99 (s, 1H); 13C NMR 
(100 MHz, CDCl3) δ 158.2, 146.5, 143.2, 136.7, 132.8, 131.4, 128.5, 128.2, 127.4, 124.7, 
123.5, 119.0, 117.7, 112.3, 61.7; IR (Neat Film, NaCl) 3404, 2895, 2358, 2224, 1416, 
1332, 1303, 1085, 1006, 840, 764, 682 cm-1; HRMS (MM:ESI-APCI+) m/z calc’d for 
C17H13N2O [M+H]+: 261.1022, found 261.1032. 
 
(3-(3-nitrophenyl)isoquinolin-1-yl)methanol (182h): Compound 182h was prepared 
from isoquinoline 181h using general procedure 4 and purified by column 
chromatography (20% EtOAc in CH2Cl2) to provide a white solid (67 mg, 38% yield); 1H 
NMR (400 MHz, CDCl3) δ 8.95 (t, J = 2.0 Hz, 1H), 8.52 (dt, J = 7.9, 1.3 Hz, 1H), 8.27 
(ddd, J = 8.2, 2.3, 1.1 Hz, 1H), 8.11 (s, 1H), 8.04 – 7.90 (m, 2H), 7.78 (ddd, J = 8.0, 6.9, 
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CDCl3) δ 158.2, 149.0, 146.1, 140.7, 136.8, 132.7, 131.4, 129.9, 128.4, 128.2, 124.7, 
123.5, 123.4, 121.6, 117.2, 61.7; IR (Neat Film, NaCl) 3389, 2614, 1538, 1520, 1505, 
1353, 1333, 1088, 1007, 892, 751, 690 cm-1; HRMS (MM:ESI-APCI+) m/z calc’d for 
C16H13N2O3 [M+H]+: 281.0921, found 281.0930. 
 
(3-(3,4,5-trifluorophenyl)isoquinolin-1-yl)methanol (182i): Compound 182i was 
prepared from isoquinoline 181i using general procedure 4 and purified by column 
chromatography (20% EtOAc in hexanes) to provide a white solid (90 mg, 82% yield); 
1H NMR (400 MHz, CDCl3) δ 7.99 – 7.89 (m, 3H), 7.84 – 7.71 (m, 3H), 7.65 (ddd, J = 
8.2, 6.9, 1.3 Hz, 1H), 5.30 (s, 2H), 4.89 (br s, 1H, OH); 13C NMR (100 MHz, CDCl3) δ 
158.0, 151.7 (ddd, J = 249.3, 10.2, 4.1 Hz), 145.4 (d, J = 2.5 Hz), 140.2 (dt, J = 253.9, 
15.7 Hz), 136.7, 135.1 (td, J = 7.6, 4.5 Hz), 131.4, 128.3, 128.0, 124.5, 123.4, 116.6 (d, J 
= 1.4 Hz), 110.9 – 110.7 (m), 61.7; 19F NMR (282 MHz, CDCl3) δ –133.8 – –133.9 (m), 
–160.1 – –160.3 (m); IR (Neat Film, NaCl) 3351, 2882, 1557, 1531, 1451, 1350, 1326, 
1080, 1039, 1008, 864, 848, 778, 747, 706 cm-1; HRMS (MM:ESI-APCI+) m/z calc’d for 
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(3-(naphthalen-2-yl)isoquinolin-1-yl)methanol (182j): Compound 182j was prepared 
from isoquinoline 181j using general procedure 4 and purified by column 
chromatography (20% EtOAc in hexanes) to provide a white solid (158 mg, 97% yield); 
1H NMR (400 MHz, CDCl3) δ 8.67 (s, 1H), 8.27 (dd, J = 8.6, 1.8 Hz, 1H), 8.16 (s, 1H), 
8.05 – 7.93 (m, 4H), 7.91 – 7.89 (m, 1H), 7.75 (ddd, J = 8.2, 6.9, 1.1 Hz, 1H), 7.62 (ddd, 
J = 8.2, 6.9, 1.2 Hz, 1H), 7.58 – 7.47 (m, 2H), 5.34 (s, 3H); 13C NMR (100 MHz, CDCl3) 
δ 157.5, 148.5, 137.1, 136.2, 133.7, 133.7, 130.9, 128.8, 128.6, 128.0, 127.8, 127.6, 
126.7, 126.6, 126.3, 124.6, 124.2, 123.3, 116.6, 61.6; IR (Neat Film, NaCl) 3393, 3056, 
1622, 1573, 1506, 1445, 1410, 1375, 1344, 1314, 1086, 1008, 856, 817, 744 cm-1; HRMS 
(MM:ESI-APCI+) m/z calc’d for C20H16NO [M+H]+: 286.1231, found 286.1226. 
 
(3-(3,5-dimethylphenyl)isoquinolin-1-yl)methanol (182k): Compound 182k was 
prepared from isoquinoline 181k using general procedure 4 and purified by column 
chromatography (20% EtOAc in hexanes) to provide a white solid (155 mg, 95% yield); 
1H NMR (400 MHz, CDCl3) δ 8.00 (s, 1H), 7.94 – 7.91 (m, 2H), 7.78 – 7.76 (m, 2H), 
7.72 (ddd, J = 8.3, 6.9, 1.2 Hz, 1H), 7.60 (ddd, J = 8.2, 6.9, 1.2 Hz, 1H), 7.09 (s, 1H), 
5.30 (s, 3H), 2.44 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 157.2, 149.0, 138.9, 138.5, 
137.1, 130.8, 130.6, 127.9, 127.4, 124.8, 124.1, 123.3, 116.3, 61.6, 21.7; IR (Neat Film, 
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750, 709 cm-1; HRMS (MM:ESI-APCI+) m/z calc’d for C18H18NO [M+H]+: 264.1382, 
found 264.1383. 
 
(3-(3,4-dimethoxyphenyl)isoquinolin-1-yl)methanol (182l): Compound 182l was 
prepared from isoquinoline 181l using general procedure 4 and purified by column 
chromatography (40% EtOAc in hexanes) to provide a white solid (180 mg, 91% yield); 
1H NMR (400 MHz, CDCl3) δ 7.95 (s, 1H), 7.93 – 7.90 (m, 2H), 7.77 – 7.67 (m, 3H), 
7.58 (ddd, J = 8.2, 6.9, 1.2 Hz, 1H), 7.03 – 7.01 (m, 1H), 5.30 (s, 2H), 5.26 (br s, 1H, 
OH), 4.03 (s, 3H), 3.97 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 157.0, 149.8, 149.3, 
148.3, 137.0, 131.8, 130.7, 127.7, 127.1, 123.8, 123.2, 119.5, 115.3, 111.3, 110.0, 61.4, 
56.1, 56.0; IR (Neat Film, NaCl) 3372, 2936, 2838, 1623, 1604, 1573, 1518, 1456, 1438, 
1314, 1260, 1237, 1134, 1027, 1008 cm-1; HRMS (MM:ESI-APCI+) m/z calc’d for 
C18H18NO3 [M+H]+: 296.1284, found 296.1283. 
 
(3-(o-tolyl)isoquinolin-1-yl)methanol (182m): Compound 182m was prepared from 
isoquinoline 181m using general procedure 4 and purified by column chromatography 
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MHz, CDCl3) δ 7.96 (dd, J = 8.4, 1.1 Hz, 1H), 7.91 (dd, J = 8.2, 1.2 Hz, 1H), 7.75 (ddd, J 
= 8.3, 6.9, 1.2 Hz, 1H), 7.71 (s, 1H), 7.64 (ddd, J = 8.3, 6.8, 1.3 Hz, 1H), 7.53 (d, J = 6.6 
Hz, 1H), 7.39 – 7.29 (m, 3H), 5.30 (s, 2H), 5.14 (s, 1H), 2.45 (s, 3H); 13C NMR (100 
MHz, CDCl3) δ 156.8, 151.4, 140.1, 136.7, 136.5, 131.0, 130.8, 130.2, 128.4, 127.8, 
127.6, 126.1, 123.7, 123.3, 120.0, 61.6, 20.9; IR (Neat Film, NaCl) 3389, 3057, 2932, 
1626, 1573, 1502, 1455, 1402, 1377, 1330, 1087, 1069, 1008, 884, 786, 757, 727 cm-1; 
HRMS (MM:ESI-APCI+) m/z calc’d for C17H16NO [M+H]+: 250.1226, found 250.1232. 
 
(3-(furan-2-yl)isoquinolin-1-yl)methanol (182n): Compound 182n was prepared from 
isoquinoline 181n using general procedure 4 and purified by column chromatography 
(20% EtOAc in hexanes) to provide a white solid (56 mg, 52% yield): 1H NMR (400 
MHz, CDCl3) δ 7.94 – 7.92 (m, 1H), 7.90 – 7.82 (m, 2H), 7.70 – 7.66 (m, 1H), 7.60 – 
7.50 (m, 2H), 7.16 – 7.14 (m, 1H), 6.58 – 6.56 (m, 1H), 5.23 (s, 2H), 5.05 (br s, 1H, OH); 
13C NMR (100 MHz, CDCl3) δ 157.5, 153.7, 143.1, 140.9, 136.6, 130.9, 127.8, 127.2, 
124.0, 123.3, 113.6, 112.1, 108.6, 61.3; IR (Neat Film, NaCl) 3390, 3118, 2886, 1624, 
1574, 1492, 1372, 1323, 1306, 1157, 1092, 1079, 1006, 884, 836, 743 cm-1; HRMS 
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(3-(thiophen-2-yl)isoquinolin-1-yl)methanol (182o): Compound 182o was prepared 
from isoquinoline 182o (0.5 mmol) using general procedure 4 and purified by column 
chromatography (10% to 20% EtOAc in hexanes) to provide a white solid (46 mg, 38% 
yield): 1H NMR (400 MHz, CDCl3) δ 7.89 (s, 1H), 7.88 – 7.83 (m, 2H), 7.75 – 7.65 (m, 
2H), 7.55 (ddd, J = 8.2, 6.9, 1.2 Hz, 1H), 7.41 (dd, J = 5.0, 1.2 Hz, 1H), 7.16 (dd, J = 5.0, 
3.6 Hz, 1H), 5.25 (s, 2H), 5.02 (br s, 1H, OH); 13C NMR (100 MHz, CDCl3) δ 157.4, 
144.4, 144.1, 136.8, 131.0, 128.2, 127.6, 127.2, 127.0, 124.1, 124.0, 123.3, 114.0, 61.3; 
IR (Neat Film, NaCl) 3382, 3066, 2868, 1621, 1589, 1573, 1501, 1452, 1402, 1329, 
1084, 1006, 878, 822, 748, 701 cm-1; HRMS (MM:ESI-APCI+) m/z calc’d for 
C14H12NOS [M+H]+: 242.0634, found 242.0637. 
 
(3-(thiophen-3-yl)isoquinolin-1-yl)methanol (182p): Compound 182p was prepared 
from isoquinoline 181p (0.58 mmol) using general procedure 4 and purified by column 
chromatography (20% EtOAc in hexanes) to provide a white solid (127 mg, 91% yield); 
1H NMR (400 MHz, CDCl3) δ 8.06 (dd, J = 3.1, 1.3 Hz, 1H), 7.94 – 7.84 (m, 3H), 7.76 
(dd, J = 5.1, 1.3 Hz, 1H), 7.71 (ddd, J = 8.2, 6.9, 1.1 Hz, 1H), 7.58 (ddd, J = 8.2, 6.9, 1.1 
Hz, 1H), 7.45 (dd, J = 5.1, 3.0 Hz, 1H), 5.27 (s, 2H), 5.19 (br s, 1H); 13C NMR (100 
MHz, CDCl3) δ 157.4, 145.0, 141.7, 137.0, 130.9, 127.8, 127.3, 126.6, 126.0, 124.1, 
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1573, 1456, 1350, 1318, 1299, 1086, 1008, 880, 842, 793, 748, 697 cm-1; HRMS 
(MM:ESI-APCI+) m/z calc’d for C14H12NOS [M+H]+: 242.0634, found 242.0631. 
 
(3-(1-methyl-1H-pyrazol-4-yl)isoquinolin-1-yl)methanol (182q): Compound 182q was 
prepared from isoquinoline 181q using general procedure 4 and purified by column 
chromatography (70% to 80% EtOAc in hexanes + 1% NEt3) to provide a pale beige 
solid (72 mg, 62% yield): 1H NMR (400 MHz, CDCl3) δ 8.08 – 7.95 (m, 2H), 7.85 – 7.79 
(m, 2H), 7.71 – 7.59 (m, 2H), 7.53 – 7.49 (m, 1H), 5.21 (s, 2H), 3.98 (s, 3H); 13C NMR 
(100 MHz, CDCl3) δ 157.3, 143.2, 137.3, 136.9, 130.8, 128.8, 127.2, 126.7, 123.5, 123.2, 
114.1 61.2, 39.2; IR (Neat Film, NaCl) 3370, 3068, 2937, 1626, 1603, 1573, 1503, 1416, 
1321, 1278, 1186, 1092, 1011, 845, 753, 702 cm-1; HRMS (MM:ESI-APCI+) m/z calc’d 
for C14H14N3O [M+H]+: 240.1131, found 240.1123. 
 
(3-(pyridin-2-yl)isoquinolin-1-yl)methanol (182r): Compound 182r was prepared from 
isoquinoline 181r using general procedure 4 and purified by column chromatography 
(10% to 20% acetone in CH2Cl2 + 1% NEt3) to provide a pale cream solid (52 mg, 86% 
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(d, J = 8.3 Hz, 1H), 7.94 (d, J = 8.3 Hz, 1H), 7.86 (td, J = 7.8, 1.8 Hz, 1H), 7.78 – 7.69 
(m, 1H), 7.63 (ddd, J = 8.1, 6.8, 1.2 Hz, 1H), 7.33 (ddd, J = 7.5, 4.8, 1.2 Hz, 1H), 5.31 (s, 
2H), 5.13 (br s, 1H, OH); 13C NMR (100 MHz, CDCl3) δ 157.2, 155.8, 149.5, 147.3, 
137.2, 137.0, 130.9, 128.7, 128.1, 125.1, 123.6, 123.3, 121.1, 117.6, 61.6; IR (Neat Film, 
NaCl) 3390, 3048, 2359, 1622, 1583, 1474, 1428, 1333, 1309, 1166, 1087, 1009, 897, 
793, 747, 681 cm-1; HRMS (MM:ESI-APCI+) m/z calc’d for C15H13N2O [M+H]+: 
237.1022, found 237.1020. 
 
7-fluoro-3-phenylisoquinolin-1-yl)methanol (184a): Compound 184a was prepared 
from isoquinoline 192a using general procedure 4 and purified by column 
chromatography (10% EtOAc in hexanes) to provide a white solid (94 mg, 81% yield): 
1H NMR (400 MHz, CDCl3) δ 8.13 (d, J = 8.0 Hz, 2H), 8.00 (s, 1H), 7.96 – 7.87 (m, 1H), 
7.57 – 7.47 (m, 4H), 7.44 (td, J = 6.9, 6.4, 1.4 Hz, 1H), 5.21 (s, 2H), 5.11 (br s, 1H, OH); 
13C NMR (100 MHz, CDCl3) δ 161.0 (d, J = 250.3 Hz), 156.8 (d, J = 5.9 Hz), 148.4, 
138.6, 134.1, 130.5 (d, J = 8.6 Hz), 129.0, 126.8, 124.7 (d, J = 8.5 Hz), 121.4 (d, J = 25.2 
Hz), 115.9 (d, J = 2.0 Hz), 107.2 (d, J = 21.3 Hz), 61.6; 19F NMR (282 MHz, CDCl3) δ –
109.5 – –109.6 (m); IR (Neat Film, NaCl) 3393, 3063, 2878, 1594, 1579, 1506, 1417, 
1392, 1321, 1232, 1185, 1085, 1015, 930, 777, 694 cm-1; HRMS (MM:ESI-APCI+) m/z 
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(7-fluoro-3-(4-methoxyphenyl)isoquinolin-1-yl)methanol (184b): Compound 184b 
was prepared from isoquinoline 192b using general procedure 4 and purified by column 
chromatography (20% EtOAc in hexanes) to provide a white solid (116 mg, 99% yield): 
1H NMR (400 MHz, CDCl3) δ 8.10 – 8.08 (m, 2H), 7.93 (s, 1H), 7.92 – 7.88 (m, 1H), 
7.52 – 7.45 (m, 2H), 7.07 – 7.02 (m, 2H), 5.21 (s, 2H), 5.14 (s, 1H), 3.90 (s, 3H); 13C 
NMR (100 MHz, CDCl3) δ 160.8 (d, J = 249.0 Hz), 160.5, 156.6 (d, J = 5.9 Hz), 148.3 
(d, J = 2.9 Hz), 134.3, 131.3, 130.4 (d, J = 8.6 Hz), 128.1, 124.3 (d, J = 8.2 Hz), 121.4 (d, 
J = 25.3 Hz), 114.8 (d, J = 1.7 Hz), 114.4, 107.2 (d, J = 21.3 Hz), 61.6, 55.6; 19F NMR 
(282 MHz, CDCl3) δ –110.2 (ddd, J = 8.9, 8.8, 5.5 Hz); IR (Neat Film, NaCl) 3388, 
2936, 1608, 1593, 1516, 1389, 1289, 1251, 1180, 1069, 1032, 1015, 929, 835 cm-1; 
HRMS (MM:ESI-APCI+) m/z calc’d for C17H15FNO2 [M+H]+: 284.1081, found 
284.1074. 
 
(7-fluoro-3-(4-(trifluoromethyl)phenyl)isoquinolin-1-yl)methanol (184c): Compound 
184c was prepared from isoquinoline 192c using general procedure 4 and purified by 
column chromatography (10% EtOAc in hexanes) to provide a white solid (80 mg, 60% 
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9.8, 5.4 Hz, 1H), 7.74 (d, J = 8.3 Hz, 2H), 7.58 – 7.47 (m, 2H), 5.21 (s, 2H), 4.94 (br s, 
1H, OH); 13C NMR (100 MHz, CDCl3) δ 161.3 (d, J = 251.5 Hz), 157.3 (d, J = 5.9 Hz), 
146.8 (d, J = 2.9 Hz), 141.8 (d, J = 1.5 Hz), 133.8, 130.7 (d, J = 8.7 Hz), 130.7 (q, J = 
33.3 Hz), 127.0, 125.9 (q, J = 3.8 Hz), 125.2 (d, J = 8.4 Hz), 124.3 (q, J = 272.7 Hz), 
121.7 (d, J = 25.3 Hz), 116.8 (d, J = 1.7 Hz), 107.4 (d, J = 21.5 Hz), 61.7; 19F NMR (282 
MHz, CDCl3) δ –62.5, –108.4 (ddd, J = 8.7, 8.7, 5.4 Hz); IR (Neat Film, NaCl) 3410, 
2886, 1619, 1597, 1504, 1416, 1391, 1328, 1233, 1165, 1124, 1111, 1074, 1016, 931, 
847, 680 cm-1; HRMS (MM:ESI-APCI+) m/z calc’d for C17H12F4NO [M+H]+: 322.0850, 
found 322.0839. 
 
(7-phenyl-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)methanol (184d): Compound 184d was 
prepared from isoquinoline 192d using general procedure 4 and purified by column 
chromatography (30% to 40% EtOAc in hexanes) to provide a white solid (135 mg, 83% 
yield): 1H NMR (400 MHz, CDCl3) δ 8.13 – 8.05 (m, 2H), 7.82 (s, 1H), 7.50 (m, 2H), 
7.44 – 7.37 (m, 1H), 7.15 – 7.06 (m, 2H), 6.10 (s, 2H), 5.28 (br s, 1H, OH), 5.10 (s, 2H); 
13C NMR (100 MHz, CDCl3) δ 154.9, 151.1, 148.6, 147.8, 138.9, 135.4, 128.8, 128.5, 
126.6, 120.9, 115.9, 103.6, 101.9, 99.3, 61.4; IR (Neat Film, NaCl) 3324, 2914, 2355, 
1597, 1497, 1463, 1436, 1422, 1236, 1066, 1036, 995, 940, 877, 775, 692 cm-1; HRMS 
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Compound 184e was prepared from isoquinoline 192e using general procedure 4 and 
purified by column chromatography (40% EtOAc in hexanes) via dry-loading to provide 
a pale pink solid (126 mg, 65% yield): 1H NMR (400 MHz, CDCl3) δ 7.77 (s, 1H), 7.69 – 
7.60 (m, 2H), 7.16 – 7.07 (m, 2H), 6.99 (d, J = 8.2 Hz, 1H), 6.11 (s, 2H), 5.26 (br s, 1H, 
OH), 5.11 (s, 2H), 4.01 (s, 3H), 3.96 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 154.7, 
151.1, 149.7, 149.2, 148.4, 147.7, 135.5, 131.9, 120.6, 119.2, 115.1, 111.3, 109.7, 103.5, 
101.8, 99.3, 61.4, 56.0, 56.0; IR (Neat Film, NaCl) 3378, 2912, 2353, 1595, 1519, 1496, 
1463, 1456, 1435, 1258, 1234, 1034, 862, 730 cm-1; HRMS (MM:ESI-APCI+) m/z calc’d 
for C19H18NO5 [M+H]+: 340.1179, found 340.1172. 
 
(2-phenylbenzo[f]isoquinolin-4-yl)methanol (184f): Compound 184f was prepared 
from isoquinoline 192f using general procedure 4 and purified by column 
chromatography (20% EtOAc in hexanes) to provide a white solid (51 mg, 62% yield): 
1H NMR (400 MHz, CDCl3) δ 8.78 – 8.76 (m, 2H), 8.23 – 8.20 (m, 2H), 7.94 – 7.92 (m, 
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Hz, 1H), 5.46 – 5.19 (m, 3H); 13C NMR (100 MHz, CDCl3) δ 156.3, 150.4, 139.2, 135.9, 
133.5, 129.0, 129.0, 129.0, 128.8, 128.6, 127.5, 127.1, 123.5, 122.1, 120.0, 120.0, 111.7, 
61.7; IR (Neat Film, NaCl) 3322, 3064, 2890, 1589, 1494, 1428, 1386, 1304, 1242, 1081, 
1050, 814, 747 cm-1; HRMS (MM:ESI-APCI+) m/z calc’d for C20H16NO [M+H]+: 
286.1226, found 286.1235. 
4.7.2.2 Syntheses of isoquinolines with different directing groups 
 
 
(3-phenylisoquinolin-1-yl)methyl acetate (186a): To a scintillation vial containing a stir 
bar and isoquinoline 182a (165 mg, 0.70 mmol) in THF (7 mL, 0.1 M) was added DMAP 
(8.6 mg, 0.07 mmol) and pyridine (0.14 mL, 1.75 mmol). Acetic anhydride (0.1 mL, 1.05 
mmol) was then added dropwise. The reaction was stirred overnight at room temperature, 
then diluted with Et2O and washed with saturated aqueous NH4Cl. The organic phase was 
collected, dried over Na2SO4, and concentrated in vacuo. The crude product was purified 
by column chromatography (10% EtOAc in hexanes) to afford 186a as a colorless 
viscous oil (194 mg, >99% yield): 1H NMR (400 MHz, CDCl3) δ 8.19 – 8.13 (m, 2H), 
8.11 (dd, J = 8.4, 1.0 Hz, 1H), 8.07 (s, 1H), 7.92 (dt, J = 8.3, 0.9 Hz, 1H), 7.71 (ddd, J = 
8.2, 6.8, 1.2 Hz, 1H), 7.61 (ddd, J = 8.2, 6.8, 1.3 Hz, 1H), 7.54 – 7.47 (m, 2H), 7.45 – 
7.38 (m, 1H), 5.79 (s, 2H), 2.20 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 170.9, 154.4, 
150.2, 139.3, 137.5, 130.5, 128.9, 128.7, 128.0, 127.6, 127.1, 126.0, 124.8, 117.2, 66.1, 
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748, 719, 678 cm-1; HRMS (MM:ESI-APCI+) m/z calc’d for C18H16NO2 [M+H]+: 
278.1176, found 278.1178. 
 
1-(methoxymethyl)-3-phenylisoquinoline (186b): To a scintillation vial containing a 
stir bar and isoquinoline 182a (165 mg, 0.70 mmol) in THF (7 mL, 0.1 M) was added 
KOt-Bu (86 mg, 0.77 mmol) at room temperature. The resulting mixture was stirred for 5 
minutes, then cooled to 0 °C, and MeI (0.05 mL, 0.77 mmol) was added. The reaction 
was allowed to slowly warm to room temperature overnight, and then was quenched with 
saturated aqueous NH4Cl. The organic phase was collected and the aqueous phase was 
extracted with EtOAc. The organic phases were combined, dried over MgSO4, and 
concentrated in vacuo. The crude product was purified by column chromatography (5% 
EtOAc in hexanes) to afford 186b as a white solid (79 mg, 45% yield): 1H NMR (400 
MHz, CDCl3) δ 8.36 (dd, J = 8.4, 1.1 Hz, 1H), 8.20 – 8.13 (m, 2H), 8.04 (s, 1H), 7.89 (d, 
J = 8.3 Hz, 1H), 7.69 (ddd, J = 8.2, 6.8, 1.2 Hz, 1H), 7.60 (ddd, J = 8.2, 6.8, 1.3 Hz, 1H), 
7.51 (td, J = 7.3, 6.5, 1.2 Hz, 2H), 7.45 – 7.37 (m, 1H), 5.14 (s, 2H), 3.51 (s, 3H); 13C 
NMR (100 MHz, CDCl3) δ 157.1, 149.9, 139.7, 137.5, 130.4, 128.9, 128.6, 127.7, 127.3, 
127.1, 126.5, 125.9, 117.1, 75.8, 58.7; IR (Neat Film, NaCl) 3058, 2918, 2817, 1622, 
1590, 1500, 1455, 1338, 1188, 1104, 885, 770, 752, 695, 668 cm-1; HRMS (MM:ESI-






THF, 0 to 23 °C
186b182a
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1-((benzyloxy)methyl)-3-phenylisoquinoline (186c): This procedure has been adapted 
from a previous report.26 To a flame-dried RBF equipped with a stir bar was added NaH 
(36.4 mg, 60% w/w in oil, 0.91 mmol) and THF (7 mL, 0.1 M). To this suspension, 
isoquinoline 182a (165 mg, 0.70 mmol) was added. After 5 minutes of stirring at room 
temperature, the reaction mixture was cooled to 0 °C and BnBr (0.91 mL, 0.91 mmol) 
was added. The reaction was allowed to slowly warm to room temperature overnight. 
Silica (1 g) was then added and the solvent was evaporated under vacuum. The crude 
product was purified by column chromatography (5% EtOAc in hexanes) to afford 186c 
as a colorless viscous oil (153 mg, 67% yield): 1H NMR (400 MHz, CDCl3) δ 8.39 (dd, J 
= 8.4, 1.1 Hz, 1H), 8.21 – 8.14 (m, 2H), 8.04 (s, 1H), 7.89 (d, J = 8.3 Hz, 1H), 7.69 (ddd, 
J = 8.2, 6.8, 1.2 Hz, 1H), 7.58 (ddd, J = 8.3, 6.8, 1.2 Hz, 1H), 7.51 (dd, J = 8.4, 6.9 Hz, 
2H), 7.45 – 7.27 (m, 6H), 5.24 (s, 2H), 4.67 (s, 2H); 13C NMR (100 MHz, CDCl3) δ 
157.2, 149.9, 139.7, 138.2, 137.6, 130.4, 128.9, 128.6, 128.5, 128.3, 127.9, 127.7, 127.3, 
127.1, 126.6, 126.1, 117.1, 73.6, 72.8; IR (Neat Film, NaCl) 3062, 2858, 1622, 1574, 
1496, 1454, 1384, 1337, 1207, 1094, 1030, 885, 796, 768, 737, 696 cm-1; HRMS 
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tert-butyl ((3-phenylisoquinolin-1-yl)methyl)carbamate (186d): This procedure has 
been adapted from a previous report.27 To a solution of aldehyde 186f (150 mg, 0.64 
mmol) and t-butyl carbamate (150 mg, 1.28 mmol) in MeCN (6.5 mL, 0.1 M) were added 
trifluoroacetic acid (0.15 mL, 1.92 mmol) and triethylsilane (1.0 mL, 6.4 mmol). The 
reaction was stirred at room temperature overnight, and then quenched with saturated 
aqueous Na2CO3 and extracted with EtOAc. The combined organic phases were washed 
with brine, dried over Na2SO4, and concentrated in vacuo. The crude product was 
purified by column chromatography (15% EtOAc in hexanes) to afford 186d as a white 
solid (160 mg, 75% yield): 1H NMR (400 MHz, CDCl3) δ 8.16 (d, J = 7.7 Hz, 2H), 8.10 
(d, J = 8.4 Hz, 1H), 8.00 (s, 1H), 7.90 (d, J = 8.2 Hz, 1H), 7.70 (ddd, J = 8.1, 6.9, 1.1 Hz, 
1H), 7.61 (ddd, J = 8.2, 6.9, 1.2 Hz, 1H), 7.53 (t, J = 7.6 Hz, 2H), 7.48 – 7.40 (m, 1H), 
6.43 (br s, 1H), 5.03 (d, J = 4.4 Hz, 2H), 1.54 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 
156.3, 155.0, 149.3, 139.4, 137.1, 130.6, 128.9, 128.8, 127.9, 127.6, 127.0, 125.1, 124.0, 
116.3, 79.6, 43.5, 28.7; IR (Neat Film, NaCl) 3418, 2976, 1713, 1622, 1574, 1487, 1367, 
1251, 1167, 1056, 882, 765, 695 cm-1; HRMS (MM:ESI-APCI+) m/z calc’d for 
C21H23N2O2 [M+H]+: 335.1754, found 335.1760. 
 
3-phenylisoquinoline-1-carbaldehyde (186f): To a Schlenk flask containing a stir bar 
was added SeO2 (140 mg, 1.26 mmol) and isoquinoline 181a (138 mg, 0.63 mmol) in 
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while stirring for 2 hours. The reaction was then cooled to room temperature and filtered 
through celite rinsing with EtOAc. The crude product was then purified by column 
chromatography (5% EtOAc in hexanes) to afford 186f as a pale yellow solid (1.32 g, 
96% yield): 1H NMR (400 MHz, CDCl3) δ 10.50 (s, 1H), 9.32 (d, J = 8.2 Hz, 1H), 8.31 
(s, 1H), 8.24 (d, J = 8.1 Hz, 2H), 7.97 (d, J = 7.3 Hz, 1H), 7.84 – 7.67 (m, 2H), 7.56 (t, J 
= 7.5 Hz, 2H), 7.47 (t, J = 7.4 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 196.2, 150.8, 
149.7, 138.5, 138.1, 131.0, 129.9, 129.3, 129.1, 127.5, 127.1, 125.9, 125.5, 121.3; IR 
(Neat Film, NaCl) 2826, 2364, 1704, 1574, 1455, 1333, 1054, 904, 783, 764, 678 cm-1; 
HRMS (MM:ESI-APCI+) m/z calc’d for C16H12NO [M+H]+: 234.0913, found 234.0914. 
4.7.2.3 Hydrogenation reactions 
General Procedure 5: Hydrogenation Reactions 
 
To an oven-dried 20-mL scintillation vial equipped with a stir bar and 
isoquinoline (0.2 mmol) was capped with a PTFE-lined septum and pierced with two 21-
gauge green needles. The vials were then placed in a Parr bomb and brought into the 
glovebox, with the exception of the pressure gauge. A layer of plastic wrap and a rubber 
band were also brought in to seal the top of the bomb. In a nitrogen-filled glovebox, a 
solution of the ligand (SL-J418-1) (4.53 mg, 0.006 mmol per reaction) and [Ir(cod)Cl]2 
(1.68 mg, 0.0025 mmol per reaction) in THF (1.8 mL per reaction) was prepared and 
allowed to stand for 10 minutes. Meanwhile, a solution of TBAI (5.54 mg, 0.015 mmol 




[Ir(cod)Cl]2 (1.25 mol %)
ligand (3 mol %)
H2 (20 bar), TBAI (7.5 mol %)
9:1 THF:AcOH (0.1 M)
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of the solution was added to each reaction vial via a syringe. Afterwards, 1.8 mL of the 
homogeneous iridium catalyst solution was added to each reaction vial via a syringe. 
After re-capping the vials with caps equipped with needles, the reactions were placed in 
the bomb and the top was covered tightly with plastic wrap secured by a rubber band. 
The bomb was then removed from the glovebox, and the pressure gauge was quickly 
screwed in place and tightened. The bomb was charged to 5-10 bar H2 and slowly 
released. This process was repeated two more times, before charging the bomb to 20 bar 
of H2 (or 60 bar H2). The bomb was then left stirring at 200 rpm at room temperature (or 
placed in an oil bath and heated to 60 °C) for 18 hours. Then, the bomb was removed 
from the stir plate and the hydrogen pressure was vented. The reaction vials were 
removed from the bomb and each solution was basified by the addition of saturated 
aqueous K2CO3. The layers were separated, and the aqueous layer was extracted with 
EtOAc. The combined organics layers were then dried over Na2SO4, and concentrated in 
vacuo. The product was then purified by column chromatography to furnish the product 
as an inseparable mixture of diastereomers.  
Please note that the NMR data listed is for the major diastereomer, and that the 
provided spectra for the following compounds reflect the inseparable mixture of cis- and 
trans-products. The enantiomeric excess was determined by chiral SFC analysis of the 
Cbz-protected amine (see Table 4.4, Section 4.7.4). The absolute configuration was 
determined for compound 183p via x-ray crystallographic analysis. Absolute 
configuration of compound 187e were determined using vibrational circular dichroism 
(VCD), vide infra. The absolute configuration for all other products has been inferred by 
analogy. 
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((1S,3R)-3-phenyl-1,2,3,4-tetrahydroisoquinolin-1-yl)methanol (183a): Compound 
183a was prepared from isoquinoline 182a using general procedure 5 and purified by 
column chromatography (5% MeOH in CH2Cl2) to provide a tan solid as a mixture of 
diastereomers (47 mg, 98% yield) (dr = 15.7:1); 92% ee for major diastereomer; [α]D25 
+110.2 (c 1.02, CHCl3); Cis-diastereomer: 1H NMR (400 MHz, CDCl3) δ 7.50 – 7.43 (m, 
2H), 7.41 – 7.34 (m, 2H), 7.34 – 7.28 (m, 1H), 7.25 – 7.17 (m, 3H), 7.15 – 7.10 (m, 1H), 
4.43 – 4.41 (m, 1H), 4.10 (dd, J = 11.1, 3.5 Hz, 1H), 4.02 (dd, J = 10.8, 3.3 Hz, 1H), 3.90 
(dd, J = 10.9, 5.4 Hz, 1H), 3.02 (ddt, J = 15.9, 11.1, 1.4 Hz, 1H), 2.90 (dd, J = 15.7, 3.5 
Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 144.3, 136.7, 134.9, 129.3, 128.8, 127.7, 126.8, 
126.7, 126.5, 125.5, 66.7, 58.7, 57.7, 39.0; IR (Neat Film, NaCl) 3296, 3060, 2910, 2360, 
1494, 1455, 1314, 1116, 1036, 909, 742, 700 cm-1; HRMS (MM:ESI-APCI+) m/z calc’d 
for C16H18NO [M+H]+: 240.1383, found 240.1385; SFC Conditions: 45% IPA, 3.5 
mL/min, Chiralpak AD-H column, λ = 210 nm, tR (min): major = 2.34, minor = 4.02.	
Trans-diastereomer: 1H NMR (400 MHz, CDCl3) δ 7.49 – 7.43 (m, 2H), 7.42 – 
7.38 (m, 2H), 7.36 – 7.27 (m, 1H), 7.26 – 7.10 (m, 4H), 4.23 (dd, J = 10.5, 4.8 Hz, 1H), 
4.16 (dd, J = 11.2, 3.9 Hz, 1H), 3.80 (dd, J = 10.8, 4.8 Hz, 1H), 3.71 (t, J = 10.7 Hz, 1H), 
3.07 (dd, J = 16.4, 3.9 Hz, 1H), 2.95 (dd, J = 15.9, 11.2 Hz, 1H);	13C NMR (100 MHz, 
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((1S,3R)-3-(4-(tert-butyl)phenyl)-1,2,3,4-tetrahydroisoquinolin-1-yl)methanol (183b):  
Compound 183b was prepared from isoquinoline 182b using general procedure 5 and 
purified by column chromatography (50% EtOAc in hexanes) to provide a tan solid as a 
mixture of diastereomers (51 mg, 87% yield) (dr = 13.3:1); 91% ee for major 
diastereomer; [α]D25 +78.8 (c 1.03, CHCl3); Major diastereomer: 1H NMR (400 MHz, 
CDCl3) δ 7.42 – 7.38 (m, 4H), 7.26 – 7.21 (m, 2H), 7.21 – 7.17 (m, 1H), 7.12 (d, J = 7.7 
Hz, 1H), 4.42 – 4.40 (m, 1H), 4.08 (dd, J = 11.2, 3.4 Hz, 1H), 4.01 (dd, J = 10.8, 3.3 Hz, 
1H), 3.89 (dd, J = 10.8, 5.4 Hz, 1H), 3.03 (dd, J = 15.8, 11.2 Hz, 1H), 2.89 (dd, J = 15.7, 
3.4 Hz, 1H), 1.34 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 150.7, 141.2, 136.7, 135.0, 
129.3, 126.7, 126.5, 126.5, 125.7, 125.5, 66.6, 58.7, 57.3, 38.8, 34.7, 31.5; IR (Neat Film, 
NaCl) 3318, 2961, 2868, 1494, 1454, 1362, 1312, 1270, 1116, 1038, 820, 743 cm-1; 
HRMS (MM:ESI-APCI+) m/z calc’d for C20H26NO [M+H]+: 296.2009, found 296.2005; 
SFC Conditions: 45% IPA, 3.5 mL/min, Chiralpak AD-H column, λ = 210 nm, tR (min): 
major = 1.81, minor = 2.73. 
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Compound 183c was prepared from isoquinoline 182c using general procedure 5 and 
purified by column chromatography (50% EtOAc in hexanes) to provide a tan solid as a 
mixture of diastereomers (50 mg, 79% yield) (dr = 9.0:1); 92% ee for major 
diastereomer; [α]D25 +73.2 (c 1.03, CHCl3); Major diastereomer: 1H NMR (400 MHz, 
CDCl3) δ 7.65 – 7.58 (m, 4H), 7.55 – 7.53 (m, 2H), 7.47 – 7.44 (m, 2H), 7.39 – 7.32 (m, 
1H), 7.28 – 7.16 (m, 3H), 7.15 (d, J = 6.2 Hz, 1H), 4.46 – 4.44 (m, 1H), 4.15 (dd, J = 
11.2, 3.4 Hz, 1H), 4.04 (dd, J = 10.9, 3.3 Hz, 1H), 3.91 (dd, J = 10.9, 5.5 Hz, 1H), 3.12 – 
3.00 (m, 1H), 2.94 (dd, J = 15.6, 3.4 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 143.2, 
141.0, 140.7, 136.5, 134.9, 129.3, 128.9, 127.5, 127.4, 127.3, 127.2, 126.8, 126.6, 125.5, 
66.6, 58.7, 57.4, 38.9; IR (Neat Film, NaCl) 3318, 3029, 2924, 2365, 1487, 1455, 1312, 
1218, 1112, 1038, 833, 763, 748, 699 cm-1; HRMS (MM:ESI-APCI+) m/z calc’d for 
C22H22NO [M+H]+: 316.1696, found 316.1686; SFC Conditions: 45% IPA, 3.5 mL/min, 
Chiralpak AD-H column, λ = 210 nm, tR (min): major = 4.08, minor = 5.18. 
 
((1S,3R)-3-(4-methoxyphenyl)-1,2,3,4-tetrahydroisoquinolin-1-yl)methanol (183d): 
Compound 183d was prepared from isoquinoline 182d using general procedure 5 and 
purified by column chromatography (50% to 60% EtOAc in hexanes + 1% NEt3) to 
provide a pale yellow solid as a mixture of diastereomers (40 mg, 75% yield) (dr = 
13.3:1); 92% ee for major diastereomer; [α]D25 +69.3 (c 1.01, CHCl3); Major 
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7.12 (d, J = 7.6 Hz, 1H), 6.94 – 6.90 (m, 2H), 4.41 – 4.39 (m, 1H), 4.07 – 3.97 (m, 2H), 
3.86 (dd, J = 10.9, 5.9 Hz, 1H), 3.83 (s, 3H), 3.06 – 2.95 (m, 1H), 2.86 (dd, J = 15.7, 3.4 
Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 159.0, 136.6, 136.3, 134.8, 129.2, 127.8, 126.6, 
126.3, 125.3, 114.0, 66.5, 58.6, 57.0, 55.4, 38.8; IR (Neat Film, NaCl) 3342, 2929, 2835, 
1612, 1514, 1494, 1453, 1302, 1250, 1176, 1108, 1036, 824, 801, 743 cm-1; HRMS 
(MM:ESI-APCI+) m/z calc’d for C17H20NO2 [M+H]+: 270.1489, found 270.1486; SFC 
Conditions: 45% IPA, 2.5 mL/min, Chiralpak AD-H column, λ = 210 nm, tR (min): major 
= 2.59, minor = 3.61. 
 
((1S,3R)-3-(4-fluorophenyl)-1,2,3,4-tetrahydroisoquinolin-1-yl)methanol (183e): 
Compound 183e was prepared from isoquinoline 182e using general procedure 5 and 
purified by column chromatography (40% EtOAc in hexanes + 1% NEt3) to provide a 
pale yellow solid as a mixture of diastereomers (51 mg, 99% yield) (dr = 10.1:1); 93% ee 
for major diastereomer; [α]D25 +79.2 (c 1.00, CHCl3); Major diastereomer: 1H NMR (400 
MHz, CDCl3) δ 7.45 – 7.41 (m, 2H), 7.24 – 7.18 (m, 3H), 7.12 (d, J = 6.9 Hz, 1H), 7.08 – 
7.04 (m, 2H), 4.42 – 4.40 (m, 1H), 4.08 (dd, J = 11.0, 3.5 Hz, 1H), 4.02 (dd, J = 10.8, 3.3 
Hz, 1H), 3.88 (dd, J = 10.9, 5.5 Hz, 1H), 3.03 – 2.91 (m, 1H), 2.87 (dd, J = 15.7, 3.5 Hz, 
1H); 13C NMR (100 MHz, CDCl3) δ 162.3 (d, J = 245.5 Hz), 140.0 (d, J = 3.0 Hz), 136.4, 
134.8, 129.3, 128.4 (d, J = 7.9 Hz), 126.8, 126.6, 125.5, 115.5 (d, J = 21.2 Hz), 66.7, 
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NaCl) 3310, 3069, 2924, 2828, 1605, 1511, 1494, 1454, 1225, 1158, 1063, 1040, 844, 
826, 744 cm-1; HRMS (MM:ESI-APCI+) m/z calc’d for C16H17FNO [M+H]+: 258.1289, 
found 258.1286; SFC Conditions: 45% IPA, 2.5 mL/min, Chiralpak AD-H column, λ = 
210 nm, tR (min): major = 1.93, minor = 2.87. 
 
((1S,3R)-3-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroisoquinolin-1-yl)methanol 
(183f): Compound 183f was prepared from isoquinoline 182f using general procedure 5 
and purified by column chromatography (30% EtOAc in hexanes + 1% NEt3) to provide 
a yellow solid as a mixture of diastereomers (49 mg, 80% yield) (dr = 4.6:1); 92% ee for 
major diastereomer; [α]D25 +35.5 (c 1.01, CHCl3); Major diastereomer: 1H NMR (400 
MHz, CDCl3) δ 7.57 – 7.55 (m, 2H, integration overlapped with minor diastereomer), 
7.51 (d, J = 8.3 Hz, 2H), 7.18 – 7.10 (m, 3H), 7.10 – 7.03 (m, 1H), 4.36 – 4.34 (m, 1H), 
4.08 (dd, J = 10.6, 4.0 Hz, 1H), 3.97 (dd, J = 10.8, 3.3 Hz, 1H), 3.81 (dd, J = 10.9, 5.8 
Hz, 1H), 2.95 – 2.78 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 148.3, 136.0, 134.7, 129.9 
(q, J = 32.3 Hz), 129.3, 127.2, 126.9, 126.7, 125.7 (q, J = 3.8 Hz), 125.5, 124.3 (q, J = 
272.2 Hz), 66.6, 58.4, 57.3, 38.8; 19F NMR (282 MHz, CDCl3) δ –115.1 (qd, J = 8.7, 5.6 
Hz); IR (Neat Film, NaCl) 3304, 2917, 1621, 1418, 1325, 1166, 1123, 1068, 1018, 844, 
745 cm-1; HRMS (MM:ESI-APCI+) m/z calc’d for C17H17F3NO [M+H]+: 308.1257, 
found 308.1265; SFC Conditions: 25% IPA, 2.5 mL/min, Chiralpak AD-H column, λ = 





Chapter 4 – Iridium-Catalyzed Enantioselective and Diastereoselective  





(183g): Compound 183g was prepared from isoquinoline 182g using general procedure 5 
and purified by column chromatography (30% EtOAc in CH2Cl2 + 1% NEt3) to provide a 
pale tan solid as a mixture of diastereomers (44 mg, 83% yield) (dr = 2.4:1); 82% ee for 
major diastereomer; [α]D25 +57.4 (c 1.00, CHCl3); Major diastereomer: 1H NMR (400 
MHz, CDCl3) δ 7.69 – 7.66 (m, 2H), 7.60 – 7.57 (m, 2H), 7.26 – 7.17 (m, 3H, integration 
overlapped with minor diastereomer), 7.16 – 7.12 (m, 1H), 4.43 – 4.41 (m, 1H), 4.16 (dd, 
J = 10.0, 4.6 Hz, 1H), 4.06 (dd, J = 10.9, 3.3 Hz, 1H), 3.89 (dd, J = 10.9, 5.8 Hz, 1H), 
2.99 – 2.84 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 149.6, 135.7, 134.5, 132.6, 129.2, 
127.6, 126.9, 126.8, 125.5, 118.9, 111.5, 66.7, 58.5, 57.4, 38.8; IR (Neat Film, NaCl) 
3314, 3060, 2925, 2227, 1608, 1494, 1454, 1311, 1115, 1040, 910, 846, 826, 780, 740 
cm-1; HRMS (MM:ESI-APCI+) m/z calc’d for C17H17N2O [M+H]+: 265.1335, found 
265.1336; SFC Conditions: 45% IPA, 3.5 mL/min, Chiralpak AD-H column, λ = 210 nm, 










Chapter 4 – Iridium-Catalyzed Enantioselective and Diastereoselective  




Compound 183h was prepared from isoquinoline 182h using general procedure 5 and 
purified by column chromatography (0% to 2% MeOH in CH2Cl2) to provide a pale 
yellow solid as a mixture of diastereomers (44 mg, 78% yield) (dr = 3.2:1); 86% ee for 
major diastereomer; [α]D25 +54.4 (c 1.02, CHCl3); Major diastereomer: 1H NMR (400 
MHz, CDCl3) δ 8.34 (s, 1H), 8.15 (d, J = 8.2 Hz, 1H), 7.81 (d, J = 8.1 Hz, 1H), 7.62 – 
7.47 (m, 1H), 7.25 – 7.07 (m, 4H, integration overlapped with minor diastereomer), 4.43 
– 4.41 (m, 1H), 4.20 (dd, J = 9.2, 5.4 Hz, 1H), 4.07 (dd, J = 10.9, 3.2 Hz, 1H), 3.91 – 
3.83 (m, 1H), 3.15 – 3.02 (m, 1H), 2.98 – 2.91 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 
148.7, 146.5, 135.7, 134.6, 133.2, 129.8, 129.4, 127.0, 126.9, 125.6, 122.9, 122.0, 66.8, 
58.7, 57.2, 38.9; IR (Neat Film, NaCl) 3388, 2924, 1635, 1531, 1495, 1454, 1350, 1220, 
1117, 1038, 802, 781, 748, 738, 682 cm-1; HRMS (MM:ESI-APCI+) m/z calc’d for 
C16H17N2O3 [M+H]+: 285.1234, found 285.1234; SFC Conditions: 45% IPA, 3.5 
mL/min, Chiralpak AD-H column, λ = 210 nm, tR (min): major = 2.45, minor = 3.23. 
 
((1S,3R)-3-(3,4,5-trifluorophenyl)-1,2,3,4-tetrahydroisoquinolin-1-yl)methanol 
(183i): Compound 183i was prepared from isoquinoline 182i using general procedure 5 
and purified by column chromatography (5% to 10% EtOAc in CH2Cl2 + 1% NEt3) to 
provide a pale yellow solid as a mixture of diastereomers (55 mg, 94% yield) (dr = 3.5:1); 
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NMR (400 MHz, CDCl3) δ 7.25 – 7.18 (m, 2H, integration overlapped with minor 
diastereomer), 7.16 – 7.08 (m, 4H), 4.40 – 4.38 (m, 1H), 4.09 – 4.00 (m, 2H), 3.87 (dd, J 
= 10.9, 5.9 Hz, 1H), 2.88 (d, J = 8.4 Hz, 2H); 13C NMR (100 MHz, CDCl3), complicated 
spectrum due to mixture of diastereomers and C–F coupling, multiplicities listed to the 
best of our ability δ 151.4 (ddd, J = 250.1, 9.8, 3.6 Hz), 139.0 (dt, J = 251.0, 15.5 Hz), 
135.5, 134.4, 129.4, 129.2, 126.9, 126.8, 125.5, 110.9 – 110.6 (m), 66.7, 58.5, 56.2, 38.8; 
19F NMR (282 MHz, CDCl3) δ –133.6 – –134.4 (m), –161.8 – –162.0 (m); IR (Neat Film, 
NaCl) 3307, 2928, 1621, 1532, 1454, 1372, 1340, 1235, 1043, 866, 804, 748, 698 cm-1; 
HRMS (MM:ESI-APCI+) m/z calc’d for C16H15F3NO [M+H]+: 294.1100, found 
294.1095; SFC Conditions: 40% IPA, 2.5 mL/min, Chiralpak AD-H column, λ = 210 nm, 
tR (min): major = 1.67, minor = 2.20. 
 
((1S,3R)-3-(naphthalen-2-yl)-1,2,3,4-tetrahydroisoquinolin-1-yl)methanol (183j): 
Compound 183j was prepared from isoquinoline 182j using general procedure 5 and 
purified by column chromatography (30% EtOAc in hexanes + 1% NEt3) to provide a 
pale yellow solid as a single diastereomer (49 mg, 80% yield); 95% ee; [α]D25 +90.7 (c 
1.00, CHCl3);  1H NMR (400 MHz, CDCl3) δ 7.90 (s, 1H), 7.88 – 7.84 (m, 3H), 7.60 (dd, 
J = 8.5, 1.8 Hz, 1H), 7.53 – 7.45 (m, 2H), 7.28 – 7.20 (m, 3H), 7.15 (d, J = 6.8 Hz, 1H), 
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(dd, J = 10.8, 5.4 Hz, 1H), 3.14 – 3.07 (m, 1H), 2.98 (dd, J = 15.7, 3.5 Hz, 1H); 13C NMR 
(100 MHz, CDCl3) δ 141.8, 136.7, 135.1, 133.7, 133.2, 129.4, 128.6, 128.1, 127.9, 126.9, 
126.7, 126.4, 126.1, 125.6, 125.3, 66.8, 58.8, 57.9, 39.1; IR (Neat Film, NaCl) 3056, 
2917, 2356, 1602, 1494, 1454, 1425, 1366, 1314, 1276, 1112, 1047, 862, 820, 743 cm-1; 
HRMS (MM:ESI-APCI+) m/z calc’d for C20H20NO [M+H]+: 290.1539, found 290.1540; 
SFC Conditions: 45% IPA, 3.5 mL/min, Chiralpak AD-H column, λ = 210 nm, tR (min): 
major = 3.61, minor = 5.81. 
 
((1S,3R)-3-(3,5-dimethylphenyl)-1,2,3,4-tetrahydroisoquinolin-1-yl)methanol (183k): 
Compound 183k was prepared from isoquinoline 182k using general procedure 5 and 
purified by column chromatography (30% EtOAc in hexanes + 1% NEt3) to provide a 
pale yellow solid as a single diastereomer (49 mg, 80% yield); 92% ee; [α]D25 +93.5 (c 
0.98, CHCl3): 1H NMR (400 MHz, CDCl3) δ 7.25 – 7.16 (m, 3H), 7.12 (d, J = 6.5 Hz, 
1H), 7.07 (s, 2H), 6.95 (s, 1H), 4.41 – 4.39 (m, 1H), 4.02 (dd, J = 10.9, 3.3 Hz, 2H), 3.90 
(dd, J = 10.8, 5.4 Hz, 1H), 3.04 – 3.00 (m, 1H), 2.88 (dd, J = 15.8, 3.4 Hz, 1H), 2.34 (s, 
6H); 13C NMR (100 MHz, CDCl3) δ 144.2, 138.3, 136.8, 135.0, 129.3, 126.7, 126.4, 
125.4, 124.6, 66.6, 58.7, 57.6, 38.9, 21.5; IR (Neat Film, NaCl) 3318, 3014, 2916, 1607, 
1494, 1454, 1313, 1117, 1038, 854, 782, 746, 725 cm-1; HRMS (MM:ESI-APCI+) m/z 
calc’d for C18H22NO [M+H]+: 268.1696, found 268.1702; SFC Conditions: 45% IPA, 3.5 
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(183l): Compound 183l was prepared from isoquinoline 182l using general procedure 5 
and purified by column chromatography (1% MeOH in CH2Cl2 + 1% NEt3) to provide a 
pale yellow solid as a single diastereomer (49 mg, 80% yield); 88% ee; [α]D25 +62.4 (c 
1.00, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.22 – 7.16 (m, 3H), 7.12 (d, J = 6.7 Hz, 
1H), 7.04 – 6.94 (m, 2H), 6.87 – 6.84 (m, 1H), 4.38 – 4.36 (m, 1H), 4.01 (dt, J = 11.2, 4.0 
Hz, 2H), 3.90 (s, 3H), 3.88 (s, 3H), 3.84 (dd, J = 11.0, 6.0 Hz, 1H), 3.08 – 3.00 (m, 1H), 
2.87 (dd, J = 15.8, 3.3 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 149.2, 148.5, 136.5, 
136.4, 134.6, 129.3, 126.7, 126.4, 125.3, 119.0, 111.2, 110.0, 66.3, 58.8, 57.6, 56.1, 38.7; 
IR (Neat Film, NaCl) 3332, 2934, 2832, 1593, 1518, 1494, 1454, 1264, 1238, 1141, 
1028, 745, 720 cm-1; HRMS (MM:ESI-APCI+) m/z calc’d for C18H22NO3 [M+H]+: 
300.1594, found 300.1600; SFC Conditions: 45% IPA, 3.5 mL/min, Chiralpak AD-H 
column, λ = 210 nm, tR (min): major = 2.28, minor = 2.93. 
 
((1S,3R)-3-(o-tolyl)-1,2,3,4-tetrahydroisoquinolin-1-yl)methanol (183m): Compound 
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column chromatography (30% EtOAc in hexanes + 1% NEt3) to provide a pale beige 
solid as a mixture of diastereomers (49 mg, 80% yield) (dr = 10.1:1); 49% ee from major 
diastereomer; [α]D25 +53.7 (c 1.01, CHCl3): 1H NMR (400 MHz, CDCl3) δ 7.60 (d, J = 
7.1 Hz, 1H), 7.29 – 7.26 (m, 1H), 7.26 – 7.17 (m, 5H), 7.14 (d, J = 7.3 Hz, 1H), 4.44 – 
4.42 (m, 1H), 4.32 (dd, J = 10.9, 3.5 Hz, 1H), 4.04 (dd, J = 10.8, 3.2 Hz, 1H), 3.92 (dd, J 
= 10.8, 5.3 Hz, 1H), 3.03 – 2.92 (m, 1H), 2.88 (dd, J = 15.8, 3.5 Hz, 1H), 2.39 (s, 3H); 
13C NMR (100 MHz, CDCl3) δ 142.2, 136.9, 135.2, 135.0, 130.6, 129.4, 127.3, 126.7, 
126.5, 125.6, 125.5, 66.6, 58.9, 53.4, 37.7, 19.5; IR (Neat Film, NaCl) 3318, 3022, 2925, 
2354, 1492, 1454, 1316, 1117, 1037, 864, 751, 743, 727 cm-1; HRMS (MM:ESI-APCI+) 
m/z calc’d for C17H20NO [M+H]+: 254.1539, found 254.1539; SFC Conditions: 30% IPA, 
2.5 mL/min, Chiralpak AD-H column, λ = 210 nm, tR (min): major = 5.91, minor = 6.39. 
 
((1S,3R)-3-(furan-2-yl)-1,2,3,4-tetrahydroisoquinolin-1-yl)methanol (183n): 
 Compound 183n was prepared from isoquinoline 182n using general procedure 5 and 
purified by column chromatography (40% EtOAc in hexanes + 1% NEt3) to provide a 
pale yellow solid as a mixture of diastereomers (34 mg, 74% yield) (dr = 3.3:1); 92% ee 
for major diastereomer; [α]D25 +35.5 (c 1.00, CHCl3); Major diastereomer: 1H NMR (400 
MHz, CDCl3) δ 7.41 – 7.39 (m, 1H), 7.24 – 7.14 (m, 4H, integration overlapped with 
minor diastereomer), 6.37 (dd, J = 3.3, 1.9 Hz, 1H), 6.28 (d, J = 3.2 Hz, 1H), 4.37 – 4.35 
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1H), 3.18 – 3.05 (m, 1H), 3.05 – 2.95 (m, 1H); 13C NMR (100 MHz, CDCl3) δ 141.8, 
135.5, 134.7, 129.4, 126.9, 126.7, 126.5, 125.3, 110.2, 105.3, 66.2, 57.9, 50.7, 34.5; IR 
(Neat Film, NaCl) 3304, 2920, 1495, 1454, 1316, 1146, 1114, 1062, 1037, 1009, 883, 
740 cm-1; HRMS (MM:ESI-APCI+) m/z calc’d for C14H16NO2 [M+H]+: 230.1176, found 
230.1181; SFC Conditions: 35% IPA, 2.5 mL/min, Chiralpak OJ-H column, λ = 210 nm, 
tR (min): major = 1.52, minor = 1.82. 
 
((1S,3R)-3-(thiophen-2-yl)-1,2,3,4-tetrahydroisoquinolin-1-yl)methanol (183o): 
Compound 183o was prepared from isoquinoline 182o using general procedure 5 and 
purified by column chromatography (40% EtOAc in hexanes + 1% NEt3) to provide a 
pale beige solid as a mixture of diastereomers (46 mg, 94% yield) (dr = 3.6:1); 90% ee 
for major diastereomer; [α]D25 +57.4 (c 1.04, CHCl3); Major diastereomer: 1H NMR (400 
MHz, CDCl3) δ 7.34 – 7.28 (m, 1H), 7.28 – 7.21 (m, 3H, integration overlapped with 
minor diastereomer), 7.19 – 7.15 (m, 1H), 7.11 – 7.09 (m, 1H), 7.07 – 7.04 (m, 1H), 4.47 
– 4.42 (m, 2H), 4.06 (dd, J = 10.9, 3.4 Hz, 1H), 3.87 (dd, J = 11.0, 5.9 Hz, 1H), 3.19 – 
2.98 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 148.1, 135.8, 134.7, 129.1, 126.7, 126.7, 
126.6, 125.3, 124.2, 123.5, 66.4, 58.5, 53.1, 39.3; IR (Neat Film, NaCl) 3312, 2923, 
2360, 1494, 1454, 1424, 1310, 1280, 1112, 1038, 850, 830, 744, 704 cm-1; HRMS 
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Conditions: 35% IPA, 2.5 mL/min, Chiralpak OJ-H column, λ = 210 nm, tR (min): major 
= 2.86, minor = 6.02. 
 
((1S,3R)-3-(thiophen-3-yl)-1,2,3,4-tetrahydroisoquinolin-1-yl)methanol (183p): 
Compound 183p was prepared from isoquinoline 182p using general procedure 5 and 
purified by column chromatography (30% EtOAc in hexanes + 1% NEt3) to provide a 
pale beige solid as a mixture of diastereomers (25.5 mg, 52% yield) (dr = 7.3:1). The 
isolated product contained long-chain hydrocarbon impurities, so it was repurified by 
partitioning between acetonitrile and hexanes. The acetonitrile layer was collected and 
concentrated to afford 183p as a pale yellow solid (24.0 mg, 49% yield); 89% ee for 
major diastereomer; [α]D25 +86.8 (c 0.99, CHCl3): 1H NMR (400 MHz, CDCl3) δ 7.24 
(dd, J = 4.9, 3.0 Hz, 1H), 7.18 – 7.16 (m, 1H), 7.13 – 7.07 (m, 4H), 7.05 – 7.02 (m, 1H), 
4.28 – 4.26 (m, 1H), 4.10 (dd, J = 10.8, 3.8 Hz, 1H), 3.93 (dd, J = 10.9, 3.4 Hz, 1H), 3.73 
(dd, J = 11.0, 6.1 Hz, 1H), 2.99 – 2.90 (m, 1H), 2.86 (dd, J = 15.8, 3.8 Hz, 1H); 13C NMR 
(100 MHz, CDCl3) δ 145.3, 136.2, 134.9, 129.3, 126.7, 126.5, 126.5, 126.2, 125.3, 120.9, 
66.3, 58.5, 53.3, 38.1; IR (Neat Film, NaCl) 3318, 2924, 2366, 1494, 1454, 1424, 1313, 
1279, 1218, 1116, 1038, 854, 782, 748 cm-1; HRMS (MM:ESI-APCI+) m/z calc’d for 
C14H16NOS [M+H]+: 246.0947, found 246.0952; SFC Conditions: 35% IPA, 2.5 mL/min, 
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(183q): Compound 183q was prepared from isoquinoline 182q using general procedure 5 
and purified by column chromatography (5% to 10% MeOH in EtOAc + 1% NEt3) to 
provide a pale yellow solid as a mixture of diastereomers (48 mg, 98% yield) (dr = 2.9:1); 
87% ee for major diastereomer; [α]D25 +37.1 (c 1.021, CHCl3); Major diastereomer: 1H 
NMR (400 MHz, CDCl3) δ 7.63 – 7.61 (m, 2H), 7.26 – 7.16 (m, 2H, integration 
overlapped with minor diastereomer), 7.19 – 7.06 (m, 2H), 4.50 – 4.98 (m, 1H), 4.20 (dd, 
J = 11.8, 3.3 Hz, 1H), 4.02 (dd, J = 11.6, 3.3 Hz, 1H), 3.84 (s, 3H), 3.34 – 3.22 (m, 1H), 
3.13 – 2.89 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 138.2, 134.7, 132.2, 129.3, 129.2, 
127.2, 126.9, 125.4, 121.5, 64.6, 58.6, 49.1, 39.0, 36.1; IR (Neat Film, NaCl) 3315, 2931, 
2371, 1560, 1494, 1455, 1408, 1295, 1169, 1031, 1008, 986, 748, 724 cm-1; HRMS 
(MM:ESI-APCI+) m/z calc’d for C14H18N3O [M+H]+: 244.1444, found 244.1448; SFC 
Conditions: 25% IPA, 2.5 mL/min, Chiralpak OJ-H column, λ = 210 nm, tR (min): minor 
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Compound 183r was prepared from isoquinoline 182r using general procedure 5 and 
purified using reverse-phase (C18) preparative-HPLC (MeCN/0.4% acetic acid in water, 
5.0 mL/min, monitor wavelength = 255 nm, 5–23% MeCN over 6 min, ramp to 95% 
MeCN over 0.5 min, and hold at 95% for 3.5 min) to provide a tan solid as a mixture of 
diastereomers (49 mg, 80% yield) (dr = 2.5:1). Note: This compound appears to be 
unstable and significant decomposition was observed under prolonged storage; 85% ee 
for major diastereomer; [α]D25 +49.0 (c 1.01, CHCl3); Major diastereomer: 1H NMR (400 
MHz, CDCl3) δ 8.60 – 8.57 (m, 1H), 7.72 – 7.67 (m, 2H), 7.43 (d, J = 7.8 Hz, 1H), 7.22 – 
7.11 (m, 4H, integration overlapped with minor diastereomer), 4.41 – 4.39 (m, 1H), 4.23 
– 4.20 (m, 1H, integration overlapped with minor diastereomer), 4.07 (dd, J = 11.1, 3.4 
Hz, 1H), 3.85 (dd, J = 11.0, 6.4 Hz, 1H), 3.08 – 3.00 (m, 2H, integration overlapped with 
minor diastereomer); 13C NMR (100 MHz, CDCl3) δ 162.2, 149.4, 137.0, 136.0, 135.3, 
129.4, 126.7, 126.5, 125.4, 122.6, 121.1, 66.4, 58.6, 58.0, 36.5; IR (Neat Film, NaCl) 
3300, 3056, 2934, 1592, 1574, 1473, 1454, 1435, 1316, 1142, 1060, 910, 744 cm-1; 
HRMS (MM:ESI-APCI+) m/z calc’d for C15H17N2O [M+H]+: 241.1335, found 241.1334; 
SFC Conditions: 30% IPA, 2.5 mL/min, Chiralpak OD-H column, λ = 210 nm, tR (min): 
minor = 2.52, major = 2.79. 
 
((1S,3R)-7-fluoro-3-phenyl-1,2,3,4-tetrahydroisoquinolin-1-yl)methanol (185a): 
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purified by column chromatography (30% EtOAc in hexanes + 1% NEt3) to provide a 
pale yellow solid as a mixture of diastereomers (49 mg, 94% yield) (dr = 11.5:1); 93% ee 
for major diastereomer; [α]D25 +76.9 (c 1.04, CHCl3); Major diastereomer: 1H NMR (400 
MHz, CDCl3) δ 7.47 – 7.42 (m, 2H), 7.40 – 7.36 (m, 2H), 7.33 – 7.30 (m, 1H), 7.08 (dd, 
J = 8.4, 5.8 Hz, 1H), 6.97 – 6.87 (m, 2H), 4.38 – 4.36 (m, 1H), 4.06 (dd, J = 10.8, 3.7 Hz, 
1H), 3.99 (dd, J = 10.9, 3.3 Hz, 1H), 3.86 (dd, J = 10.9, 5.2 Hz, 1H), 3.00 – 2.82 (m, 2H); 
13C NMR (100 MHz, CDCl3) δ 161.5 (d, J = 243.8 Hz), 144.0, 136.9 (d, J = 6.8 Hz), 
132.2 (d, J = 3.0 Hz), 130.6 (d, J = 7.9 Hz), 128.8, 127.8, 126.8, 113.9 (d, J = 21.3 Hz), 
112.1 (d, J = 21.8 Hz), 66.4, 58.6 (d, J = 2.1 Hz), 57.7, 38.2; 19F NMR (282 MHz, 
CDCl3) δ –116.2 – –116.4 (m); IR (Neat Film, NaCl) 3309, 2918, 1614, 1498, 1455, 
1428, 1255, 1221, 1031, 911, 868, 808, 758, 745 cm-1; HRMS (MM:ESI-APCI+) m/z 
calc’d for C16H17FNO [M+H]+: 258.1289, found 258.1281; SFC Conditions: 40% IPA, 
2.5 mL/min, Chiralpak AD-H column, λ = 210 nm, tR (min): major = 2.56, minor = 3.04. 
 
((1S,3R)-7-fluoro-3-(4-methoxyphenyl)-1,2,3,4-tetrahydroisoquinolin-1-yl)methanol 
(185b): Compound 185b was prepared from isoquinoline 184b using general procedure 5 
and purified by column chromatography (30% to 40% EtOAc in hexanes + 1% NEt3) to 
provide a pale yellow solid as a single diastereomer (57 mg, 99% yield); 90% ee; [α]D25 
+57.8 (c 0.99, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.38 – 7.34 (m, 2H), 7.07 (dd, J = 
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Hz, 2H), 3.86 – 3.84 (m, 1H), 3.82 (s, 3H), 2.99 – 2.87 (m, 1H), 2.83 (dd, J = 15.6, 3.5 
Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 161.5 (d, J = 243.7 Hz), 159.2, 136.9 (d, J = 6.7 
Hz), 136.2, 132.3, 130.6 (d, J = 7.9 Hz), 127.9, 114.1, 113.8 (d, J = 21.3 Hz), 112.1 (d, J 
= 21.8 Hz), 66.4, 58.7 (d, J = 2.0 Hz), 57.1, 55.5, 38.3; 19F NMR (282 MHz, CDCl3) δ –
116.3 – –116.4 (m); IR (Neat Film, NaCl) 3305, 2930, 2838, 1614, 1591, 1514, 1498, 
1304, 1249, 1178, 1111, 1034, 912, 868, 830, 736 cm-1; HRMS (MM:ESI-APCI+) m/z 
calc’d for C17H19FNO2 [M+H]+: 288.1394, found 288.1404; SFC Conditions: 30% IPA, 
2.5 mL/min, Chiralpak OJ-H column, λ = 210 nm, tR (min): major = 1.93, minor = 2.42. 
 
((1S,3R)-7-fluoro-3-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroisoquinolin-1-
yl)methanol (185c): Compound 185c was prepared from isoquinoline 184c using general 
procedure 5 and purified by column chromatography (20% to 30% EtOAc in hexanes + 
1% NEt3) to provide a pale yellow solid as a mixture of diastereomers (50 mg, 77% 
yield) (dr = 6.7:1); 94% ee for major diastereomer; [α]D25 +44.2 (c 1.002, CHCl3); Major 
diastereomer: 1H NMR (400 MHz, CDCl3) δ 7.64 (d, J = 8.3 Hz, 2H), 7.58 (d, J = 8.1 Hz, 
2H), 7.09 (dd, J = 8.4, 5.7 Hz, 1H), 7.00 – 6.87 (m, 2H), 4.39 – 4.37 (m, 1H), 4.13 (dd, J 
= 8.9, 5.7 Hz, 1H), 4.02 (dd, J = 10.9, 3.3 Hz, 1H), 3.88 (dd, J = 10.9, 5.4 Hz, 1H), 2.94 – 
2.84 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 161.6 (d, J = 244.2 Hz), 148.0, 136.7 (d, J 
= 6.7 Hz), 131.5 (d, J = 3.1 Hz), 130.6 (d, J = 7.9 Hz), 130.1 (q, J = 32.5 Hz), 127.2, 
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Hz) 66.4, 58.5 (d, J = 2.0 Hz), 57.4, 38.2; 19F NMR (282 MHz, CDCl3) δ –62.5, –115.8 – 
–115.9 (m); IR (Neat Film, NaCl) 3304, 2922, 1620, 1593, 1500, 1428, 1326, 1255, 
1222, 1165, 1125, 1068, 1018, 868, 836, 816 cm-1; HRMS (MM:ESI-APCI+) m/z calc’d 
for C17H16F4NO [M+H]+: 326.1163, found 326.1175; SFC Conditions: 20% IPA, 2.5 
mL/min, Chiralpak AD-H column, λ = 210 nm, tR (min): major = 3.93, minor = 4.46. 
 
((5S,7R)-7-phenyl-5,6,7,8-tetrahydro-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)methanol 
(185d): Compound 185d was prepared from isoquinoline 184d using general procedure 5 
and purified by column chromatography (75% EtOAc in hexanes + 1% NEt3) to provide 
a pale beige solid as a mixture of diastereomers (17 mg, 30% yield) (dr = 4.9:1); 58% ee 
for major diastereomer; [α]D25 +29.2 (c 0.940, CHCl3); Major diastereomer: 1H NMR 
(400 MHz, CDCl3) δ 7.47 – 7.41 (m, 2H), 7.39 – 7.37 (m, 2H), 7.33 – 7.27 (m, 1H), 6.71 
(s, 1H), 6.60 – 6.58 (m, 1H), 5.95 – 5.89 (m, 2H), 4.32 – 4.30 (m, 1H), 4.04 (dd, J = 11.1, 
3.4 Hz, 1H), 3.93 (dd, J = 10.9, 3.2 Hz, 1H), 3.82 (dd, J = 10.9, 5.1 Hz, 1H), 2.97 – 2.88 
(m, 1H), 2.78 (dd, J = 15.5, 3.4 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 146.5, 146.4, 
144.2, 130.0, 128.8, 127.9, 127.7, 126.8, 109.0, 105.5, 101.0, 66.7, 58.6, 57.7, 39.0; IR 
(Neat Film, NaCl) 3324, 3028, 2897, 1504, 1486, 1454, 1434, 1384, 1306, 1279, 1231, 
1128, 1038, 936, 910, 858, 750, 733, 701 cm-1; HRMS (MM:ESI-APCI+) m/z calc’d for 
C17H18NO3 [M+H]+: 284.1281, found 284.1276; SFC Conditions: 45% IPA, 2.5 mL/min, 
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5-yl)methanol (185e): Compound 185e was prepared from isoquinoline 184e using 
general procedure 5 and purified by column chromatography (100% EtOAc to 10% 
MeOH in EtOAc + 1% NEt3) to provide a pale yellow solid as a single diastereomer (28 
mg, 41% yield); 54% ee; [α]D25 +25.5 (c 0.197, CH3OH); 1H NMR (400 MHz, CDCl3) δ 
6.99 – 6.96 (m, 2H), 6.87 – 6.85 (m, 1H), 6.71 (s, 1H), 6.60 – 6.58 (m, 1H), 5.94 – 5.91 
(m, 2H), 4.32 – 4.30 (m, 1H), 3.99 (dd, J = 11.1, 3.4 Hz, 1H), 3.94 (dd, J = 11.1, 3.4 Hz, 
1H), 3.91 (s, 3H), 3.89 (s, 3H), 3.83 (dd, J = 11.0, 5.0 Hz, 1H), 2.97 – 2.85 (m, 1H), 2.76 
(dd, J = 15.6, 3.4 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 149.3, 148.7, 146.7, 146.5, 
136.9, 130.1, 127.8, 119.0, 111.4, 110.0, 109.1, 105.6, 101.1, 66.7, 58.8, 57.7, 56.2, 39.1; 
IR (Neat Film, NaCl) 3374, 2890, 2360, 1505, 1487, 1268, 1260, 1237, 1140, 1076, 
1024, 971, 932, 918, 730 cm-1; HRMS (MM:ESI-APCI+) m/z calc’d for C19H22NO5 
[M+H]+: 344.1492, found 344.1483; SFC Conditions: 45% IPA, 2.5 mL/min, Chiralpak 
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Compound 185f was prepared from isoquinoline 184f using general procedure 5 and 
purified by column chromatography (40% to 60% EtOAc in hexanes + 1% NEt3) to 
provide a pale yellow solid as a mixture of diastereomers (25 mg, 43% yield) (dr = 
15.7:1); 82% ee for major diastereomer; [α]D25 +85.7 (c 1.01, CHCl3); Major 
diastereomer: 1H NMR (400 MHz, CDCl3) δ 7.93 – 7.91 (m, 1H), 7.85 – 7.82 (m, 1H), 
7.75 (d, J = 8.6 Hz, 1H), 7.55 (d, J = 7.2 Hz, 2H), 7.50 – 7.47 (m, 2H), 7.45 – 7.34 (m, 
4H), 4.61 – 4.59 (m, 1H), 4.20 (dd, J = 11.0, 3.4 Hz, 1H), 4.09 (dd, J = 10.9, 3.2 Hz, 1H), 
4.01 (dd, J = 10.9, 4.8 Hz, 1H), 3.50 – 3.39 (m, 1H), 3.23 – 3.10 (m, 1H); 13C NMR (100 
MHz, CDCl3) δ 144.4, 132.2, 132.1, 132.0, 131.9, 128.8, 128.4, 127.7, 126.8, 126.7, 
126.3, 125.5, 123.4, 122.9, 66.4, 59.1, 57.6, 35.4; IR (Neat Film, NaCl) 3306, 3056, 
2918, 1417, 1308, 1034, 910, 884, 813, 762, 700, 736, 682 cm-1; HRMS (MM:ESI-
APCI+) m/z calc’d for C20H20NO [M+H]+: 290.1539, found 290.1534; SFC Conditions: 
45% IPA, 2.5 mL/min, Chiralpak AD-H column, λ = 210 nm, tR (min): major = 5.31, 
minor = 10.01. 
 
((1S,3R)-3-phenyl-1,2,3,4-tetrahydroisoquinolin-1-yl)methyl acetate (187a): 
Compound 187a was prepared from isoquinoline 186a using general procedure 5 and 
purified by column chromatography (5% EtOAc in CH2Cl2 + 1% NEt3) to provide a 
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CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.51 – 7.45 (m, 2H), 7.41 – 7.37 (m, 2H), 7.34 – 
7.30 (m, 1H), 7.27 – 7.24 (m, 1H), 7.23 – 7.18 (m, 2H), 7.16 – 7.10 (m, 1H), 4.78 (dd, J 
= 10.8, 3.5 Hz, 1H), 4.54 – 4.51 (m, 1H), 4.14 (dd, J = 10.8, 8.7 Hz, 1H), 4.05 (dd, J = 
11.1, 3.4 Hz, 1H), 3.08 – 3.01 (m, 1H), 2.90 (dd, J = 15.5, 3.6 Hz, 1H), 2.08 (s, 3H); 13C 
NMR (100 MHz, CDCl3) δ 171.1, 144.4, 136.3, 134.1, 129.5, 128.8, 127.7, 126.9, 126.9, 
126.3, 125.3, 69.1, 57.9, 56.4, 39.2, 21.2; IR (Neat Film, NaCl) 3024, 2926, 2802, 1741, 
1494, 1454, 1386, 1366, 1314, 1229, 1118, 1034, 754, 701 cm-1; HRMS (MM:ESI-
APCI+) m/z calc’d for C18H20NO2 [M+H]+: 282.1489, found 282.1492; SFC Conditions: 
20% IPA, 2.5 mL/min, Chiralpak OJ-H column, λ = 210 nm, tR (min): major = 3.32, 
major = 3.93. 
 
(1S,3R)-1-(methoxymethyl)-3-phenyl-1,2,3,4-tetrahydroisoquinoline (187b): 
Compound 187b was prepared from isoquinoline 186b using general procedure 5 and 
purified by column chromatography (10% EtOAc in CH2Cl2+ 1% NEt3) to provide a 
viscous yellow oil as a single diastereomer (40 mg, 80% yield); 89% ee; [α]D25 +94.3 (c 
0.98, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.48 – 7.46 (m, 2H), 7.39 – 7.35 (m, 2H), 
7.32 – 7.27 (m, 1H), 7.25 – 7.20 (m, 1H), 7.20 – 7.15 (m, 2H), 7.16 – 7.10 (m, 1H), 4.45 
– 4.42 (m, 1H), 4.07 – 3.94 (m, 2H), 3.59 (t, J = 8.7 Hz, 1H), 3.43 (s, 3H), 3.06 (dd, J = 
16.0, 11.1 Hz, 1H), 2.92 (dd, J = 16.0, 3.6 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 
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39.0; IR (Neat Film, NaCl) 3028, 2895, 2812, 1604, 1494, 1454, 1313, 1194, 1112, 1072, 
1030, 958, 923, 840, 744, 700 cm-1; HRMS (MM:ESI-APCI+) m/z calc’d for C17H20NO 
[M+H]+: 254.1539, found 254.1531; SFC Conditions: 20% IPA, 2.5 mL/min, Chiralpak 
OD-H column, λ = 210 nm, tR (min): major = 4.82, major = 5.25. 
 
(1S,3R)-1-((benzyloxy)methyl)-3-phenyl-1,2,3,4-tetrahydroisoquinoline (187c): 
Compound 187c was prepared from isoquinoline 186c using general procedure 5 and 
purified by column chromatography (5% EtOAc in CH2Cl2 + 1% NEt3) to provide a pale 
yellow oil as a single diastereomer (60 mg, 90% yield); 88% ee; [α]D25 +80.4 (c 1.02, 
CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.48 – 7.46 (m, 2H), 7.40 – 7.34 (m, 6H), 7.32 – 
7.28 (m, 2H), 7.22 – 7.16 (m, 3H), 7.14 – 7.11 (m, 1H), 4.61 (s, 2H), 4.48 (dd, J = 8.7, 
3.4 Hz, 1H), 4.12 (dd, J = 9.0, 3.6 Hz, 1H), 4.04 (dd, J = 11.1, 3.5 Hz, 1H), 3.67 (t, J = 
8.7 Hz, 1H), 3.05 (dd, J = 15.9, 11.1 Hz, 1H), 2.91 (dd, J = 15.8, 3.5 Hz, 1H); 13C NMR 
(100 MHz, CDCl3) δ 144.6, 138.3, 136.3, 135.3, 129.5, 128.7, 128.6, 127.9, 127.8, 127.5, 
126.9, 126.6, 126.1, 124.9, 74.8, 73.6, 58.1, 57.5, 39.2; IR (Neat Film, NaCl) 3060, 3028, 
2862, 1494, 1454, 1366, 1312, 1098, 1028, 742, 698 cm-1; HRMS (MM:ESI-APCI+) m/z 
calc’d for C23H24NO [M+H]+: 330.1852, found 330.1857; SFC Conditions: 25% IPA, 2.5 
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(187d): Compound 187d was prepared from isoquinoline 186d using general procedure 5 
and purified by column chromatography (15% EtOAc in hexanes + 1% NEt3) to provide 
a white solid as a mixture of diastereomers (44 mg, 71% yield) (dr = 9.0:1); 90% ee for 
major diastereomer; [α]D25 +50.4 (c 0.99, CHCl3); Major diastereomer: 1H NMR (400 
MHz, CDCl3) δ 7.46 (d, J = 7.1 Hz, 2H), 7.38 (t, J = 7.5 Hz, 2H), 7.36 – 7.26 (m, 2H), 
7.26 – 7.14 (m, 2H), 7.11 (d, J = 6.7 Hz, 1H), 5.02 (s, 1H), 4.44 (s, 1H), 4.04 (dd, J = 
11.0, 3.5 Hz, 1H), 3.77 – 3.72 (m, 1H), 3.49 (dt, J = 13.2, 6.3 Hz, 1H), 3.00 (dd, J = 15.8, 
10.9 Hz, 1H), 2.89 (dd, J = 15.8, 3.5 Hz, 1H), 1.41 (s, 9H); 13C NMR (100 MHz, CDCl3) 
δ 156.4, 144.4, 136.4, 135.2, 129.2, 128.7, 127.7, 126.8, 126.6, 126.4, 125.7, 79.4, 58.0, 
57.1, 46.3, 39.1, 28.5; IR (Neat Film, NaCl) 3352, 2978, 2932, 1704, 1495, 1455, 1392, 
1366, 1247, 1171, 752, 701 cm-1; HRMS (MM:ESI-APCI+) m/z calc’d for C21H27N2O2 
[M+H]+: 339.2067, found 339.2063; SFC Conditions: 40% IPA, 2.5 mL/min, Chiralpak 
AD-H column, λ = 210 nm, tR (min): major = 1.41, major = 1.76. 
 
(1R,3R)-1-methyl-3-phenyl-1,2,3,4-tetrahydroisoquinoline (187e): Compound 187e 







Chapter 4 – Iridium-Catalyzed Enantioselective and Diastereoselective  
Hydrogenation of 1,3-Disubstituted Isoquinolines 
  
632 
purified by column chromatography (10% to 20% EtOAc in hexanes + 1% NEt3) to 
provide a colorless oil as a single diastereomer (29 mg, 64% yield); 90% ee; [α]D25 
+133.3 (c 0.79, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.49 – 7.46 (m, 2H), 7.41 – 7.37 
(m, 2H), 7.33 – 7.29 (m, 1H), 7.28 – 7.23 (m, 1H), 7.23 – 7.14 (m, 2H), 7.11 (d, J = 6.9 
Hz, 1H), 4.34 (q, J = 6.6 Hz, 1H), 4.08 (dd, J = 11.1, 3.9 Hz, 1H), 3.12 – 3.01 (m, 1H), 
2.96 (dd, J = 16.2, 4.1 Hz, 1H), 1.55 (d, J = 6.5 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 
144.5, 139.9, 135.2, 129.1, 128.7, 127.5, 126.7, 126.2, 126.2, 125.4, 58.8, 53.6, 38.9, 
22.4; IR (Neat Film, NaCl) 3024, 2962, 2926, 2792, 1602, 1494, 1453, 1372, 1352, 1306, 
1140, 1118, 1031, 790, 753, 733, 700 cm-1; HRMS (MM:ESI-APCI+) m/z calc’d for 
C16H18N [M+H]+: 224.1434, found 224.1426; SFC Conditions: 20% IPA, 3.5 mL/min, 
Chiralpak AS-H column, λ = 210 nm, tR (min): major = 2.16, minor = 2.62. 




To a 1-dram vial equipped with a stir bar was added tetrahydroisoquinoline 183l (20.0 
mg, 0.067 mmol) in 1,2-dichloroethane (1.3 mL, 0.05 M). Formaldehyde solution (37 
wt% in H2O, 9.2 µL, 0.124 mmol) was then added and the reaction was stirred for 15 
minutes at room temperature. The reaction was then basified with K2CO3, and extracted 
with CH2Cl2. The collected organic layers were dried over Na2SO4, and concentrated 
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in hexanes + 1% NEt3) to afford 188 as a white solid (19.3 mg, 93% yield): [α]D25 +134.8 
(c 1.03, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.25 – 7.14 (m, 3H), 7.04 (d, J = 2.0 Hz, 
1H), 7.02 – 6.90 (m, 2H), 6.83 (d, J = 8.2 Hz, 1H), 4.58 – 4.43 (m, 2H), 3.97 (t, J = 7.6 
Hz, 1H), 3.94 – 3.87 (m, 2H), 3.89 (s, 6H), 3.83 (dd, J = 10.6, 4.8 Hz, 1H), 3.23 (dd, J = 
16.8, 10.6 Hz, 1H), 3.11 (dd, J = 16.8, 4.8 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 
149.4, 148.7, 135.1, 134.7, 134.6, 128.6, 127.2, 126.3, 125.0, 119.6, 110.9, 110.2, 84.2, 
71.5, 62.9, 61.3, 56.1, 56.0, 37.3; IR (Neat Film, NaCl) 2930, 1592, 1513, 1454, 1263, 
1237, 1167, 1060, 1027, 918, 752, 680 cm-1; HRMS (MM:ESI-APCI+) m/z calc’d for 
C19H22NO3 [M+H]+: 312.1594, found 312.1594. 
 
To a 1-dram vial equipped with a stir bar was added tetrahydroisoquinoline 183l (10.0 
mg, 0.033 mmol), THF (0.7 mL, 0.05 M), and CDI (21.7 mg, 0.134 mmol). The solution 
was stirred at 50 °C for 15 h. After complete conversion of the starting material 
monitored by TLC, the reaction concentrated and the crude product was purified by 
preparative-TLC (100% EtOAc) to afford 189 as a white solid (9.2 mg, 84% yield): 
[α]D25 +71.4 (c 0.76, CHCl3); 1H NMR (400 MHz, CDCl3) δ 7.34 (dd, J = 8.3, 7.0 Hz, 
1H), 7.30 – 7.23 (m, 1H), 7.08 (t, J = 6.6 Hz, 2H), 6.66 (d, J = 8.2 Hz, 1H), 6.52 (dd, J = 
8.2, 2.1 Hz, 1H), 6.33 (d, J = 2.1 Hz, 1H), 5.14 – 5.02 (m, 2H), 4.92 (t, J = 7.9 Hz, 1H), 
4.49 (dd, J = 10.1, 8.2 Hz, 1H), 3.78 (s, 3H), 3.60 (s, 3H), 3.36 (dd, J = 14.9, 6.4 Hz, 1H), 















Chapter 4 – Iridium-Catalyzed Enantioselective and Diastereoselective  
Hydrogenation of 1,3-Disubstituted Isoquinolines 
  
634 
136.0, 134.2, 133.9, 129.4, 128.5, 127.5, 122.4, 118.5, 110.9, 109.3, 67.5, 55.9, 55.6, 
54.6, 53.4, 36.8; IR (Neat Film, NaCl) 2933, 1756, 1515, 1464, 1396, 1260, 1234, 1139, 
1025, 779, 762, 748 cm-1; HRMS (MM:ESI-APCI+) m/z calc’d for C19H20NO4 [M+H]+: 
326.1387, found 326.1386. 
 
To a 1-dram vial equipped with a stir bar was added tetrahydroisoquinoline 183l (20.0 
mg, 0.067 mmol) in 1,2-dichloroethane (1.3 mL, 0.05 M). Glyoxal solution (40 wt% in 
H2O, 0.15 mL, 1.336 mmol) was then added, and the reaction was stirred at room 
temperature overnight. After complete conversion of the starting material monitored by 
TLC, the reaction was diluted with H2O, and extracted with CH2Cl2. The collected 
organic layers were dried over Na2SO4, and concentrated under vacuum. The crude 
product was purified by preparative-TLC (50% EtOAc in hexanes) to afford 190 as a 
white solid (9.2 mg, 41% yield): [α]D25 +187.8 (c 0.61, CHCl3); 1H NMR (400 MHz, 
CDCl3) δ 7.29 – 7.20 (m, 2H), 7.20 – 7.10 (m, 2H), 6.95 – 6.81 (m, 3H), 4.84 (dd, J = 
10.5, 3.4 Hz, 1H), 4.33 (t, J = 10.7 Hz, 1H), 4.04 – 3.94 (m, 1H), 3.90 (s, 6H), 3.62 (d, J 
= 17.7 Hz, 1H), 3.43 (dd, J = 11.2, 3.2 Hz, 1H), 3.32 – 3.19 (m, 1H), 2.98 – 2.85 (m, 2H); 
13C NMR (100 MHz, CDCl3) δ 167.7, 149.8, 149.1, 135.0, 132.8, 130.6, 129.1, 127.7, 















Chapter 4 – Iridium-Catalyzed Enantioselective and Diastereoselective  
Hydrogenation of 1,3-Disubstituted Isoquinolines 
  
635 
NaCl) 2932, 1745, 1511, 1463, 1421, 1263, 1242, 1137, 1028, 809, 746 cm-1; HRMS 
(MM:ESI-APCI+) m/z calc’d for C20H22NO4 [M+H]+: 340.1543, found 340.1545. 
 
To a 1-dram vial equipped with a stir bar was added tetrahydroisoquinoline 183l 
(10.0 mg, 0.033 mmol) in 1,2-dichloroethane (0.5 mL, 0.07 M). 2,2-
Dimethoxyacetaldehyde solution (60 wt% in H2O, 9.2 µL, 0.061 mmol) was then added 
and the reaction stirred at room temperature overnight. The reaction was then 
concentrated under vacuum to afford a yellow oil, which was then used in the next step 
without further purification.  
To a 1-dram vial was added the crude product and CH2Cl2 (0.5 mL, 0.07 M). 
Eaton’s reagent (0.28 mL, 0.134 mmol) was then added dropwise, and the reaction was 
stirred for 3 hours. The reaction was then quenched by slow addition of saturated aqueous 
NaHCO3, diluted with H2O and extracted with CH2Cl2. The collected organic phases 
were dried over Na2SO4, and concentrated under vacuum. The crude product was purified 
by preparative-TLC (100% EtOAc) twice to afford 191 as a white solid as a single 
diastereomer (4.3 mg, 38% yield over 2 steps): [α]D25 +32.0 (c 0.29, CHCl3); 1H NMR 
(400 MHz, CDCl3) δ 7.29 – 7.26 (m, 1H), 7.24 – 7.20 (m, 1H), 7.16 (d, J = 6.0 Hz, 1H), 
7.08 (d, J = 6.8 Hz, 1H), 6.97 (s, 1H), 6.69 (s, 1H), 4.89 – 4.82 (m, 1H), 4.79 (t, J = 7.8 
Hz, 1H), 4.71 (dd, J = 8.3, 2.1 Hz, 1H), 4.65 (d, J = 2.1 Hz, 1H), 4.47 (dd, J = 9.1, 7.0 















38% yield over 2 steps
1. 60% aq. 2,2-dimethoxyacetaldehyde 
DCE, 23 °C, 18 h
2. Eaton’s Reagent
DCM, 23 °C, 3 h
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2.79 (d, J = 8.4 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 149.4, 148.6, 136.5, 133.1, 
130.9, 129.3, 127.3, 127.3, 126.8, 126.6, 113.6, 109.2, 86.7, 74.4, 67.9, 57.3, 56.2, 56.1, 
54.2, 31.1; IR (Neat Film, NaCl) 3442, 2918, 1610, 1515, 1464, 1380, 1353, 1270, 1242, 
1160, 1117, 1074, 1010, 868, 762, 732, 642 cm-1; HRMS (MM:ESI-APCI+) m/z calc’d 
for C20H22NO4 [M+H]+: 340.1543, found 340.1548. 
The stereochemistry of 191 was assigned using diagnostic nOe correlations 
(highlighted arrows, vide infra). Due to the ambiguous nOe correlations observed in 191, 
the stereochemistry was determined by derivatizing the hydroxyl group of 191 to the 
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4.7.3  Additional optimization results 







Ir(cod)Cl (2.5 mol %)
ligand (3.0 mol %)
H2 (60 bar), TBAI (7.5 mol %)

























































86% yield, 49% ee
56% conversion
37% yield, –61% ee
23% conversion
9% yield, ee ND
59% conversion
59% yield, –61% ee
36% conversion
23% yield, 19% ee
50% conversion
20% yield, ee ND
15% conversion
16% yield, ee ND
59% conversion
46% yield, –41% ee
50% conversion
20% yield, ee ND
65% conversion

































46% yield, 5% ee
F3C CF3
0% conversion






















































10% yield, ee ND
Monophos
42% conversion







74% yield, –19% ee
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Table 4.3 Additive Effects in Ir-Catalyzed Enantio- and Diastereoselective Hydrogenation.a 
 
[a] Reactions conditions: 0.04 mmol of 182a, 1.25 mol % [Ir(cod)Cl]2, 3 mol % ligand, 7.5 mol % TBAI, 60 bar H2 in 2.0 mL 
9:1 solvent:AcOH. [b] Determined from crude 1H NMR using 1,3,5-trimethoxybenzene as a standard. [c] Determined by 
chiral SFC analysis of Cbz-protected product. 
 
4.7.4  Determination of enantiomeric excess 
Table 4.4 Determination of Enantiomeric Excess. 
 
entry acid cis:transbsalt additive % conversionb % ee of cisc
1 TBAI >95 89AcOH
2 LiI >95 89AcOH
3 NaI >95 90AcOH
4 KI 92 87AcOH
5 TBACl >95 31AcOH
6 TBABr >95 63AcOH
7 none 50 27AcOH
8 TBAI 31 67none
9 TBAI >95 90TFA













[Ir(cod)Cl]2 (1.25 mol %)
 L57 (3 mol %)
H2 (60 bar), salt (7.5 mol %)

















Chiralpak AD-H, λ = 210 nm
45% IPA/CO2, 3.5 mL/min
tR (min) major 2.34, minor 4.02
Chiralpak AD-H, λ = 210 nm
45% IPA/CO2, 3.5 mL/min
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Chiracel AD-H, λ = 210 nm
45% IPA/CO2, 3.5 mL/min
tR (min) major 4.08, minor 5.18
Chiralpak AD-H, λ = 210 nm
45% IPA/CO2, 2.5 mL/min















Chiralpak AD-H, λ = 210 nm
45% IPA/CO2, 2.5 mL/min







Chiralpak AD-H, λ = 210 nm
25% IPA/CO2, 2.5 mL/min
tR (min) major 3.11, minor 5.54
92





Chiralpak AD-H, λ = 210 nm
45% IPA/CO2, 3.5 mL/min
tR (min) major 2.03, minor 3.33
Chiralpak AD-H, λ = 210 nm
45% IPA/CO2, 3.5 mL/min
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Chiracel AD-H, λ = 210 nm
40% IPA/CO2, 2.5 mL/min
tR (min) major 1.67, minor 2.20
Chiralpak AD-H, λ = 210 nm
45% IPA/CO2, 3.5 mL/min
tR (min) major 3.61, minor 5.81
95
11
Chiralpak AD-H, λ = 210 nm
45% IPA/CO2, 3.5 mL/min
tR (min) major 1.95, minor 3.02
92
12
Chiralpak AD-H, λ = 210 nm
45% IPA/CO2, 3.5 mL/min

























Chiralpak AD-H, λ = 210 nm
30% IPA/CO2, 2.5 mL/min
tR (min) major 5.91, minor 6.39
Chiralpak OJ-H, λ = 210 nm
35% IPA/CO2, 2.5 mL/min
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Chiracel OJ-H, λ = 210 nm
35% IPA/CO2, 2.5 mL/min
tR (min) major 2.86, minor 6.02
Chiralpak AD-H, λ = 210 nm
45% IPA/CO2, 3.5 mL/min
tR (min) major 3.19, minor 4.05
89
17
Chiralpak OJ-H, λ = 210 nm
25% IPA/CO2, 2.5 mL/min
tR (min) minor 1.84, major 2.60
87
18
Chiralpak OD-H, λ = 210 nm
30% IPA/CO2, 2.5 mL/min
























Chiralpak AD-H, λ = 210 nm
40% IPA/CO2, 2.5 mL/min
tR (min) major 2.56, minor 3.04
Chiralpak OJ-H, λ = 210 nm
30% IPA/CO2, 2.5 mL/min
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Chiracel AD-H, λ = 210 nm
20% IPA/CO2, 2.5 mL/min
tR (min) major 3.93, minor 4.46
Chiralpak AD-H, λ = 210 nm
45% IPA/CO2, 2.5 mL/min
tR (min) major 5.00, minor 7.22
58
23
Chiralpak AD-H, λ = 210 nm
45% IPA/CO2, 2.5 mL/min
tR (min) major 3.89, minor 5.16
54
24
Chiralpak AD-H, λ = 210 nm
45% IPA/CO2, 2.5 mL/min


























Chiracel OD-H, λ = 210 nm
20% IPA/CO2, 2.5 mL/min
tR (min) major 4.82, minor 5.25
Chiralpak OJ-H, λ = 210 nm
20% IPA/CO2, 2.5 mL/min
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4.7.5  Determination of relative and absolute configuration via VCD & OR 
Method 1 – Vibrational Circular Dichroism (VCD) 
Experimental Protocol.  A solution of 187e (60 mg/mL) was prepared in CDCl3 and 
loaded into a front-loading SL-4 cell (International Crystal Laboratories) possessing BaF2 
windows and 100 μm path length.   Infrared (IR) and VCD spectra were acquired on a 
BioTools ChiralIR-2X VCD spectrometer as a set of 27 one-hour blocks (27 blocks, 3120 
scans per block) in dual PEM mode.  A 15-minute acquisition of neat (-)-α-pinene control 
(separate 75 μm BaF2 cell) yielded a VCD spectrum in agreement with literature spectra.  
IR and VCD spectra were background-corrected using a 30-minute block IR acquisition 
of the empty instrument chamber under gentle N2 purge, and were solvent corrected using 
an 8-hour (8 blocks, 3120 scans per block) IR/VCD acquisition of CDCl3 in the same 100 




Chiralpak AS-H, λ = 210 nm
20% IPA/CO2, 3.5 mL/min
tR (min) major 2.16, minor 2.62
Chiralpak OD-H, λ = 210 nm
25% IPA/CO2, 2.5 mL/min
tR (min) major 5.66, minor 6.38
88
29
Chiralpak AD-H, λ = 210 nm
40% IPA/CO2, 2.5 mL/min











Chapter 4 – Iridium-Catalyzed Enantioselective and Diastereoselective  
Hydrogenation of 1,3-Disubstituted Isoquinolines 
  
644 
μm BaF2 cell as used for 187e.  The reported spectra represent the result of block 
averaging. 
Computational Protocol.  The arbitrarily chosen (S,S) stereoisomer of compound 187e 
((S) at methyl, (S) at phenyl; thus cis) was subjected to an exhaustive initial molecular 
mechanics-based conformational search (MMFF94 force field, 0.08 Å geometric RMSD 
cutoff, and 30 kcal/mol energy window) as implemented in MOE 2019.0102 (Chemical 
Computing Group, Montreal, CA).  All conformers retained the (S) configuration at both 
centers.  Separately, a study involving the trans stereoisomer possessing the (R) 
configuration at the methyl group and (S) configuration at phenyl was performed in 
identical fashion, with stereochemical integrity again retained throughout the stochastic 
conformational search. All MMFF94 conformers within a 10 kcal/mol energy window 
were then subjected to geometry optimization, harmonic frequency calculation, and VCD 
rotational strength evaluation using density functional theory.  All quantum mechanical 
calculations first utilized the B3LYP functional, small 6-31G* basis, and IEFPCM model 
(chloroform solvent) as an initial filter, followed by subsequent optimization using 
B3PW91 functional, cc-pVTZ basis, and implicit IEFPCM chloroform solvation model 
on all IEFPCM-B3LYP/6-31G* conformers below 5 kcal/mol.   All calculations were 
performed with the Gaussian 16 program system (Rev. C.01; Frisch et al., Gaussian, Inc., 
Wallingford, CT).  Resultant IEFPCM-B3PW91/cc-pVTZ harmonic frequencies were 
scaled by 0.98. All structurally unique conformers possessing all positive Hessian 
eigenvalues were Boltzmann weighted by relative free energy at 298.15 K.  The predicted 
IR and VCD frequencies and intensities of the retained conformers were convolved using 
Lorentzian line shapes (γ = 4 cm-1) and summed using the respective Boltzmann weights 
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to yield the final predicted IR and VCD spectra of the species described above.  The 
predicted VCD of the corresponding enantiomers were generated by inversion of sign.  
From a combination of (a) the best overall agreement of (R,R)-187e with experiment 
among all of the theoretical spectra in the useful range of the VCD (~ 1000-1450 cm-1, 
regions A-D; see below) coupled with (b) support of this assignment by the agreement 
between predicted versus measured optical rotation (see Method 2) the absolute 
configuration of 6e was established as cis and (R,R). 
Figure 4.3 Experimental (left) and computed (right) IR and VCD spectra for the cis isomers of 187e.   
 
The better agreement with the (R,R) stereoisomer, upon alignment of the achiral IR 
spectra and correlation to VCD signals, is readily evident. 
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Figure 4.4 Experimental (left) and computed (right) IR and VCD spectra for the trans isomers of 
187e.   
 
The worse agreement with experiment between either of the predicted trans 
stereoisomers, compared to the cis- and (R,R) stereoisomer above, can be seen.  This 
assertion is further supported to an extent by the optical rotation data below. 
Method 2 – Optical Rotation (OR) 
Computational Protocol.  The ensemble of unique IEFPCM-B3PW91/cc-pVTZ 
conformers of 187e generated in Method 1 above were subjected to optical rotation 
calculation at 589.0 nm using the B3LYP hybrid density functional, the large and diffuse 
6-311++G(2df,2pd) basis set, and the IEFPCM implicit chloroform solvent model.  The 
computed IEFPCM-B3LYP/6-31++G(2df,2pd) optical rotations (weighted by IEFPCM-
B3PW91/cc-pVTZ free energies at 298.15 K) along with those resulting from 
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alternatively weighting by either the IEFPCM-B3PW91/cc-pVTZ total energies or 
IEFPCM-B3LYP/6-31++G(2df,2pd)//IEFPCM-B3PW91/cc-pVTZ total energies are 
reported in (a)-(d) below. 
(a)  
Predicted OR, weighted by IEFPCM-B3PW91/cc-pVTZ free energies:  -144.5° 
Predicted OR, weighted by IEFPCM-B3PW91/cc-pVTZ total energies:  -144.6° 
Predicted OR, weighted by IEFPCM-B3LYP/6-31++G(2df,2pd)//IEFPCM-B3PW91/cc-
pVTZ total energies:  -147.0°     
(b)  
Predicted OR, weighted by IEFPCM-B3PW91/cc-pVTZ free energies:  +144.5° 
Predicted OR, weighted by IEFPCM-B3PW91/cc-pVTZ total energies:  +144.6° 
Predicted OR, weighted by IEFPCM-B3LYP/6-31++G(2df,2pd)//IEFPCM-B3PW91/cc-
pVTZ total energies:  +147.0°     
(c)  
Predicted OR, weighted by IEFPCM-B3PW91/cc-pVTZ free energies:  -94.5° 
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Predicted OR, weighted by IEFPCM-B3LYP/6-31++G(2df,2pd)//IEFPCM-B3PW91/cc-
pVTZ total energies:  -100.1°     
 (d)  
Predicted OR, weighted by IEFPCM-B3PW91/cc-pVTZ free energies:  +94.5° 
Predicted OR, weighted by IEFPCM-B3PW91/cc-pVTZ total energies:  +101.0° 
Predicted OR, weighted by IEFPCM-B3LYP/6-31++G(2df,2pd)//IEFPCM-B3PW91/cc-
pVTZ total energies:  +100.1°     
Measured optical rotation: [α]D25 +133.3 (c 0.79, CHCl3). Assuming only that the 
sign of the optical rotation is correctly predicted by theory, given the experimentally 
measured value of  +133.3°, the absolute configuration of 187e must either be: (i) (R) at 
both chiral centers (and therefore cis); or (b)  (S) at phenyl and (R) at methyl (trans).   
Scenario (b) is unlikely, given the wrong (opposite) directionality of the VCD signals in 
regions C and D of the experimental spectrum.   Scenario (a) also gives rise to the best 
agreement between the predicted and measured VCD spectra. 
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Figure A11.3 13C NMR (100 MHz, CDCl3) of compound 179a. 
 
Figure A11.2 Infrared spectrum (Thin Film, NaCl) of compound 179a. 
 


























































































































Figure A11.6 13C NMR (100 MHz, CDCl3) of compound 179b. 
 
Figure A11.5 Infrared spectrum (Thin Film, NaCl) of compound 179b. 
 




















































Figure A11.7 19F NMR (282 MHz, CDCl3) of compound 179b. 
 
 


























































































































Figure A11.10 13C NMR (100 MHz, CDCl3) of compound 179c. 
 
Figure A11.9 Infrared spectrum (Thin Film, NaCl) of compound 179c. 
 



























































































































 Figure A11.13 13C NMR (100 MHz, CDCl3) of compound 179d. 
 
Figure A11.12 Infrared spectrum (Thin Film, NaCl) of compound 179d. 
 


























































































































Figure A11.16 13C NMR (100 MHz, CDCl3) of compound 180a. 
 
Figure A11.15 Infrared spectrum (Thin Film, NaCl) of compound 180a. 
 




















































     
Figure A11.17 19F NMR (282 MHz, CDCl3) of compound 180a. 
 
 






























































































































 Figure A11.20 13C NMR (100 MHz, CDCl3) of compound 180b. 
 
Figure A11.19 Infrared spectrum (Thin Film, NaCl) of compound 180b. 
 


















































   
Figure A11.21 19F NMR (282 MHz, CDCl3) of compound 180b. 
 
 


























































































































Figure A11.24 13C NMR (100 MHz, CDCl3) of compound 180c. 
 
Figure A11.23 Infrared spectrum (Thin Film, NaCl) of compound 180c. 
 






















































Figure A11.25 19F NMR (282 MHz, CDCl3) of compound 180c. 
 
 



























































































































Figure A11.28 13C NMR (100 MHz, CDCl3) of compound 180d. 
 
Figure A11.27 Infrared spectrum (Thin Film, NaCl) of compound 180d. 
 




















































Figure A11.29 19F NMR (282 MHz, CDCl3) of compound 180d. 
 
 












































































































Figure A11.32 13C NMR (100 MHz, CDCl3) of compound 181a. 
 
Figure A11.31 Infrared spectrum (Thin Film, NaCl) of compound 181a. 
 


























































































































Figure A11.35 13C NMR (100 MHz, CDCl3) of compound 181b. 
 
Figure A11.34 Infrared spectrum (Thin Film, NaCl) of compound 181b. 
 



























































































































Figure A11.38 13C NMR (100 MHz, CDCl3) of compound 181c. 
 
Figure A11.37 Infrared spectrum (Thin Film, NaCl) of compound 181c. 
 



























































































































Figure A11.41 13C NMR (100 MHz, CDCl3) of compound 181d. 
 
Figure A11.40 Infrared spectrum (Thin Film, NaCl) of compound 181d. 
 


























































































































Figure A11.44 13C NMR (100 MHz, CDCl3) of compound 181e. 
 
Figure A11.43 Infrared spectrum (Thin Film, NaCl) of compound 181e. 
 





















































Figure A11.45 19F NMR (282 MHz, CDCl3) of compound 181e. 
 
 





















































































































































Figure A11.48 13C NMR (100 MHz, CDCl3) of compound 181f. 
 
Figure A11.47 Infrared spectrum (Thin Film, NaCl) of compound 181f. 
 




















































Figure A11.49 19F NMR (282 MHz, CDCl3) of compound 181f. 
 
 



























































































































Figure A11.52 13C NMR (100 MHz, CDCl3) of compound 181g. 
 
Figure A11.51 Infrared spectrum (Thin Film, NaCl) of compound 181g. 
 



























































































































Figure A11.55 13C NMR (100 MHz, CDCl3) of compound 181h. 
 
Figure A11.54 Infrared spectrum (Thin Film, NaCl) of compound 181h. 
 

























































































































Figure A11.58 13C NMR (100 MHz, CDCl3) of compound 181i. 
 
Figure A11.57 Infrared spectrum (Thin Film, NaCl) of compound 181i. 
 




















































Figure A11.59 19F NMR (282 MHz, CDCl3) of compound 181i. 
 
 















































































































Figure A11.62 13C NMR (100 MHz, CDCl3) of compound 181j. 
 
Figure A11.61 Infrared spectrum (Thin Film, NaCl) of compound 181j. 
 



























































































































Figure A11.65 13C NMR (100 MHz, CDCl3) of compound 181k. 
 
Figure A11.64 Infrared spectrum (Thin Film, NaCl) of compound 181k. 
 































































































































Figure A11.68 13C NMR (100 MHz, CDCl3) of compound 181l. 
 
Figure A11.67 Infrared spectrum (Thin Film, NaCl) of compound 181l. 
 




























































































































Figure A11.71 13C NMR (100 MHz, CDCl3) of compound 181m. 
 
Figure A11.70 Infrared spectrum (Thin Film, NaCl) of compound 
181m. 
 
























































































































  Figure A11.74 13C NMR (100 MHz, CDCl3) of compound 181n. 
 
Figure A11.73 Infrared spectrum (Thin Film, NaCl) of compound 181n. 
 

























































































































Figure A11.77 13C NMR (100 MHz, CDCl3) of compound 181o. 
 
Figure A11.76 Infrared spectrum (Thin Film, NaCl) of compound 181o. 
 

























































































































Figure A11.80 13C NMR (100 MHz, CDCl3) of compound 181p. 
 
Figure A11.79 Infrared spectrum (Thin Film, NaCl) of compound 181p. 
 



























































































































Figure A11.83 13C NMR (100 MHz, CDCl3) of compound 181q. 
 
Figure A11.82 Infrared spectrum (Thin Film, NaCl) of compound 181q. 
 


























































































































Figure A11.86 13C NMR (100 MHz, CDCl3) of compound 181r. 
 
Figure A11.85 Infrared spectrum (Thin Film, NaCl) of compound 181r. 
 

























































































































Figure A11.89 13C NMR (100 MHz, CDCl3) of compound 192a. 
 
Figure A11.88 Infrared spectrum (Thin Film, NaCl) of compound 192a. 
 






















































Figure A11.90 19F NMR (282 MHz, CDCl3) of compound 192a. 
 
 






























































































































Figure A11.93 13C NMR (100 MHz, CDCl3) of compound 192b. 
 
Figure A11.92 Infrared spectrum (Thin Film, NaCl) of compound 192b. 
 























































Figure A11.94 19F NMR (282 MHz, CDCl3) of compound 192b. 
 
 























































































































Figure A11.97 13C NMR (100 MHz, CDCl3) of compound 192c. 
 
Figure A11.96 Infrared spectrum (Thin Film, NaCl) of compound 192c. 
 






















































Figure A11.98 19F NMR (282 MHz, CDCl3) of compound 192c. 
 
 














































































































Figure A11.101 13C NMR (100 MHz, CDCl3) of compound 192d. 
 
Figure A11.100 Infrared spectrum (Thin Film, NaCl) of compound 
192d. 
 






























































































































Figure A11.104 13C NMR (100 MHz, CDCl3) of compound 192e. 
 
Figure A11.103 Infrared spectrum (Thin Film, NaCl) of compound 
192e. 
 


























































































































Figure A11.107 13C NMR (100 MHz, CDCl3) of compound 192f. 
 
Figure A11.106 Infrared spectrum (Thin Film, NaCl) of compound 
192f. 
 
























































































































Figure A11.110 13C NMR (100 MHz, CDCl3) of compound 182a. 
 
Figure A11.109 Infrared spectrum (Thin Film, NaCl) of compound 
182a. 
 
























































































































 Figure A11.113 13C NMR (100 MHz, CDCl3) of compound 182b. 
 
Figure A11.112 Infrared spectrum (Thin Film, NaCl) of compound 
182b. 
 

























































































































Figure A11.116 13C NMR (100 MHz, CDCl3) of compound 182c. 
 
Figure A11.115 Infrared spectrum (Thin Film, NaCl) of compound 
182c. 
 




























































































































Figure A11.119 13C NMR (100 MHz, CDCl3) of compound 182d. 
 
Figure A11.118 Infrared spectrum (Thin Film, NaCl) of compound 
182d. 
 


























































































































Figure A11.122 13C NMR (100 MHz, CDCl3) of compound 182e. 
 
Figure A11.121 Infrared spectrum (Thin Film, NaCl) of compound 
182e. 
 








    












































Figure A11.123 19F NMR (282 MHz, CDCl3) of compound 182e. 
 
 















































































































Figure A11.126 13C NMR (100 MHz, CDCl3) of compound 182f. 
 
Figure A11.125 Infrared spectrum (Thin Film, NaCl) of compound 
182f. 
 








    
    











































Figure A11.127 19F NMR (282 MHz, CDCl3) of compound 182f. 
 
 

























































































































Figure A11.130 13C NMR (100 MHz, CDCl3) of compound 182g. 
 
Figure A11.129 Infrared spectrum (Thin Film, NaCl) of compound 
182g. 
 



























































































































Figure A11.133 13C NMR (100 MHz, CDCl3) of compound 182h. 
 
Figure A11.132 Infrared spectrum (Thin Film, NaCl) of compound 
182h. 
 


























































































































Figure A11.136 13C NMR (100 MHz, CDCl3) of compound 182i. 
 
Figure A11.135 Infrared spectrum (Thin Film, NaCl) of compound 
182i. 
 



















































Figure A11.137 19F NMR (282 MHz, CDCl3) of compound 182i. 
 
 





















































































































Figure A11.140 13C NMR (100 MHz, CDCl3) of compound 182j. 
 
Figure A11.139 Infrared spectrum (Thin Film, NaCl) of compound 
182j. 
 





























































































































Figure A11.143 13C NMR (100 MHz, CDCl3) of compound 182k. 
 
Figure A11.142 Infrared spectrum (Thin Film, NaCl) of compound 
182k. 
 





























































































































Figure A11.146 13C NMR (100 MHz, CDCl3) of compound 182l. 
 
Figure A11.145 Infrared spectrum (Thin Film, NaCl) of compound 
182l. 
 



























































































































Figure A11.149 13C NMR (100 MHz, CDCl3) of compound 182m. 
 
Figure A11.148 Infrared spectrum (Thin Film, NaCl) of compound 182m. 
 


























































































































Figure A11.152 13C NMR (100 MHz, CDCl3) of compound 182n. 
 
Figure A11.151 Infrared spectrum (Thin Film, NaCl) of compound 
182n. 
 


























































































































Figure A11.155 13C NMR (100 MHz, CDCl3) of compound 182o. 
 
Figure A11.154 Infrared spectrum (Thin Film, NaCl) of compound 
182o. 
 



























































































































Figure A11.158 13C NMR (100 MHz, CDCl3) of compound 182p. 
 
Figure A11.157 Infrared spectrum (Thin Film, NaCl) of compound 
182p. 
 




























































































































Figure A11.161 13C NMR (100 MHz, CDCl3) of compound 182q. 
 
Figure A11.160 Infrared spectrum (Thin Film, NaCl) of compound 
182q. 
 


























































































































Figure A11.164 13C NMR (100 MHz, CDCl3) of compound 182r. 
 
Figure A11.163 Infrared spectrum (Thin Film, NaCl) of compound 
182r. 
 


























































































































Figure A11.167 13C NMR (100 MHz, CDCl3) of compound 184a. 
 
Figure A11.166 Infrared spectrum (Thin Film, NaCl) of compound 
184a. 
 



















































Figure A11.168 19F NMR (282 MHz, CDCl3) of compound 184a. 
 
 



















    
  









































































































Figure A11.171 13C NMR (100 MHz, CDCl3) of compound 184b. 
 
Figure A11.170 Infrared spectrum (Thin Film, NaCl) of compound 
184b. 
 




















































Figure A11.172 19F NMR (282 MHz, CDCl3) of compound 184b. 
 
 





























































































































Figure A11.175 13C NMR (100 MHz, CDCl3) of compound 184c. 
 
Figure A11.174 Infrared spectrum (Thin Film, NaCl) of compound 
184c. 
 




















































Figure A11.176 19F NMR (282 MHz, CDCl3) of compound 184c. 
 
 


















































































































































Figure A11.179 13C NMR (100 MHz, CDCl3) of compound 184d. 
 
Figure A11.178 Infrared spectrum (Thin Film, NaCl) of compound 
184d. 
 
































































































































Figure A11.182 13C NMR (100 MHz, CDCl3) of compound 184e. 
 
Figure A11.181 Infrared spectrum (Thin Film, NaCl) of compound 
184e. 
 























































































































Figure A11.185 13C NMR (100 MHz, CDCl3) of compound 184f. 
 
Figure A11.184 Infrared spectrum (Thin Film, NaCl) of compound 
184f. 
 
























































































































Figure A11.188 13C NMR (100 MHz, CDCl3) of compound 186a. 
 
Figure A11.187 Infrared spectrum (Thin Film, NaCl) of compound 
186a. 
 

























































































































Figure A11.191 13C NMR (100 MHz, CDCl3) of compound 186b. 
 
Figure A11.190 Infrared spectrum (Thin Film, NaCl) of compound 
186b. 
 
























































































































Figure A11.194 13C NMR (100 MHz, CDCl3) of compound 186c. 
 
Figure A11.193 Infrared spectrum (Thin Film, NaCl) of compound 
186c. 
 


























































































































Figure A11.197 13C NMR (100 MHz, CDCl3) of compound 186d. 
 
Figure A11.196 Infrared spectrum (Thin Film, NaCl) of compound 
186d. 
 

























































































































Figure A11.200 13C NMR (100 MHz, CDCl3) of compound 186f. 
 
Figure A11.199 Infrared spectrum (Thin Film, NaCl) of compound 
186f. 
 
























































































































Figure A11.203 13C NMR (100 MHz, CDCl3) of compound 183a. 
 
Figure A11.202 Infrared spectrum (Thin Film, NaCl) of compound 
183a. 
 



















































































































































































































































Figure A11.208 13C NMR (100 MHz, CDCl3) of compound 183b. 
 
Figure A11.207 Infrared spectrum (Thin Film, NaCl) of compound 
183b. 
 





















































































































Figure A11.211 13C NMR (100 MHz, CDCl3) of compound 183c. 
 
Figure A11.210 Infrared spectrum (Thin Film, NaCl) of compound 
183c. 
 























































































































Figure A11.214 13C NMR (100 MHz, CDCl3) of compound 183d. 
 
Figure A11.213 Infrared spectrum (Thin Film, NaCl) of compound 
183d. 
 





















































































































Figure A11.217 13C NMR (100 MHz, CDCl3) of compound 183e. 
 
Figure A11.216 Infrared spectrum (Thin Film, NaCl) of compound 
183e. 
 





















































Figure A11.218 19F NMR (282 MHz, CDCl3) of compound 183e. 
 
 





















































































































Figure A11.221 13C NMR (100 MHz, CDCl3) of compound 183f. 
 
Figure A11.220 Infrared spectrum (Thin Film, NaCl) of compound 
183f. 
 



















































Figure A11.222 19F NMR (282 MHz, CDCl3) of compound 183f. 
 
 





















































































































Figure A11.225 13C NMR (100 MHz, CDCl3) of compound 183g. 
 
Figure A11.224 Infrared spectrum (Thin Film, NaCl) of compound 
183g. 
 
























































































































Figure A11.228 13C NMR (100 MHz, CDCl3) of compound 183h. 
 
Figure A11.227 Infrared spectrum (Thin Film, NaCl) of compound 
183h. 
 





















































































































Figure A11.231 13C NMR (100 MHz, CDCl3) of compound 183i. 
 
Figure A11.230 Infrared spectrum (Thin Film, NaCl) of compound 
183i. 
 



















































Figure A11.232 19F NMR (282 MHz, CDCl3) of compound 183i. 
 
 













































































































Figure A11.235 13C NMR (100 MHz, CDCl3) of compound 183j. 
 
Figure A11.234 Infrared spectrum (Thin Film, NaCl) of compound 
183j. 
 























































































































Figure A11.238 13C NMR (100 MHz, CDCl3) of compound 183k. 
 
Figure A11.237 Infrared spectrum (Thin Film, NaCl) of compound 
183k. 
 


































































































































Figure A11.241 13C NMR (100 MHz, CDCl3) of compound 183l. 
 
Figure A11.240 Infrared spectrum (Thin Film, NaCl) of compound 
183l. 
 





















































































































 Figure A11.244 13C NMR (100 MHz, CDCl3) of compound 183m. 
 
Figure A11.243 Infrared spectrum (Thin Film, NaCl) of compound 
183m. 
 





















































































































Figure A11.247 13C NMR (100 MHz, CDCl3) of compound 183n. 
 
Figure A11.246 Infrared spectrum (Thin Film, NaCl) of compound 
183n. 
 






















































































































 Figure A11.250 13C NMR (100 MHz, CDCl3) of compound 183o. 
 
Figure A11.249 Infrared spectrum (Thin Film, NaCl) of compound 
183o. 
 






















































































































Figure A11.253 13C NMR (100 MHz, CDCl3) of compound 183p. 
 
Figure A11.252 Infrared spectrum (Thin Film, NaCl) of compound 
183p. 
 
































































































































Figure A11.256 13C NMR (100 MHz, CDCl3) of compound 183q. 
 
Figure A11.255 Infrared spectrum (Thin Film, NaCl) of compound 
183q. 
 




















































































































Figure A11.259 13C NMR (100 MHz, CDCl3) of compound 183r. 
 
Figure A11.258 Infrared spectrum (Thin Film, NaCl) of compound 
183r. 
 




















































































































Figure A11.262 13C NMR (100 MHz, CDCl3) of compound 185a. 
 
Figure A11.261 Infrared spectrum (Thin Film, NaCl) of compound 
185a. 
 





















































Figure A11.263 19F NMR (282 MHz, CDCl3) of compound 185a. 
 
 


























































































































Figure A11.266 13C NMR (100 MHz, CDCl3) of compound 185b. 
 
Figure A11.265 Infrared spectrum (Thin Film, NaCl) of compound 
185b. 
 




















































Figure A11.267 19F NMR (282 MHz, CDCl3) of compound 185b. 
 
 






















































































































Figure A11.270 13C NMR (100 MHz, CDCl3) of compound 185c. 
 
Figure A11.269 Infrared spectrum (Thin Film, NaCl) of compound 
185c. 
 




















































Figure A11.271 19F NMR (282 MHz, CDCl3) of compound 185c. 
 
 





















































































































Figure A11.274 13C NMR (100 MHz, CDCl3) of compound 185d. 
 
Figure A11.273 Infrared spectrum (Thin Film, NaCl) of compound 
185d. 
 

























































































































Figure A11.277 13C NMR (100 MHz, CDCl3) of compound 185e. 
 
Figure A11.276 Infrared spectrum (Thin Film, NaCl) of compound 
185e. 
 


















































































































Figure A11.280 13C NMR (100 MHz, CDCl3) of compound 185f. 
 
Figure A11.279 Infrared spectrum (Thin Film, NaCl) of compound 
185f. 
 



















































































































Figure A11.283 13C NMR (100 MHz, CDCl3) of compound 187a. 
 
Figure A11.282 Infrared spectrum (Thin Film, NaCl) of compound 
187a. 
 


























































































































Figure A11.286 13C NMR (100 MHz, CDCl3) of compound 187b. 
 
Figure A11.285 Infrared spectrum (Thin Film, NaCl) of compound 
187b. 
 




















































































































Figure A11.289 13C NMR (100 MHz, CDCl3) of compound 187c. 
 
Figure A11.288 Infrared spectrum (Thin Film, NaCl) of compound 
187c. 
 





















































































































Figure A11.292 13C NMR (100 MHz, CDCl3) of compound 187d. 
 
Figure A11.291 Infrared spectrum (Thin Film, NaCl) of compound 
187d. 
 






















































































































Figure A11.295 13C NMR (100 MHz, CDCl3) of compound 187e. 
 
Figure A11.294 Infrared spectrum (Thin Film, NaCl) of compound 
187e. 
 






















































































































Figure A11.298 13C NMR (100 MHz, CDCl3) of compound 188. 
 
Figure A11.297 Infrared spectrum (Thin Film, NaCl) of compound 188. 
 






















































































































Figure A11.301 13C NMR (100 MHz, CDCl3) of compound 189. 
 
Figure A11.300 Infrared spectrum (Thin Film, NaCl) of compound 189. 
 


























































































































Figure A11.304 13C NMR (100 MHz, CDCl3) of compound 190. 
 
Figure A11.303 Infrared spectrum (Thin Film, NaCl) of compound 190. 
 



























































































































Figure A11.307 13C NMR (100 MHz, CDCl3) of compound 191. 
 
Figure A11.306 Infrared spectrum (Thin Film, NaCl) of compound 191. 
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A12.1   GENERAL EXPERIMENTAL 
A crystal was mounted on a polyimide MiTeGen loop with STP Oil Treatment 
and placed under a nitrogen stream. Low temperature (100K) X-ray data were collected 
with a Bruker AXS KAPPA APEX II diffractometer running at 50 kV and 30 mA (Mo 
Ka = 0.71073 Å; PHOTON 100 CMOS detector with TRIUMPH graphite 
monochromator). All diffractometer manipulations, including data collection, integration, 
and scaling were carried out using the Bruker APEX3 software. An absorption correction 
was applied using SADABS in point group 2. The space group was determined and the 
structure solved by intrinsic phasing using XT.  Refinement was full-matrix least squares 
on F2 using XL. All non-hydrogen atoms were refined using anisotropic displacement 
parameters. Hydrogen atoms were placed in idealized positions and the coordinates 
refined (each of the two disordered pairs were constrained to the same position). The 
isotropic displacement parameters of all hydrogen atoms were fixed at 1.2 times (1.5 
times for methyl groups and alcohol) the Ueq value of the bonded atom. 
 
A12.2   X-RAY CRYSTAL STRUCTURE ANALYSIS OF THIQ 183P 
The tetrahydroisoquinoline (THIQ) product 183p (87% ee) was crystallized by 
slow evaporation from chloroform at 23 °C to provide crystals suitable for X-ray 
analysis. Compound d19110 (183p) crystallizes in the monoclinic space group P21(#4) 
with one molecule in the asymmetric unit. The S atom and one C atom were disordered 
60:40; the anisotropic displacement parameters of each of the C–S bonded pairs were 
constrained to be the same. 
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Figure A12.1 X-ray crystal structure of THIQ  183p. 
 
 
Table A12.1 Crystal data and structure refinement for product 183p. 
 
Identification code  d19110 
Empirical formula  C14 H15 N O S 
Formula weight  245.33 
Temperature  100 K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P 1 21 1 
Unit cell dimensions a = 8.3309(19) Å a= 90° 
 b = 6.6556(18) Å b= 96.337(8)° 
 c = 10.916(3) Å g = 90° 
Volume 601.6(3) Å3 
Z 2 
Density (calculated) 1.354 g/cm3 
Absorption coefficient 0.251 mm-1 
F(000) 260 
Crystal size 0.38 x 0.17 x 0.08 mm3 
Theta range for data collection 1.877 to 35.613°. 
Index ranges -13 £ h £ 13, -10 £ k £ 10, -17 £ l £ 17 
Reflections collected 25734 
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Independent reflections 5228 [R(int) = 0.0337] 
Completeness to theta = 25.242° 99.5 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.0000 and 0.9299 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5228 / 1 / 209 
Goodness-of-fit on F2 1.058 
Final R indices [I>2sigma(I)] R1 = 0.0383, wR2 = 0.0909 
R indices (all data) R1 = 0.0484, wR2 = 0.0960 
Absolute structure parameter [Flack] 0.04(2) 
Absolute structure parameter [Hooft] 0.03(2) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.457 and -0.227 e.Å-3 
 
Table A12.2 Atomic coordinates (x 10
5





), and population for 183p. U(eq) is defined as one third of the trace of the orthogonalized 
Uij tensor. 
________________________________________________________________________  
 x y z U(eq)                   pop 
_______________________________________________________________________  
S(1) -1782(9) 10112(13) 8554(8) 192(2) 0.61(1) 
S(1A) -12835(17) 26880(20) 15351(16) 200(4) 0.40(1) 
O(1) 46731(15) 90530(20) 2239(13) 250(3) 1 
N(1) 38190(14) 60130(20) 16462(10) 126(2) 1 
C(1) 31520(15) 47500(20) 25761(12) 119(2) 1 
C(2) 45361(17) 34360(20) 31317(14) 146(2) 1 
C(3) 59104(16) 47440(20) 36870(12) 135(2) 1 
C(4) 69583(19) 40430(30) 46858(14) 193(3) 1 
C(5) 81732(19) 52630(30) 52519(15) 236(3) 1 
C(6) 83610(20) 71900(30) 48189(15) 243(4) 1 
C(7) 73300(20) 79110(30) 38302(15) 210(3) 1 
C(8) 60916(17) 66970(20) 32554(13) 140(2) 1 
Appendix 12 – X-Ray Crystallography Reports Relevant to Chapter 4 
 
871 
C(9) 49394(17) 75610(20) 22155(13) 133(2) 1 
C(10) 58373(18) 84320(30) 11976(14) 174(3) 1 
C(11) 16954(16) 36170(20) 20222(13) 127(2) 1 
C(12) 17083(17) 18760(20) 13110(13) 147(2) 1 
C(13) -10370(60) 29940(90) 16190(50) 192(2) 0.61(1) 
C(13A) 1840(80) 11730(130) 9760(70) 200(4) 0.40(1) 
C(14) 1166(19) 42160(30) 21889(15) 177(3) 1 
 
Table A12.3 Bond lengths [Å] and angles [°] for 183p. 
_____________________________________________________  
S(1)-C(12)  1.6959(16) 
S(1)-C(13)  1.755(6) 
S(1A)-C(13A)  1.746(9) 
S(1A)-C(14)  1.6492(19) 
O(1)-H(1)  0.93(3) 
O(1)-C(10)  1.419(2) 
N(1)-H(1A)  0.90(2) 
N(1)-C(1)  1.4732(18) 
N(1)-C(9)  1.4799(19) 
C(1)-H(1B)  1.03(2) 
C(1)-C(2)  1.5193(19) 
C(1)-C(11)  1.4985(19) 
C(2)-H(2A)  0.98(2) 
C(2)-H(2B)  1.00(2) 
C(2)-C(3)  1.511(2) 
C(3)-C(4)  1.400(2) 
C(3)-C(8)  1.396(2) 
C(4)-H(4)  0.91(3) 
C(4)-C(5)  1.389(2) 
C(5)-H(5)  0.93(3) 
C(5)-C(6)  1.382(3) 
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C(6)-H(6)  0.85(3) 
C(6)-C(7)  1.388(3) 
C(7)-H(7)  0.99(3) 
C(7)-C(8)  1.403(2) 
C(8)-C(9)  1.517(2) 
C(9)-H(9)  0.99(2) 
C(9)-C(10)  1.521(2) 
C(10)-H(10A)  0.96(3) 
C(10)-H(10B)  1.01(3) 
C(11)-C(12)  1.395(2) 
C(11)-C(14)  1.405(2) 
C(12)-C(13A)  1.365(6) 
C(12)-H(12)  0.94(2) 
C(12)-H(12A)  0.94(2) 
C(13)-H(13)  0.91(5) 
C(13)-C(14)  1.357(5) 
C(13A)-H(13A)  1.04(8) 
C(14)-H(14A)  0.90(3) 
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) for 183p. The anisotropic displacement 
factor exponent takes the form: -2p2 [ h2 a*2U11 + ... + 2 h k a* b* U12 ] 
________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
________________________________________________________________________  
S(1) 146(4)  220(4) 204(4)  -44(3) -7(3)  -76(3) 
S(1A) 121(7)  246(7) 223(6)  -49(5) -15(4)  -92(4) 
O(1) 205(6)  302(7) 251(6)  151(5) 60(4)  14(5) 
N(1) 133(5)  113(5) 131(5)  14(4) 8(4)  -15(4) 
C(1) 109(5)  126(5) 121(5)  0(4) 13(4)  -11(4) 
C(2) 129(6)  135(6) 168(6)  39(5) -7(4)  -20(5) 
C(3) 101(5)  182(6) 123(5)  1(5) 14(4)  5(5) 
C(4) 157(6)  274(8) 144(6)  12(6) 2(5)  45(5) 
C(5) 127(6)  437(10) 143(6)  -57(6) 2(5)  35(6) 
C(6) 148(6)  416(11) 167(6)  -123(7) 23(5)  -95(6) 
C(7) 191(7)  255(8) 193(6)  -75(6) 54(5)  -94(6) 
C(8) 125(5)  173(6) 126(5)  -31(5) 35(4)  -21(5) 
C(9) 150(6)  94(5) 161(6)  -5(5) 45(4)  -16(4) 
C(10) 171(6)  166(6) 191(6)  30(5) 53(5)  -35(5) 
C(11) 124(5)  138(6) 114(5)  5(4) -2(4)  -20(4) 
C(12) 150(6)  141(6) 147(6)  -16(5) 10(4)  -27(5) 
C(13) 146(4)  220(4) 204(4)  -44(3) -7(3)  -76(3) 
C(13A) 121(7)  246(7) 223(6)  -49(5) -15(4)  -92(4) 
C(14) 153(6)  197(7) 186(6)  -13(5) 45(5)  -5(5) 
________________________________________________________________________ 
Table A12.5 Hydrogen coordinates(x 10
4




) for 183p. 
________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________  
H(1) 5130(30) 9700(50) -410(30) 38 
H(1A) 3010(30) 6680(40) 1220(20) 15 
H(1B) 2770(20) 5620(40) 3270(20) 14 
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H(2A) 4220(30) 2540(40) 3780(20) 18 
H(2B) 4930(30) 2550(40) 2490(20) 18 
H(4) 6740(30) 2820(40) 5010(20) 23 
H(5) 8820(30) 4820(50) 5950(20) 28 
H(6) 9050(30) 8010(40) 5180(20) 29 
H(7) 7390(30) 9310(40) 3530(20) 25 
H(9) 4290(30) 8670(40) 2510(20) 16 
H(10A) 6490(30) 9530(40) 1520(20) 21 
H(10B) 6600(30) 7400(40) 910(20) 21 
H(13) -2130(60) 2800(70) 1480(40) 23 
H(13A) -450(70) -40(120) 550(60) 24 
H(12) 2610(30) 1210(40) 1060(20) 21 
H(12A) 2610(30) 1210(40) 1060(20) 21 
H(14A) -150(30) 5310(40) 2600(20) 21 
H(14) -150(30) 5310(40) 2600(20) 21 
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Table A12.7 Hydrogen bonds for 183p [Å and °]. 
________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
________________________________________________________________________  
 O(1)-H(1)...N(1)#1 0.93(3) 1.90(3) 2.8310(18) 177(2) 
________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms: #1 -x+1,y+1/2,-z .  








Notebook Cross-Reference for New Compounds 
 
 
The following notebook cross-reference provides the file name for all original 
spectroscopic data obtained for new compounds presented within this thesis. The 
information is organized by chapter or appendix and sequentially by compound number. 
All 1H NMR, 13C NMR, as well as 19F NMR and any two-dimensional NMR data, if 
applicable, are electronically stored on the Caltech NMR laboratory server 
(mangia.caltech.edu, most typically under the usernames ‘angamnit,’ ‘ewelin,’ ‘cjette,’ or 
‘akim2’) and on the Stoltz group server. Electronic copies of all IR spectra can also be 
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Table A13.1 Notebook cross-reference for compounds in Chapter 1. 
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Table A13.2 Notebook cross-reference for compounds in Chapter 2. 
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Table A13.3 Notebook cross-reference for compounds in Chapter 3. 
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Compound Chemical Structure 1H NMR 13C NMR IR 
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Table A13.4 Notebook cross-reference for compounds in Appendix 7. 
 

















































































Appendix 13 – Notebook Cross-Reference for New Compounds 
	
893 































































































Appendix 13 – Notebook Cross-Reference for New Compounds 
	
894 










































































































Appendix 13 – Notebook Cross-Reference for New Compounds 
	
895 















































































































Appendix 13 – Notebook Cross-Reference for New Compounds 
	
896 






















































































































Appendix 13 – Notebook Cross-Reference for New Compounds 
	
897 
























































































Appendix 13 – Notebook Cross-Reference for New Compounds 
	
898 
Table A13.5 Notebook cross-reference for compounds in Chapter 4. 
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